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Biomarker Development in Endometrial Cancer: Circulating Tumour Cells, Tissue Methylation 
and Genotyping Studies 
 
Abstract 
 
Endometrial cancer (EC) is the most common gynaecological malignancy in the developed 
world and 4th most common women’s cancer in the UK.  Although approximately 75% of 
women present with surgically resectable disease, 20% of these will relapse and 25% of initial 
diagnoses occur with metastatic disease.  There are currently no validated biomarkers to 
assess treatment response or target molecular therapies, despite evidence for targetable 
aberrations in the literature.  The PI3K pathway in particular is commonly mutated in EC and 
stathmin is a recently identified phosphoprotein associated with PI3K pathway activation and 
with prognostic significance in EC.   
I investigated biomarker development and novel pathways in EC in two ways: firstly, through a 
feasibility study of circulating tumour cell (CTC) enumeration and molecular profiling (MP) in 
patients with advanced endometrioid and non-endometrioid EC (EEC and NEEC); and secondly, 
through methylation and copy number variation (CNV) studies on formalin-fixed paraffin-
embedded (FFPE) and fresh frozen (FF) EEC.   
CTCs have prognostic and predictive significance in a number of cancers, with increasing 
evidence on CTC MP.  CTC enumeration and assessment of stathmin overexpression was 
performed on the validated Veridex CellSearch platform and shown to be feasible.  In addition, 
CTC positivity was associated with worse survival and there was a subset of patients for whom 
a positive CTC count was predictive of outcome on chemotherapy. 
The second component focused on methylation and CNV analysis in the different phases of 
endometrial carcinogenesis from normal endometrium to atypical endometrial hyperplasia 
(AEH) and EEC.   By extracting DNA from FFPE and FF EEC and using the Illumina Infinium 
HumanMethylation450 BeadChip, I was able to demonstrate these methods were feasible and 
that differential methylation and CNV was evident in the transition from normal endometrium 
through to AEH and EEC.    
This research provides a basis for further biomarker development and novel target selection in 
EC.  
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ALK: anaplastic lymphoma receptor tyrosine kinase 
APC: adenomatous polyposis coli 
ARID 1A/5B: AT-rich interactive domain 1A/5B 
ATF2: activating transcription factor 2 
ATXN10: ataxin 10 
AXIN1/2: axis inhibition protein 1/2 
BCL9: B-cell CLL/lymphoma 9 
BDNF: brain-derived neurotrophic factor 
BIN1: bridging integrator 2 
BIS: bisulfite 
BMP2/4/5/6/8A/8B: bone morphogenetic protein 2/4/5/6/8A/8B 
BRAF: v-raf murine sarcoma viral oncogene homolog B 
BRCA: breast cancer associated 
C: cytosine 
CA125: cancer antigen 125 
CACNB2: calcium channel, voltage-dependent, beta 2/4 subunit 
CALM2: calmodulin 2 
CALML3/5: calmodulin-like 3/5 
CARD11: caspase recruitment domain family, member 11 
CASP8: caspase 8/9, apoptosis-related cysteine peptidase 
CCND3/E1: cyclin D3/E1 
CD8B: CD (cluster of differentiation) 8B molecular 
CDC42/25A: cell division cycle 42/25A 
CDH1: cadherin 1, type 1, E-cadherin (epithelial) 
CDH13: cadherin 13 
CDKN1A: cyclin-dependent kinase inhibitor 1A 
CDKN2A: cyclin-dependent kinase inhibitor 2A (also known as P16INK4A or P14ARF) 
CFLAR: CASP8 and FADD-like apoptosis regulator 
CGI: 5’cytosine-phosphate-guanine-3’ dinucleotide island 
ChAMP:  Chip Analysis Methylation Pipeline 
CHFR: checkpoint with forkhead and ring finger domains 
CHUK: conserved helix-loop-helix ubiquitous kinase 
CIMP: CpG island methylator phenotype 
CLDN4: claudin 4 
c-met: c-met proto-oncogene 
CN: chromosomal copy number 
CNV: chromosomal copy number variation  
COL1A1: collagen, type I, alpha 1 
COL4A2/4: collagen, type IV, alpha 2/4 
COMT: catechol-O-methyltransferase 
COX2: cyclooxygenase 2 
CpG: 5’cytosine-phosphate- guanine-3’ dinucleotide 
Cq: quantification cycle 
CRH: corticotrophin releasing hormone 
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CRK: v-crk avian sarcoma virus CT10 oncogene homolog 
CSF3R: colony stimulating factor 3 receptor (granulocyte) 
CSNK1E: casein kinase 1, epsilon 
CT: computed tomography 
CTBP1/2: c-terminal binding protein 1/2 
CTC: circulating tumour cell 
CTGF: connective tissue growth factor 
CTNNA2/3: catenin (cadherin-associated protein) alpha a2 1, 102kD/a3 
CTNNB1: catenin (cadherin-associated) protein Beta 1 
CXCL12: chemokine (C-X-C motif) ligand 12 
CYTH2: cytohesin 2 
DAAM2: dishevelled associated activator of morphogenesis 2 
DAB: 3,3’-Diaminobenzidine tetrahydrochloride 
DAXX: death-domain associated protein 
DCC: deleted in colorectal carcinoma 
DEFB130: beta-defensin 130 
DM: diabetes mellitus 
DMRs: differentially methylated regions  
DNA: deoxyribonucleic acid 
DNM2: dynamin 2 
dsDNA: double stranded deoxyribonucleic acid 
DUSP6: dual specificity phosphatase 6 
EBRT: external beam radiotherapy 
EC: endometrial cancer 
ECOG: Eastern Cooperative Oncology Group 
EEC: endometrioid endometrial cancer 
EGFR: epidermal growth factor receptor 
EOMES: eomesodermin 
EpCAM: epithelial cell adhesion molecule 
ER: oestrogen receptor 
ERG: erythroblast transformation-specific related gene 
ERBB2: see HER2 
ERBB4: v-erb-b2 avian erythroblastic leukaemia viral oncogene homolog 4 
ERK: extracellular signal-regulated kinase 
ERN1: endoplasmic reticulum to nucleus signalling 1 
ETS1: v-ets erythroblastosis virus E26 oncogene homolog 1 
ETX1: sushi-repeat containing protein, X-linked (SRPX) 
EXOC2: exocyst complex component 2 
FAK: focal adhesion kinase 
FAS: Fas cell surface death receptor 
FF: fresh frozen 
FFPE: formalin-fixed, paraffin-embedded 
FGF/R: fibroblast growth factor/receptor  
FIGO: International Federation of Gynaecology and Obstetrics 
FOXA1/G1/O3: forkhead box A1/G1/O3  
G: guanine 
GADD45A: growth arrest and DNA-damage-inducible, alpha 
GALNT 6/12: polypeptide N-acetylgalactosaminyltransferase 6/12 
GATA5: GATA binding protein 5 
GCLP: good clinical laboratory practice 
GCP: good clinical practice 
GFRA1: GDNF family receptor alpha 1 
GLI2: GLI family zinc finger 2 
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GNA12: guanine nucleotide binding protein (G protein) alpha 12 
GOG: Gynaecologic Oncology Group 
GPR54: G-protein coupled receptor 54; KISS1 receptor 
GRB2: growth factor receptor-bound protein 2 
GSC: goosecoid homeobox 
H2AFY: H2A histone family, member Y 
HBA1/2: haemoglobin, alpha 1/2 
HBQ1: haemoglobin, theta 1 
HDAC1/2/5: histone deacetylase 1/2/5 
HER2: human epidermal growth factor receptor 2 (ERBB2) 
HGD: homogentisate 1,2-dioxygenase 
HGFR: hepatocyte growth factor receptor 
HIC: hypermethylated in cancer 
HIPK2: homeodomain interacting protein kinase 2 
HLA-A/C/G: major histocompatibility complex, class I, A/C/G 
HLA-DMB: major histocompatibility complex, class II, DM beta 
HNPCC: hereditary non-polyposis colorectal cancer 
HOXAII: homeobox A2 
HSP90AB1: heat shock protein 90kDa alpha (cytosolic), class B member 1 
HSPA1A: heat shock 70kDa protein 1A 
ICH: institute for Child Health 
IGFALS: insulin-like growth factor binding protein, acid labile subunit 
IGR: intergenic region 
IHC: immunohistochemistry 
IHH: indian hedgehog 
IRF4/5: interferon regulatory factor 4/5 
ITG A2B/3/A6/AV/B5: integrin, alpha 2b/alpha 3/alpha 6/alpha V/beta 5 
ITGB1: integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, 
MSK12) 
JAK1: janus kinase 1 
Jak-STAT: janus kinase-signal transducer and activator of transcription 
JUN: jun proto-oncogene 
KEGG: Kyoto encyclopaedia of genes and genomes 
KIAA0240: GLTSCR1-like (glioma tumour suppressor candidate region gene 1 protein-like) 
KIFC3: kinesin family member C3 
KRAS: kirsten rat sarcoma viral oncogene homolog 
KRT8: keratin 8 
LAMA3/4: laminin, alpha 3/4 
LN: lymph node 
LOH: loss of heterozygosity 
LUC7L: LUC7-like (S.Cerevisiae) 
LVSI: lymphovascular space invasion 
MADCAM1: mucosal vascular addresin cell adhesion molecule 1 
MAGUK: membrane-associated guanylate kinase (member of the CARD protein family) 
MAP2K 3/4/6: mitogen-activated protein kinase kinase 3/4/6 
MAP3K 1/2/3/4/6/7/14: mitogen-activated protein kinase kinase kinase 1/2/3/4/6/7/14 
MAPK: mitogen-activated protein kinase 
MAPK8IP3: mitogen activated protein kinase 8 interacting protein 3 
MDFIC: MyoD family inhibitor domain containing 
MDS: multidimensional scaling 
MeDIP: methylated DNA immunoprecipitation 
MEF2D: myocyte enhancer factor 2D 
MKNK1: MAP kinase interacting serine/threonine kinase 1 
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MLH1: mutL homolog 1 
MMI: myometrial invasion 
MMP: matrix metallopeptidase 
MMR: mismatch repair 
MRI: magnetic resonance imaging 
MSH2/3/6: mutS homolog 2/3/6 
MSI: microsatellite instability 
MSP: methylation specific PCR 
MSRE: methylation-sensitive restriction enzyme 
mTOR: mammalian target of rapamycin 
MVPs: methylation variable positions  
MYC: v-myc avian myelocytomatosis viral oncogene homolog 
MYL9: myosin, light chain 9, regulatory 
MYOD: myogenic differentiation 
NCAM2: neural cell adhesion molecule 2 
NDRG2: N-myc downstream-regulated gene family member 2 
NEDD4L: neural precursor cell expressed, developmentally down-regulated 4-like, E3 ubiquitin 
protein ligase 
NEEC: non-endometrioid endometrial cancer 
NFKB2: nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/p100) 
NGS: next generation sequencing 
NKD1: naked cuticle homolog 1 
NOD: nucleotide-binding oligomerization domain 
NOD2: nucleotide-binding oligomerization domain containing 2  
NPM1: nucleophosmin (nucleolar phosphoprotein B23,  numatrin) 
NRG1/3: neuregulin1/3 
NT5C3: 5’-nucleotide, cytosolic III1 
NTRK1: neurotrophic tyrosine kinase, receptor type 1 
OPRM1: opioid receptor, mu 1 
OR4F4: olfactory receptor, family 4, subfamily F, member 4 
OS: overall survival 
P14ARF: see CDKN2A 
P16INK4A: see CDKN2A 
P53: see TP53 
P70S6kinase: p70 ribosomal protein S6 kinase 
PARVG: parvin gamma 
PAX2/8: paired box 2/8 
PBC: peak based correction 
PBX1: pre-B-cell leukaemia homeobox 1 
PC: pyruvate carboxylase 
PCSK2: proprotein convertase subtilising/kexin type 2 
PDE6B: phosphodiesterase 6B, cGMP- specific rod beta 
PDGFR: platelet derived growth factor receptor 
PENK: proenkephalin 
PET: positron emission tomography 
PFS: progression-free survival 
PI3K: phosphoinositide 3-kinase 
PI4K2A: phosphatidylinositol 4-kinase type 2 alpha 
PIK3CA/D: phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha/delta 
PIK3R1/R3/R5: phosphoinositide 3-kinase, regulatory subunit 1(alpha)/3(gamma)/5 
PIM1: pim-1 oncogene 
PIPP4K2A: phosphatidylinositol-5-phosphate 4-kinase, type 2 alpha 
PITX2: paired-like homeodomain 2 
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PLA2G 1B/2C/2E/5: phospholipase A2, group IB/IIC/IIE/V 
PMS2: postmeiotic segregation increased 2 
PORTEC: post-operative radiation therapy in endometrial carcinoma 
POU4F2: POU class 4 homeobox 2 
PPP3CB/C: protein phosphatase 3, catalytic subunit, beta/gamma isozyme 
PPP3R1: protein phosphatase 3, regulatory subunit B, alpha 
PPARD: peroxisome proliferator-activated receptor delta 
PPP1R13L: protein phosphatase 1, regulatory subunit 13 like 
PR: progesterone receptor 
PRKCA/E/Z: protein kinase C, alpha/epsilon/zeta 
PROKR1/2: prokineticin receptor 1/2 
PRR5: proline rich 5 (renal) 
PTCH2: patched 2 
PTEN: phosphatase and tensin homologue 
PTPN6: protein tyrosine phosphatase, non-receptor type 6 
PTPRE: protein tyrosine phosphatase receptor type E 
AQP5: aquaporin 5 
PTPRN: protein tyrosine phosphatase receptor type N 
PXN: paxilin 
RAC3: ras-related C3 botulinum toxin substrate 3 (rho family, small GTP binding protein Rac3) 
RAPGEF1: Rap guanine nucleotide exchange factor (GEF) 1 
RARA: retinoic acid receptor alpha 
RASA1: Ras p21 protein activator (GTPase activating protein) 1 
RASGRF2: Ras protein-specific guanine nucleotide-releasing factor 2 
RASGRP3: Ras guanyl releasing protein 3 (calcium and DAG-regulated) 
RASSF1A: Ras association (RalGDS/AF-6) domain family member 1A 
REC: research ethics committee 
RET: ret proto-oncogene 
RGMA: repulsive guidance molecule family member a 
RLGS: restriction landmark genomic scanning 
RNA: ribonucleic acid 
ROBO1: roundabout axon guidance receptor, homolog 1 
ROCK1: Rho-associated, coiled-coil containing protein kinase 1 
RPL7L1: ribosomal protein L7-like 1 
RPS6KA1/2: ribosomal protein S6 kinase, 90kDa, polypeptide 1/2 
RPTOR: regulatory associated protein of MTOR, complex 1 
RR: response rate 
RRM2: ribonucleotide reductase M2 
RSK4: ribosomal protein S6 kinase 
RT: radiotherapy 
RT-PCR: real-time polymerase chain reaction 
RUNX1: runt-related transcription factor 1 
RXRB: retinoid X receptor, beta 
SERPINB5: serpin peptidase inhibitor, clade B, member 5 
SFN: stratifin 
SFRP1/2/4/5: secreted frizzled-related protein 1/family2/4/5 
SH B/C1: Src homology 2 domain containing adaptor protein B/transforming protein 1 
SHH: sonic hedgehog/ smoothened signalling pathway 
SKI: v-ski avian sarcoma viral oncogene homolog 
SMURF2: SMAD specific E3 ubiquitin protein ligase 2 
SNP: single nucleotide polymorphism 
SOS1: son of sevenless homolog 1 (Drosophila) 
SOX17: SRY (sex-determining region Y)-box 17 
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SPP1: secreted phosphoprotein 1 
SPRY2: sprouty homolog 2 (Drosophila) 
ssDNA: single stranded deoxyribonucleic acid 
STAT3/5AB/5BA: signal transducer and activator of transcription 3/5A/5B 
STMN1: stathmin 1 
STXBP4: syntaxin binding protein 4 
SUFU: suppressor or fused homolog (Drosophila) 
SVD: singular valve decomposition 
SWAN: subset-quantile within array normalisation 
T: thymine 
TAHBSO: total abdominal hysterectomy and bilateral salpingo-oophorectomy 
TAOK1/3: TAO kinase 1/3 
TBCC: tubulin folding cofactor C 
TBL1XR1: transducing beta-like 1 X-linked receptor 1 
TCGA: the cancer genome atlas 
TERT: telomerase reverse transcriptase 
TFAP2A: transcription factor AP-2 alpha (activating enhancer binding protein 2 alpha) 
TGFA/B: transforming growth factor, alpha/beta 
TGFB3: transforming growth factor beta 3 
TGFBR3: transforming growth factor, beta receptor 3  
TGIF: TGFB-induced factor homeobox 
THBS2: thrombospondin 2 
THY1: thy-1 cell surface antigen 
TIMP3: tissue inhibitor of metalloproteinases-3 
TIS: tumour immunostaining score 
TJP2: tight junction protein 2 
TLE1: transducer-like enhancer of split 1 (E(sp1) homolog, Drosophila) 
TNF: tumour necrosis factor/receptor 
TNXB: tenascin XB 
TP53: tumour protein p53 
TP53AIP1: tumour protein p53 regulated apoptosis inducing protein 1 
TP73: tumour protein p73 
TRAF4: TNF receptor-associated factor 4 
TRIAP1: TP53 regulated inhibitor of apoptosis 1 
Trk: tyrosine kinase receptor 
TSG: tumour suppressor gene 
TSS: transcription start site 
UCL: University College London 
UCLH: University College London Hospital 
UTR: untranslated region 
VBT: vaginal brachytherapy 
VEGF(R): vascular endothelial growth factor (receptor) 
VHL: von Hippel-Lindau tumour suppressor 
WebGestalt:  Web-based gene set analysis toolkit 
Wnt:  wingless-type MMTV integration site family 
WNT3/3A/4/6/8B/9B/10A/16: wingless-type MMTV integration site family, member 
3/3A/4/6/8B/9B/10A/16 
WRN: werner syndrome, RecQ helicase-like 
WT1: Wilms’ tumour gene 
ZNF154: also known as pHZ-92; member of the Kruppel C2H2 zinc finger protein family 
ZYX: zyxin 
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CHAPTER 1: Endometrial Cancer, its Treatment and Molecular Aberrations 
1.1. Background on Endometrial Cancer   
1.1.1. Incidence  
Endometrial cancer (EC) is the most common gynaecological cancer in the developed world 
and 4th most common cancer in women in the UK [1].  It is the 7th most common cause of death 
from cancer in Western Europe and is an increasing health problem due to rising incidence in 
both the UK and Europe [2].  The European age-standardised incidence rate has risen by 46% 
between 1992-1994 and 2008-2010, with the largest increase occurring in women aged 65 to 
79 years [3].  For women aged 40 to 54 years, the incidence rate has been relatively stable with 
a smaller increase of 16% between 1999-2001 and 2008-2010.   
Although an estimated 75% of patients present with surgically resectable early stage disease, 
approximately 20% have regional metastases and 5% have distant metastases.  Of the patients 
with surgically resectable disease, up to 20% of these cases relapse [4, 5].  For early stage 
disease, the 5 year survival is 85%, though this decreases to 66% for disease with regional 
spread and 25% for disease with distant spread [4].  
 
1.1.2. Risk Factors 
Risk factors for EC have largely been attributed to hyperoestrogenic and genetic factors, with 
the increase in incidence thought to be due to more women being overweight or obese, having 
few or no children and being older at first birth [3, 6].   
Historically, Type I EC is associated with increased levels of oestrogen (for example from 
obesity, diabetes and high-fat diet) as well as early age at menarche, nulliparity, late age at 
menopause, and tamoxifen use [7].  Recent data however suggests that the two EC types share 
many common etiologic factors [8] with parity, oral contraceptive use, cigarette smoking, age 
at menarche and diabetes associated with type I and type II tumours to a similar extent and 
only body mass index having a greater effect on type I than type II tumours.  As such, 
oestrogenic risk factors may also be associated with type II tumours and the traditional type I 
and type II distinction may not accurately reflect characteristics of the disease. 
Although EC is usually associated with sporadic mutations, about 6% of cases are caused by 
germline genetic alterations, namely Lynch syndrome/hereditary non-polyposis colorectal 
cancer (HNPCC) [9].  Lynch syndrome is an autosomal dominant hereditary cancer 
predisposition syndrome, caused by a germline mutation in one of the mismatch repair (MMR) 
genes, MLH1, MSH2, MSH6 or PMS2.  EC associated with Lynch syndrome tends to occur 10-20 
years earlier than sporadic cancers and in women below 50 years, 9% have one of the MMR 
gene mutations [9].    
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1.1.3. Symptoms and Diagnosis 
The most common presenting symptom is irregular vaginal bleeding, predominantly in 
postmenopausal patients.  As such, patients tend to be investigated and diagnosed at an 
earlier stage compared to ovarian cancer for example.    
If EC is suspected, initial evaluation includes history and physical examination as well as pelvic 
imaging and endometrial biopsy.  Historically, tumour markers including cancer antigen 125 
(CA125) have also been performed and used in follow-up, though may be falsely increased 
with peritoneal inflammation, infection or radiation injury and may not predict recurrence in 
patients in absence of clinical findings [10, 11], with one study reporting CA125 elevation in 
only 58% of patients with recurrent disease [12].  Genetic counselling should be considered for 
patients less than 50 years or with a significant family history of endometrial, colorectal and/or 
ovarian cancer.  
Diagnostic pelvic and/or transvaginal ultrasound assesses endometrial thickness in the 
anteroposterior dimension.  A cut-off of 5mm in postmenopausal women and 15mm in 
premenopausal women [13] is used and tissue diagnosis via endometrial biopsy is then 
required.  Negative endometrial biopsy in a symptomatic patient should be followed by 
dilation and curettage under anaesthesia [14].  Hysteroscopy may also be helpful in evaluating 
endometrial lesions if there is persistent or recurrent undiagnosed bleeding [15]. 
Additional pre-operative staging generally includes magnetic resonance imaging (MRI) of the 
pelvis and computed tomography (CT) or positron emission tomography (PET) of the 
chest/abdomen/pelvis to assess the extent of local and distant disease respectively and to 
assist with surgical planning.  Although CT staging provides limited assessment of cervical 
invasion, it is useful for extrauterine spread, organ invasion, lymphadenopathy and peritoneal 
spread [16].  MRI provides the most accurate evaluation of the uterus including information on 
tumour bulk, depth of myometrial invasion (MMI), cervical involvement and extrauterine 
spread [17].  Evaluation of MMI is key because invasion greater than 50% is associated with an 
increased risk of pelvic and para-aortic lymph node metastases [18], and thus can help with 
planning of lymphadenectomy.  PET may also show utility in lymph node staging and early 
detection of recurrence, as well as in investigation of equivocal lesions on CT [19]. 
Interestingly, the nature of the treatment provider may also impact on outcomes [20] with 
evidence that patients treated by gynaecologic oncologists were more likely to undergo 
complete staging surgery, receive adjuvant chemotherapy for advanced stage disease and 
have improved survival in high-risk cancers and advanced disease.   
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1.1.4. Atypical Endometrial Hyperplasia  
In many cases, endometrial carcinogenesis is thought to follow a continuum from normal 
endometrium to endometrial hyperplasia without atypia, endometrial hyperplasia with atypia, 
through to EC.  The presence of nuclear atypia is the most important indicator off EC risk in 
women with atypical endometrial hyperplasia (AEH), though there can be significant inter-
observer variability in reporting with a concordance rate of 38-47% [21, 22].   
Most commonly, AEH presents with abnormal uterine bleeding in women aged 50-54 years 
and is rarely found in women less than age 30 years [23].  The risk factors are the same as 
those for endometrioid endometrial cancer (EEC) and generally involve exposure of the 
endometrium to continuous unopposed oestrogen. 
The risk of progression from AEH to EC is approximately 23-29% [24].  In addition, for patients 
diagnosed with AEH on biopsy, between 17-52% are subsequently found to have concurrent 
EC at hysterectomy [25, 26].  Thus, the current recommendation for management of AEH is 
total abdominal hysterectomy with bilateral salpingo-oophorectomy (TAHBSO).  Some 
gynaecologic oncologists may attempt conservative hormone therapy to preserve fertility in 
younger women or to avoid hysterectomy in women who decline surgery or who have high-
risk comorbidities.   
This current management strategy will significantly over-treat a number of women who do not 
have and will not develop EC, but there are no current biomarkers to guide selective 
treatment. 
 
1.1.5. Current Classification and Prognostic Factors in Endometrial Cancer   
An expert pathology review is required to classify the tumour into the precise histological 
subtype, whether epithelial (endometrioid, serous, clear cell adenocarcinoma or 
carcinosarcoma) or stromal/mesenchymal (endometrial stromal sarcoma, high-grade 
endometrial sarcoma or uterine leiomyosarcoma).   
Historically, the risk of recurrent epithelial EC has been determined according to 
clinicopathologic criteria that define two groups, Type I and Type II [27]. Type I tumours 
comprise up to 90% of EC and are associated with low stage, low grade, better prognosis, EEC 
histology, oestrogen exposure, obesity and concurrent or preceding AEH [28].  On the other 
hand, type II tumours are typically high stage, high grade, have a poor prognosis, have non-
endometrioid (NE) histology, and occur in atrophic endometrium in older women. Although 
type I cancers are more common, type II cancers account for a high proportion of EC-related 
deaths with a higher risk of recurrence even when treated at an early stage [29].  As discussed 
however, the risk factors for type I and II tumours share greater similarities than originally 
thought [8] and molecular aberrations also cross these two subgroups, as will be discussed in 
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section 1.4 [30].   The current classification into type I and II tumours is also often of limited 
prognostic value given that approximately 20% of type I cancers recur and 50% of type II do 
not [31].  Applicable molecular classification of EC that accurately predicts prognosis and 
response in defined subgroups is urgently needed.  Most clinical trials do not stratify patients 
according to type and both types are managed with the same chemotherapy regimens with a 
similar extent of benefit expected [32].  
EEC resembles the epithelium of normal, proliferative endometrium and a number of variants 
exist, as outlined in Table 1.1 [33].  Serous carcinoma comprises the majority of type II cancers 
and histologically resembles serous ovarian cancer, with a more aggressive natural history 
[34].   
 
Table 1.1: The Histological Subtypes of Endometrial Cancer 
Type I: Endometrioid EC Type II: Non-endometrioid EC 
Variant with squamous differentiation 
Villoglandular differentiation 
Secretory variant 
Ciliated-cell variant 
Serous adenocarcinoma  
Clear cell adenocarcinoma  
Carcinosarcoma 
Mucinous adenocarcinoma  
Squamous-cell carcinoma 
Other (mixed adenocarcinomas, transitional-cell 
carcinoma, small-cell carcinoma and 
undifferentiated carcinoma) 
 
 
The prognostic value of certain laboratory parameters has also been investigated in EC.  
Anaemia pre-operatively has been associated with NEEC, advanced International Federation of 
Gynaecology and Obstetrics (FIGO) stage, lymphovascular space invasion (LVSI), cervical 
involvement, adnexal involvement, positive peritoneal cytology, lymph node involvement and 
lower 5 year overall survival (OS) compared to patients with haemoglobin levels >12g/dL [35, 
36]. Similarly, pre-treatment hypoalbuminaemia has been associated with more advanced 
FIGO stage and higher grade, as well as with disease-free and progression-free survival (PFS) 
[37].  However, there is little data for the prognostic utility of anaemia and hypoalbuminaemia 
in the advanced setting and is not sufficiently discriminatory to be helpful for therapeutic 
planning.   
 
1.1.6. Staging of Endometrial Cancer 
The FIGO staging system is the most commonly used system for staging EC.  It has evolved 
from the 1970 criteria based on pre-surgical evaluation through to the 1988 system and the 
current 2009 criteria based on surgical and pathologic staging criteria, with separate systems 
for epithelial tumours and uterine sarcomas [38, 39].  Staging is performed by a multi-
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disciplinary team of radiologists, pathologists, surgeons as well as medical and clinical gynae-
oncologists.  
The 1988 system first modified the staging to incorporate surgical and pathologic data 
including histologic grade, MMI and the extent and location of extrauterine spread.  The 2009 
system, outlined in Table 1.2, revised differences in stage I and II disease, based on correlation 
with survival rates.  Stage IA and IB now differentiate between less than or greater than 50% 
MMI and stage II includes patients with cervical stromal invasion.  Stage IIIC disease was 
subdivided into C1 and C2 based on the absence or presence of para-aortic nodes, as survival is 
worse if para-aortic nodes are positive.   
Compared to the 1998 system, the 2009 system better correlates with prognosis and clinical 
outcomes [40]. 
 
Table 1.2: The 2009 FIGO Staging System 
FIGO stage TNM  Surgical-Pathologic Findings 
 TX/NX Primary tumour/regional lymph nodes cannot be assessed 
 T0/N0/M0 No evidence of primary tumour/regional lymph nodes/distant 
metastases 
 Tis Carcinoma in situ (preinvasive carcinoma) 
I T1 Tumour confined to the corpus uteri 
IA T1a Tumour limited to endometrium or invades less than one-half of 
myometrium 
IB T1b Tumour invades one-half or more of the myometrium 
II T2 Tumour invades stromal connective tissue of the cervix but does not 
extend beyond the uterus 
IIIA T3a Tumour involves serosa and/or adnexa (direct extension or 
metastasis) 
IIIB T3b Vaginal involvement (direct extension or metastasis) or parametrial 
involvement 
IIIC  Metastases to pelvic and/or para-aortic lymph nodes 
IIIC1 N1 Regional lymph node metastasis to pelvic lymph nodes 
IIIC2 N2 Regional lymph node metastasis to para-aortic lymph nodes, with or 
without positive pelvic lymph nodes 
IV  Tumour involves bladder and/or bowel mucosa and/or distant 
metastases 
IVA T4 Tumour involves bladder mucosa and/or bowel 
IVB M1 Distant metastases (includes metastasis to inguinal lymph nodes, 
intra-peritoneal disease, or lung, liver or bone.  It excludes 
metastasis to para-aortic lymph nodes, vagina, pelvic serosa or 
adnexa) 
TNM: tumour node metastasis staging classification system 
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1.2. Treatment  
This section covers the surgery, radiotherapy (RT) and chemotherapy options for EEC and 
NEEC.  Less common pathologic subtypes of EC including uterine sarcomas have a different 
natural history and as this thesis does not analyse samples from this patient group, uterine 
sarcomas are not discussed further. 
 
1.2.1. Surgery 
Surgery is the mainstay of treatment for localised EC, though the optimal techniques are still 
debated.  Traditionally, surgical treatment involves TAHBSO with or without lymphadenectomy 
for early stage disease and including lymphadenectomy for higher stage disease. 
Hysterectomy may be performed via laparotomy, vaginally or via laparoscopy.  Laparoscopy 
for stage I-IIA disease, compared to laparotomy, is associated with shorter hospital stay, few 
moderate-to-severe postoperative adverse events, improved body image, and similar 3 year 
recurrence rate and estimated 5 year OS [41, 42]. Thus it is a reasonable alternative to 
laparotomy for treatment and staging of early-stage EC. 
Interestingly, timing of surgery also appears to impact survival with recent evidence 
demonstrating that wait times of <2 weeks and >12 weeks were adversely prognostic for 5 
year survival [43].  Wait time <2 weeks was generally associated with surgery being performed 
for acute issues or more advanced disease, contributing to poorer outcomes, while wait times 
beyond 12 weeks resulted in a decreased 5 year OS of 71.9% compared to 81.8% if the wait 
time was 2-6 weeks.   
As part of surgery, visual assessment of the peritoneal, diaphragmatic and serosal surfaces 
with biopsy of any suspicious lesions and peritoneal cytology is important to exclude 
extrauterine disease.  Pelvic lymph node dissection for staging may include the external iliac, 
internal iliac, obturator and common iliac nodes as well as para-aortic nodal dissection for 
high-risk tumours.  The role of lymphadenectomy is to stage disease, define prognosis and 
decide on adjuvant therapy.  There is conflicting data however on its therapeutic role [44, 45] 
as well as its prognostic role [46] and as such, a selective approach to pelvic and para-aortic 
lymphadenectomy is recommended, to avoid systematic overtreatment and associated 
morbidity [47].  In early stage disease confined to the uterus, there is no demonstrated benefit 
in disease-free nor OS between pelvic lymphadenectomy compared to standard surgery and 
no lymphadenectomy [48] [44].   One approach is to base decisions regarding 
lymphadenectomy on preoperative and intraoperative findings, including degree of MMI, 
tumour size less than 2cm and grade 1-2 histology [49], though this may be difficult to assess 
intraoperatively [50].  Sentinel lymph node mapping has also been investigated and appears 
feasible [51] but its utility needs to be established in clinical trials.  Thus, the identification of 
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reproducible, validated biomarkers to guide optimal treatment from the earliest stages of 
disease is imperative. 
In the setting of locally advanced or metastatic disease, maximal debulking should be 
performed and palliative surgery should still be considered in patients with good performance 
status.  For suspected or gross cervical involvement, radical or modified radical hysterectomy is 
recommended along with lymph node dissection, bilateral salpingo-oophorectomy and 
peritoneal lavage for cytology.  For intra-abdominal extra-uterine disease, surgical intervention 
is still warranted for maximum debulking aiming to eradicate measurable residual disease, 
which may improve survival [52].  In this scenario, pelvic external beam radiotherapy (EBRT), 
vault brachytherapy (VBT) and/or chemotherapy may be used to reduce tumour burden and 
allow delayed surgery.  For extra-abdominal disease, palliative TAHBSO may still be considered 
and combined with chemotherapy, RT and/or hormone therapy.   
Pathologic assessment of any surgical specimen should include tumour size, location (fundus 
vs lower uterus), histology subtype and grade, LVSI, ratio of depth of myometrial/stromal 
invasion to myometrial thickness, cervical stromal or glandular involvement, fallopian 
tubes/ovarian involvement, peritoneal cytology and nodal status.  Screening with 
immunohistochemistry (IHC) and/or microsatellite instability (MSI) for inherited MMR gene 
mutations should be considered in patients deemed at risk of Lynch syndrome [9]. 
 
1.2.2. Adjuvant Treatment and Surveillance 
Risk of recurrence after surgery for early-stage disease is currently defined by a number of 
factors including higher age, histological subtype, grade 3 histology, LVSI, lower uterine 
(cervical/glandular) involvement and tumour diameter >2cm.  Adjuvant RT and/or 
chemotherapy are then considered based on these factors.  In general, as grade, MMI and risk 
factors increase, more aggressive adjuvant treatment is given.  However, criteria for guiding 
these treatment decisions remain poorly defined.     
Overall, adjuvant RT improves disease control in the pelvis but does not appear to improve OS 
[53] [54, 55].  For stage I disease, although grade 1 disease can be managed with a watchful 
waiting approach, VBT or pelvic EBRT or both for higher grade disease is recommended and 
chemotherapy should also be considered for grade 3, stage IB disease [56].  The post-operative 
radiation therapy in endometrial cancer (PORTEC) 2 study showed that for high-intermediate 
risk stage I or IIA disease, VBT was as effective as EBRT for local control with less 
gastrointestinal toxicity [55].   Importantly, for women less than 60 years and with stage I 
disease, there is no difference demonstrated in OS between VBT and EBRT but women 
younger than 60 years have higher mortality rates and a greater risk of secondary cancer after 
EBRT [57].  With stage II disease, either VBT or EBRT may be used at a lower grade but both are 
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required with the consideration of chemotherapy for higher grade disease [56].  A number of 
trials have investigated, yet not definitively answered the question regarding the role of 
combination chemotherapy and pelvic radiotherapy for stage I-III disease.  Many of these were 
small and underpowered to detect an OS difference, though a combined analysis of the ILIADE-
III and NSGO-EORTC [56] trials showed an improvement in PFS with the addition of adjuvant 
chemotherapy to radiation.  The role of concurrent chemoradiotherapy versus radiotherapy 
alone in high risk stage I (stage IA with invasion, grade 3, LVSI; stage IB grade 3), stage II, stage 
III and serous/clear cell stage IA (invasive), IB, II or III will be reported in PORTEC-3 [58].  This 
study will also help answer the question regarding the role of adjuvant chemotherapy for 
Stage IB and II, grade 3 disease, as these patients continue to have a risk of distant metastases 
despite pelvic RT.  Previous studies have demonstrated improved PFS but no OS benefit and 
further studies are pending [56, 59].  Although the role of adjuvant chemotherapy in high-
grade, uterine-confined disease is yet to be confirmed, for stage III disease, the overall 
evidence suggests a benefit from adjuvant chemotherapy with RT [60]. 
After adjuvant therapy is completed, post-treatment surveillance occurs every 3-6 months for 
the first 3 years and then every 6-12 months thereafter [61].  The value of more intensive 
surveillance and ancillary testing has not been demonstrated [62] and there remains a 
significant risk of recurrence for later stage disease.  If disease recurs, it tends to do so within 
the first 3-5 years and is symptomatic in up to 75% of patients.  In up to 60% of patients, 
disease recurrence will occur at a distant location and prognosis is limited, regardless of 
timing.   
In terms of follow-up interventions, asymptomatic recurrences may be detected by physical 
exam in 5-33%, vaginal vault cytology in 0-4%, chest X-ray in 0-14%, abdominal ultrasound in 4-
13%, abdominal/pelvic CT in 5-21% and CA125 in up to 15% [62]. There are no validated 
tumour markers however used for monitoring patients routinely during follow-up for EC.   
CA125 has been demonstrated to be increased in approximately 50% of patients at the time of 
recurrence [12] while up to 35% of women in follow-up may have elevated CA125 but no 
evidence of recurrence [10, 63].  Thus, although the use of CA125 for monitoring in EC has 
been extrapolated from the ovarian cancer setting and may be used by clinicians, there is in 
fact limited evidence of its utility.   
1.2.3. Treatment of Recurrent or Metastatic Disease 
If there is a suspicion of recurrent disease, it is important to establish whether this is localised 
and still potentially curable or whether there are distant metastases in which case treatment 
will be palliative. 
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Isolated vaginal recurrence can be treated with RT and/or surgery and 5-year survival may be 
up to 50-70% [64].  Radical surgery, specifically pelvic exenteration, has been reported to have 
a 5-year survival up to 20% [65].  Hormonal and/or chemotherapy should also be considered 
for isolated relapse, either as primary treatment if the disease is unresectable or as additional 
treatment if surgical resection is achieved.  For patients who have received adjuvant RT 
however, it is uncommon for recurrences to be confined to the pelvis.   
There have been a number of studies of the optimal combination of cytotoxic therapy, though 
prognosis is poor with limited response rates (RR) [60, 66] often of short duration and with a 
reported median OS between 4.1–17.6 months [66-68].  Among women who are 
chemotherapy-naïve, RR over 40% have been reported with doublet chemotherapy [66].   
Historically, doxorubicin/cisplatin was the combination of choice with a reported RR of 42%, 
PFS of 5.7 months and OS of 12 months [69].  Three-drug regimens were compared to this 
doublet but did not consistently show superiority and have higher toxicity, therefore are not 
routinely used [70, 71].  A taxane and platinum combination is now the preferred first-line 
chemotherapy option, with a reported RR of 40-67% and OS up to 32 months [72, 73].  Again, 
comparison with a triplet regimen in the Gynaecologic Oncology Group (GOG) 209 study 
showed similar outcomes and more tolerable toxicity with the doublet arm of paclitaxel and 
carboplatin, compared to doxorubicin, paclitaxel and cisplatin [73].  Single agent 
chemotherapy is also an option if there is concern regarding tolerability of doublet treatment 
and paclitaxel, cisplatin, carboplatin, doxorubicin, liposomal doxorubicin, topotecan and 
docetaxel are all options, though paclitaxel on a weekly schedule is often preferred due to 
better tolerance and some evidence suggesting improved efficacy [74].  These agents can also 
be considered in the second line setting however disease recurring after first-line 
chemotherapy is more chemoresistant. This is an area of significant unmet clinical need and 
there are efforts in clinical trials to define groups of patients that may benefit from novel 
therapies in this setting. 
Hormonal therapy is used most frequently in endometrioid histologies, namely progestogens 
agents, but also daily tamoxifen with intermittent weekly megestrol [75] and more recently, 
aromatase inhibitors [76].  Single-agent progestogens have demonstrated a RR of 
approximately 20%, with a higher response in progesterone receptor (PR) positive and lower-
grade tumours [77].  Reported RR with megestrol and tamoxifen is 33% with a PFS up to 3 
months and OS up to 5 years in those women with high expression of oestrogen receptor (ER) 
on their tumours.  Retrospective review of aromatase inhibitors demonstrated a clinical RR up 
to 70%, though radiological data was limited in this study.  These agents may play a role 
particularly for well-differentiated tumours with expression of ER and PR, if there is a long 
disease-free interval and if there are pulmonary metastases. 
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More recently, the focus of drug development has shifted to molecularly targeted agents, 
though correlation with predictive and prognostic biomarkers has been limited.  Anti-
angiogenic agents, mammalian target of rapamycin (mTOR) pathway inhibitors and fibroblast 
growth factor receptor (FGFR) inhibitors have been studied in EC with early evidence of 
efficacy.  Bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor, has shown a RR 
of 13.5% and OS of 10.5 months in a phase II trial for persistent or recurrent EC [78] while 
aflibercept, another anti-angiogenic agent, has also demonstrated clinical activity in a phase II 
study but there was significant toxicity with two treatment-related deaths [79].  There has 
been limited assessment of small molecular inhibitors of angiogenesis.   
The use of mTOR inhibition has been attractive in EC due to the frequency of aberrations in the 
phosphoinositide 3-kinase (PI3K) pathway.  Both temsirolimus and everolimus have 
demonstrated efficacy and acceptable tolerability in phase II studies with partial response rate 
(PR) of 4-5% and stable disease (SD) at 4 months being 48% for temsirolimus and for 
everolimus, 36% at 3 months in the recurrent disease setting [80-82].  Ridaforolimus has also 
been assessed as single agent treatment in recurrent or persistent EC in a phase II study.  
Clinical benefit (PR or prolonged SD) was seen in 29% with a 6 month PFS rate of 18% [83].   
There are also planned studies of adding an mTOR inhibitor to chemotherapy or hormone 
therapy in the advanced or recurrent setting.  
Phase II studies have also assessed agents targeting epidermal growth factor receptor  (EGFR) 
over-expression and human epidermal growth factor receptor 2 (HER2) amplification, which 
occur in 50-80% and 20% of ECs respectively, though limited efficacy has been seen at this 
stage [84, 85].   
Targeting the FGFR pathway may also show promise with evidence of FGFR2 mutations in 12-
16% of EC and pre-clinical data that FGFR2 blockade leads to cell death [86].  A phase II study is 
underway with Dovitinib, an anti-VEGFR/FGFR tyrosine kinase inhibitor, as second-line therapy 
in patients with FGFR2-mutated or non-mutated advanced and/or metastatic EC [87].   
To improve understanding of the molecular aberrations driving endometrial tumorigenesis and 
better develop translational research and drug trials, GOG has created a large biospecimen 
repository to provide tissue, serum and epidemiologic survey data as well as clinical 
information.  This aims to define predictive and prognostic biomarkers and identify novel 
targets to improve therapy [68].  Developing the optimal techniques to analyse tissue from this 
repository from FF, FFPE and blood samples will be key in maximising its therapeutic relevance 
and utility. 
 
The identification and validation of biomarkers from blood and tumour tissue is a priority in EC 
to allow better selection and administration of targeted agents and define prognosis.  For 
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example, aberrations in the PI3K pathway are well documented and yet the studies with 
temsirolimus and everolimus failed to correlate markers of PI3K pathway activation with 
patient response [80, 81] .  Understanding the tumour biology and identifying biomarkers that 
accurately define this will allow better translation of targeted therapies into the clinical setting 
with the overall aim of improved efficacy.  This thesis focuses on two methods to define novel 
biomarkers in EC, one based on peripheral blood samples and one on archival FFPE tissue 
analysis. 
 
1.3. The Rationale for Circulating Tumour Cells in Endometrial Cancer  
1.3.1. Background  
Circulating tumour cells (CTCs) are epithelial cancer cells known to circulate in the peripheral 
blood of patients including in breast, prostate, ovarian, colorectal and lung cancers, and are 
not detected in healthy individuals [88].  One of the earliest reports of their presence in the 
blood of a patient with cancer was in 1869 by Thomas Ashworth, an Australian physician [89].  
In a post-mortem examination, he identified circulating cells in the lower limb venous system 
that were morphologically similar to the cancer at a different site and concluded that “cells 
identical with those of the cancer itself being seen in the blood may … throw some light upon 
the mode of origin of multiple tumours existing in the same person”.   
 CTCs are thought to be a mixture of cells including cancer stem cells capable of seeding, 
recirculation and evolution in metastatic clones, as well as non-viable cells shed from primary 
or metastatic tumours [90].  They are rare events, estimated to account for 1 cell in 109 
nucleated cells [91].   
As CTCs can be analysed from a peripheral blood draw, they are an attractive option for 
further investigation and validation as a surrogate marker across cancer types.  A surrogate 
biomarker is defined as a biomarker intended to substitute for a clinical endpoint, while a 
biomarker is defined as a characteristic that is objectively measured and evaluated as an 
indication of a normal biologic, pathogenic process or pharmacologic response to a therapeutic 
intervention [92].  If biomarkers, such as CTC count or molecular profile, can be substituted for 
longer-term endpoints such as response to therapy, PFS or OS, then they may offer greater 
efficiency in clinical studies, with the generation of useful results based on shorter study 
duration or smaller sample size [93]. 
 
A number of methods for detecting CTCs have been described based on different physical and 
molecular properties of these cells, but the only regulatory approved and validated detection 
method is the Veridex CellSearch platform.  This detection technique relies on the use of a 
ferrofluid epithelial cell adhesion molecule (EpCAM)-based capture reagent and a further 
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series of immunofluorescent reagents to create cell images that are classified by the operator 
[88], described in detail in Chapter 2. 
The expression of EpCAM on the CTCs forms the basis of the enrichment method used in the 
CellSearch system.  EpCAM is an epithelial cell adhesion molecule, frequently overexpressed in 
primary and metastatic adenocarcinomas, and has been demonstrated across a broad range of 
tumours, particularly colorectal, pancreatic, gastric and prostate cancers [94] with a poor 
prognostic association in gallbladder, ovarian [95] and pancreatic cancers [96].    If the tumour 
either does not express EpCAM or there is a reduced expression of EpCAM with metastases or 
on peripheral circulating cells, than there will be limitations to CTC detection with this method.   
While there is some evidence for correlation of EpCAM expression between primary tumour 
tissue and metastatic tissue [97], other studies demonstrate variation in its gene expression 
and loss of epithelial antigens as occurs during epithelial to mesenchymal transition (EMT) in 
the development of metastases [98].  As such there is an argument for testing EpCAM 
expression in metastatic lesions rather than primary tissue to determine the utility of CTC 
enumeration in certain cancer types and patients. 
In regards to EC, 65- 80% of tumours demonstrate strong EpCAM staining, across all grades 
and stages [97, 99].   
 
Initial analysis of the CellSearch technology demonstrated that CTCs were detectable in 
approximately 44% of patients with metastatic carcinoma with CTCs ≥2 in 57% of prostate 
cancers, 37% of breast and ovarian cancers, 30% of colorectal cancers and 26% of other 
cancers [88].  Importantly, only 5.5% of healthy subjects demonstrated 1 CTC and only 7.5% of 
subjects with non-malignant disease demonstrated 1 CTC.  0.3% of healthy subjects or with 
non-malignant disease had ≥2 CTCs per 7.5ml blood. 
 
1.3.2. Current CTC Data in Breast, Prostate and Colorectal Cancer 
The CellSearch Epithelial Kit and CellSearch Analyser were approved for use by the US Food 
and Drug Administration (FDA) in 2004 based on data generated in breast, prostate and 
colorectal cancers, and a summary of these data are presented here. 
In breast cancer patients both in the metastatic and adjuvant setting, a CTC count ≥5 per 7.5ml 
of blood, occurring in just under 50% of patients, has been shown to be associated with a 
shorter median PFS and OS [100-103].  On multivariate analysis in the metastatic breast cancer 
setting, the CTC count at baseline and first follow-up was the strongest predictor of PFS and OS 
compared to other clinical and pathological factors including ER and PR status, ECOG 
performance status, time to metastasis, HER2 status and type of therapy.  This predictive value 
persisted not only with newly diagnosed disease [104], but also at each follow-up time point 
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during therapy [105] and CTCs have been demonstrated to predict OS better than imaging 
[101].  In the adjuvant setting in early breast cancer, the presence of CTCs both before and 
after chemotherapy was also associated with poor disease-free survival, breast cancer-specific 
survival and OS [103].   
 
Similarly, in castrate-refractory prostate cancer, the presence of CTCs has been demonstrated 
to predict OS and response to therapy and is increasingly being incorporated in clinical trials, 
both as an eligibility criteria and as a predictive marker to correlate with patient symptoms and 
radiographic findings.   
A CTC count ≥5 has been shown to discriminate between favourable and unfavourable groups 
and identify patients with a shorter OS across studies in both chemotherapy and hormonal 
agents [106, 107].  Those patients whose CTC count decreases from ≥5 to <5 also have a better 
prognosis and survival while those whose CTC counts increase from <5 to ≥5 do worse.    
Moreover, changes in CTC counts may predict OS better than PSA decrement [108].  CTCs 
measured during treatment with abiraterone for patients with prostate cancer have also been 
shown to fulfil Prentice’s criteria for surrogacy for OS [109] based on the following parameters; 
that the treatment was prognostic for survival, that the treatment was prognostic for the CTC 
count, that CTCs were prognostic for survival and that the full effect of the treatment on 
survival was captured by the CTC count [109, 110].   
 
The CTC count in colorectal cancer has also demonstrated prognostic and predictive 
significance, with unfavourable and favourable prognostic groups defined based on CTC levels 
of ≥3 or <3 respectively [111], though only 26% of patients have ≥3 CTCs at baseline.  Patients 
with CTCs ≥3 at baseline have a shorter median PFS and OS with an improvement in PFS and 
OS if CTCs decrease from ≥3 to <3 after 3-5 weeks on treatment [112].   The association of CTC 
count ≥3 with inferior PFS and OS is also consistent across a number of subgroups including 
patients receiving first- or second-line therapy, having liver involvement, age ≥65 years and 
ECOG performance status [112]. 
 
The evidence for CTCs as a surrogate marker for survival has the potential to streamline clinical 
trial and drug development, both to improve efficiency and shorten timelines in development 
of novel anticancer agents and assessing at earlier time points whether patients should 
continue with a particular therapeutic strategy or not.  Assessment of CTCs may allow earlier 
detection of relapse as well as molecular analysis, potentially allowing earlier intervention with 
an appropriately targeted therapy.  Similarly, if early assessment of CTC count after initiation 
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of treatment indicates a favourable or unfavourable outcome, it raises the argument that this 
should be used in clinical practice to trigger a change in treatment.   
Thus, clinical trials are underway in a number of solid tumours to assess the utility of CTC 
changes to drive therapeutic changes and where possible incorporate molecular analysis [113].    
   
1.3.3. CTCs in Gynaecologic Malignancies 
CTCs in gynaecologic malignancies, particularly ovarian cancer, have been demonstrated in a 
limited percentage of patients and have not shown an association with survival according to 
current data.  While some studies report correlation between CTC counts and prognosis in 
recurrent ovarian cancer, others report no such correlation and investigation is ongoing into 
other molecular techniques both for enumeration and characterisation.  CTC analysis, for 
example, in a phase III study of pegylated liposomal doxorubicin with trabectedin 
demonstrated baseline CTCs >2 in 14.4% of patients (31/216), which correlated with a higher 
risk for progression and decreased survival and was independent  of established factors such 
as CA125, platinum sensitivity status and ECOG performance status [114].  However, an 
analysis of 50 patients with platinum resistant and sensitive recurrent ovarian cancer at Dana-
Farber Cancer Institute showed low numbers of CTCs in these patients with no correlation with 
CA125, treatment response, type or duration of chemotherapy [115].   
There are limited published data regarding CTC enumeration in endometrial and cervical 
cancers and there is a need in both cancer types to develop biomarkers to better guide 
therapeutic management. 
 
1.3.4. The Role of CTCs in Clinical Trials 
With the increasing evidence for the predictive and prognostic role for CTCs across a number 
of tumour types, longitudinal assessment of CTCs is being incorporated into clinical trials to 
determine their utility as a biomarker with novel targeted therapies at different stages of 
disease.  A longitudinal approach may also enable detection of molecular changes that may be 
driving resistance or progression. 
CTC enumeration has been investigated in regards to decision making for patients entering 
phase I oncology trials for example, and patients with a higher CTC count have been shown to 
have a greater risk of death [116, 117]. 
In the breast cancer setting, a number of phase III trials are ongoing that incorporate CTC 
count into the treatment decision algorithm.  In the metastatic setting, CTCs are under 
evaluation to guide both change of treatment and use of chemotherapy versus endocrine 
therapy [118].   In the adjuvant setting, trials are assessing HER2-positive CTCs in HER2-
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negative primary tumours and testing the role of HER2-directed therapies in these patients 
[118]. 
In the prostate cancer setting, some trials of novel agents are including CTC count ≥5 as an 
eligibility criteria to select a poorer prognostic group that may demonstrate the utility of the 
agent in a more time-efficient manner [119].  
 
1.3.5. Molecular Characterisation of CTCs 
Molecular characterisation of CTCs is the next step beyond enumeration that could guide 
clinical decision making and targeted drug development, with its ability to provide longitudinal 
assessment of a tumour’s molecular profile and possible causes of drug resistance and tumour 
progression.  This is currently an experimental approach with much promise but not routinely 
used in any solid tumour type.   
There are a number of different technologies that describe isolation of DNA from CTCs and 
subsequent molecular characterisation.  Within the CellSearch system, there is a fourth 
channel in which a fluorescein-conjugated antibody can be applied that is then analysed along 
with the routine CTC morphological and staining features.  Using a fourth channel antibody has 
been investigated in this study.   
 
1.4. Molecular Aberrations in Endometrial Cancer 
1.4.1. Genetic Aberrations 
1.4.1.1. Background 
The most common genetic aberrations in EC have been found in the PI3K pathway, but 
changes in other molecular pathways do co-exist, as outlined in Table 1.3 [33].  This 
demonstrates the differences between Type I and II EC, though more recent studies suggest 
the reclassification of EC based on genomic characterisation beyond these two groups to assist 
with treatment stratification [30]. 
In general, type I cancers express ER and PR, are associated with hyperoestrogenic risk factors 
and demonstrate MSI and mutations of kirsten rat sarcoma viral oncogene homolog (KRAS), 
phosphatase and tensin homologue (PTEN), phosphatidylinositol-4,5-bisphosphate 3-kinase, 
catalytic subunit alpha (PIK3CA) and β-catenin.  Type II tumours are generally aneuploid and 
historically, were not thought to be related to hyperoestrogenic factors nor changes in the ER 
pathway.  They have been associated with genetic aberrations in the tumour suppressor genes 
CDKN2A and p53 and the HER2 oncogene [33].  There is significant overlap however, so that 
these definitions cannot be routinely clinically applied. 
As previously outlined, EC as a result of Lynch syndrome accounts for up to 6% of all cases and 
patients with this syndrome have a 50-fold lifetime risk of developing EC.  MSI can be tested on 
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archival tumour tissue, and in hereditary cancer, is associated with a germ line mutation in the 
MMR genes, while in sporadic tumours, is associated with hypermethylation of the MLH1 
promoter.   
Although some of these alterations have demonstrated prognostic implications, they generally 
have not assisted with treatment choice and unlike in breast, lung and colorectal cancers, 
there are no genetic aberrations identified that guide treatment decisions.   
 
Table 1.3: Molecular Aberrations in Endometrial Cancer  
Alteration Role Type I (%) Type II (%) 
PI3K/AKT/mTOR pathway  
PIK3CA mutation (Exon 9/20) 
[120, 121] 
PIK3CA amplification [122] 
AKT mutation [123] 
PTEN loss of function [124, 125] 
 
Oncogene 
 
~30 (7-15.5/10-34) 
2-14 
3 
83 
 
~20 (0/21) 
46 
0 
5 
KRAS mutation [126, 127] Oncogene 11-26 2 
FGFR2 mutations [86, 128, 129] Oncogene 12-16 1 
HER2 overexpression [130] 
HER2 amplification [131] 
Oncogene 3-10 
1 
32 
17 
Microsatellite instability [132, 133] MMR genes 20-45 0-5 
Nuclear accumulation of β-catenin [134] Oncogene 18-47 0 
E-cadherin loss [135, 136] TSG 5-50 62-87 
p53 mutation [127, 137] TSG ~20 ~90 
Loss of function of p16 [138] TSG 8 45 
TSG: tumour suppressor gene, MMR: mismatch repair 
[139] 
The majority of studies outlined focus on reporting single genetic or pathway based 
aberrations, such as in the PI3K or WNT pathways, MSI or hormone receptor signalling, and are 
outlined in further detail below.  However, with improvement in next generation sequencing 
techniques and other technologies, there is increasing information regarding the crosstalk 
between multiple pathways and how this may impact on treatment delivery and drug 
resistance. 
For example, analysis of multiple oncogenic pathways in patients selected from the PORTEC-2 
trial demonstrated that the presence of two or more aberrations was associated with 
decreased disease-free survival [140].  The presence of two or more aberrations affecting the 
PI3K, Wnt/β-catenin, p53 and MSI pathways identified patients with clinically aggressive 
disease, compared to patients with no alterations in these pathways that had a very low risk of 
disease progression. 
 
The Cancer Genome Atlas (TCGA) Research Network [30] has performed integrated genomic, 
transcriptomic and proteomic characterisation of EC fresh frozen (FF)  tissue using whole-
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exome sequencing, whole-transcriptome sequencing, genome-wide copy number (CN) 
analysis, expression profiling, reverse-phase protein array, methylation profiling and MSI 
assessment.  They interrogated 186 endometrioid, 42 serous and 4 mixed-histology EC in an 
integrated manner and suggested a novel classification system based on this analysis.  Some of 
their findings were similar to those previously reported in terms of the frequency of PI3K 
pathway aberrations and in fact, EC was found to have more frequent mutations in the PI3K 
pathway than any other tumour type studied by the TCGA to date.  EEC was also associated 
with PTEN, CTNNB1, PIK3CA and KRAS mutations as well as ARID1A and ARID5B, involved in 
chromatin-remodelling and controlling gene expression.  They confirmed the frequency of p53 
mutations in NEEC, found in 91%.   
However, they also proposed a new classification based on four categories: polymerase 
epsilon (POLE) ultramutated (7%), MSI/hypermutated (28%), CN low (endometrioid, 39%) and 
CN high (serous-like, 26%).  POLE, a catalytic subunit of DNA polymerase epsilon involved in 
DNA replication and repair, was a novel mutation identified and occurred in both EEC and 
NEEC with an association with better PFS.  Interestingly, serous-like EC clustered into the CN 
high group, as did 25% of tumours classified as high-grade EEC, which may have treatment 
implications for some EEC patients, as this group had a worse PFS.  This CN high group showed 
focal amplifications in MYC (8q24.12), HER2 (17q12), CCNE1 (19q12), FGFR3 (4p16.3) and 
SOX17 (8q11.23).  The CN low group showed 1q amplification and was made up of 
predominantly EEC. 
Thus, an integrated approach to molecular characterisation rather than single pathway 
analysis may yield novel and more clinically useful information on classification and 
appropriate targeted therapies.  Much of the literature in EC to date however has focused on 
specific pathways and these are outlined in further detail in the following 5 sections.  
 
1.4.1.2. The PI3K pathway in Endometrial Cancer 
The PI3K/AKT/mTOR pathway is one of the most studied pathways in EC, with evidence of 
aberrations in both type I and II cancers including oncogenic PIK3CA mutations, PTEN loss of 
function and upstream changes in KRAS, FGFR2, HER2 and EGFR leading to PI3K pathway 
activation.  Reproducible, predictive, time- and cost-efficient markers of PI3K pathway 
activation however remain elusive.  Changes in the PI3K and upstream pathways are 
summarised in Table 1.4 and Figure 1.1. 
PTEN loss of function and subsequent activation of the PI3K pathway is the most common 
aberration currently reported in EC.  This loss of function can be due to PTEN mutations as well 
as PTEN gene promoter methylation, microRNA regulation of the PTEN gene or alterations of 
PTEN protein stability and degradation mechanisms [124].   
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There are contradictory findings regarding the prognostic implications of PTEN loss of function 
and challenges with methodology and interpretation of PTEN IHC may contribute to this.  PTEN 
expression by IHC can yield varied results due to difficulties with sensitivity and specificity of 
anti-PTEN antibodies when applied to FFPE tumours [141].  Although there are limitations to 
the reproducibility of PTEN loss by IHC, detection of functional PTEN loss by sequencing alone 
will not detect all causative mechanisms [142].   Thus, alternatives to PTEN IHC in detecting the 
spectrum of changes that can contribute to PI3K pathway activation have been investigated. 
 
Table 1.4: Examples of PI3K Pathway and Upstream Pathway Aberrations 
Author 
[ref] 
Aberration Frequency EC type Significance n Associated 
with  
Catasus  
[121] 
PIK3CA mtn 
Exon 9 
(Helical) 
Exon 20 
(kinase 
domain) 
29% EEC Exon 9 ass’d 
with G1 & 
MMI<50% 
Exon 20 ass’d 
with G3, 
MMI>50%, cerv 
invasion 
109 MSI 
Mtns in PTEN, 
CTNNB1, 
KRAS, BRAF 
Oda  
[120] 
PIK3CA mtn 
Exon 9 
Exon 20 
36% No ass’n No ass’n with 
grade, stage or 
prognosis 
66 Mtns in PTEN 
Rudd 
[143] 
PIK3CA mtn 
Exons 1-7 
16% EEC > 
NEEC 
 108 Mtns in PTEN 
& KRAS 
Mutter  
[124] 
 
PTEN 
mtn/loss 
83/61% vs 
55/75% vs 
0  
EEC vs 
AEH vs 
normal 
PTEN loss of 
function is an 
early event in 
EC & ass’d with 
oestrogen 
exposure 
84 - 
Mackay  
[144] 
PTEN loss  
(IHC) 
55% 57.9% 
EEC 
42.9% 
NEEC 
PTEN loss ass’d 
with improved 
survival in 
advanced 
disease 
128 No ass’n with 
MSI 
Kanamori  
[145] 
PTEN loss or 
mixed 
staining  
(IHC) 
65.3% EEC only PTEN loss ass’d 
with worse 
survival in 
advanced 
disease.  No 
ass’n with age, 
FIGO stage, 
MMI or grade 
98 ne 
Birkeland  
[146] 
KRAS mtn 
 
KRAS amp’n 
14.7% 
 
3 vs 18% 
EEC>NEEC 
 
P vs M 
Ass’d with low 
grade & obesity 
Ass’d with poor 
outcome, FIGO 
stage, NEEC, 
high grade. 
414 
P 
61 
M 
ne 
40 
 
Dutt 
[86] 
FGFR2 mtn 12% EEC>NEEC Oncogenic in 
cell lines 
40 Co-occur with 
CTNNB1,PTEN 
& PIK3CA, not 
with KRAS 
mtns 
Konecny  
[131] 
HER2 amp’n 
(FISH) 
EGFR exp’n 
(IHC) 
17 vs 1% 
 
34 vs 46% 
NEEC vs 
EEC 
No ass’n with 
survival 
Ass’d with poor 
survival in NEEC 
279 ne 
EEC: endometrioid endometrial cancer, NEEC: non-endometrioid endometrial cancer  
Mtn: mutation, ne: not evaluated, ass’n: association, amp’n: amplification, exp’n: expression,  
P: primary, M: metastatic.  Gene abbreviations are outlined in the Abbreviations section. 
 
 
Figure 1.1: An overview of PI3K/Akt/mTOR pathway signalling and cross-talk with other 
pathways relevant to endometrial cancer [147] 
 
Solid lines represent activation and dashed lines represent inhibition. 
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1.4.1.3. The Role of Stathmin in Endometrial Cancer and the PI3K pathway 
Stathmin is a cytosolic phosphoprotein expressed in all tissues and plays an important role in 
the regulation of the microtubule cytoskeleton and cell cycle [148].  It is involved in protein 
activity and cell division, intracellular transport, cell motility and regulation of apoptosis [149] 
and MAPK and PI3K pathway kinases can activate stathmin [150].  Stathmin is overexpressed 
on IHC in several malignancies and has been demonstrated to have prognostic significance in 
ovarian [151], cervical [152], breast [153, 154], prostate [155], urothelial [156], gastric [157] 
and oral squamous cell carcinoma [158] and predictive value in preclinical studies of breast, 
prostate and leukemic cancer cells [159-161].  Stathmin has been shown to act as a surrogate 
marker of PI3K pathway activation, is associated with PTEN loss as well as PIK3CA amplification 
and/or overexpression [122, 162] and there is also evidence that it is a better correlate of PI3K 
pathway activation than PTEN loss [162].   
In the clinical setting, stathmin is overexpressed in between 27-57% of EC, can predict EC 
lymph node metastases [163] and is associated with NEEC, higher grade as well as lower 
recurrence-free and disease-specific survival [164].  Even in the otherwise low-risk EEC 
subgroup, it still carries prognostic value [122].  As there is evidence that it can change 
between primary and recurrent tumours, reassessment on progression may be important in 
treatment selection [165].  There is also evidence that stathmin may be a predictive marker for 
response to taxane chemotherapy [151, 166, 167], including in EC, where high stathmin levels 
have been associated with a poor response to paclitaxel containing chemotherapy and 
reduced disease specific survival [168].   
In addition, phospho-stathmin (pStathmin, serine38) has been shown to be a biomarker of 
increased tumour cell proliferation and poor prognosis in endometrial cancer and in fact may 
be a stronger prognostic indicator than stathmin [169] 
Thus, stathmin is a highly relevant marker in EC, with evidence as both a prognostic and 
predictive biomarker when overexpressed on IHC.  Based on current data, it may play a role in 
stratifying patients to lymph node sampling, though this requires further validation.  
Furthermore, as it can potentially change over time and may reflect PI3K pathway activation in 
this fashion, longitudinal assessment of it and pStathmin’s activity may be important to further 
establish its role as a predictive marker of PI3K activation and in monitoring response to PI3K 
inhibition.  In this study, a method to detect stathmin in CTCs has been established.   
 
1.4.1.4. The Wnt pathway 
Wnt pathway aberrations are also common in EC, with different aberrations documented in 
EEC and NEEC involving the cadherins, cell-surface glycoproteins, and catenins, both of which 
combine to mediate cell-cell adhesion.  However, specific drug targeting of this pathway is not 
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defined, unlike PI3K signalling.  E-cadherin is linked to cytoskeletal actin filaments through α, ß 
or γ catenins, key in the Wnt signal transduction pathway [134].  Reduced E-cadherin 
expression, measured by IHC, is found in 5-53% of EEC and 62-87% of NEEC [135, 136] and 
such tumours are more likely to be poorly differentiated, have cervical extension, positive 
peritoneal cytology and adnexal spread and be of more advanced stage when compared with 
E-cadherin positive tumours [135, 136].   
CDH1 is a tumour suppressor gene that codes for E-cadherin [170].  LOH of the gene occurs in 
57.1% of NEECs and 22.5% of EECs, with CDH1 promoter hypermethylation in a further 21.2% 
of ECs [136].  Hypermethylation of the CDH1 promoter with subsequent gene silencing, is 
associated with low expression of E-cadherin in EC as well as higher grade, MMI, higher FIGO 
stage and shorter 5-year survival [171].  Aberrations of ß- and γ-catenins and resultant Wnt 
pathway disruption has also been implicated in EC [172].   
Although genetic abnormalities in the Wnt pathway are common in EC, so far they have not 
translated into novel therapies nor treatment stratification. 
Figure 1.2 illustrates an overview of the Wnt signalling pathway. 
 
Figure 1.2: An overview of the Wnt signalling pathway [173] 
 
Interaction of a Wnt ligand with a receptor complex including a Frizzled family member 
triggers downstream phosphorylation.  Β-catenin can accululate and enter the nucleus, 
interacting with coactivator proteins and leading to cell proliferation. 
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1.4.1.5. Microsatellite Instability 
MSI is another well-described molecular aberration in EC with Lynch Syndrome accounting for 
1.8-6% of cases [174] and another 15-31% of sporadic cancers also having high MSI [132, 175].  
Lynch syndrome results from germline mutations in DNA MMR genes, MLH1, MSH2, MSH6 and 
PMS2 whereas in sporadic cases, methylation and transcriptional silencing of the MLH1 gene 
promoter occurs [176].   
MSI may occur concurrently with PTEN mutations, particularly in NEEC [176, 177] and 
interestingly, MLH1 promoter methylation appears to be an early event during EC 
tumorigenesis [178].  There is no clear correlation between MSI and survival [133, 144]. 
 
1.4.1.6. Hormone Receptor Pathway Signalling 
Although hormonal therapies have some demonstrated efficacy in EC, their use is limited by a 
lack of predictive biomarkers for response.  ER and PR expression is observed in approximately 
80% of sporadic ECs and is associated with low histological grade, good prognosis and 
response to hormonal therapies [179].  Expression of ERα, PR-A and PR-B are associated with 
earlier stage EC and lower grade tumours, and absence of ERα and PR-A is associated with 
increased risk of death [180].  Interestingly, a recent study of ERα gene amplification 
demonstrated similar frequencies in both EEC and NEEC [181].  Although this was hypothesis 
generating in terms of the role of hormonal signalling in EC, the methodology and 
reproducibility of the findings was questioned [182]. 
There is evidence for the interaction between hormone receptor signalling and other signalling 
pathways.  Oestrogen exposure may contribute to PTEN loss in AEH and subsequent 
development into EC [183].  Thus, combination therapies targeting PI3K pathway and hormone 
pathway aberrations may be of interest.   
 
1.4.2. Epigenetic Aberrations 
1.4.2.1. Background 
Epigenetics refers to the alteration in gene expression potential during development and cell 
proliferation, without any change in gene sequence [184].  DNA methylation is one of the most 
well documented mechanisms of epigenetic aberrations and refers to the reversible covalent 
modification of cytosines through the addition of a methyl group to the carbon-5 position of 
cytosine bases by one or more DNA methyltransferase (DNMT) enzymes, occurring 
predominantly in the context of cytosine-guanine dinucleotides (CpGs).  Other epigenetic 
mechanisms include histone modification, and non-coding, small-interfering RNAs, all of which 
can affect transcript stability, DNA folding, nucleosome positioning, chromatin compaction and 
overall nuclear organisation, determining whether a gene is silenced or activated [185, 186].  
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The epigenetic silencing of a gene that is not normally suppressed or activation of a gene that 
is not normally activated is called an epimutation [187].  
CpGs can occur randomly throughout the genome and tend to be methylated.  They can also 
occur in clusters, known as CpG islands (CGIs), which range from 500 up to 2000 base pairs and 
tend to be unmethylated, unequally distributed and localized within and around the promoter 
regions of mammalian genes [188].  Hypermethylation in CGIs has proven to be a significant 
event in carcinogenesis [188, 189].   
Global hypomethylation and/or CGI hypermethylation occurs in many cancers  [190, 191] and 
was first described in colorectal cancer in 1983 [192].  Recent studies suggest that within each 
tumour, hundreds of genes may be silenced by DNA methylation, compared to 10-15 genes 
that may be silenced by genetic mutations [193].  DNA methylation in cancer also appears to 
be tissue and tumour-type specific [190], thus DNA methylation profiles may act as biomarkers 
for diagnosis, prognosis and response to treatment.   
More recently, there is data to suggest that considerable DNA methylation occurs in CpG 
shores and in the gene body and can also be of significance in carcinogenesis [189, 194].  A 
representative diagram of CpG content is detailed in Figure 1.1 [195]. 
 
Figure 1.3: Representative diagram of CpG content [195] 
 
Open Sea (white): isolated CpGs in the genome  Shelf (brown): 2-4kb from CpG island 
Shore (blue): up to 2kb from CpG island   CpG Island (green): >200bp in length 
   
 
1.4.2.2. Epigenetic Aberrations in Endometrial Cancer 
Epigenetic alterations may be more frequent than genetic alterations in EC and there are 
documented epigenetic abnormalities in genes encoding tumour suppressor genes, 
oncogenes, apoptosis inhibitors, cell cycle regulators, steroid receptors, transcription factors 
and angiogenesis modulators [196].   
A high frequency of methylation in tumours and cell lines has been reported for APC (-40%), 
CASP8 (-35%), CDH1 (-25%), ERα-promoter-C (94%), hMLH1 (41%), PR-promoter-B (75%), 
RASSF1A (33%) and THBS2 (62%) with a much lower frequency (-15%) of hypermethylation of 
p16INK4A (CDKN2A), p14ARF, p73 and PTEN [197-201].  Other genes silenced by 
hypermethylation that have been reported in EC include E-cadherin, CHFR, TGFBR3, p73, 
HOXAII, COMT, SPRY2, GPR54 and RSK4.    
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Most recently, TCGA has identified EC as having four subgroups as described previously [30], 
with one subgroup, the MSI/hypermutated group, displaying MLH1 promoter 
hypermethylation and a CpG island methylator phenotype (CIMP).  CIMP refers to extensive 
DNA hypermethylation of a subset of CpG islands that normally remain unmethylated [202].  
This subgroup consisted of both EEC and NEEC and did not contain TP53 somatic mutations nor 
extensive somatic CN alterations.   
The subgroup of EC that was CN high had a normal-like DNA methylation profile and was found 
particularly in serous-type tumours and with TP53 somatic mutations. 
The methylation analysis performed by TCGA using genome-wide bead chip technology 
provides a more extensive assessment of methylation changes with clinical correlation, 
compared to historical literature which tended to focus on a specific area of the genome 
through candidate gene methylation methods.  These historical data however provide a 
framework for the current methylation data and a summary of some of these studies in EC is 
presented in Table 1.5.  Of note, there is often limited correlation with clinical outcomes, such 
that the significance of the epigenetic change may only be partially understood.  How best to 
use this data in the clinical setting has also not been established. 
 
Table 1.5: Summary of studies of Epigenetic Aberrations in Endometrial Cancer 
Author 
(year) 
Gene 
(function) 
Implication Frequency n 
Ignatov  
[203] 
APC (TSG) Promoter hypermethylation found in AEH 
and early EC  
77.4% I/II 
24.2% III/IV 
23.5% AEH 
0 normal 
86 
Kang 
[204, 205] 
 
Pallares 
[206] 
Jo [207] 
Fiolka 
[208] 
RASSF1A 
(TSG) 
Common in solid tumours 
Negative regulator of RAS-MAPK 
Found in early and late stage EC 
Occurs with KRAS mtn in MSI+ EC 
Promoter hypermethylation in EC 
Associated with advanced stage, high 
grade, LN + and poor DFS 
Present in AEH and EC 
33.3% 
 
 
 
 
 
 
75 
 
 
 
 
 
 
 
Velasco  
[209] 
SPRY2 
(TSG) 
Antagonist of FGF & RAS-MAPK pathways 
Promoter hypermethylation correlated 
with RASSF1A and cell proliferation 
53.4% 58 
Dewdney  
[210] 
 
RSK4 (TSG) ERK substrate; inhibits FGFR2 & RAS/ERK 
pathways 
Frequently hypermethylated in EC 
63% 158 
Catasus 
[211] 
TIMP3 
(TSG) 
Promoter hypermethylation ass’d with 
high stage EEC & extrauterine spread 
Also ass’d with MSI+ & MLH1 
hypermethylation 
25% 60 
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Wang  
[212] 
CHFR 
(TSG) 
Potential marker of microtubule-
targeting drugs 
Promoter hypermethylation leads to 
weak CHFR expression & greater taxane 
sensitivity 
Hypomethylation of CHFR & high 
expression leads to resistance 
Cell lines 6 
Sanchez-
Vega  
[213] 
ZNF154 
VHL (TSG) 
CASP8 
(TSG) 
Promoter hypermethylation of ZNF154 
(little known on biological function)  
Hypomethylation in CASP8 and VHL. 
 
ne 26 
Dvorakova 
[214] 
Multiple 
TSGs 
Promoter hypermethylation of CDH13, 
WT1 and GATA5 genes 
80%, 20%, 10% 59 
Wu [215] 
 
 
PAX2 
(oncogene) 
Methylated and silenced in normal 
endometrium; hypomethylated in 
malignant cells 
75% 53 
Teodoridis 
[216] 
Risinger  
[217] 
 
 
 
 
Whitcomb 
[200] 
MSI MSI+ ass’d with widespread gene 
mutations and CIMP 
MSI epigenetic repression of MMR genes 
(hMLH1, MGMT, WRN, BRCA1) more 
common than mutations of same genes 
MSI+ ass’d with promoter 
hypermethylation of hMLH1, PTEN, APC, 
SFRP1/4, RASSF1A 
MSI+ ass’d with HOXA11& THBS2 
methylation  
ne 
 
38% 
 
 
 
 
 
Ne 
 
24 
 
 
 
 
Kang  
[218] 
GPR54 Receptor of KISS1; suppressor of cancer 
metastasis; high expression ass’d with 
increased survival 
Promoter hypermethylation reduces 
GPR54 expression 
 
Cell lines only ne 
Katoh  
[219] 
 
SFRP1 Negatively regulates Wnt signalling 
Promoter hypermethylation leads to its 
downregulation 
ne ne 
 
 [220] 
HOXA10 Promoter hypermethylation in EC. 
No clinicopathologic correlation. 
20% 19 
Di 
Domenico  
[221] 
Multiple Promoter hypermethylation in ERα, PRα, 
hMLH1, CDKN2A, SFRP1/2/5 in EEC 
 
Hypomethylation of SFRP4. 
 
38,38,84, 
92,54,15, 53% 
(1 of 7 in 100%) 
16 
Zhang 
[222] 
Multiple Promoter hypermethylation p14, p16, 
ER, COX-2 & RASSF1A. 
CIMP+ (hypermethylation in >2 genes) in 
EC 
 
40, 23, 29, 43 & 
34% 
46% 
35 
Powell  
[223] 
Ribosomal 
DNA genes 
Hypomethylation ass’d with shortened 
OS, esp in African-American women 
74% 215 
Mtn: mutation, ass’d: associated, ne: not evaluated, esp: especially 
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1.4.2.3. Methods of Methylation Analysis  
There are a number of available techniques to characterise methylation profiles, the choice of 
which depends on the type of information required, whether global or locus-specific, genome-
wide or candidate gene, quantitative or qualitative [224].  Methods including methylation-
sensitive restriction enzyme digestion, sodium bisulfite (BIS) conversion and 
immunoprecipitation all provide different information, vary in time-intensity and require 
differing amounts of DNA.   
Gene-specific methylation analysis includes both genome-wide and candidate gene 
approaches.  Candidate gene approaches rely on the use of primers that detect methylated 
and unmethylated alleles of interest, whereas genome-wide analysis uses either array based or 
non-microarray based methods.  Table 1.6 summarises some of the available techniques for 
methylation analysis. 
 
Table 1.6:  Techniques for Methylation Analysis 
Technique Genome-
wide or 
candidate 
gene 
Description Pros Cons 
Methylation-
sensitive 
restriction 
enzyme 
(MSRE) 
digestion 
[225] 
Candidate 
gene 
Analyses the 
methylation status of 
CpGs within the 
recognition sequences 
of specific REs 
Little starting 
DNA required 
Only CpGs 
within the RE 
sites are 
analysed 
False+ result if 
incomplete 
digestion 
Methylation 
specific PCR 
(MSP) 
 
e.g. 
Methylight 
 
[226] 
Candidate 
gene 
PCR amplification of 
BIS converted DNA. 
 
Methylight uses 
fluorescence based 
PCR and specifically 
designed primers and 
probes for genes of 
interest 
Highly sensitive 
 
Low cost 
 
Lower starting 
DNA conc 
 
Quantitative 
 
Only CpG 
dinucleotides 
covered by the 
primers and 
probe will be 
assessed for 
methylation  
BIS 
sequencing & 
restriction 
analysis 
(COBRA) 
[227] 
Candidate 
gene 
Provides data only for 
the specific restriction 
enzyme cutting sites 
 Time-
consuming 
Large DNA 
starting conc 
Methylated 
DNA 
immunoprecip
itation 
(MeDIP) 
[228] 
Genome 
wide 
Antibodies target the 
methyl-CpG binding 
domain or the 
methylated cytosines, 
then hybridizes the 
Does not 
require 
restriction 
digestion or BIS 
conversion 
Requires large 
amounts of 
genomic DNA 
 
Lacks 
sensitivity in 
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immunoprecipitated 
DNA to microarrays 
regions with a 
low density of 
CpG sites 
Restriction 
landmark 
genomic 
scanning 
(RLGS) 
[229] 
Genome 
wide 
DNA gel 
electrophoresis in 
combination with 
MSRE  
Analyses 
thousands of 
loci at once. 
Labour 
intensive 
Requires large 
DNA conc  
Bead chip 
technology 
[230] 
Genome 
wide 
BIS conversion with 
fluorescence detection 
at individual CpG sites 
Quantitative 
Can use 
fragmented 
DNA 
 
BIS: bisulfite, Conc: concentration 
The TCGA methylation analysis is based on bisulfite-sequencing techniques on the Illumina 
HumanMethylation 450K BeadChip array, carried out on FF tumour specimens.  Treatment of 
DNA with bisulfite converts cytosine to uracil and leaves methylated cytosine unaffected.  
Further analysis is then performed to extract this information regarding the methylation status 
of a segment of DNA, as described in Methods section 2.2.5.   
The 450K array can assess methylation signatures in both FF and FFPE tissue, as evidenced by 
Bibikova et al [231] and Thirlwell et al [232] and analyses over 450 000 CpG sites on 12 samples 
in parallel.  It was designed with the guidance of a consortium of methylation researchers and 
is comparable to whole-genome bisulfite sequencing data generated on a HiSeq2000 using 
NGS technology, including coverage of 99% RefSeq genes with multiple probes per gene, 96% 
of CpG islands from the UCSC (University of California, Santa Cruz) database, CpG island shores 
and additional content from whole genome bisulfite sequencing data and input from DNA 
methylation experts [233] [234].   
 
1.5.  Study Aims and Objectives 
 
The current prognostic and predictive factors used to identify high-risk groups and guide 
therapeutic decisions in EC have been unchanged and unchallenged for many years, despite an 
increasing body of literature on the genetic and epigenetic aberrations that contribute to 
endometrial carcinogenesis.  The recent TCGA data on EC molecular aberrations support its 
reclassification beyond the Type I and II subdivision, to better assist with risk stratification and 
treatment selection for EC patients, and to translate evidence on the molecular changes into 
the clinical trial setting with concurrent biomarker development.  However, this data set does 
not interrogate the transition from normal endometrium to AEH to EC and was carried out in 
FF tissue which is not easily obtainable from patients.  This latter point means large 
retrospective analyses and longitudinal analyses using historical tissue cannot be carried out 
unless banks of FF tissue exist. 
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The two main components of this thesis investigate the feasibility and clinical correlation in EC 
firstly with CTCs as a biomarker strategy and secondly with epigenetic analysis.  The platforms 
used for both biomarker analyses are well-established.  However, this work examines 
important novel aspects of these technologies that can be incorporated easily into clinical 
practice.  These novel approaches are epigenetic analysis of methylation using EC FFPE tissue 
on the Illumina 450K array and detection of stathmin as a novel marker in CTC applied to EC.  
Thus, determining feasibility was one of the main objectives.  Further to testing on FF tissue 
alone, as has been done by TCGA, profiling FFPE endometrial tissue would provide a far larger 
body of samples for study.  In addition, identifying the aberrations which occur early in 
endometrial tumorigenesis in AEH, may assist with improving treatment strategies at an earlier 
stage of disease.   
CTC enumeration and molecular profiling, if feasible, may not only provide one of the first 
predictive biomarkers to monitor patients’ treatment in EC but also may allow for longitudinal 
assessment of molecular changes to assist with targeted therapy development. 
Thus, through these two studies, a platform for further research in EC could be established 
into further practical, clinically applicable biomarker development and treatment strategies to 
improve patient outcomes.    
They key objectives of both study components are outlined in Figures 1.1 and 1.2 below. 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 1.4. CTC Enumeration and Molecular Profiling in EC 
 (EEC and NEEC) 
 
 Feasibility of CTC enumeration and molecular profiling in EC on 
the Veridex CellSearch platform 
 Correlation with clinical data and treatment 
 Correlation  of tumour tissue IHC with CTC profiling 
 
Figure 1.5. Epigenetic and Genetic studies in EEC only 
 
 Feasibility and reproducibility of epigenetic and CNV analysis 
from FFPE and FF EC tissue on the Illumina 450K array  
 Analysis and comparison of methylation patterns in normal 
endometrium, AEH and EEC and correlation with clinical data 
 Correlation of epigenetic and CNV data with TCGA and other 
published literature 
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CHAPTER 2: Methods 
2.1. Development of the CTC Protocol: from approval to enumeration and profiling 
2.1.1 Protocol Approval 
The Research Ethics Committee (REC) submission, Site-Specific Information (SSI) form and 
Research and Development (R&D) submissions were uploaded and completed via the 
Integrated Research Approval System (IRAS) and were approved by the local REC (National 
Research Ethics Service Committee, NRES, London, Bloomsbury).  There were two major and 
one minor amendment made to the protocol.  The first involved an increase in the blood 
volume taken at sample collection from one vial (10ml) to two vials (20ml) to allow adequate 
blood volume for CTC enumeration and molecular analysis via the 4th channel.  The second 
amendment added Sarah Cannon Research Institute UK (SCRI-UK) as an additional site for 
sample collection to improve patient recruitment.  The third amendment increased the 
number of patients to be evaluated in the study, as some consented patients did not have 
evaluable samples or had limited follow-up.  These documents are available for review via the 
NRES Committee London, Bloomsbury. 
Approval for IHC on the corresponding archival tumour tissue blocks was approved by the 
University College London (UCL) Cancer Institute Biobank REC and was performed on tissue 
from the UCL hospital (UCLH) histopathology department only. 
 
2.1.2. Patient Selection and Consent 
Patients with locally advanced or metastatic EEC or NEEC were identified from the weekly 
UCLH Gynae-oncology MDT meetings, as well as from the weekly Gynae-oncology outpatient 
clinics.  Patients older than 18 years who had a confirmed histopathological diagnosis of EC 
and signed informed consent were eligible for the study.  Patients were excluded if there was a 
prior history of another cancer within the last 5 years, except non-melanoma skin cancer, or if 
there was a high risk that the patient would not comply with protocol requirements. 
At SCRI-UK, patient referrals were reviewed weekly and potential patients identified. 
The study was discussed with identified patients at the consultation with their treating team.  
If patients were interested in the study, they were approached by myself or the treating team, 
given the patient information sheet and this was discussed in detail.  Once all questions were 
answered, patients gave their informed consent and blood collection was arranged thereafter.  
Patients with advanced stage EC were recruited at any timepoint of their treatment, whether 
pre or post-surgery, or pre, during or post chemotherapy or RT.  Patients were followed over 
time and further tests taken for CTC enumeration every 3-6 months, or if there was a change 
in the clinical status, with up to 4 samples taken per patient.  
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2.1.3. Sample and Data Collection 
Following consent, a peripheral blood sample of up to 20ml for CTC isolation and enumeration 
was collected in two CellSave Preservative tubes (Cat No 7900005), either by a phlebotomist or 
chemotherapy nurse.  The samples were pseudoanonymised and transported from the UCLH 
outpatients department to the UCL Cancer Institute, where they were received by a member 
of staff that was GCP and GCLP trained.  Each specimen was processed within 72 hours of 
being received, as per the Veridex and UCL Cancer Institute lab protocols. 
Clinical data were collected on these patients from the UCLH patient information system 
including demographic, clinicopathologic information, details of treatment, disease recurrence 
and survival.  These data were also pseudo-anonymised and stored on a password-controlled 
UCL Cancer Institute computer.  The last time-point of data and CTC collection was February 
2014. 
If they had tissue collection, either biopsy or surgery, performed at UCLH, this was retrieved 
from the pathology department archive to be sectioned for EpCAM, Stathmin and p70S6kinase 
IHC. 
 
2.1.4. Sample Preparation 
From the peripheral blood draw, 7.5ml of blood was combined with 6.5ml of Dilution Buffer 
(CellSearch CTC Kit, Cat No 7900001) in a 15ml conical tube, centrifuged at 800xg for 10 
minutes at room temperature and processed on the CellTracks AutoPrep system (Cat No 9541) 
within one hour of sample preparation.  
 
A Veridex control sample (CellSearch CTC Control Kit, Cat No 7900003) was prepared for each 
kit run.  The control sample was spiked with two different cell lines at a low and high 
concentration.  This demonstrated at each run that the automated system was detecting CTC 
counts correctly, based on what was detected in the control specimen.  This was stored at 4°C 
and warmed to room temperature 20 minutes prior to the analysis.   
After inverting 5 times and vortexing for 5 seconds, the control sample was added to a 15ml 
conical tube and placed on the CellTracks AutoPrep system.   
 
The Veridex platform also has a 4th channel (FITC) that allows molecular analysis to be 
performed.  Stathmin antibody (Biorbyt catalogue number orb 104103) was used in the 4th 
channel in this study, after having been validated for use in cell lines and CTCs at the UCL 
Cancer Institute, as described in section 2.1.7.  For the Stathmin solution, 30µl of antibody mix 
was diluted with 570microl PBS in a 1:20 dilution to 50µg/ml.  300µl was required dead volume 
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for each kit run and 150µl was required per specimen analysis.  This total volume was then 
placed in the 4th channel. 
 
Once on the CellTracks Autoprep system, the plasma and buffer layer were aspirated from the 
blood sample.  Ferrofluids containing nanoparticles with a magnetic core surrounded by a 
polymeric layer coated with antibodies to EpCAM were then added and incubated.  Magnetic 
separation would then occur and the remaining unbound cells and plasma were aspirated out.  
Staining reagents and permeabilization buffer were then added to fluorescence label the 
immunomagnetically labelled cells and identify the presence of CTCs.   
The fluorescent reagents that were added were cytokeratins 8, 18, 19 (CK-PE), 4’6 –diamidino-
2-phenylindole (DAPI) and an antibody to CD45 conjugated to allophycocyanim (CD45-APC).  
CK-PE is specific for the intracellular protein cytokeratin, characteristic of epithelial cells, while 
DAPI stains the cell nucleus and CD45-APC is specific for leukocytes.   
Cells were then resuspended in the MagNest cell presentation fixture.   A strong magnetic field 
was generated by the MagNest and caused the magnetically-labelled target cells to move to 
the surface of the cartridge, distribute uniformly over the analysis surface of the cartridge and 
orient for analysis at a single focal depth. The cartridge containing stained CTCs was then 
placed onto the CellTracks Analyzer II (Cat No 9555 RUO), a four-colour semi-automated 
fluorescence microscope, for scanning.   
This process is illustrated in Figure 2.1 below. 
 
 
Figure 2.1:  The Veridex CellSearch CTC Detection System 
 
2.1.5. CTC Analysis and Enumeration 
On the CellTracks Analyzer II, image frames covering the entire surface of the cartridge were 
captured.  Once the cartridge had been scanned, the system displayed tumour cell candidates 
that were positive for cytokeratin and DAPI, and could then be reviewed by the operator.   
 
A CTC was defined as positive for CK-PE and DAPI, negative for CD45-APC and having the 
correct morphology to be characterised as a tumour cell.  The CellTracks Analyzer II presented 
the images with overlays of CK-PE and DAPI signals, to show whether the nuclear and 
cytokeratin staining were overall consistent with a tumour cell.  The object in the CK-PE filter 
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channel needed to be an intact cell, at least 4 microns in diameter and generally round or oval, 
though could be polygonal or elongated.  The nuclear area should be smaller than the 
cytoplasmic area and more that 50% of the nucleus needed to be visibly surrounded by the 
cytoplasm.   
An image that was very bright in the CK-PE channel could result in spectral spillover and create 
a visible cytoplasmic image in the CD45-APC channel.  This could still be classified as a tumour 
cell and differentiated from leukocytes that would be positive for CD45-APC and DAPI but 
negative for CK-PE. 
Squamous cells and other artefacts were also often present in samples.  Squamous cells may 
have been due to contamination from the needle stick or from handling the specimen.  They 
were identified by their low nuclear to cytoplasmic ratio and their large, polygonal appearance.  
Artefacts usually appeared in all channels with the same shape. 
All samples were reviewed by two trained laboratory staff, as well as by myself.  Examples of 
CTCs and other artefacts are illustrated in Figure 2.2. 
 
 
 
Figure 2.2.  A screenshot from the CellTracks Analyzer demonstrating the Criteria for CTC 
Analysis   
The first column is the CK-PE and DAPI overlay, the second column is CK-PE staining only, the 
third column is DAPI staining only and the 4th column is CD45-APC.  The fifth column was not 
used in this diagram but when used, would show the 4th channel staining for molecular 
characterisation. 
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2.1.6. FFPE Tissue Processing and IHC assessment 
For patients who had a biopsy or surgery performed at UCLH, EpCAM (1/4 dilution; mouse 
anti-human, RTU-ESA; Novocastra, Newcastle, UK), stathmin (1/30 dilution; 3352 
CellSignalling, Hertfordshire, UK) and p70S6kinase (1/25 or 1/50 dilution; Clone E135, Genetex, 
Cat No GTX 61056, California, USA) IHC was performed on the available FFPE tumour blocks, 
obtained from the UCL Histopathology Department.   
Each archival tumour block was sectioned at 3 micron thickness onto charged slides, drained 
and baked at 60°C for 60 minutes.  Unstained slides were labelled and placed for IHC staining 
of EpCAM, stathmin or p70S6kinase primary antibodies on the Leica Bond III autostainer 
platform, using the Bond Polymer Refine Detection Kit (Cat No DS9800).   
The general methodology is summarised below while the specific protocols for each primary 
antibody are outlined in Table 2.1. 
On-board dewax and rehydration were performed followed by epitope retrieval by either 
heat-induced (HIER with ER2, EDTA-based, Cat No AR9961) or enzymatic digestion (with 
Enzyme 1 diluted 1/2000, Bond Enzyme Pretreatment Kit, Cat No AR9551) to break the 
formalin-protein crosslinks that occur in FFPE tissues.  Peroxide block provided in the Bond 
Polymer Refine Detection Kit (Cat No DS9800) was then applied to neutralise the endogenous 
peroxidase in human tissue.  
The primary antibody was applied for 15 or 30 minutes at room temperature, as detailed in 
Table 2.1, followed by a rabbit anti-mouse post primary antibody and goat anti-rabbit 
horseradish peroxidase conjugated polymer (components of DS9800).  
Antigens were visualised with the substrate chromogen 3,3’-Diaminobenzidine 
tetrahydrochloride (DAB, Cat No 9800) which formed an insoluble brown precipitate at the 
antigen site on reaction with horseradish peroxidase conjugated to the polymer.  Bond DAB 
Enhancer (Cat No AR9432) was then added to darken the DAB precipitate.  
Slides were counterstained with haematoxylin (component of DS9800) to allow the 
visualization of cell nuclei.  All washes between reagents were with either Bond Wash solution 
1x (AR9590) or deionised water. The staining was run over a 2.5hr period. 
 
In addition to the standard protocol, 10% goat serum was used after stathmin antibody 
application for those slides sectioned from surgical resection samples.  This blocked non-
specific antibody binding that occurred in these samples, though was not required for the 
biopsy samples.  Further details of stathmin antibody validation are detailed in section 2.1.7.    
Different protocols were also used for biopsy and surgical resection tissue for p70S6 kinase 
antibody to optimise staining.  A 1/50 dilution was used for the biopsy samples and a 1/25 
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dilution, with longer retrieval time and antibody incubation time, was used for the control and 
surgical resection specimens.   
 
Table 2.1:  Staining protocols for EpCAM, Stathmin and p70S6kinase 
Step EpCAM  Stathmin 
B/S 
 p70S6 k 
B/S 
 
Part 1 Time (min) Temp (°C) Time (min) Temp (°C) Time (min) Temp (°C) 
Bake 60 60 60 60 60 60 
Bond dewax 
solution 
0.5 x1 
0 x1 
0 x1 
72 
72 
Room 
0.5 x1 
0 x1 
0 x1 
72 
72 
Room 
0.5 x1 
0 x1 
0 x1 
72 
72 
Room 
Alcohol 0 x3 Room 0 x3 Room 0 x3 Room 
BWS 0 x2 
5 x1 
Room 0 x2 
5 x1 
Room 0 x2 
5 x1 
Room 
*ER2 
ER2 
ER2 
BWS 
BWS 
OR 
*Enzyme 1  
BWS 
- 
 
 
 
 
 
10 
0 x3 
- 
 
 
 
 
 
37 
Room 
0 x2 
20 
12 
0 x3 
3 
 
- 
Room 
100 
Room 
35 
Room 
 
- 
0 x2 
30/40 
12 
0 x3 
3 
 
- 
Room 
100 
Room 
35 
Room 
 
- 
Peroxide block 5 Room 5 Room  5 Room 
BWS 0 x3 Room  0 x3 Room 0 x3 Room 
1° Ab 15 Room 30 Room 30/60 Room 
BWS 2 x3 Room  0 x3 Room 0 x3 Room 
10% goat serum - - 20  
(S only) 
Room 
(S only) 
- - 
BWS - - - - 0 x3 Room 
Post-1° Ab 8 Room 20 Room 20 Room 
BWS 2 x3 Room  2 x3 Room 2 x3 Room 
Polymer 8 Room 20 Room 20 Room 
BWS 2 x2 Room  2 x2 Room 2 x2 Room 
DW 0 Room  0 Room 0 Room 
Mixed DAB 
refine 
0 & 10 Room 0 & 10 Room 0 & 10 Room 
DW 0 x3 Room  0 x3 Room 0 x3 Room 
Bond DAB 
enhancer 
5 room 5 Room 5 Room 
BWS 0 x3 Room  0x3 Room 0x3 Room 
Haematoxylin 1 Room  1 Room  1 Room 
DW 0 Room  0 Room  0 Room 
BWS 0 Room  0 Room  0 Room 
DW 0 Room  0 Room  0 Room 
Time 0 indicates a wash was performed, X3 indicates the wash occurred 3 times 
BS2: bond solution 2, BWS: bond wash solution, DW: deionised water,  
B: biopsy specimen, S: surgical resection specimen, k: kinase 
*This row indicates the epitope retrieval method; either with the ER2 HIER technique or 
enzymatic epitope retrieval technique with Enzyme 1. 
Bolded entries refer to where there was a difference between protocols for biopsy and surgical 
resection specimens. 
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Once the staining procedure was complete, slides were rinsed in tap water and dehydrated 
through graded alcohols as follows for permanent mounting: 
- Industrial methylated spirit (IMS; Barrettine Industrial Ltd, Bristol, UK) 100% x3 for 2 
min  
- Absolute ethanol x1 for 2 min (Analar NORMAPUR 20821.321 VWR, BDH)  
- Xylene x4 for 2 minutes (Analar NORMAPUR 28975.325 VWR, BDH) 
Then the xylene-based ClearVue mountant (Thermo Fisher, 23-425-401) was used to attach 
the coverslip and the slides were baked at 60°C for 20 minutes. 
 
The EpCAM, stathmin and p70S6 kinase IHC analyses were interpreted with a consultant 
histopathologist, specialised in gynae-oncology, who was blinded as to the CTC status of each 
patient. 
The Tumour Immunostaining Score (TIS) was used to evaluate EpCAM expression, similar to 
the Allred score in the evaluation of oestrogen receptor positivity [97, 163, 235].  The TIS is a 
product of a proportion score and an intensity score.  The proportion score describes the 
estimated fraction of positively stained tumour cells (0: none; 1: <10%; 2: 10-50%; 3: 51-80%; 
4: >80%).  The intensity score represents the estimated staining intensity as compared with a 
normal FFPE control, in this case appendix (0: no staining; 1: weak; 2: moderate; 3: strong).  
The TIS ranges from 0-12 and is classified into 4 subgroups as follows: no expression (TIS 0), 
weak expression (TIS 1-4), moderate expression (TIS 6 and 8), intense expression (TIS 9 and 
12). 
The reported TIS score for stathmin overexpression was different to that used for EpCAM IHC 
[163].  It is also defined by a semiquantitative grading system that incorporates staining 
intensity (score 0-3), as per the EpCAM scoring system, and area of tumour with positive 
staining (0: no staining, 1: <10%, 2: 10-50%, 3: >50% of tumour cells).  The staining index is 
then calculated as the product of staining intensity and staining area, with a range 0-9 [163].  
Some consider the upper quartile for the data set as positive [138, 163], while others define 
moderate/high expression as an index ≥4/9 and absent/minimal expression as an index <4 
[138, 235].  This quantification method is well documented [163, 235] and was used in this 
study.   
Similarly, p70S6 kinase staining scores vary within the literature depending on the specific 
antibody and tissue type.  For consistency and based on reported data, the same staining score 
was used as for EpCAM, based on the product of staining intensity (0-3) multiplied by the 
proportion of immunoreactive cells in the areas of interest (1-4), with a score of ≥6 
representing positive staining [236]. 
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2.1.7. Validation of Stathmin Antibody for Detection on CTCs and FFPE IHC 
2.1.7.1. Stathmin Antibody Validation on CTCs 
Stathmin antibody (Biorbyt catalogue number orb10403) validation for detection on CTCs was 
performed between February to May 2012 in UCL Cancer Institute ECMC GCLP Facility 
laboratories by Helen Lowe and Natalie Griffin [237].  Firstly, immunofluorescence work was 
performed on cell lines to confirm their stathmin expression.  Secondly, the suitable cell lines 
were spiked into whole blood from healthy donors along with different concentrations of the 
stathmin antibody for analysis on the CellSearch system.   
For this validation study, 3 cell lines, Hela (epithelial cervical cancer), A549 (epithelial lung 
cancer) and SKOV3 (epithelial ovarian adenocarcinoma), all known to express stathmin [238-
240], were analysed to confirm the binding of stathmin antibody.  SKOV3 was found to be a 
higher expressing cell line for stathmin compared to A549, while the Hela cells autofluoresced 
in the absence of stathmin antibody.  Thus, the A549 and SKOV3 cell lines alone were taken 
forward for analysis on the CellSearch system.  Stathmin antibody was used at a concentration 
of 500µg/ml and demonstrated binding to the cell lines, with no batch variation. 
 
For analysis on the CellSearch system, whole blood was collected from healthy donors and 
spiked with the cell lines, either Hela or A549.  Blank samples were also assessed to rule out 
any false positives.  A control CTC sample was used with all experiment on the CellSearch 
system to ensure that it was performing correctly.  The only parameters that could be altered 
on the CellSearch Analyser II were the exposure time for the 4th channel and the concentration 
of stathmin antibody.   
Nine experiments were performed to determine the optimal stathmin concentration and 
exposure time and this was set at 1:20 dilution (50µg/ml) and 0.8 seconds respectively.   
The percentage of CTCs positive for stathmin expression in the cell lines was between 0.2-1%, 
consistent across 2 experiments and thus deemed suitable for clinical use.   
 
2.1.7.2. Stathmin antibody validation for FFPE IHC 
Use of stathmin antibody (3352 CellSignaling) for FFPE IHC was validated by Jennifer Paterson 
and Gabrielle Elshtein at UCL-Advanced Diagnostics. 
The Biorbyt stathmin antibody used for CTCs did not demonstrate overexpression on FFPE 
tissue, therefore the CellSignalling antibody was used based on published evidence off its 
utility for FFPE IHC [163].  Tonsil was used as a control tissue due to documentation of 
positivity and experience with staining and analysis [241].  Different dilution and retrieval 
times and techniques were assessed to determine optimal staining, first in tonsillar then in EC 
tissue.  Based on local assessment, biopsy specimens were best analysed with protocol 30-20-
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20, retrieval H2(20) and dilution 1:30.  The same parameters were used for the surgical 
resection specimens but with the addition of 10% goat serum to block non-specific antibody 
binding, as previously detailed in Table 2.1.   
 
2.2.  Endometrial Sample Collection and DNA Modification 
2.2.1. Protocol Approval 
The protocol and standard operating procedures for this study were approved by the UCL 
Cancer Institute Biobank REC.  Standard operating procedures covered both FFPE and FF tissue 
collection, transportation and use.  Tissue processing only commenced once the study was 
approved.  This approval allowed archival FFPE to be used for research purposes without 
individual patient consent, provided the tissue was collected from the living and was surplus to 
diagnostic requirements. 
For FF tissue, a consent form approved by the UCL Biobank REC was used by the Gynae-
oncology medical and surgical team to allow the collection of tissue, surplus to diagnostic 
requirements, for research under the ethical approval for the gynaecological biobank at UCL.  
This was approved by the REC for the UCL/UCLH Biobank for Studying Health and Disease, 
based at Pathology-Rockefeller Building and UCL Cancer Institute.   
 
2.2.2. Patient Selection and Consent 
For collection of FFPE tissue, a retrospective search of the UCLH archival histopathology 
database was performed by the histopathology team for cases of grade 1 and grade 3 EEC, 
surgically resected between January 2009 and December 2013.  Once identified, the slides 
were retrieved from storage and reviewed with a consultant Gynae-oncology histopathologist 
to select the appropriate blocks for DNA extraction. 
 
FF samples were obtained through collaboration with the gynaecological surgical team at 
UCLH.  No patient underwent surgery or biopsies specifically for the purpose of this study and 
only tissue surplus to diagnostic requirements was used.  The patients were identified during 
review in the gynaecological surgical clinics, MDT and via review of the weekly surgical list.  
Patients were approached by a member of the clinical or research team during their pre-
admission clinic or on the morning of surgery to discuss consent for collection of normal 
endometrial and cancer tissue, if present in excess to diagnostic requirements.  Donation of 
tissue samples under the Biobank approval was discussed and they received the UCL/UCLH 
Biobank for Studying Health and Disease written patient information sheet with consent form 
attached.  Written, informed consent was then obtained after the patient had read and 
understood the information sheet and all questions were answered.  An original of the consent 
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was given to the patient and a copy scanned into the patient’s secure electronic medical notes.  
A paper original was filed in the patient’s medical notes and a paper copy was securely stored 
in a locked cabinet on the ground floor of the UCL Cancer Institute. 
 
2.2.3. Sample and Data Collection  
For FFPE samples, the most recent specimens of each tissue type surplus to diagnostic 
requirements were identified, selecting specimens that contained histologically normal tissue 
as well as EC and where possible, AEH.  The haematoxylin and eosin (H&E) stained slides of 
each case were reviewed with Consultant Histopathologist, Dr Rupali Arora, to identify for 
which cases there was adequate amounts of normal endometrium, AEH and grade 1 or 3 EEC 
within the specimen.  At this time, representative areas for sampling within the tumour block 
were marked out on the corresponding H&E slides.  Each case was pseudoanonymised and 
allocated a number based on the order of identification.  All subsequent analysis used only the 
study-specific number and whether normal, atypical or cancer tissue was present. 
For FF samples, the tissue sample was collected at the time of the surgical procedure by the 
research nurse or fellow and transported to the UCL pathology department at the Rockefeller 
Building.  Tissue was reviewed by a senior histopathologist for diagnostic purposes, and where 
possible, surplus tissue, both normal and cancer from the same specimen were identified and 
dissected for collection.  This tissue was snap frozen in cryovials within a Dewar flask of liquid 
nitrogen using appropriate precautions.  The frozen tissue was taken to the ground floor of the 
UCL Cancer Institute (Room G12 allocated to the Institute for Women’s Health) and stored in 
drawer 9 of the designated -80 °C freezer.  
The FF specimens were logged and pseudo-anonymised in LabVantage and appropriately 
labelled to ensure ease of tracking and traceability.  LabVantage is a password-secured, 
electronic database that records sample identification details as well as the precise location of 
each individual sample to include room number, shelf, rack, box number and co-ordinates of 
the boxed samples where applicable.  The sample log was updated each time a sample was 
added, moved, transferred or returned to the storage freezer and recorded the date, name of 
receiving researcher, name of lead researcher, description of tissue, details of consent and 
location.  A unique identifier was assigned for use in the database and a number assigned in 
order of recruitment.  This identifier was held separately on a password secured computer by 
the two staff members who updated LabVantage.   
All tissue analyses fulfilled requirements of the Human Tissue Act 2004 and the Human Tissue 
Authority and was conducted in accordance with the ethical principles in the Declaration of 
Helsinki, Good Clinical Practice and applicable regulatory requirements.  
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Clinical data from the UCLH patient information system was collected for the patients who had 
FFPE or FF specimens processed on the arrays including demographics, clinicopathologic 
information, details of recurrence and survival.  This data was pseudoanonymised and stored 
on a password secured database at UCL Cancer Institute, accessible only to relevant members 
of the research team at UCL/UCLH.   
 
2.2.4. DNA Extraction and Modification for the Illumina 450K array 
2.2.4.1. Formalin-Fixed Paraffin-Embedded Tissue 
2.2.4.1.1. DNA Extraction 
Each block, corresponding to the selected slide for each histopathology sub-type, was 
sectioned at 6 micron thickness onto between 20 and 40 plain glass slides, depending on the 
amount of tissue available per slide, and were left to air dry.  
Slides were de-waxed using a standard protocol, whereby a series of washes were performed, 
first in Histoclear (National Diagnostics UK, AGTC Bioproducts, Yorkshire, HU13 9LX, UK) for 10 
minutes, repeated three times; then in industrial methylated spirits (IMS) 100% for 10 
minutes, repeated twice; then in IMS 70% for 5 minutes and finally in double-distilled (dd) 
water for 5 minutes.  Slides were then left to air dry at room temperature. 
Once the slides were dry, the marked sections were macro-dissected from the slide using a 
sterile 21-gauge needle with buffer ATL on its tip and placed in a 1.5ml microcentrifuge tube 
with 180µl buffer ATL.  After the addition of 20-40µl of proteinase K, the sample was mixed by 
vortexing and incubated on a spinning cycle overnight to digest. 
The process of DNA extraction using the QIAmp DNA mini-kit (Qiagen GmbH D-40724 Hilden, 
Cat No 51304) was then performed using the manufacturer’s instructions and is summarised 
as follows: 
i) The 1.5ml tube was centrifuged to remove drops from inside the lid 
ii) 200µl Buffer AL was added, pulse vortexed for 15 seconds and incubated at 
70°C for 10minutes then briefly centrifuged 
iii) 200µl ethanol (96-100%) was added, pulse vortexed for 15 seconds and briefly 
centrifuged 
iv) This mixture was applied to the QIAmp mini spin column, placed in a 2ml 
collection tube, without wetting the rim.  The cap was closed and it was 
centrifuged at 6000xg for 1 minute, the placed in a clean 2ml collection tube, 
discarding the filtrate 
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v) 500µl Buffer AW1 was added and centrifuged at 6000xg for 1 minute, then 
placed in a clean 2ml collection tube, discarding the filtrate 
vi) 500µl Buffer AW2 was added and centrifuged at 20 000xg for 3 minutes, then 
placed in a new 2ml collection tube, discarding the filtrate.  
vii) The tube was centrifuged at 20 000xg for 1 minute, then the mini spin column  
was placed in a clean 1.5ml microcentrifuge tube, discarding the filtrate  
viii) To elute the DNA, 100µl buffer AE was added and incubated at room 
temperature for at least 5 minutes, then centrifuged at 6000xg for 1 minute 
 
2.2.4.1.2. DNA Concentration Analysis 
The two most commonly utilised methods for quantification of DNA are based on 
spectrophotometric and fluorescence technologies and both methods were used in this 
analysis.   
The concentration of the DNA was checked using the NanoDrop spectrometer (Thermo 
Scientific, Wilmington, DE) alone for the first 10 specimens, then both the NanoDrop 
spectrometer and Qubit 2.0 Fluorometer, when this was introduced to the lab.   
NanoDrop is a spectrophotometric instrument with a patented sample retention system that 
uses fibre optic technology and surface tension to hold a 1µl sample in place between two 
optical surfaces that define the pathlength [242].  During each measurement, the sample is 
evaluated at a 1mm and 0.2mm path to measure DNA concentration across a wide range from 
2ng/µl to 3700ng/µl.   
The quantification of DNA by NanoDrop relies on the fact that its peak light absorption is 
260nm.  Protein absorbs at 280nm, thus to determine the purity of the DNA, a ratio of the 
absorbance values is calculated.  The 260/280nm ratio should be 1.7-1.8 for pure DNA, 
whereas lower values may reflect protein contamination.  Higher ratios usually indicate the 
presence of RNA, which has a 260/280 ratio of approximately 2.2-2.3.  The 260/230nm ratio is 
also used as peptide bonds absorb at 228nm and may be a more reliable indicator of proteins 
or peptides present in nucleic acid samples.  The 260/230 ratio should be >1.5.  Buffer salts can 
also contribute to absorbance readings below 260nm, and it is important to blank the 
spectrophotometer prior to use in the same buffer in which your DNA sample is diluted.   
 
Fluorescence methods of DNA quantification on the other hand, rely on the use of sensitive 
dyes that fluoresce in proportion to the component of interest, whether that is protein, RNA or 
DNA.  
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The Qubit 2.0 fluorometer (Life Technologies, Paisley, UK; Cat No Q32866) utilises fluorometric 
technology and Molecular Probes dyes to quantify biomolecules of interest, whether DNA, 
RNA or protein.  The fluorescent dye emits signals only when bound to specific target 
molecules, even at low concentrations and have extremely low fluorescence when unbound.  
The Qubit DNA dye binds to DNA by intercalation between the bases, where it assumes a more 
rigid shape and becomes fluorescent.    It binds within seconds and reaches equilibrium in less 
than 2 minutes.  At a specific dye concentration, the amount of fluorescence is proportional to 
the concentration of DNA in the sample, and the Qubit fluorometer uses DNA standards of 
known concentration to convert the fluorescence signal of a sample into a DNA concentration. 
 
The protocol of sample assessment on the Qubit Fluorometer is as follows: 
i) The number of 0.5ml Qubit assay tubes (Life Technologies, Paisley, UK; Cat No 
Q32856) needed for the samples and two standards were prepared 
ii) The Qubit working solution was made by diluting the Qubit dsDNA reagent 1:200 
in Qubit dsDNA buffer 
iii) For preparation of the two standards, 190µl of Qubit working solution was added 
to 10µl of each Qubit standard and mixed by vortexing for 2-3 seconds 
iv) For sample preparation, 199µl of Qubit working solution was added to 1µl of each 
sample, to make a total volume of 200µl and mixed by vortexing for 2-3 seconds. 
v) All the tubes were incubated for 2 minutes then run on the Qubit fluorometer, 
following the screen instructions. 
vi) Using the Calculate Stock Concentration option, the concentration given in µl/ml 
was converted to ng/µl. 
The Qubit dsDNA broad range (BR) assay kit (Life Technologies, Paisley, UK; Cat No Q32853) 
detects concentrations between 100pg/µl and 1000ng/µl, while the Qubit dsDNA high 
sensitivity (HS) assay kit (Life Technologies, Paisley, UK; Cat No Q32854) detects concentrations 
between 10pg/µl and 100ng/µl.   The concentration measured on NanoDrop was used as an 
estimate for the appropriate Qubit assay kit.  If the concentration could not be detected on 
initial assessment and was out of range, the alternate kit was used. 
Once the concentration was measured, specimens were stored at -20°C for further 
modification and analysis. 
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 2.2.4.1.3. FFPE Quality Check  
After the first run on Illumina HumanMethylation 450K array was performed, a further quality 
control step was introduced to assess the integrity of the DNA that was extracted.  This step 
was designed to reduce the likelihood of performing an array on DNA of poor quality.  The 
Applied Biosystems 7300 Real-Time (RT) PCR System was used for this analysis in 7300 mode. 
This step was performed using the Illumina Infinium HD FFPE QC Kit (Cat number WG-321-
1001), as per the manufacturer’s instructions and summarised below: 
i) 1µl of extracted DNA was diluted to concentration of 1ng/µl using dd H20 
ii) SybrGreen, QC Primer Reagent and QC Template (QCT) reagent were thawed to 
room temperature   
iii) 1µl QC Template Reagent was added to 990µl ddH20, vortexed and centrifuged 
briefly 
iv) A mastermix for 20µl reaction volumes was prepared including 10µl SybrGreen, 
2µl QC Primer Reagent and 4µl ddH20 for each DNA sample to be run in triplicate 
as well as for the QCT reagent and dd H20 controls and for approximately 33% 
overage.  It was mixed by inverting 10 times and tapped onto the bench to collect 
droplets.  16µl of this mastermix was pipetted into each well of a 96-well PCR plate 
v) To the designated triplicate wells, 4µl of the diluted QCT reagent was added 
vi) To the further designated wells, 4µl of dd H20 in triplicate was added 
vii) 4µl of genomic DNA in triplicate into the other designated wells was added 
viii) The plate was sealed and briefly centrifuged at 280xg 
ix) The plate was placed in the 7300 RT-PCR machine and programmed for the 
following thermal profile: 95°C for 10 minutes, 95°C for 30 seconds x40, 57°C for 
30 seconds x 40, 72°C for 30 seconds x40, followed by a dissociation stage (where 
dsDNA breaks into ssDNA) 
For data analysis: 
i) The H20 wells were checked for amplification as this should be 0. 
ii) Other samples were checked for good amplification across all triplicates and that 
the threshold/quantification cycle (Cq) values, generated by the 7300 RT-PCR, 
were consistent within half a unit  
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iii) The average Cq values were obtained for the triplicate wells for each FFPE and QCT 
sample 
iv) The average Cq value for the QCT sample was subtracted from the average Cq 
value for each sample to compute the Delta Cq value for each sample.   
 
2.2.4.1.4. DNA Ligation 
Using the REPLI-g FFPE kit (Qiagen GmbH D-40724 Hilden, Cat No 150245), ligation of the FFPE-
extracted DNA was performed.  2.5µg DNA in a total volume of 10µl (concentration 250ng/µl) 
was required for this step and samples were either concentrated or diluted with dd H20 to 
make up the appropriate concentration.  If the DNA concentration was too low to provide 
2.5µg DNA, 1.5-2µg was used. 
 A mastermix was prepared on ice from contents of the REPLI-g FFPE kit, including 8µl FFPE 
buffer, 1µl of ligation enzyme and 1 µl of FFPE enzyme per sample to be processed.  This was 
added to the 10µl of DNA, vortexed and centrifuged.  Using a thermocycler, the specimen was 
then incubated at 24°C for 90 minutes for ligation to occur, followed by a denaturing step at 
95°C for 5 minutes, then cooled to 4°C. 
  
2.2.4.1.5. Bisulfite Conversion 
The EZ DNA Methylation kit (Zymo Research Cop, Orange, CA 92867, USA, Cat No D5001) was 
used for bisulfite conversion and is summarised as follows: 
i) The CT conversion reagent was prepared by adding 750µl autoclaved H20 and 
210µl M-dilution buffer to the CT tube, mixing at room temperature for 10 
minutes with frequent vortexing.  This prepared reagent could be store for up to 1 
month at -20°C but needed to be warmed to 37°C and vortexed prior to use 
ii) M-Wash buffer was prepared by adding 96ml of 100% ethanol to the 24ml M-
Wash buffer concentrate 
iii) In a 12-PCR tube row, 20µl of ligated DNA was added to 5µl of M-dilution buffer 
and 25µl H20 to make a total volume of 50µl, and incubated at 37°C for 15 minutes 
to denature the DNA. 
iv) 100µl of CT conversion reagent was added to each sample and mixed with minimal 
exposure to light 
v) Bisulfite conversion was performed by incubating the samples in the dark at 50°C 
for 16 hours.  Every 60 minutes, the DNA was denatured through thermocycling at 
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95°C for 30 seconds before returning to 50°C for further incubation.  The hourly 
denaturing step improved bisulfite conversion efficiency.  Once completed, the 
sample was returned to 0-4°C for 10 minutes or longer if required. 
vi)  400µl of M-Binding Buffer was then added to the sample in a Zymo-Spin IC 
column, which was then inverted several times to mix, placed in a collection tube 
and centrifuged at full speed ≥10 000xg for 30 seconds, discarding the flow-
through 
vii)  100µl of M-Wash Buffer was added to the column and centrifuged at full speed 
for 30 seconds, discarding the flow-through. 
viii) 200µl of M-Desulphonation Buffer was added to the column and left to stand at 
room temperature (20-30°C) for 15-20 minutes, then centrifuged at full speed for 
30 seconds. 
ix) 200µl of M-Wash Buffer was added to the column, centrifuged at full speed for 30 
seconds, followed by a further addition of 200µl of M-Wash Buffer and centrifuged 
for an additional 30 seconds. 
x) The column was then placed in a 1.5ml microcentrifuge tube and 10µl of M-Elution 
Buffer was added directly to the column matrix.   The sample was incubated for 5 
minutes then centrifuged for 30 seconds at full speed to elute the DNA. 
The DNA could then be stored at -20°C prior to analysis. 
 
2.2.4.1.6. Quality Control of Bisulfite Conversion 
This quality control step was performed to check the percentage success of the bisulfite 
conversion, through the use of PCR reaction and primer sets specific for bisulfite converted 
and unconverted DNA.  The Applied Biosystems 7300 Real-Time PCR System was used for this 
analysis in 7300 mode. 
From each specimen, 1µl of bisulfite converted DNA was added to 9µl autoclaved water.  At 
the same time, a mastermix was prepared containing SybrGreen 6.25µl, primers 0.625µl, 
autoclaved H20 4.375µl, calculated for each specimen to be run in triplicate.  The primers used 
were actin positive and actin negative (Sigma-Aldrich, Dorset, England; Batch No HA05224892-
5) and a separate mastermix was prepared for each.  The actin positive primer would bind to 
bisulfite converted DNA and the actin negative primer would bind unconverted DNA, such that 
comparison of the two, would generate the percentage bisulfite conversion for each sample.   
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Both the actin positive and negative primers consisted of forward and reverse oligo sequences 
(5’-3’) as follows: 
Actin BisConv Pos Forward: TGGTGATGGAGGAGGTTTAGTAAGT 
Actin BisConv Pos Reverse: AACCAATAAAACCTACTCCTCCCTTAA 
Actin BisConv Neg Forward: TGGTGATGGAGGAGGCTCAGCAAGT 
Actin BisConv Neg Reverse: AGCCAATGGGACCTGCTCCTCCCTTGA 
A water sample and template control were also run in triplicate as a comparator for the 
specimens. 
11.25µl of mastermix was pipetted into the designated wells of a 96-well PCR plate (an 
example is illustrated in Table 2.2).  1.25µl either of the water, control or sample were added, 
placing the pipette to the bottom of the well to ensure adequate mixing and to avoid bubble 
formation.   
An optical seal was then placed on top of the PCR plate without touching the sides.  The plate 
was flat vortexed to mix for 10 seconds, then centrifuged for 30-60 seconds. 
The plate was then analysed on the RT-PCR machine as follows: 
- Stage 1: 95°C for 10 min 
- Stage 2: 95°C for 15sec x40, 60°C for 1min 
- Dissociation stage: 95°C for 15sec, 60°C for 1min, 95°C for 15sec, 60°C for 1min 
- hold at 4°C 
 
Table 2.2: Example of a plate prepared for Bisulfite Conversion QC 
 Wells 1-3 Wells 4-6 Wells 7-9 Wells 10-12 
A S1 A+ S1 A- S2 A+ S2 A- 
B S3 A+ S3 A- S4 A+ S4 A- 
C S5 A+ S5 A- S6 A+ S6 A- 
D S7 A+ S7 A- S8 A+ S8 A- 
E S9 A+ S9 A- S10 A+ S10 A- 
F S11 A+ S11 A- S12 A+ S12 A- 
G S13 A+ S13 A- S14 A+ S14 A- 
H H20 A+ H20 A- Control A+ Control A- 
S: sample, A: actin 
 
Data was then analysed both visually and from quantitative data that was extracted and 
analysed in Microsoft Excel.  If bisulfite conversion was successful, the samples were then 
ready to be analysed on the Illumina HumanMethylation 450K BeadChip array. 
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2.2.4.2. Fresh Frozen Tissue 
2.2.4.2.1. DNA Extraction 
For DNA extraction, tissue was transferred from the cryovials onto a petri dish placed on dry 
ice, to minimise thawing of unused tissue.  In a fume hood, a 25-50mg section of tissue was 
dissected using a sterile scalpel and placed in a 1.5ml microcentrifuge tube.  
DNA was then extracted using the DNeasy Blood and Tissue Kit (Qiagen GmbH D-40724 Hilden, 
Category number 69504 and 69506) and the protocol below: 
i) 180µl buffer ATL and 20µl proteinase K were added to the tube, then mixed by 
vortexing and incubated at 56°C until completely lysed (up to 24-48 hours). 
ii) 200µl buffer AL was added and mixed by vortexing then incubated at 56°C for 10 
minutes 
iii) 200µl 100% ethanol was added and mixed by vortexing 
iv) The mixture was pipetted into a DNeasy Mini spin column placed in a 2ml 
collection tube, centrifuged at ≥6000 xg (8000rpm) for 1 minute, discarding the 
flow-through and the collection tube. 
v) The spin column was placed in a new 2ml collection tube, 500µl buffer AW1 was 
added and then centrifuged for 1 minute at ≥6000 xg (8000rpm), discarding the 
flow-through and the collection tube. 
vi) The spin column was placed in a new 2ml collection tube, 500µl buffer AW2 was 
added and then centrifuged for 3 minutes at 20 000 xg (14 000rpm), discarding the 
flow-through and the collection tube. 
vii) The spin column was placed in a new 2ml collection tube and centrifuged at 
20000xg for 1 minute, discarding the filtrate and tube and then placed in a clean 
1.5ml microcentrifuge tube. 
viii) The DNA was eluted by adding 100µl buffer AE to the centre of the spin column 
membrane, incubated for 5-10 minutes at room temperature and then centrifuged 
for 1 minute at ≥6000 xg (8000rpm).   
ix) The eluted DNA was then stored at -20°C for bisulfite conversion and further 
analysis. 
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2.2.4.2.2. DNA Concentration Analysis 
As for the FFPE samples, DNA concentration for the FF samples was measured using both the 
NanoDrop spectrophotometer and the Qubit fluorometer. 
 
2.2.4.2.3. Bisulfite Conversion 
As for the FFPE samples, the same method was used for bisulfite conversion; however, the 
ligation step was not required. 
 
2.2.5. The Illumina HumanMethylation 450K BeadChip array 
2.2.5.1. Background to the Illumina HumanMethylation 450K BeadChip array 
The Illumina bead array technology is a more recent addition to the methylation technologies 
described in section 1.4.2.3, and started with the GoldenGate and Infinium HumanMethylation 
27 array platforms.    These technologies used shorter stretches of target DNA including 
fragmented DNA extracted from FFPE tissue.  The Infinium HumanMethylation 27K platform 
was a high throughput single nucleotide extension or methylation sensitive single nucleotide 
primer extension that analysed over 27 000 CpG dinucleotide sites, selected predominantly 
from the promoter regions of 14 000 annotated genes.  Data was expressed as ß, continuous 
variables between 0 and 1, and represented the ratio of the intensity of the methylated bead 
type to the combined locus intensity.  The BeadChip technology allowed detection of 
methylation levels down to as little as 2.5% [230].   
The Infinium methylation array uses beads with long target-specific probes designed to 
interrogate individual CpG sites, with a span of 50 bases.  In the Infinium HumanMethylation 
27K array, the Infinium type I primer extension assay was used where there were two probes 
per CpG locus, one as an unmethylated and one as a methylated query probe.   The 3’ prime 
terminus of the probe matched either the protected cytosine (C, methylated) or the thymine 
base (T, unmethylated) resulting from bisulfite conversion and whole genome amplification.  
As methylation changes are regionally correlated and 90% of CpG sites within 50 bases have 
the same methylation status [243][244], the use of probes with a span of 50 bases is thought 
to give highly correlated results. 
The Infinium type II assay design has one probe per locus to detect CpG sites located in regions 
of low CpG density, as illustrated in Figure 2.3.  The 3’ terminus of the probe complements the 
base directly upstream of the query site while a single base extension results in the addition of 
a labelled G or A base, complementary to either the methylated C or unmethylated T.  The 
Infinium II probes can have up to 3 underlying CpG Sites within the probe sequence without 
compromising data quality.  This allows the methylation status at a query site to be assessed 
independently of neighbouring CpG sites.  The Illumina HumanMethylation 450K BeadChip 
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array (450K array) is made up of both Infinium type I (28%) and II (72%) assays and allows rapid 
genome-wide methylation analysis of hundreds of thousands of CpG sites across a large 
number of samples.   
 
Figure 2.3: Infinium Methylation Type I versus Type II Assay [231] 
2.3A shows the Infinium I assay design with 2 bead types to bind methylated (C) and 
unmethylated (T) CpG loci respectively.   
2.3B shows the Infinium I assay with a single bead type for each CpG locus. Methylation state 
is detected by a single-base extension with ‘A’ incorporated at an unmethylated query site (T) 
and ‘G’ incorporated at a methylated query site (C).  
 
 
 
 
2.2.5.2. Processing of the Illumina HumanMethylation 450K BeadChip array 
The array analysis was carried out by UCL genomics, ICH microarray centre, Institute for Child 
Health, according to standard, quality assured techniques.  
The 450K BeadChip protocol comprised a number of steps including whole genome 
amplification, fragmentation, precipitation, hybridisation, washing, counterstaining and 
scanning, as per the standard Infinium protocol and took approximately 4 days.   
In the whole genome amplification reaction, 4µl of bisulfite-converted DNA was mixed with 
MA1 and NaOH, vortexed, centrifuged, then incubated at 22°C for 10 minutes.  Further MA1 
and MSM was then added, mixed, centrifuged and incubated in the Illumina hybridisation oven 
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at 37°C  for 20-24 hours.  Enzymatic fragmentation was then required to produce bisulfite 
converted DNA at a length that would hybridise to the oligonucleotides on the array.  The 
sample was removed from the oven and FMS was added to each sample, vortexed, centrifuged 
and incubated at 37°C for 1 hour.  Isopropranol was then added to cause precipitation of 
fragmented DNA and incubated at 37°C for 5 min, then 4°C for 20 minutes.  Precipitated DNA 
was then resuspended prior to hybridisation in RA1 buffer and placed in the hybridisation oven 
at 48°C for 1 hour.  The samples were then denatured by heating the plate to 95°C for 20 
minutes.  Hybridisation to the BeadChips then occurred at 48°C for 16-24 hours.  After 
hybridisation, the BeadChips were washed in solutions WB1 and PB1 to remove any 
unhybridised DNA.  Labelled nucleotides were added to extend the oliogonucleotides to which 
the template DNA had hybridised.  The signal from the stain was amplified via a multi-layer IHC 
staining process and the BeadChip were then scanned in the Illumina iScan. 
 
2.2.6. Data Analysis 
Data analysis was carried out using R statistical software (version 3.03) and validated 
algorithms developed at UCL Cancer Institute.  Data for all epigenetic and genetic analysis was 
processed by a trained staff member and stored on a password secured database, accessible 
only to relevant members of the research team.   
 
2.2.6.1. Methylation Data 
For methylation data analysis, R statistical software and ChAMP packages were used, as these 
are validated and in use at the UCL Cancer Institute [245] and provide an integrated pipeline of 
the most commonly used normalization methods with novel techniques to detect differentially 
methylated regions (DMRs) and copy number(CN) aberrations. 
The R console is a language and environment for statistical computing and graphics with a 
suite of software facilities for data manipulation, calculation and graphical display. 
The ChAMP package is a pipeline that integrates both available 450K analysis methods as well 
as several analysis options not available in other packages [245].  It uses the data import, 
quality control and SWAN (subset-quantile within array normalisation) functions as part of the 
minfi package.  The PBC (Peak Based Correction) method and the BMIQ normalization method 
are also utilised. 
It includes SVD (singular valve decomposition) methods to assess batch effects and allows 
correction for this using the ComBat method.  The new Probe Lasso method also allows 
identification of DMRs and there is additional functionality to analyse 450K for CN variation.   
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After R was installed, the required packages were downloaded including minfi, DNAcopy, 
impute, marray, limma, preprocessCore, RPMM, sva and 
IlluminaHumanMethylation450kmanivest., followed by the ChAMP package. 
Script 1 (appendix 2A) contains the instructions to enter into R as part of the ChAMP pipeline 
to load the data and run the quality control steps described. 
The data was processed through a number of quality control and normalisation packages, as 
demonstrated in Figure 2.4.  The raw data generated from the 450K array was loaded from 
.idat files using the minfi package and ChAMP filtered the data to detect probes with a 
detection p-value greater than 0.01 in at least one sample.  A sample list was generated 
showing each sample and the fraction of failed probes per sample.  Samples with a failure rate 
of >5%-10% were then removed manually and the data was reloaded into R to increase the 
number of probes that could be analysed.   
The load function then generated 3 images, a density plot, MDS (multidimensional scaling) plot 
and sample cluster plot.  The density plot showed unnormalised beta values and could identify 
any samples with significantly different profiles.  The beta MDS plot allowed a visualisation of 
the similarity of the samples based on the top 1000 most variable probes.  The cluster plot also 
visualised the similarity of samples based using hierarchical clustering on all probes.   
A second control step was the intra-array normalisation of data using BMIQ to adjust the data 
for bias introduced by the Infinium type II probe design.  As outlined above, Infinium type I and 
II probes are used on the 450K array and have two different designs with different DNA 
methylation distributions that may bias downstream analysis.  The Infinium type II probes are 
generally less accurate and reproducible than the Infinium I probes [246] and thus, BMIQ 
normalisation was used to reduce this technical variation and eliminate bias caused by the 
type II probes.  Poorly performing probes were automatically removed and three further 
images were then generated of the normalised beta MDS plot, cluster plot and density plot.   
A third control was performed via Singular Value Decomposition (SVD) that assessed the most 
significant components of variation and batch effects, associated with both biological aspects 
and technical factors of the array.  SVD was applied to the data matrix to compute p-values 
based on the significance of each component and generated a heatmap of 18 internal controls 
as well as the top 6 principle components correlated to the provided information.   
The ComBat function was then used to correct for batch effects. 
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Figure 2.4: An Overview of the ChAMP Pipeline  
SVD: singular valve decomposition, CNA: copy number alteration, MVP: methylation variable 
positions, SNP: single nucleotide polymorphism, DMR: differentially methylated regions. 
 
The limma package was then utilised to calculate the p-value for differential methylation using 
a linear model.  It generated a file including all probes with methylation variable positions 
(MVPs) between the two groups of interest, with a given p-value.  A file was also saved with 
the significant MVPs that could be used for downstream pathway analysis. 
The DMR hunter-probe lasso then computed a data frame of probes divided into discrete 
differentially methylated regions (DMRs), with accompanying p-values.  DMRs are segments of 
the genome that show a quantitative alteration in DNA methylation levels between 2 groups.   
The DMR and MVP files contained information on the probes, associated genes, 
hypomethylation and hypermethylation, genomic distribution and CpG content.  This was 
performed for NvC, NvA and NvC comparisons, as only 2 groups could be compared per 
pipeline analysis for MVPs and DMRs. 
 
There were a number of other features in addition to the ChAMP pipeline that were 
performed for further data analysis.   
Firstly, cluster dendrograms and heatmaps showing either the 500 or 1000 most variable 
probes between two or three comparator groups could be generated using  script 2 (appendix 
2B).  These figures demonstrated which samples clustered together, regardless of whether 
significant MVPs or DMRs were detected, and could also incorporate clinical data and its 
relationship to sample clustering.  This was performed for NvC, NvA, AvC and NvAvC 
comparisons.  For the NvAvC comparison, the raw data was loaded as above but the limma 
package and hunter probe lasso steps were not performed. 
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The heatmaps demonstrate differential methylation changes based on a beta value between 0 
and 1.  The beta value is the fluorescence intensity ratio between methylated and 
unmethylated probes.  A ratio value of 0 (yellow) equals non-methylation of the locus, 1 equals 
total methylation (blue) and 0.5 means that one copy is methylated and the other is not. 
 
Study data could also be compared to publicly available TCGA data through Marmal-aid [247], 
using script 3 (appendix 2C).  This is a standardised, freely available database for DNA 
methylation that incorporates the majority of publicly available Illumina 
HumanMethylation450 data into a single repository, including data from TCGA.   
 
Secondly, when MVPs and DMRs were present, a gene list was generated based on the 
associated probes and could be further analysed.  The Web-based Gene Set Analysis Toolkit 
(Web Gestalt) was used to perform enrichment analysis via KEGG analysis or Pathway 
Commons analysis to determine the gene associations and pathways involved [248].  
WebGestalt is designed for functional genomic, proteomic and large-scale genetic studies from 
which a large number of gene lists are generated.  WebGestalt uses information from different 
public resources to inform these gene associations.  To initiate the search, an organism 
(hsapiens) and a gene ID type (hsapiens_gene_symbol) were defined.  The gene list was then 
uploaded and could be compared to a predefined reference set (hsapienes_genome).  A 
hypergeometric statistical method was used and a significance level was selected of p<0.001.   
Once the enrichment analysis was performed through WebGestalt, the gene list was reviewed 
within the MVP and DMR tables to assess the location of the gene, whether in the promoter 
region (TSS200, TSS1500 or 1xt exon), body or other location.   
 
Thirdly, genes of interest were analysed through the R console using script 4 (appendix 2D), 
and differential methylation across normal endometrium, AEH and EC tissue and within a 
specific locality of the gene could be identified and assessed for statistical significance using 
the Welch Two Sample t-test.   
 
2.2.6.2. Copy Number Variation analysis 
The raw data from the 450K array could also be used for analysis of CN variation (CNV).  After 
the normalisation, SVD and batch correction steps were performed, CNV was analysed using 
script 5 (appendix 2E).  The CNV analysis only allowed 2 groups to be compared at one time 
and as such, the following comparisons were performed:  NvC, NvA, AvC.  The difference in 
CNV between normal, AEH and EC tissue could then be analysed to see where the change in 
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CNV occurred, whether between the normal and atypical transition or between atypical and 
cancer.   
This step also generated raw data per sample demonstrating CN amplification and deletion per 
chromosome.  This raw data was analysed through the GISTIC2 module Version 6.2 on the 
Broad Institute GenePattern web-based server [249], using the following parameters. 
- Refgene file: Human Hg18 (contains information about the location of genes and 
cytobands on a given build of the genome) 
- Seg file: segmented data for all the samples.  The file includes sample name, 
chromosome number, start position (in bases), end position (in bases), number of 
markers in the segment and the SegCN [log2()-1 of CN]. 
- Markers file: contains the marker names and positions based on the markers in the 
original dataset.  This file includes the marker name (probe number for 450K array), 
chromosome location and marker position.  
- Gene GISTIC: yes  (flag indicating that the gene GISTIC algorithm should be used to 
calculate the significance of deletions at a gene level) 
- Amplifications threshold: 0.1 (threshold for copy amplifications.  Regions with a log2 
ratio above this value are considered amplified)  
- Deletions threshold: 0.1 (threshold for copy deletions.  Regions with a log2 ratio below 
the negative of this value are considered deletions) 
- Join segment size: 4 (smallest number of markers to allow in segments from the 
segmented data.  Segments that contain a number of markers less than or equal to 
this number are joined to the neighbouring segment that is closest in CN) 
- Qv threshold: 0.25 (threshholding value for q-values) 
- Remove X: yes (flag indicating whether to remove data from the x-chromosome before 
analysis) 
- Cap val: 1.5 (minimum and maximum cap values on analysed data.  Regions with a log2 
ratio greater than the cap are set to the cap value; regions with a log2 ratio less than –
cap are set to –cap) 
- Confidence level: 0.75 (confidence level used to calculate the region containing a 
driver) 
 
The GISTIC2 module identified regions of the genome that were significantly amplified or 
deleted across the samples for comparison.  A number of parameters were assessed including 
the G-score, Q-values, peak region, wide peak and broad versus focal events.   The G-score is 
based on the amplitude of the aberration as well as the frequency of its occurrence across 
samples.  The Q-value indicates the false discovery rate for the aberrant regions and 
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probability that the event is due to a chance fluctuation.  This defines the statistical 
significance of each aberration based on comparing the observed statistic to that expected by 
chance.  Regions with a Q-value below a defined threshold are considered significant. 
For each significant region, a ‘peak region’ is identified with the greatest amplitude and 
frequency of alteration and a ‘wide peak’ is defined for identifying the most likely gene targets 
in the region.  Each region is also labelled as resulting from a broad event (longer than half a 
chromosome arm) or from a focal event or both. 
Thus, the GISTIC module reported the genomic location and Q-values for each of the regions 
with CNV, along with the genes found in regions of significant amplification or deletion. 
 
Details of the output files from GISTIC2 module are outlined as follows: 
- Segmented CNV heat map per comparison  
- Amplification plot for each comparison  
- CN amplification loci and associated genes  
- Deletion plot for each comparison  
- CN deletion loci and associated genes  
 
The loci and gene data were then analysed similar to the methylation data through Web 
Gestalt and the KEGG and Pathway Commons enrichment analyses to identify the significant 
cancer related genes and associated pathways.  A p-value ≤0.1 was used for this analysis. 
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CHAPTER 3: Enumeration and Clinical Correlation of CTCs in Endometrial Cancer 
3.1. Introduction 
The currently used prognostic and predictive parameters that guide patient management in EC 
are based on historical clinicopathologic factors, without correlation with molecular profiling 
that is standard in breast, lung and colorectal cancers for example.  There is a need to develop 
validated prognostic and predictive biomarkers to better guide therapeutic management and 
streamline the drug development process in EC.    
CTCs are epithelial cancer cells known to circulate in the peripheral blood of patients, including 
in breast, prostate, ovarian, colorectal and lung amongst others, and are not detected in 
healthy individuals [88].   As CTCs can be analysed from a simple blood draw, their use for 
predictive purposes and to assess drug response and resistance is appealing, as it can spare 
patients undergoing more invasive procedures.  Novel technologies also allow molecular 
profiling on CTCs that could assist with treatment selection and identify changes in the 
molecular profile of an individual’s tumour over time. 
Numerous techniques for the isolation and enumeration of CTCs have been reported over the 
years, but only the Veridex CellSearch method is analytically validated and FDA approved for 
use for prostate, breast and colorectal cancers as a predictive and prognostic biomarker.  In 
prostate and breast cancer, a CTC count ≥5 [102, 107] is used to define a poor prognostic 
group, while in colorectal cancer, a CTC count ≥3 [111] is used.   
The first step in CellSearch CTC detection is based on an anti-EpCAM ferrofluid capture 
reagent.  There are arguments for and against the use of EpCAM as a selection tool for CTC 
detection; however, as the CellSearch platform is the only FDA approved and standardized 
system to capture and quantify CTCs and EC has a reported high expression of EpCAM [250], it 
was used for this feasibility study.   
As detailed in the introduction section 1.4.1.3, stathmin is a cytosolic phosphoprotein and 
regulator of the microtubule cytoskeleton and cell cycle [148] that has also been shown to be a 
highly relevant biomarker in EC [163].  Not only is it overexpressed in EC with evidence of 
predictive value for metastases and survival, it may also predict response to chemotherapy 
and act as a surrogate marker of PI3K pathway activation [122], one of the most commonly 
aberrant pathways in EC.  At the UCL Cancer Institute, stathmin has been validated for IHC 
assessment on FFPE tissue, as well as for use in cell lines and CTCs, as outlined in Methods 
section 2.1.7. 
 
Here, a feasibility study was conducted for the enumeration and molecular analysis of CTCs as 
a prognostic and predictive biomarker in EC.  Peripheral blood samples were taken from 
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patients with locally advanced or metastatic EC at any stage of their treatment and patients 
were then followed over time with repeat CTC assessment.  In conjunction with the CTC 
collection, clinical data was collected on clinicopathologic parameters and treatment history. 
 
The aims of the study are summarised in Figure 3.1 below. 
 
 
 
 
 
 
 
 
 
  
Figure 3.1. CTC Enumeration and Molecular Profiling in EC (EEC and NEEC) 
 
 Feasibility of CTC enumeration and molecular profiling in EC on the 
Veridex CellSearch platform 
 Correlation with clinical data and treatment 
 Correlation  of tumour tissue IHC with CTC profiling 
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3.2.  Summary of Patient Recruitment and CTC Enumeration 
35 patients were consented for involvement in this study.  Figure 3.2 summarises the CTC 
testing and results for patients on study, related to whether they had dual pathology with 
endometrial and ovarian/primary peritoneal cancers, locally advanced or metastatic disease. 
 
Figure 3.2: CTC Enumeration in the 35 Consented Study Patients 
 
 
EC: endometrial cancer; m: metastatic; LA: locally advanced, +: positive, -: negative 
* 1 consented but did not have a further blood test for CTC collection, and the other had a 
sample collected, but the CellSearch system malfunctioned at the time of analysis. 
# 3 patients (10, 16, 18) had pre-operative CTC assessment performed based on staging as 
locally advanced endometrial cancer, and were then confirmed at surgery to have synchronous 
stage I endometrial and stage III or IV ovarian/primary peritoneal cancers.   
 
35 consented
33 evaluable CTC 
30 with EC
3 with LA EC
0 CTC + 3 CTC -
27 mEC
18 CTC + 9 CTC -
3 with dual 
pathology#
1 CTC + 2 CTC -
2 not evaluable*
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3.3. CTC Detection on CellTracks Analyser II 
As outlined in the methods section 2.1.5, the CellTracks Analyser II displays CTC candidate 
images generated after a blood specimen has been processed on the CellTracks Autoprep 
system.   These images were reviewed by the operator and researcher to assess if any fulfilled 
the criteria for a CTC.  A CTC was defined as being positive for cytokeratins (CK-PE) and nuclear 
staining (DAPI), negative for leucocyte staining (CD45-APC) and as having the correct 
morphology and CK-PE and DAPI overlay to be characterised as a tumour cell.   
Figure 3.3 demonstrates examples of patients with positive and negative CTCs detected, with 
or without Stathmin positivity.  Figure 3.4 illustrates the total number of patients with positive 
CTC counts and those with positive Stathmin. 
 
Figure 3.3:  CellTracks Analyser CTC Candidate Images and Interpreter Detection 
A: Patient 9, B: Patient 10, C: Patient 22, D: Patient 26, E: Patient 27 
Orange boxes mark those images which met the criteria for a positive CTC. 
 
A: Patient 9.  There is one CTC positive and Stathmin positive image with appropriate overlay 
of positive CK-PE and DAPI images.  Of the 2 negative images, one has incorrect overlay of CK-
PE and DAPI images and the second is CD45-APC positive.  
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B: Patient 10.  There are 3 positive CTC images that are also Stathmin positive, with 
appropriate overlay of positive CK-PE and DAPI images.  Of the 2 negative images, one has 
incorrect overlay of positive CK-PE and DAPI images and the second is a blurred image that is 
CD45-APC positive.   
 
 
 
 
 
 
C: Patient 22. There are 2 positive CTCs with appropriate CK-PE and DAPI overlay and 
negative/non-specific CD45-APC staining.  Both are also stathmin positive.  Of the 2 negative 
images, both have incorrect CK-PE and DAPI overlay and the top image also has positive CD45-
APC staining. 
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D: Patient 26.  There are 3 positive CTC images, with appropriate overlay of positive CK-PE and 
DAPI images, but none are stathmin positive.  Of the 2 negative images, both are CD45-APC 
positive. 
 
 
 
 
 
E: Patient 27.  There are 3 positive CTC images with appropriate overlay of positive CK-PE and 
DAPI images and one of which is stathmin positive.  The negative image does not have correct 
overlay of the CK-PE and DAPI images and is CD45-APC positive. 
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Figure 3.4:  Number of Patients with Positive CTC counts and Stathmin Staining at Baseline 
The majority of patients that are CTC positive have counts of 1-2, though there are 7 patients 
with CTC counts of ≥3 and 4 patients with CTC counts ≥5. 
 
 
 
1 patient with CTC 2 had dual endometrioid endometrial cancer and primary peritoneal cancer.  
Stathmin was not assessed for 3 patients with CTC 1, 1 patient with CTC 3 and patients with 
CTC 7, 22 & 172.  
 
 
From the 19 patients with positive CTC count, 7 patients did not have stathmin assessed due to 
supplier restrictions.  Of the 12 remaining patients, all demonstrated positive stathmin 
staining, though the proportion of positive cells varied between patients. 
From the 12 patients, 9 had all CTCs stain positive with stathmin while the remaining 3 
patients had 1-2 cells stain positive for stathmin, from a total count of 4-8.  This is detailed in 
Table 3.1.
0
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patients
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3.4. Clinical Data, Treatment Course and Observations 
The clinical course at the time of CTC collection for the 19 (58%) CTC positive (+) patients and 
the 14 (46%) CTC negative (-) patients are outlined in Tables 3.1 and 3.2 respectively including 
stage and treatment at the time of CTC collection, results of CTC assessment, time to 
recurrence for patients who had early stage disease at initial diagnosis and survival.   
When patients with dual pathology are excluded, 18 from 30 patients (60%) were CTC+ and 12 
from 30 patients (40%) were CTC-. 
Further details of the initial treatment and treatment at relapse is included in the Appendix 
Sections 3A & 3B.  A summary of the key findings from the comparison of these clinical factors 
in the CTC+ and CTC- patients are presented in Table 3.3.   
 
Pathologic features from primary surgery, haemoglobin and albumin results are included in the 
Appendix in Table 3C.    A summary of the key findings from the comparison of these 
pathological factors in the CTC+ and CTC- patients are presented in Table 3.4. 
 
Table 3.1:  Clinical Course of CTC positive (+) Patients’ with Endometrial Cancer 
Pt Disease 
status at 
CTC 
collection 
Time to 
recurrence 
(m) 
Treatment at CTC collection CTC 
count 
Stathmin 
count 
Survival 
at Feb 
2014 
(m) 
3 RM 38  Ch C1 7  ne 2 
7 IV ne  1m post chemo 1  ne 21 
8 RM 11  At relapse, no treatment 22  ne 1 
17 RM 19  Ch C6 8  1 9 
14 RM 9  1m post relapse 
4m post relapse 
0 
1  
0 
1 
12 
(alive) 
6 RM 27 Ch C2 
C4 
172 
3878 
ne 
0 
4 
9 IV ne Ch C1 
C4 
4m post ch 
6m post ch 
2  
0 
2  
2  
2 
0 
2 
ne 
12 
12 RM 24  Ch C1 
C4 
1m post ch 
4m post ch 
0 
0 
0 
3  
0 
0 
0 
ne 
12 
(alive) 
13 RM 26  Ch C2 
C4 
1  
0 
1  
0 
26 
(alive) 
24 RM 22 Ch C1 
C3 
C6 
2  
1  
H 
2 
1 
H 
10 
(alive) 
26 IV ne Ch C1 
C3 
C6 
4  
1  
H 
2 
1 
H 
5 (alive) 
27 IV ne Ch C1 4  2 7 (alive) 
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C4 
C6 
0 
0 
0 
0 
31 RM 8 1m post relapse, 2m pre-ch 
C1 
C2 
0 
1  
0 
0 
1 
0 
5 (alive) 
11 IV ne  Ch C1 
C6 
1m post ch 
3m post ch, at relapse 
0 
2  
0 
0 
0 
2 
0 
0 
15 
15 RM 29  Ch2 C1 
C6 
5m post ch2, 1m pre ch3 
0 
1  
0 
0 
1 
0 
10 
(alive) 
22 IV ne Ch C1 
C4 
2  
0 
2 
0 
9 
25 RM 10  Pre-S 
Post-S 
Ch C3 
0 
0 
1  
0 
0 
ne 
7 (alive) 
28 IV ne Ch C2 
C4 
C6 
0 
1  
0 
0 
ne 
0 
5 (alive) 
10 RM 3  Pre-S 
Ch2 C2 
Ch2 C3 
2  
0 
1  
2 
0 
1 
na 
 
Patients 3, 7, 8 and 17 had only 1 sample taken for CTC enumeration.  Patient 14 had 2 CTC 
samples taken during follow-up but received no active treatment.   
Patients 6, 9, 12, 13, 24, 26, 27, 31 had multiple samples taken for CTC assessment and the CTC 
results were concordant with clinical outcome.  Patients 11, 15, 22, 25, 28 had multiple 
samples taken for CTC assessment and the CTC results were discordant with clinical outcome 
RM: recurrent, metastatic disease, IV: FIGO stage IV, S: surgery, Ch: chemo, Ch2: second-line 
chemotherapy, Ch3: third-line chemotherapy, C: cycle number, H: haemolysed, ne: not 
evaluable, na: not available 
Survival is based on time from diagnosis with either stage IV or recurrent metastatic disease. 
All chemotherapy cycles were given for stage IV or for recurrent metastatic disease, unless 
stated otherwise. 
Bolded row (patient 10) had dual IA endometrioid endometrial and IIIC primary peritoneal 
cancer at diagnosis.  First CTC assessment was pre-operative.  The 2nd and 3rd CTC counts were 
taken after diagnosis with recurrent disease.  This patient is excluded from subsequent analysis 
due to the dual pathology. 
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Table 3.2:  Clinical Course of CTC negative (-) patients’ with Endometrial Cancer  
Pt Disease status 
at CTC 
collection 
Time to 
recurrence 
(m) 
Treatment at CTC collection CTC 
count 
Survival at 
Feb 2014 
(m) 
1 IV ne  Ch C1 
C6  
0 
H 
13 
2 RM 51  10m post relapse 
1m post ch & pre RT brain 
0 13 
34 IV ne 44m post diagnosis, pre-ch3 0 45 (alive) 
35 RM 11  Ch C2 0 3 (alive) 
4 IIIb ne 3m post diagnosis, pre-RT 
14m post diagnosis 
17m post diagnosis 
0 
0 
0 
18 (alive) 
20 RM 5  28m post relapse (on H) 
32m post relapse (on H) 
0 
0 
36 (alive) 
21 RM 18  Ch C1 
C4 
0 
0 
9 (alive) 
23 IB ne 9m post diagnosis, 1m post 
Ch & RT  
3m post Ch & RT 
6m post Ch & RT 
0 
 
0 
0 
15 (alive) 
29 IIIC ne Ch C2 
C5 
H 
0 
5 (alive) 
30 RM 95  Ch C2 
C6 
0 
0 
5 (alive) 
33 IV ne Ch C1 
C3 
0 
0 
4 (alive) 
19 RM 5  Post-S 
Post RT 
At relapse 
0 
0 
0 
3 (alive) 
16 RM 7 Pre-S 
Ch C4 
C6 
Post relapse, Ch2 C2 
0 
0 
0 
0 
na 
18 RM 28 Post relapse, Ch C4 
Refused repeat 
0 na 
Patients 1, 2, 34, 35 had only 1 sample taken for CTC enumeration. 
Patients 4, 20, 21, 23, 29, 30, 33 had multiple samples taken for CTC assessment and results 
were concordant with clinical outcome.  Patient 19 had multiple samples taken for CTC 
assessment and results were discordant with clinical outcome. 
Patients indicated in italicised rows (patients 4, 23, 29) had stage I-III disease at time of CTC 
collection.  
Patients indicated in bolded rows (patients 16, 18) had dual IA endometrial with IIIB serous 
ovarian and IIIA primary peritoneal cancers respectively at diagnosis.   
Patients 16 and 18 were excluded in further analysis and survival data was not collected. 
RM: recurrent, metastatic disease, IV: FIGO stage IV, S: surgery, RT: radiotherapy, Ch: chemo, 
Ch2: second-line chemotherapy, Ch3: third-line chemotherapy, H: hormones, C: cycle number, 
H: haemolysed, ne: not evaluable, na: not available 
Survival is based on time from diagnosis with either stage IV or recurrent metastatic disease, 
except for patients with stage I-III disease who did not relapse. 
All chemotherapy cycles were given for stage IV or for recurrent metastatic disease, unless 
stated otherwise. 
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Table 3.3:  Differences in Treatment and Clinical Course between CTC+ and CTC- Patients 
 CTC - (%), n=12 EC CTC  + (%), n=18 EC 
Age (years) 66 66 
Stage at diagnosis for EC pts I/II: 5 (42), III/IV: 7 (58)  I/II: 6 (33) , III/IV: 12 (67) 
Stage at collection for EC pts I: 1 (8), III: 2 (17), IV/RM: 9 
(75) 
IV/RM: 18 (100) 
Sites of metastases 
Peritoneal, LN, Liver 
 
4 (44), 7 (77), 1 (8) 
 
13 (72), 15 (83), 5 (27) 
Grade 3 disease 7 (58) 15 (83) 
Surgery alone* 0 from 9 4 from 11 (2 each of IA & IB) 
Adjuvant chemo/RT/ both* 0/5/4 1/2/4 
Time to recurrence (months) Based on IA,B,II,IIIB,IIIC (n=6) 
30.8 
Based on IA,IB,IIIA,IIIC 
(n=11)  20.3 
Survival (pts alive with stage 
IV disease at Feb 2014) 
7 from 9 (78) 10 from 18 (55) 
Survival status with stage IV 
disease based on f/u time 
 
2 from 9 died at >12m (22) 
5 alive at ≤12m f/u (56) 
2 alive >12m f/u (22) 
6 from 18 died ≤12m (33) 
2 died >12m (11) 
9 alive  ≤12m f/u (50) 
1 alive >12m f/u (6) 
*based on patients that had stage I-III disease at diagnosis, f/u: follow-up 
RM: recurrent metastatic, pts: patients 
 
 
There were more patients with FIGO stage IV or recurrent metastatic disease at first CTC 
collection in the CTC+ group with 100% of patients having stage IV or recurrent metastatic 
disease when CTC+ compared to 75% when CTC -.  Similarly, stage at initial diagnosis, which 
may have been years prior to CTC collection, was also higher when CTC+ with 67% having stage 
III/IV disease compared to 58% when CTC-.   Grade 3 disease and the presence of peritoneal 
and liver metastases were also more common in CTC+ patients. 
For patients who were sampled after disease recurrence, average time to recurrence was 
shorter in CTC+ patients at 20.3 months (range 9-38m) compared to 30.8 months (range 5-
95m) in CTC- patients.  The hazard ratio for recurrence was 1.7 in favour of CTC- patients, 
though the 95% confidence interval was wide, 0.5-5.2.  The Kaplan-Meier plot for time to 
recurrence shows no significant difference between the groups, as demonstrated in Figure 3.5   
In terms of the treatment received at initial diagnosis, all patients that were CTC- had received 
adjuvant therapy, including stage I patients.  In contrast, for patients that were CTC+, 4 
patients received surgery alone for stage IA/IB disease.  This suggests that in these patients 
with early stage disease who recurred, the traditional clinicopathological features used to 
guide primary treatment, may not have adequately reflected the likelihood of recurrence.   
 
In addition, more CTC- patients were alive at last follow-up compared to CTC+ patients.  For 
patients who had died during follow-up, more CTC+ patients were deceased within 12 months 
after diagnosis with stage IV or recurrent metastatic disease compared to CTC- patients.    The 
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hazard ratio for survival was 3.3, but the confidence interval was wide, from 0.7 to 16.2.  The 
small sample size and limited follow-up time for some patients limit the statistical analysis of 
this data. 
 
Figure 3.5: Kaplan-Meier plot for time to recurrence for CTC positive and CTC negative 
patients 
 
 
 
 
Table 3.4: Differences in Histology and Pathology Results between CTC Positive (+) and 
Negative (-) Patients 
 CTC negative (%), n=12 CTC  positive (%), n=18 
Type II EC 6 (50) 14 (78) 
Tumour size  
2-5cm 
≥ 5cm 
2 na (17) 
4 (33) 
6 (50) 
3 na (17) 
4 (22) 
11 (61) 
MMI>50% 8 (67) 10 (56) 
LVSI 6 (50) 8 (44) 
Cervical invasion 3 (25) 5 (28) 
Mean Haemoglobin  11.5 11.2 
Mean Albumin 41.8 40.3 
EC: endometrial cancer, MMI: myometrial invasion, LVSI: lymphovascular space invasion 
 
There were more type II EC tumours and tumours larger than 5cm in the CTC+ patients 
compared to the CTC- patients.  There were more CTC- patients with evidence of MMI greater 
than 50%.  Other pathological features were similar between the two groups, and there was 
no difference in mean haemoglobin nor albumin. 
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3.5. Correlation of Clinical Data with CTC Status 
Of the 18 patients with EC only and CTC+, 12 patients had follow-up samples taken during first-
line chemotherapy for metastatic disease and 1 patient had follow-up samples taken during 
clinical trial involvement.  4 patients had only 1 sample taken before they clinically 
deteriorated and died.  1 CTC+ patient was too unwell for systemic therapy but was monitored 
in follow-up and had a rise in CTC count and clinical deterioration. 
 
From the 13 CTC+ patients during first-line treatment, 8 had CTC results that were concordant 
with their clinical and radiological progress and 5 results were less clearly correlated, as 
demonstrated in Figure 3.6.   
For the patients with concordant CTC trend and clinical course: 
- Patient 6’s CTC count rose markedly while on chemotherapy and the patient 
deteriorated shortly after.   
- Patient 9 was baseline CTC+ and had a decrease in CTC count during chemotherapy 
with a radiographic response.  At disease progression post-chemotherapy, the CTC 
count rose.   
- Patient 12 was CTC- while on chemotherapy but CTC+ post-chemotherapy with 
evidence of disease progression.   
- Patients 13, 24, 26 and 27 all were baseline CTC+ and had a decrease in CTC count 
during chemotherapy that correlated with a radiographic response.   
- Patient 31 was CTC- on initial documentation of disease progression but was CTC+ at 
cycle 1 of the clinical trial.  By cycle 2, the CTC count had again decreased with a 
corresponding radiographic response.    
 
From the 5 patients with discordant CTC trend and clinical course, as illustrated in Figure 3.5: 
- Patient 11 was CTC- at the beginning of chemotherapy and CTC+ at cycle 6, though a 
CT scan was stable at this time.  Over the next 3 months, she had two further negative 
CTC counts, the last count proceeding disease progression by only one month.   
- Patient 15 was CTC- at baseline and CTC+ at the end of chemotherapy, though the CT 
scan was stable at this time.  The patient had new brain metastases 3 months later.  A 
further 2 months later, the repeat CTC count was 0 but the CT demonstrated disease 
progression.    
- Patient 22 was CTC+ at baseline and the count decreased at cycle 4.  However, the 
patient had radiographic disease progression at that time and died.   
89 
 
- Patient 25 was CTC- at baseline and CTC+ at cycle 3, when the patient was clinically 
stable.  A CT scan 2 months later showed her to be disease-free.   
- Patient 28 was CTC- at baseline and CTC+ at cycle 4, when a progress CT showed a 
partial response to treatment. At cycle 6, an end of treatment scan confirmed this 
response and the CTC count also returned to 0 at this point.   
 
 
Figure 3.6: CTC Trends and Clinical Course for Patients during Chemotherapy  
 
 
Patients marked in a green shade (9, 12, 13, 24, 26, 27, 31): CTC trend concordant with clinical 
course.  Patient 6 was not included as the CTC count was too high to depict here. 
Patients marked in a red shade (11, 15, 22, 25, 28): CTC trend discordant with clinical course 
 
For the 12 patients with EC alone who were CTC- at baseline and in follow-up, 7 patients had a 
clinical and/or radiological picture that correlated with the CTC result, 1 had a discordant 
picture and 4 had only a single CTC assessment and evaluation of concordance was limited.   
 
Of the 7 patients with concordant CTC results and clinical outcome: 
- Patients 4, 23 and 29 had localised or locally advanced disease at first CTC assessment 
and remained disease-free or stable during follow-up.   
- Patients 21, 30 and 33 had metastatic disease at diagnosis and had CTC assessment 
performed during first-line chemotherapy.  All had CTC counts of 0 pre-chemotherapy 
and either mid or post chemotherapy, corresponding with radiological response at 
these time points.   
9 12
13 24
26 27
31 11
15 22
25 28
0
0.5
1
1.5
2
2.5
3
3.5
4
9
12
13
24
26
27
31
11
15
22
25
28
90 
 
- Patient 20 had metastatic lung disease, managed with hormonal therapy and was 
clinically stable throughout the follow-up period. 
 
For the patients with discordant results or limited follow-up:  
- Patient 19 had 3 CTC samples taken, of which the first was post-operatively and the 2nd 
and 3rd at the time of disease recurrence.  All were 0 despite the development of 
ascites and omental disease at the time of the last assessment. 
- Patients 2 and 34 were CTC- though the samples were taken at the time of 
progression, one in the brain and one in the lung.   
- Patients 1 and 35 had a pre-chemotherapy sample taken but further samples either 
haemolysed or were not taken so further evaluation was limited.  
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3.6. Evaluation of a CTC Cut-off 
As detailed in the introduction section 1.3.2 and discussed further in section 3.7, CTC values ≥5 
for breast and prostate cancer and ≥3 for colorectal cancer have been used for prognostic and 
predictive purposes.   
In this patient group, 7 from 18 EC patients had CTC ≥3 and 4 patients had CTC ≥5.  In section 
3.3, it is outlined that higher stage at diagnosis and CTC collection, the presence of type II 
disease, grade 3 disease, liver metastases, shorter time to recurrence and decreased survival 
were associated with CTC positivity.  These parameters are reviewed in further detail in Table 
3.5, for patients with CTC 1-2, CTC ≥3 and CTC <3, as well as for CTC ≥5 and CTC <5, though 
there are limitations to this with the smaller patient numbers.  
 
Table 3.5: Clinicopathological Features of Patients with CTC ≥3 vs <3 and CTC≥5 vs <5. 
 CTC- 
(%)  
n=12  
CTC+   
(%) 
n=18 
CTC 1-2 
(%) 
n=11 
CTC<3 
(%) 
n=23 
CTC≥3 
(%)  
n=7 
CTC<5 
(%) 
n=26 
CTC≥5 
(%) 
n=4 
Stage at diagnosis 
I/II 
III/IV 
 
5 (42) 
7 (58) 
 
6 (33) 
12 (67) 
 
3 (27) 
8 (73) 
 
8 (35) 
15 (65) 
 
3 (43) 
4 (57) 
 
8 (31) 
18 (69) 
 
3 (75) 
1 (25) 
Sites of 
metastases 
Peritoneal  
Liver 
 
 
4 (44) 
1 (8) 
 
 
13 (72) 
5 (27) 
 
 
8 (73) 
0 
 
 
11 (48) 
1 (4) 
 
 
6 (86) 
5 (71) 
 
 
14 (54) 
2 (8) 
 
 
3 (75) 
4 (100) 
Grade 3 7 (58) 15 (83) 9 (82) 16 (70) 6 (86) 19 (73) 3 (75) 
Type II EC 6 (50) 14 (78) 9 (82) 15 (65) 5 (71) 18 (69) 2 (50) 
Time to 
recurrence  (m) 
30.8 20.3 20.5 24.1 23.8 24.6 23.8 
Pts alive with 
stage IV/RM 
disease, based on 
f/u time  
5 ≤12m 
(56) 
2 >12m 
(22) 
9 ≤12m 
(50) 
1>12m 
(6) 
6 ≤12m 
(55) 
1 >12m 
(9) 
11 ≤12m 
(55) 
3 >12m 
(15) 
3 ≤12m 
(43) 
 
14 ≤12m 
(61) 
3 >12m 
(13) 
0 
Pts deceased 
with stage IV/RM 
disease, based on 
f/u time 
0 ≤12m 
 
2 >12m 
(22) 
6 ≤12m 
(33) 
2 >12m 
(11) 
2 ≤12m 
(18) 
2 >12m 
(18) 
2 ≤12m 
(10) 
4 >12m 
(20) 
4 ≤12m 
 (57) 
2 ≤12m 
(9) 
4 >12m 
(17) 
4 ≤ 12m 
(100) 
RM: recurrent metastatic, m: months, f/u: follow-up 
For survival figures, all CTC+ patients are included, whereas 3 CTC- patients had stage I-III 
disease and are not included in the survival analysis. 
   
There is a progressive decrease in survival for patients with CTC 1-2, CTC ≥3 and CTC ≥5.  In 
both the CTC ≥3 and CTC ≥5 patient groups, there were a higher percentage of patients with 
peritoneal and liver metastases and poorer survival, compared to those patients with CTC <3 
and CTC <5 respectively.   
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In the CTC ≥3 patient group, grade 3 disease and type II EC were more common than in the CTC 
<3 patient group, as with the CTC+ patients overall, but this difference was not maintained in 
the CTC ≥5 patient group. 
There were fewer patients with stage IV disease in the CTC ≥3 and CTC ≥5 groups compared to 
the CTC <3 and CTC <5 groups respectively.  The difference in time to recurrence seen in the 
CTC+ group compared to the CTC- group was also less prominent in the CTC ≥3 and CTC ≥5 
patient groups compared to the CTC <3 and CTC <5 groups respectively. 
Thus, although the use of a higher CTC cut-off continues to show an association with survival, 
the smaller patient number in the subgroups limits interpretation of other parameters. 
 
3.7. Correlation of EpCAM and Stathmin IHC with CTC status 
EpCAM and Stathmin IHC were performed on those blocks available at UCLH Histopathology 
Department.  The Tumour Immunostaining Score (TIS) was used to evaluate EpCAM and 
stathmin expression, based on the product of staining intensity multiplied by the proportion of 
immunoreactive cells in the areas of interest, as outlined in the Methods section 2.1.6 [97, 
163].  For both EpCAM and stathmin, an intensity score was assessed as 0 (no staining), 1 
(weak), 2 (moderate) and 3 (strong).  For the EpCAM TIS, the fraction of positively stained 
tumour cells was defined as 0 (none), 1 (<10%), 2 (10-50%), 3 (51-80%) and 4 (>80%).  For the 
stathmin TIS, the fraction of positively stained tumour cells was defined as 0 (none), 1 (<10%), 
2 (10-50%) and 3 (>50%).  The CTC results, EpCAM and stathmin IHC are outlined in Table 3.6.  
Table 3.7 summarises the staining intensity of EpCAM and stathmin in the CTC+ and CTC- 
patient groups. 
Another research antibody for the PI3K pathway, p70S6 kinase, was also investigated to 
correlate with the stathmin findings.  However, even with the optimisation techniques 
described in the methods to improve staining, consistency was not seen across the tested 
controls, nor in the small number of samples evaluated.  As such, it was not reviewed on the 
blocks listed.  In comparison, stathmin produced far more consistent staining.   
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Table 3.6:  CTC Enumeration and Stathmin Analysis and FFPE tissue EpCAM and Stathmin IHC  
Patient 
number 
CTC 
positive 
CTC 
Stathmin 
EC FFPE EpCAM TIS FFPE Stathmin TIS 
11 Y Y NE No (0) – sarc 0 
31 Y Y NE Weak (4) na 
7 Y na NE Moderate (6) Moderate (6) 
28 Y na NE Intense (12) na 
3 Y na E Intense (12) Moderate (4) 
8 Y na NE Intense (12) Moderate (4) 
9 Y Y NE Intense (12) Moderate (4) 
17 Y Y NE Intense (12) Moderate (4) 
25 Y na E Intense (12) Moderate (4) 
11 Y Y NE Intense (12) Moderate (6) 
12 Y na NE Intense (12) Moderate (6) 
13  Y Y NE Intense (12) Moderate (6) 
14 Y Y E Intense (12) Moderate (6) 
15 Y Y NE Intense (12) Moderate (6) 
26 Y Y NE Intense (12) Intense (9) 
23 N na NE Weak (3) Weak (2) 
19 N na NE Moderate (8) Moderate (6) 
4 N na E Intense (12) na 
20 N na E Intense (12) Moderate (4) 
34 N na E Intense (12) Moderate (4) 
35 N na E Intense (12) Moderate (4) 
Patients 4, 28, 31 did not have adequate tissue for Stathmin assessment or the blocks were 
recalled for trial testing.  Patients in grey rows are CTC positive. 
E: endometrioid, NE: non-endometrioid, sarc: sarcoma, B: biopsy, S: surgical resection sample, 
S I-III: stage I-III, S IV: stage IV, na: not available 
 
Table 3.7: EpCAM and Stathmin IHC results relative to CTC Status 
 CTC positive; n=15 (%) CTC negative; n=6 (%) 
EpCAM TIS 
Intense 
Moderate 
Weak 
No staining 
 
12 (79.9) 
1 (6.7) 
1 (6.7) 
1 (6.7) 
 
4 (66) 
1 (17) 
1 (17) 
0 
Stathmin TIS 
Intense 
Moderate all [4,6]  
None/Weak 
Not available 
 
1 (6.7) 
11 [5, 6] (73.3 [33.3, 40]) 
1 (6.7) 
2 (13.3) 
 
0 
4 [3,1] (66 [50, 16])  
1 (17) 
1 (17) 
 
Overall, tissue samples of those patients that were CTC + demonstrated stronger staining for 
both EpCAM and Stathmin than the tissue from CTC- patients, though the degree of EpCAM 
staining could not be used to predict CTC status.   
More intense stathmin IHC in the CTC+ patients may be consistent with the prognostic 
association with stathmin overexpression.  
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The majority of specimens assessed for staining were NEEC.  Interestingly, all the EEC samples 
demonstrated intense EpCAM and moderate Stathmin overexpression.  For the NEEC samples, 
there was greater variation in both EpCAM and Stathmin overexpression, ranging from weak 
to intense, though most of the stathmin staining had moderate intensity.   
From the 7 patients that had Stathmin positive CTCs and tissue available, 6 demonstrated a 
moderate Stathmin TIS and 1 demonstrated an intense TIS.   
As all the CTC samples that were evaluated for stathmin stained positive, correlation between  
CTC stathmin status with and stathmin IHC TIS was limited.  As such, any difference in CTC 
status and in expression between tissue taken at initial diagnosis compared to that from 
metastatic disease, or that between surgical and biopsy specimens could not be assessed. 
 
3.8. Discussion 
3.8.1. CTC Enumeration 
CTC enumeration and molecular analysis with stathmin on the Veridex CellSearch platform is 
feasible in advanced EEC and NEEC, with CTCs detected in 60% of patients with EC alone.  
Interestingly, there was a trend between CTC positivity and higher stage, grade 3 disease, type 
II EC, shorter time to recurrence and reduced survival, though the interpretation of these 
results is limited by the small sample size and small number of events in follow-up.   
There were a number of parameters that did not correlate with CTC positivity, including MMI, 
LVSI and cervical invasion, all being traditional parameters currently used to guide primary 
treatment post-surgery.  There was also no correlation with haemoglobin nor albumin.  This 
may reflect the limitations of these traditional pathologic factors in guiding primary treatment 
or limitations in CTC evaluation, and thus requires further validation in a larger patient cohort.   
There was also a group of CTC+ patients, for whom there was concordance between CTC 
trends and their clinical outcome while on first-line chemotherapy for metastatic disease, 
suggesting that CTCs may act as a predictive biomarker in this setting.  At the same time 
however, there were patients whose CTC follow-up did not correlate with their clinical course 
and there are a number of factors that need further investigation that might explain this. 
 
EpCAM may be down-regulated in CTCs, as they undergo EMT to escape their local 
microenvironment and enter the circulation.  In a comparison of EpCAM expression on CTCs 
versus FFPE tissue and other benign disease, EpCAM expression was demonstrated to be 10-
fold lower on CTCs compared to primary or metastatic tissue [251], such that the Veridex 
CellSearch platform may not be sensitive enough to detect CTCs reliably and reproducibly.  
When cancers and CTCs undergo EMT, they develop a more invasive phenotype with 
metastatic potential.  EMT is a complex process whereby cells switch their epithelial 
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phenotype into a mesenchymal one, resulting in a down-regulation of epithelial markers 
including EpCAM and an up-regulation of mesenchymal markers [252].  Other factors that may 
drive EMT include EGFR, TGFB, transcription factors and small non-coding RNAs.  The right 
combination of markers or other detection techniques may thus be required to better 
enumerate and characterise CTCs in EC. 
 
3.8.2. Correlation of CTC Analysis and FFPE IHC for EpCAM and Stathmin   
Correlation of EpCAM and stathmin IHC with CTC positivity demonstrated more intense 
staining intensity of FFPE tissue from CTC+ compared to CTC- patients, though the overall 
presence/absence of staining was similar between the two groups.  Even with this difference in 
intensity in EpCAM and stathmin IHC, it was not possible to define a level of overexpression for 
predicting CTC results, either for CTC positivity, or for stathmin positivity.   
 
Consistent with the published literature which reports moderate to intense EpCAM 
overexpression in 80-88% [95, 250] of EC specimens, overexpression at this level was reported 
in 86% of samples here, with more intense expression in EEC compared to NEEC.  Stathmin 
overexpression on IHC is reported in between 27% and 57% of primary tumours [164, 165].  
Stathmin overexpression on FFPE IHC was higher here at 80%, though a higher antibody 
concentration was used and scoring was based on the TIS versus the upper quartile of scoring 
reported elsewhere [164, 165].  Stathmin overexpression is also more common in NEEC [164] 
and interestingly, the majority of the tested blocks here were NEEC rather than EEC, which 
may also have contributed to the higher reported overexpression.  Although other markers of 
the PI3K pathway were not analysed here, there is already evidence that stathmin is a more 
reliable marker of PI3K activation than AKT and p-AKT for example [164].  Thus for further 
study, the ability to detect stathmin on CTCs, the reproducibility of staining and evidence as a 
marker of PI3K activation [162] make stathmin an attractive choice of antibody. 
 
Further investigation with a greater availability of tumour tissue in a larger patient cohort 
would be required to better a assess changes in these markers over time and correlation 
between IHC and CTC status.  Longitudinal tissue review would also be of interest to better 
delineate the change in EpCAM and stathmin that may occur in EC between primary diagnosis 
and subsequent relapse.  If the tissue analysis could then be mapped through changes in CTC 
molecular analysis, this could provide evidence for using CTCs both to predict response to 
standard chemotherapy as well as molecularly targeted agents for each patient.   
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3.8.3. Challenges in Defining a CTC Cut-off 
Although the feasibility of CTC enumeration in EC was demonstrated here, the overall sample 
size was small for drawing conclusions on the prognostic and predictive nature of CTCs in EC.  
While it was possible to generate hypotheses, with the suggestion that CTCs may act as a 
prognostic and predictive biomarker in some EC patients, longitudinal data is required over a 
longer time period and from a larger patient cohort to validate these early findings.   
 
While this study demonstrated a trend between higher CTC count and survival, this was too 
small a study to definitively address the question of a significant CTC cut-off.  The CTC cut-off 
of 5 as a prognostic factor was first defined in breast cancer [100] by correlating CTC 
thresholds with PFS in a training set of 102 patients.  Median PFS and a difference between 
slow and rapid progression was best defined by 5 CTCs per 7.5ml blood.  Further evaluation in 
a validation set of 75 patients then confirmed that this CTC cut-off was an independent 
predictor of PFS and OS in metastatic breast cancer.  In prostate cancer, the cut-off derived 
from the breast cancer setting was used and a correlation was then demonstrated between 
CTC count at baseline and during follow-up with prognosis in 231 patients [107].  The 
colorectal cancer CTC cut-off was defined based on correlation of CTC count with response on 
first imaging in a training set of 109 patients and then taken forward to a validation set of 321 
patients, where its prognostic and predictive utility was demonstrated [111].   Thus, although 
there is a trend between higher CTC count and poorer survival in EC, greater patient numbers 
are required to validate this finding. 
 
3.8.4.  Key Findings and Future Directions 
Key findings for the analysis of CTCs in EC are outlined in Figure 3.7.  CTCs in EC are worthy of 
further study in view of their prognostic and predictive potential.  This may involve further 
evaluation with the current Veridex CellSearch methodology as well as expanding assessment 
into novel CTC markers and detection techniques, which will be discussed further in Chapter 6.  
Although, there were limitations with sample size here, the data was hypothesis generating in 
terms of the clinical and pathologic associations, as well as correlation with patient outcomes 
over time.  Further longitudinal molecular analysis on blood and tissue samples in this setting 
is also important for further studies and again, with these early signs of its feasibility, 
expansion of this type of study with incorporation of novel techniques would be of great 
interest.    
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Figure 3.7: Key Findings of CTC enumeration in EC 
 Detection of CTCs in EC patients and molecular analysis with 
Stathmin performed on the CellSearch platform is feasible 
 CTC+ in EC is associated with stage IV and recurrent metastatic 
disease, type II EC, higher grade and reduced survival 
 CTC count correlates with clinical course in some EC patients and 
could be used to predict outcome on first-line chemotherapy 
 A CTC cut-off for predictive and prognostic purposes is still to be 
defined 
 EpCAM IHC does not reliably predict CTC detection, though 
correlation with metastatic tissue is required 
 Stathmin IHC overexpression was associated with CTC positivity 
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CHAPTER 4: Results from DNA Extraction, Modification and Quality Assessment 
4.1. Introduction 
Historically, oncology drug development has been hampered by clinical trials being performed 
in unselected patient groups, even when testing newer targeted agents.  Improved 
understanding of tumour biology and incorporation of biomarkers into as early a setting as 
possible however can lead to more rapid drug approval and improved patient outcomes.  
Compared to other solid tumours, there has been little correlation between clinical outcomes, 
genetic aberrations and drug development in EC.  For example, despite substantial literature 
on PI3K pathway aberrations, studies of temsirolimus and everolimus were developed in an 
unselected patient population with limited biomarker assessment and no current predictive 
markers to guide treatment [81].  Similarly, although FGFR mutations have been well 
documented in EC, studies to correlate mutation status and response are only recently 
underway [253].  The molecular basis for distinctions between and within Type I and Type II EC 
are only partly characterised and the transition of normal endometrium to AEH and EC is 
poorly understood.  Thus, further research into genetic and epigenetic abnormalities and 
profiling on FFPE endometrial tissue may be better able to identify genes and molecular 
pathways that drive carcinogenesis and move treatment from a “one-size-fits-all” strategy to a 
targeted approach that improves clinical outcomes for this disease.   
 
There are a number of methods used for epigenetic analysis as outlined in section 1.4.2.3, one 
of which has been developed and validated within the UCL Cancer Institute for use in both FF 
and FFPE tissue.  This method utilises bisulfite-ligated DNA to assess methylation signatures in 
FFPE tissue on the Illumina Human Methylation 450K BeadChip array [231][232].  This platform 
promoted that FFPE tissue could be used, but there was limited published data on this until 
Thirlwell et al [232] published their protocol to analyse FFPE-derived DNA on the Infinium 
platform using the HumanMethylation27 BeadChip.  The Illumina Infinium assay requires the 
template DNA to be >1kb in length for the amplification to work.  As such, the protocol 
included a DNA ligation step to increase DNA fragment length for subsequent whole-genome 
amplification and analysis.  This method was demonstrated to be feasible with ligated FFPE 
samples performing as well as FF samples on the 27K array, including FFPE DNA from tissue up 
to 10 years of age [232].   
 
The Illumina 450K array can also be used to detect CNV, with comparable sensitivity to SNP 
platforms [254], including the HumanCytoSNP-12 BeadChip and publicly available Affymetrix 
SNP6.0 segmented data.   To date, interrogation of methylation and CNV data have been 
performed on separate array platforms which increases cost and the amount of tissue 
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required.  Thus, developing methodology that utilises methylation arrays to detect CN and 
methylation changes in a single experiment may decrease both these components.  In view of 
the limited tissue available in some of the endometrial samples, this was particularly relevant. 
 
Interpretation of the methylation and CNV data utilised the validated ChAMP pipeline on the R 
console [245].  This has been outlined in Chapter 2, but for ease of reference, is summarised 
again here.  The ChAMP package is a pipeline that integrates available 450K analysis methods 
with several analysis options, including CNV.  It uses the data import, quality control and SWAN 
(subset-quantile within array normalisation) functions as part of the minfi package, as well as 
PBC (Peak Based Correction), BMIQ normalization, SVD (singular valve decomposition) and 
ComBat methods to select the best performing samples, correct for probe bias and correct for 
batch effects respectively. 
In this study, DNA methylation and CNV analysis on FFPE endometrial tissue was performed, 
with FF tissue as a control, using the Illumina 450K array.  Samples for comparison included 
normal endometrium, AEH and EEC.  EEC was chosen in this study rather than both EEC and 
NEEC to maintain as molecularly homogenous a sample group as possible for testing.     
Figure 4.1 outlines the components for assessing sample selection, DNA quality and 
preparation prior to epigenetic and CNV analysis.   These processes are detailed in this chapter 
to demonstrate methodological quality control and validation.    
 
 
 
 
 
 
 
Figure 4.1: Key Components of Sample Management for Epigenetic and CNV 
analysis 
 Accurate sample selection for tissue type 
 Optimisation of DNA extraction 
 Accurate DNA concentration analysis 
 Assessment of DNA quality 
 Assessment of bisulfite conversion 
 Quality control on the ChAMP pipeline on the R console 
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4.2. Sample Selection 
From the UCLH histopathology database search, 36 archival FFPE cases were identified from 
between 2009 and 2013 and 6 fresh frozen cases between 2013 and 2014.   
Selected cases had the required tissue type (normal +/- AEH +/- EEC) and were deemed 
amenable to macrodissection based on review with a Gynae-oncology consultant 
histopathologist. 
A total of 42 patient cases identified equated to dissection of 91 FFPE  normal, AEH or EEC 
samples and 10 FF normal or EEC samples.  The number of samples with the dissected tissue 
type and grade is outlined in Figure 4.2.  Note that the 91 FFPE samples does not include 
duplicates that may have been collected if there was adequate tumour tissue or if analysis was 
repeated.  The FF cases that demonstrated grade 2 and sarcomatous disease post-operatively 
were also not used in the final analysis through the ChAMP pipeline. 
  
Figure 4.2: Samples available for DNA Extraction of Normal Endometrium, Atypical 
Endometrial Hyperplasia and Endometrioid Endometrial Cancer   
 
N: normal endometrium, A: atypical endometrial hyperplasia, C: endometrial cancer. 
G1: grade 1, G3: grade 3, S: sarcoma 
 
4.3. DNA Extraction and Concentration 
The first 10 samples dissected were analysed on the Illumina 450K array prior to the dissection 
of any further samples for review of methodological quality control.  These 10 samples 
consisted of normal, AEH and EC tissue from 6 patient cases and DNA concentrations were 
detected on the NanoDrop spectrometer alone using wavelength assessment as a quality 
guide, as demonstrated in Figure 4.3.   DNA modification and bisulfite conversion QC were 
then performed and the samples were run on the Illumina 450K array.   
Shortly after this array was performed, two additional steps were added to the DNA analysis.  
Firstly, a Qubit fluorometer was introduced in the laboratory and was used for subsequent 
Total cases 42
(101 samples)
FFPE cases 36
(91 samples)
NAC 19 
G1 13, G3 6
(57 samples)
NC 15 
G1 9, G3 5, Both 1
(31 samples)
AC G1 1
(2 samples)
A G1
(1 sample)
FF cases 6
(10 samples)
NC 4 
G1 1, G3 2, S1
(8 samples)
C 2 
G2 1, G3 1
(2 samples)
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DNA concentration alongside NanoDrop spectrometry, and secondly the Illumina QC step to 
assess DNA quality prior to performing bisulfite conversion, was also introduced. 
The concentrations for the first 10 samples were then retrospectively assessed using the Qubit 
fluorometer and subsequent samples were analysed using both the NanoDrop spectrometer 
and Qubit fluorometer.  Wavelength values were also collected from NanoDrop to assist with 
quality assessment.  The concentrations and wavelengths are recorded in the Appendix (Table 
4A for these first 10 samples, Table 4B for the remaining FFPE samples and Table 4C for the FF 
samples).  Overall, the concentrations on the Qubit fluorometer tended to be lower than that 
recorded on NanoDrop spectrometry.  As such, the Qubit derived DNA concentrations were 
used for the calculations of the volumes required for further DNA modification.   
The FFPE specimens were all extracted with needle dissection following microscopic review 
with a Gynae-oncology consultant histopathologist and the FF specimens were classified 
macroscopically by the same histopathologist at the time of specimen delivery and prior to 
freezing.   
 
Figure 4.3: NanoDrop Spectrometry Assessment of Concentration and Wavelength 
 
  
 
  
Note the 260/280 ratio of 1.97 
and 260/230 ratio of 2.23, 
along with the wavelength 
shape peaking at 260-270nm 
were consistent with adequate 
DNA quality as per NanoDrop 
assessment 
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4.4. DNA Quality Analysis 
The Illumina Infinium HD FFPE QC assay was designed to determine DNA quality and to predict 
if the DNA samples were candidates for FFPE restoration and likely to yield valid results on the 
subsequent Illumina 450K array analysis.   
This was performed in retrospect for the first 10 samples to correlate with the array results 
and prospectively for the remaining samples.  All specimens were run in triplicate to 
demonstrate intra-sample reproducibility on the 7300 real time-polymerase chain reaction 
(RT-PCR) system.  The results of the QC analysis and Delta Cq (average quantification cycle for 
each sample minus the average quantification cycle for the control) for FFPE samples, based 
on the raw data from the RT-PCR analysis, are illustrated in Table 4.1.  QC analysis was not 
required for FF specimens as the DNA was not degraded with formalin during the preservation 
process. 
The protocol for the Illumina Infinium HD FFPE QC [255], as outlined in Chapter 2.2.4.1.3, 
advises that samples with a Delta Cq value <5 can be selected for FFPE restoration and array 
analysis, but also recommends the use of the Illumina restoration kit for further modification.   
A higher Delta Cq cut-off up to 11 was used here for a number of reasons.  Firstly, the Delta Cq 
cut-off recommended by Illumina was based on their own restoration protocol while an 
alternate method [232] for DNA modification was utilised here with a tissue type that is less 
well studied and for which a different Delta Cq cut-off may apply.  Secondly, there was a 
moderate amount of variation in Delta Cq values generated here, such that some samples with 
a higher Delta Cq were analysed further to better correlate the Delta Cq with this 
methodology.  Thirdly, a less stringent approach was deemed worthwhile to balance the 
practicalities of limited sample number with a need to better define the optimum cut-off in 
this tissue type.  
 
Table 4.1: Illumina Infinium HD FFPE QC results for all samples 
Specimen Delta Cq Specimen Delta Cq Specimen Delta Cq 
1A¹ 5.27* 18N 10.07* 29C 8.49 
2N¹ -0.11* 18A 8.24* 29C2 8.94 
2C¹ 2.45* 18C 8.39* 30N 4.74* 
5N¹ 3.12* 19N 9.7* 30A 3.03* 
5A¹ 2.90* 19A 9.4* 30C 2.86* 
5C¹ 3.90* 19C 8.9* 31N 3.45* 
6C¹ 4.59* 20N 4.42* 31C1 3.59* 
7C¹ 5.66* 20C 4.71* 31C3 5.24* 
9N¹ 8.45* 21N 2.83* 32N 2.04* 
9C¹ 6.27* 21A 3.21* 32C 0.49* 
3N 5.73* 21C 5.96* 33N 1.29* 
4A 2.37* 22N 1.48* 33C 2.21* 
6N 10.19* 22C 1.5* 34N 3.23* 
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6A 6.23* 23N 13.5 34A 2.43* 
10N 6.15* 23A 14.3 34C 5.12* 
10A 5.98* 23C 15 35N 5.38* 
10C 3.47* 24N 0.73* 35C 6.36* 
12N 6.16* 24A 1.26* 36N 4.95* 
12C 9.78* 24C 0.53* 36C 4.31* 
13N 2.6* 25N 10.5 1N² 9.18 
13A 0.84* 25C 9.32 1A² 8.34 
13C 3.14* 26N 10.19 1C² 9.66 
14N 6.37* 26C 9.65 3N² 5.49* 
14C 6.57* 26C2 10.45 3A² 6.02* 
15N 6.48* 27N 5.87* 3C² 7.09* 
15C 5.57* 27A 5.18* 7N² 9.42* 
16N 7.18* 27C 5.20* 7A² 7.02* 
16A 9.94* 28N 1.41* 7C² 8.73* 
16C 9.08* 28A 0.18* 8N² 8.99* 
17N 9.14* 28C 0* 8A² 8.7* 
17A 7* 29N 9.06 8C² 11.3* 
17C 8.58* 29N2 12.11 11A² 7.3* 
    11C² 6.92* 
¹QC for first 10 samples was assessed in retrospect 
²Samples that were re-extracted due to initial QC concerns or limitations in extraction   
*Samples that underwent further modification for the arrays.   
 
The consistency of the Delta Cq within a case as well as the tissue types available for analysis 
were also taken into consideration.  If all specimens within a given patient case had a high 
Delta Cq, the case was not used; however, if the Delta Cq value was lower for one of the tissue 
types or if all 3 tissue types were available for potential comparison, than the entire case was 
used for analysis.  For example, for cases 23, 25, 26 and 29, all the Delta Cq values were 
between 8 - 15 and 4 of these specimens only had normal and cancer tissue available for 
comparison, so these specimens were not analysed on the Illumina 450K array.   
However, for both specimens 9 and 12, one of the Delta Cq values for the specimens was 
measured as 6, so deemed worthwhile to analyse the entire case.  For specimens 7, 8, 16, 17, 
18 and 19, there was a range in Delta Cq values, but as all 3 tissue types were available for 
comparison, it was again deemed worthwhile to analyse these cases.   
Overall, 41 from 97 specimens (42%) had a Delta Cq <5, 49 specimens (51%) had a Delta Cq 
value ≤5, 38 specimens (39%) had a Delta Cq value between 6-9 and 10 specimens (10%) had a 
Delta Cq value ≥10. 
 
Analysis was based on both raw numerical data, as in Table 4.1, as well as a visual assessment 
of the amplification plots produced on the RT-PCR System as illustrated in Figures 4.4 and 4.5.  
When interpreting the RT-PCR plots, it is important to be aware of the baseline, threshold and 
threshold cycle.  The baseline of the reaction refers to the signal level during cycles 3-15, 
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where there is little change in the fluorescence signal and background ‘noise’ of the reaction is 
recorded.  The threshold of the RT-PCR is the level of signal that reflects a statistically 
significant increase over the baseline signal (horizontal green line in the figures).  The 
threshold cycle (Ct) is the cycle number at which the fluorescent signal of the reaction crosses 
the threshold, related to the amount of DNA present.   
 
Figure 4.4: Amplification plot demonstrating the Difference between the QC Template and 
H20 samples 
Note that QC Template (left, red arrow) amplifies at an earlier cycle number as a DNA control.  
The H20 sample (right, blue arrow) amplifies at a later cycle.  Samples with good quality DNA 
should amplify close to the QC Template Reagent.  All samples are run in triplicate and the 
triplicate readings for each sample should amplify at a similar cycle, as demonstrated for the 
QC template and H20 samples below.  The purple arrow indicates the low-level signal at the 
baseline of the PCR reaction. 
 
 
 
 
Figure 4.5:  Amplification plot of QC Template (left, red arrow), H20 (right, blue arrow) and 2 
samples, 26N and 26C (centre, green arrow) 
Note that the samples with good quality DNA will lie closer to the QC Template plot.  The 
samples here are 26N and 26C, which did not demonstrate good quality DNA on this QC step 
and were not used for further analysis.  All specimens were run in triplicate and demonstrate 
intra-specimen concordance. 
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4.5. DNA Bisulfite Conversion Analysis 
This step determines the success or failure of the DNA modification and BIS conversion, 
through the use of RT-PCR and primer sets specific for BIS converted (actin positive) and 
unconverted DNA (actin negative).   
Figures 4.6 and 4.7 demonstrate examples of the amplification plots generated on the RT-PCR 
system that are visually analysed to assess success of bisulfite conversion. 
Table 4.2 lists the calculated bisulfite conversion percentage for each sample, based on the 
raw data from the RT-PCR System analysis.   
 
Figure 4.6:  Amplification plot of a Bisulfite Converted Lab Control with Actin positive (left, 
red arrow) and Actin negative (right, blue arrow) primers   
Note the BIS converted DNA detected in the actin positive sample amplifies earlier than the 
Actin negative sample which detects unconverted DNA.  The baseline low-level signal of the 
RT-PCR reaction is also shown (purple arrow). 
 
 
 
Figure 4.7: Amplification plot demonstrating successful Bisulfite Conversion of sample 24C   
All samples are run in triplicate and these curves should amplify within 2-3 cycles of each 
other, as illustrated.  The actin positive sample is on the right (red arrow) and amplifies earlier 
than the actin negative sample (blue arrow) when the DNA modification has been successful, 
as it detects the bisulfite converted DNA.  The 24C plot lies close to the actin positive sample. 
 
 
 
106 
 
 
Table 4.2: Bisulfite Conversion Analysis for all FFPE and fresh frozen samples 
Sample Conversion % Sample Conversion % Sample Conversion % 
1A 98.58 18N 52.38* 34N 95.79 
2N 99.9 18A 87.13* 34A 96.30 
2C 99.23 18C 69.81* 34C 91.05 
5N 99.84 19N 98.52 35N 96.53 
5A 99.58 19A 95.02 35C 95.25 
5C 99.66 19C 98.88 36N 98.22 
6C 99.3 20N 99.46 36C 99.62 
7C 92.78  20C 99.79 3N 97.52 
9N 56.97  21N 99.83 3A 96.17 
9C 85.73  21A 99.88 3C 95.77 
3N 94.42 21C 99.65 7N 62.10 
4A 99.99 22N 99.89 7A 55.58* 
6N 21.29  22C 99.98 7C 30.49 
6A 99.93 24N 99.85 8N 75.41* 
10N 92.15  24A 99.93 8A 63.77* 
10A 98.81 24C 99.89 8C 38.84* 
10C - 27N 99.71 11A 82.64 
12N 99.95 27A 99.39 11C 98.34 
12C 98.40 27C 99.48 37N 89.98 
13N 99.87 28N 99.77 37C 99.87 
13A 99.81 28A 99.98 38C 97.36 
13C 98.97 28C 99.92 39C 99.73 
14N 98.95 30N 99.65 40N 98.5 
14C 99.45 30A 99.62 40C 96.95 
15N 99.84 30C 99.45 41N 96.9 
15C 99.96 31N 98.28 41C 99.49 
16N 86.44* 31C1 99.82 41N2 95.47 
16A 98.43* 31C3 99.45 41C2 99.88 
16C 97.37* 32N 99.58 42N 99.92 
17N 71.39 32C 99.99 42C 98.95 
17A 98.79 33N 99.80   
17C 83.87 33C 99.85   
* BIS QC run performed 1 week after conversion due to RT-PCR machine break-down.   The BIS 
conversion for these samples was lower overall than for those analysed immediately.   
- 10C was not assessable as the actin negative triplicate was not analysable by the QT-PCR. 
# Illumina Delta Cq>5 
 
A cut-off of 98% is generally used to demonstrate successful BIS conversion. For the above 
specimens: 
- 60 from 94 specimens (64%) showed BIS conversion ≥98%   
- 12 specimens (13%) showed BIS conversion of  95-97% (16C, 19A, 34N, 34A, 35N, 35C, 
3N, 3A, 3C, 38C, 40C, 41N)  
- 4 specimens (4%) showed BIS conversion 90-94% (7C, 3N, 10N, 34C)  
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- 17 specimens (18%) showed BIS conversion less than 90% (9N, 9C, 6N, 16N, 17N, 17C, 
18N, 18A, 18C, 7N, 7A, 7C, 8N, 8A, 8C, 11A, 37N).  The correlation between BIS 
conversion percentage and Illumina Delta Cq is summarised in Table 4.6 below 
- 1 specimen (1%) could not be analysed (10C) 
 
Table 4.3:  Correlation of BIS conversion and Illumina Cq values 
BIS conversion 
percentage 
Mean Illumina Cq 
value 
Range of Illumina Cq 
values 
>98% 4.0 -0.11 - 9.94 
95-98% 6.4 2.43 - 9.4 
90-94% 5.7 5.12 - 6.15 
<90% 8.6 6.27 - 11.3 
 
As demonstrated in Table 4.3, a higher Delta Cq value on the Illumina QC analysis correlated 
overall with a lower BIS conversion percentage, indicating potentially poorer DNA integrity 
that may not have been amenable to further modification.  Note that the range on those 
specimens with a BIS conversion of greater than 95% however is quite broad and elevated 
Delta Cq does not always predict BIS conversion failure. These results are further correlated 
with the ChAMP analysis in section 4.6. 
 
4.6. Sample Analysis from the ChAMP pipeline 
The ChAMP pipeline [245] incorporates a number of steps for quality control and 
normalisation of the samples and their data.  It can compare 2 variables at a time when 
generating data on MVPs and DMRs.  As there were 3 tissue types for analysis here, the data 
was analysed through paired comparisons of normal endometrium, AEH and EEC tissue 
including all specimens initially and then based on grade and tissue type.  This allowed 
selection of the best quality samples for data analysis and generated differential methylation 
data between the two comparator groups.  A simultaneous comparison between all 3 tissue 
types could be performed to demonstrate clustering based on differential methylation on 
heatmaps and dendrograms, but did not generate specific information on DMRs and MVPs. 
 
The first three comparator groups used all the modified DNA specimens and were between 
normal endometrium and endometrioid endometrial cancer (NvC), normal endometrium and 
atypical endometrial hyperplasia (NvA) and atypical endometrial hyperplasia and endometrioid 
endometrial cancer (AvC).  Subsequent comparisons subdivided these main groups based on 
grade (1 or 3) and tissue type (normal, atypical or cancer).  Comparison was also made just on 
those cases for which all 3 tissue types were available (referred to as matched samples and 
including cases 13, 21, 24, 27, 28, 30 and 34). 
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As detailed in the methods section 2.2.6.1, the ChAMP quality control and normalisation 
involves the following:  
- filtering out probes with non-significant detection (p-value >0.01) in more than one 
sample and excluding samples with a fraction of failed probes >5-10%.  Table 4.4 
outlines the number of samples that were filtered in this step based on the three 
comparator groups outlined above.  
- intra-array normalisation using BMIQ to adjust the data for the Illumina 450K array 
which uses both Infinium I and II probes.  Infinium type II probes are generally less 
accurate and reproducible than the Infinium I probes [246], thus BMIQ normalisation is 
performed to overcome this bias. The pre- and post- normalised plots for NvC, NvA, 
AvC and NvAvC comparisons are presented in Figure 4.8.   
This step also generates a normalised multidimensional scaling (MDS) plot and sample 
cluster plot that gives a preliminary assessment of the 1000 most variable probes 
between the two groups, outlined in Figure 4.9.   
The MDS plot, also known as a Principal Coordinates Analysis, assesses the level of 
similarity of cases in a dataset.  The axes values are not absolute but are a 
representation of the spread of the samples. 
- Singular Value Decomposition (SVD) to control for batch effects associated with 
technical aspects of the array.  The heatmaps generated at this step are presented in 
Figure 4.10.  The ComBat normalization method then corrects for batch variation but 
requires at least 2 specimens per array per comparison. 
After these steps, the data is then analysed to detect segmentation of MVPs and DMRs, as well 
as analysing CNV. 
 
Table 4.4: Comparison of the total unfiltered evaluable samples and significant probes with 
the filtered samples and significant probes 
Comparator groups Total unfiltered samples & 
significant probes 
Filtered samples and significant 
probes  
N v C 
N v A 
A v C 
N v A v C 
69 & 12 750 
53 & 24 737 
57 & 14 422 
- 
39 & 400 812 
26 & 424 168 
29 & 405 496 
47 & 400 515 
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Figure 4.8:  Pre and post normalisation Density plots for  
A: Normal Endometrium v Endometrioid Endometrial Cancer (NvC),  
B: Normal Endometrium v Atypical Endometrial Hyperplasia (NvA),  
C: Atypical Endometrial Hyperplasia v Endometrioid Endometrial Cancer (AvC)  
D: Normal Endometrium v Atypical Endometrial Hyperplasia v Endometrioid Endometrial 
Cancer (NvAvC)  
Note that for all 4 plots showing the raw data on the left, there is a wider variation in density 
between all the samples related to the Infinium type I and II assays.  This variation is reduced 
post normalisation within ChAMP, as demonstrated on the plots on the right side. 
A:  
 
 
B:  
 
 
C:  
 
D:  
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Figure 4.9: Normalised Multidimensional Scaling (MDS) and Cluster Plots for  
A: Normal Endometrium v Endometrioid Endometrial Cancer (NvC),  
B: Normal Endometrium v Atypical Endometrial Hyperplasia (NvA),  
C: Atypical Endometrial Hyperplasia v Endometrioid Endometrial Cancer (AvC)  
D: Normal Endometrium v Atypical Endometrial Hyperplasia v Endometrioid Endometrial 
Cancer (NvAvC)  
The MDS plot (left) allows visualisation of the similarity of the samples based on the top 1000 
most variable probes.  The cluster plot (right) is a second way to visualise the similarity of 
samples based on all probes. 
 
A: NvC MDS and cluster plots showing differential methylation between the 2 groups with 
normal samples on the right (green arrow) and cancer samples on the left (red arrow) on the 
MDS plot; and on the cluster plot, normal samples are clustered on the left and cancer samples 
on the right. 
 
  
 
 
 
B: NvA MDS and cluster plots showing some differential methylation and some overlap 
between the 2 groups with normal samples in general on the left (green arrow) and atypical 
samples on the right (orange arrow) on both the MDS plot and on the cluster plot. 
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C: AvC MDS and cluster plots showing some differential methylation but greater overlap 
between the 2 groups, with atypical samples more on the right (orange arrow) and cancer 
samples on the left (red arrow) on the MDS plot; and on the cluster plot, atypical samples are 
on the left and cancer samples are on the right.  
 
 
 
 
 
D: Normal v Atypical v Cancer MDS and Cluster plots showing a trend towards differential 
methylation between the three groups with normal samples in general on the left (green 
arrow), atypical samples in the centre (orange arrow) and cancer samples towards the right 
(red arrow) of the MDS plot and similarly on the cluster plot. 
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Figure 4.10: Singular Valve Decomposition (SVD) Heatmaps for  
A: Normal Endometrium v Endometrioid Endometrial Cancer (NvC),  
B: Normal Endometrium v Atypical Endometrial Hyperplasia (NvA),  
C: Atypical Endometrial Hyperplasia v Endometrioid Endometrial Cancer (AvC)  
D: Normal Endometrium v Atypical Endometrial Hyperplasia v Endometrioid Endometrial 
Cancer (NvAvC)  
 
A:     B:     
           
 
 
 
C:      D:  
             
 
 
Note that all of these comparisons have technical batch effects demonstrated, particularly in 
the bisulfite conversion parameters.  The ComBat normalisation step corrects for batch 
variation. 
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From the MDS and cluster plots, there is evidence of differential methylation between normal 
endometrium, AEH and EEC samples, based on the 1000 most variable probes.   
An important control in this study was that the FF samples behaved similarly to the FFPE 
samples in terms of methylation status.  Other than specimen 42 (discussed in section 4.8), this 
was evident on the MDS and cluster plots. 
There were some samples however that did not demonstrate differential methylation between 
tissue types.  This included 4 specimens (33C, 36N, 42N, 42C) in the NvC comparison, as well as 
3 specimens (24A, 30A, 34A) in the NvA comparison.    Note that specimen 2N had to be 
removed for the ComBat normalisation and subsequent ChAMP analysis, as it was the only 
specimen from the 1st array. 
The analyses for NvC and NvA were then rerun on ChAMP with these further specimens 
excluded to re-assess clustering and the spectrum of differential methylation.  The AvC 
comparison was also rerun with these samples excluded, but is not illustrated here as it 
showed a greater overlap between specimens in terms of methylation patterns and no 
significant DMRs nor MVPs.   
The pre and post normalisation density plots, MDS and cluster plots and SVD heatmaps for the 
2 comparisons NvC and NvA are presented in Figure 4.11.  These demonstrate more consistent 
sample clustering in the MDS and cluster plots, with a reduction in batch effects on the SVD 
plots.  They also generate a higher number of MVPs and DMRs for the NvC and NvA 
comparisons though not for the AvC comparison, as illustrated in Table 4.5. 
However, due to the already reduced sample size, further analysis of the MVPs and DMRs was 
based on the samples and probes after the initial ChAMP sample filtering, rather than with 
further specimens excluded, as outlined in the bolded column in Table 4.5.  This is detailed 
further in section 4.8 of this chapter. 
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Figure 4.11: Pre and post normalisation density plots, Multidimensional scaling (MDS) and 
cluster plots and Singular Valve Decomposition (SVD) heatmaps for  
A: Normal Endometrium v Endometrioid Endometrial Cancer (NvC) with samples excluded  
B: Normal Endometrium v Atypical Endometrial Hyperplasia (NvA) with samples excluded  
 
A: NvC Comparison with 4 specimens excluded 
On the density plots, there is wider variation on the raw data density plot on the left, while the 
normalised plot on the right has narrower density readings.  The MDS plot shows the cancer 
specimens clustered on the left (red arrow) and normal specimens on the right (green arrow) 
based on the 1000 most variable probes, except for specimen 22C that lies with the normal 
specimens.  The cluster plot shows the normal specimens towards the left and cancer 
specimens towards the right based on the 401 116 probes analysed.  The SVD plot shows less 
batch effect than that when all NvC specimens were analysed. 
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B: NvA Comparison with 3 specimens excluded 
On the density plots, there is wider variation on the raw data density plot on the left, while the 
normalised plot on the right has narrower density readings.  The MDS plot shows the normal 
specimens clustered on the left (green arrow) and atypical specimens on the right (orange 
arrow) based on the 1000 most variable probes.  The cluster plot shows the normal specimens 
towards the right and atypical specimens towards the left based on the 425 496 probes 
analysed.  The SVD plot shows less batch effect than that when all NvA specimens were 
analysed. 
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Table 4.5:  Comparison of the total unfiltered evaluable samples and significant probes with 
the filtered samples and significant probes, including assessment of Methylation Variable 
Positions (MVPs) and Differentially Methylated Regions (DMRs) 
Comparator 
groups 
Total 
unfiltered 
samples & 
significant 
probes 
Filtered 
samples and 
significant 
probes  
Significant 
MVPs and 
DMRs 
Revised 
sample 
number* 
MVPs and 
DMRs 
N v C 
N v A 
A v C 
69 – 12 750 
53 – 24 737 
57 – 14 422 
39 – 400 812 
26 – 424 168 
29 – 405 496 
23572, 706 
4, 0 
0, 0 
35 – 401 116 
21 – 425 496 
25 – 405 400 
54841,1832 
27908, 727 
0,0 
*removed 4 specimens (36N, 42N, 42C, 33C) from NvC; 5 specimens (30A, 24A, 34A, 36N 42N) 
from NvA; 5 specimens (30A, 24A, 34A, 33C, 42C) from AvC  
The columns marked in bold indicate the sample number, probes, MVPs and DMRs that were 
used for further analysis. 
 
 
4.7. Comparison of the Illumina QC and ChAMP QC Steps  
To assess the utility of the Illumina Infinium QC step and bisulfite conversion percentage in 
relationship to the ChAMP analysis, the values for samples that passed and failed on ChAMP 
were compared, as outlined in Table 4.6.  As expected, the FF specimens 37-42 all passed the 
ChAMP QC steps and are not included in the summary table. 
In the majority of cases (68 from 82 specimens; 82%), there was a correlation between the 
Illumina QC value being ≤5 and the successful specimens on ChAMP.  In addition, 11 specimens 
(13%) had an Illumina QC≤5 but failed on ChAMP, while a further 3 specimens (5%) had an 
Illumina QC>5 but were successful on ChAMP, though all of these were ≤6. 
From the 11 specimens that had an Illumina QC≤5 but failed on ChAMP, 7 were analysed on 
the first array, which seemed to behave poorly compared to subsequent arrays.  This may have 
been due to the use of NanoDrop derived concentrations for subsequent modification and 
array calculations, such that less DNA was actually available for analysis.  As such, a Delta Cq 
cut-off ≤5, rather than the Illumina cut-off <5 was reviewed further here, to define a broader 
number of evaluable samples. 
 
Samples that had poor percentage bisulfite conversion also tended to have a higher Illumina 
Delta Cq as illustrated in Table 4.6, as DNA with poor integrity may have been less amenable to 
subsequent modification.  This was confirmed on correlation with the ChAMP QC. 
For the 52 samples with BIS conversion ≥98%: 
- 41 had Cq ≤5, of which 7 failed on ChAMP; 11 had Cq ≥6, of which 9 failed on ChAMP 
For the 9 specimens with BIS conversion 95-97%:  
- 4 had Cq≤5, of which 1 failed ChAMP; 5 had Cq ≥6, of which 4 failed ChAMP  
For the 4 specimens with BIS conversion 90-94%: 
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- 3 had Cq≤5, of which 2 failed ChAMP; 1 had Cq ≥6 and failed on ChAMP   
For the 16 FFPE specimens with BIS conversion <90%, all had a QC>5 and failed ChAMP QC. 
 
Table 4.6:  Correlation of the Illumina Infinium QC and Bisulfite Conversion values with 
Filtered samples through ChAMP 
Sample Illumina Cq/ 
BIS QC 
ChAMP 
result 
Sample Illumina Cq/ 
BIS QC 
ChAMP 
result 
Sample Illumina 
Cq/ BIS QC 
ChAMP 
result 
1A 5.27/98.58 F* 16C 9.08/97.37 F 30A 3.03/99.62 P 
2N -0.11/99.9 P 17N 9.14/71.39 F 30C 2.86/99.45 P 
2C 2.45/99.23 F* 17A 7/98.79 F 31N 3.45/98.28 P 
5N 3.12/99.84 F* 17C 8.58/83.87 F 31C1 3.59/99.82 P 
5A 2.90/99.58 F* 18N 10.07/52.38 F 31C3 5.24/99.45 P 
5C 3.90/99.66 F* 18A 8.24/87.31 F 32N 2.04/99.58 P 
6C 4.59/99.3 F* 18C 8.39/69.81 F 32C 0.49/99.99 P 
7C 5.66/92.78 F* 19N 9.7/98.52 F 33N 1.29/99.8 P 
9N 8.45/56.97 F 19A 9.4/95.02 F 33C 2.21/99.85 P 
9C 6.27/85.73 F 19C 8.9/98.88 F 34N 3.23/95.79 P 
3N 5.73/94.42 F* 20N 4.42/99.46 P 34A 2.43/96.30 P 
4A 2.37/99.99 P 20C 4.71/99.79 P 34C 5.12/91.05 P 
6N 10.19/21.29 F 21N 2.83/99.83 P 35N 5.38/96.53 P 
6A 6.23/99.93 F 21A 3.21/99.88 P 35C 6.36/95.25 P* 
10N 6.15/92.15 F 21C 5.96/99.65 P 36N 4.95/98.22 P 
10A 5.98/98.81 F* 22N 1.48/99.89 P 36C 4.31/99.62 P 
10C 3.47/- F* 22C 1.5/99.98 P 3N 5.49/97.52 F* 
12N 6.16/99.95 F 24N 0.73/99.85 P 3A 6.02/96.17 F 
12C 9.78/98.40 F 24A 1.26/99.93 P 3C 7.09/95.77 F 
13N 2.6/99.87 P 24C 0.53/99.89 P 7N 9.42/62.1 F 
13A 0.84/99.81 P 27N 5.87/99.71 P 7A 7.02/55.58 F 
13C 3.14/98.97 P 27A 5.18/99.39 P 7C 8.73/30.49 F 
14N 6.37/98.95 F 27C 5.20/99.48 P 8N 8.99/75.41 F 
14C 6.57/99.45 P* 28N 1.41/99.77 P 8A 8.7/63.77 F 
15N 6.48/99.84 P* 28A 0.18/99.98 P 8C 11.3/38.84 F 
15C 5.57/99.84 P 28C 0/99.92 P 11A 7.3/82.64 F 
16N 7.18/86.44 F 30N 4.74/99.65 P 11C 6.92/98.34 F 
16A 9.94/98.43 F       
P: passed, F: failed 
*samples where the Illumina recommended Delta Cq≤5 did not predict the ChAMP filtering 
 
Using an Illumina Delta Cq≤5, 49 from 82 specimens (60%) met the criteria for DNA 
modification.  From these, 38 specimens (46%) were evaluable for analysis on ChAMP. 
Using an Illumina Delta Cq≤6, 59 from 82 specimens (72%) met the criteria for DNA 
modification.  From these, 41 specimens (50%) were evaluable for analysis on ChAMP.   
 
Using a Cq cut-off ≤6 compared to ≤5 captures a greater number of cases and specimens that 
are then analysable on ChAMP, but also results in a greater proportion of sample failures.  In 
terms of the number of specimens, using a Cq≤5 yielded 38 analysable specimens on ChAMP 
from 49 identified by the Illumina QC method (78% correlation).  Using a Cq≤6 yielded 41 
analysable specimens on ChAMP from 59 identified by the Illumina QC method (69% 
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correlation), with an extra 3 specimens that were analysable.  However the subsequent failure 
rate also increased from 11 from 49 specimens (22%) to 18 from 59 specimens (31%).  Thus, a 
Delta Cq≤5 and BIS conversion ≥95% seemed to correlate best with these samples for further 
analysis on ChAMP. 
 
A summary of the patient cases and samples selected that then went on to pass each QC 
analysis is presented in Figure 4.12.  In total from the ChAMP analysis, there were 47 samples 
of normal endometrium, AEH and EEC that passed the QC process.  This included 40 FFPE 
samples (2N was excluded from the total of 41 analysable samples as it was the only sample 
from the 1st array and as such could not be analysed via the ComBat normalisation method) 
and 7 FF samples (sample 39 was excluded as it was grade 2 and 41 was excluded as it was 
sarcomatous). 
 
Figure 4.12: Samples available for DNA extraction and that passed the Illumina and ChAMP 
QC Analyses  
 
QC: quality control, I: Illumina QC, R: R console ChAMP QC 
N: normal endometrium, A: atypical endometrial hyperplasia, C: endometrial cancer. 
G1: grade 1, G3: grade 3, S: sarcoma 
 
 
Total cases 42
(101 samples)
FFPE cases 36
(91 samples)
NAC 19 
G1 13, G3 6
(57 samples)
QC passed 
I:9 (G1 6) 
R:7 (G1 4)
(21 samples)
NC 15 
G1 9, G3 5, Both 1
(31 samples)
QC passed 
I:10 (G1 7) 
R:9 (G1 5)
(18 samples)
AC G1 1
(2 samples)
QC passed 
I:0, R:0
A G1
(1 sample)
QC passed
I:1, R:1
(1 sample)
FF cases 6
(10 samples)
NC 4 
G1 1, G3 2, S1
(8 samples)
QC passed
R:4
(8 samples, 2 
excluded)
C 2 
G2 1, G3 1
(2 samples)
QC passed
R:2
(2 samples, 1 
excluded)
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4.8. Review of Sample Selection  
Based on the data in section 4.6, dissected specimens were re-reviewed to see if the 
specimens that clustered with another tissue sub-group were at higher risk of specimen 
contamination at the time of DNA extraction due to location and/or size.  This is summarised in 
Table 4.7. 
 
Table 4.7: Evaluation of Sample Slides and Risk of Contamination 
Sample Slide review Risk  (high/low) Cluster 
pattern 
2* Small area of A next to N High (for NvA) Not run 
4 N and A on separate slides Low Only A 
dissected* 
13 N and C adjacent on same slide, A on separate 
slide 
High (for NvC) N&C sep 
A&C same 
14 N and C on separate slides Low N failed on 
ChAMP 
15 N and C on separate slides Low N&C sep 
20 N and C on separate slides Low N&C sep 
21 N, A, C on separate slides Low N&C sep 
22 N and C on separate slides Low N&C same 
24 N, A, C on separate slides, A very small High (for A) N&A same 
C sep 
27 N and C adjacent on one slide, A on separate 
slide 
High (for NvC) N&C sep 
N&A same 
28 A and C adjacent on one slide High (for AvC) N sep 
A&C same 
30 N, A adjacent on same slide; C separate on 
same slide 
High (for NvA) N&A same 
C sep 
31 N and C on separate slides Low N&C sep 
32 N and C on separate slides, N small High (for N) N&C sep 
33 N and C on separate slides but both small 
areas 
High (for NvC) N&C similar 
34 N on separate slide, A and C on adjacent slide 
and small. 
High (for AvC) N,A,C same 
35 N, C on separate slides; both centrally 
located. 
High (for NvC) N&C similar 
36 N and C on separate slides, N small High (for N) N&C similar 
42 Query at time of dissection if could 
differentiate N and C 
High (for NvC) N&C same 
N: normal endometrium; A: atypical endometrial hyperplasia; C: endometrioid endometrial 
cancer 
Sep: specimens in separate clusters on cluster plot; Same: specimens in the same cluster on 
cluster plot; Similar: specimens lie in the same main cluster but not directly adjacent on cluster 
plot 
*sample 2 was not analysable on ChAMP as it could not be reviewed in the ComBAT 
normalisation step.  Sample 4 normal tissue was centrally located and not amenable to needle 
dissection. 
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Although the specimens 24A, 30A, 33C, 34A, 36N, 42 would be at risk of being contaminated 
with other tissue types, there are other evaluable samples that were also at risk of 
contamination that clustered separately as well as low risk samples that appeared to cluster 
together.  In addition, the clustering that was demonstrated for these samples was not always 
consistent with what may occur from dissection technique.  For example, for specimen 24, the 
3 histological subtypes were on different slides.  Thus, the clustering of the normal and AEH 
samples together may not be explained by technical dissection factors alone.  
As such, rather than exclude any of these specimens, all were included in evaluation of MVPs 
and DMRs through ChAMP for this study, as the differences seen in clustering could not be 
attributed to contamination alone but may equally have reflected the differential methylation 
being investigated.  Particularly with the small number of atypical specimens available for 
comparison, sample exclusion would also restrict subsequent analysis and interpretation.  Only 
the cluster dendrograms and heatmaps in Chapter 5 (Figure 5.2) were analysed with these 
specimens excluded to visualise the spectrum of differential methylation compared to that 
with all specimens included.   
 
The slides of three cases, two deemed at high risk and one at low risk of contamination, are 
shown in Figure 4.13.  The remainder are included in the Appendix section 4A.   
 
Figure 4.13:  Examples of the Slide Review of ChAMP Evaluable Samples  
Case 21 is deemed low risk as the normal (N), atypical and cancer (T) are all on separate slides.  
All cluster with the corresponding tissue group on ChAMP analysis. 
Case 27 is deemed high risk as it has normal (N) and cancer (Ca) tissue adjacent on the same 
slide (centre slide).  Both cluster with the corresponding tissue group on ChAMP analysis. 
Case 30 is deemed high risk as the normal (N), atypical and cancer (Ca) tissue is adjacent on 
the same slide (on the right).  30A clusters with the normal specimens on ChAMP analysis.  
  
     
21    27    30 
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4.9. Discussion 
Given the complexity of the sample processing for analysis, detailed evaluation of each step for 
QC was performed.  This included selection of specimens that were accurate for tissue type, 
extraction of quality DNA for analysis, accurate concentration assessment and quality bisulfite 
conversion.  
 
4.9.1. Review of Dissection Technique 
A number of techniques are available for FFPE DNA extraction including needle dissection, 
laser microdissection and core dissection using a tissue microarrayer.  Needle dissection was 
the method chosen for DNA extraction, and relies on the replication of the same area of tissue, 
on each sectioned slide such that the tissue type of interest can be dissected based on an H&E 
slide template.  In cases where the tissue area of interest is of a reasonable size and in a 
location amenable to dissection, this method is preferred.  For smaller areas of tissue where 
there may be uncertainty regarding reproducibility in sectioned slides, each slide was reviewed 
under light microscopy at the time of dissection.  Needle dissection however does exclude 
some samples where the tissue of interest is of small volume in the centre of the slide for 
example, and the reliability of accurate dissection is reduced.  For large areas of tissue, this 
method is also relatively time efficient in that only 10-20 slides may need to be dissected.  
However, for smaller area of tissue, up to 40 slides will need dissection to ensure adequate 
DNA extraction. 
Laser capture microdissection (LCM) is an alternative method ideal for small areas of tissue or 
in difficult locations, such as in the centre of a slide.  This involves direct visualisation of the 
cells of interest via microscopy and transfer of the cells via laser energy into specific collection 
tubes [256].  This method requires specific slides, at increased cost, for tissue sectioning, and it 
is also more time consuming for small amounts of tissue, again with up to 40 slides required 
for dissection and each slide taking 15-20 minutes to process.  Core dissection via a tissue 
microarrayer is the most time efficient method of collection and uses the microarrayer to 
extract larger cores of tissue measuring up to 2mm in diameter and 6-8mm in depth.  This 
method again relies on the reproducibility of the H&E slide with the tissue block but there is a 
higher risk of tissue contamination, as there is no option to microscopically review the tissue at 
the time of dissection.  Thus, although there were some limitations to needle dissection, it was 
deemed the most suitable for DNA extraction in this study as it best balanced time and cost 
efficiency with tissue accuracy, as would be required to expand the clinical utility of this 
analysis.   
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In terms of FF tissue dissection, this was based on macroscopic assessment by the 
histopathologist at the time of initial specimen review.  In this study, there was no microscopic 
review of these samples as the tissue type was clear to the histopathologist at 
macrodissection, except for one specimen (42).  To improve on the process in cases such as 
these, the FF tissue could also be sectioned while frozen into 5-10 micron thickness slides and 
a representative H&E slide evaluated every 25-50 microns to check changes in architecture and 
tissue type.   
 
4.9.2. Review of Concentration Analysis  
As the DNA concentration forms the basis of the subsequent modification steps, accuracy at 
this point was critical and was improved with the introduction of Qubit fluorometer to the 
protocol.  As outlined in the methods section 2.2.4.1.2, NanoDrop is a spectrophotometric 
instrument that measures the DNA concentration based on the peak light absorption of a 
sample.  It is time-efficient in that no dilutions are required to measure the concentration but 
it does not reliably distinguish between double and single stranded DNA, RNA, free nucleotides 
and other contaminants which scatter light or are UV-absorbing materials.  Thus although it is 
quick and easy to run, it tends to overestimate the concentration of DNA that is present in the 
sample. 
As the Qubit fluorometer utilises fluorescent dyes that only emit signals when bound to the 
specific target molecule, it provides a more accurate assessment of DNA concentrations 
compared to NanoDrop.  It is more time consuming to use, in that each of the specimens has 
to be diluted and then processed on the fluorometer, but results achieved on the later 450K 
arrays compared to the initial array were improved, which in part may have been due to more 
accurate assessment of concentration with the Qubit fluorometer.  For the initial array, even 
with Illumina Infinium QC≤5, the majority of specimens were not assessable on ChAMP, 
potentially due to the lack of DNA available for bisulfite conversion and analysis if the 
NanoDrop derived concentration was incorrect. 
 
4.9.3. Review of the Illumina quality control assay for DNA modification 
The Illumina QC assay is designed to select the specimens with the best quality DNA to take 
forward to further modification and analysis.  It is based on the assessment of FFPE DNA prior 
to performing the Illumina Infinium HD restoration protocol, rather than the alternative 
method of ligation and bisulfite conversion that was used here.  As limited EC specimens have 
been modified using this method of ligation and bisulfite conversion, a range of specimens 
with different QC values was analysed to determine if the pre-defined Illumina cut-off was 
consistent with what was generated with endometrial tissue and this methodology.  Overall, 
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the majority of specimens with an Illumina Cq value ≤5 were successful in subsequent 
modification and as analysed on ChAMP, with a correlation of 78%.  This allows a broader 
definition of specimens than the Illumina Delta Cq cut-off <5 used for the Illumina restoration 
protocol.  Accurate definition of evaluable samples is of particular importance in the clinical 
setting when trying to maximise sample utility but eliminate samples that will fail on the 
Illumina 450K array that is expensive to run. 
 
4.9.4. Review of Tissue Sample Selection 
The ChAMP pipeline for processing the Illumina 450K methylation data includes stringent QC 
parameters to optimise the results generated.  This study showed early evidence of differential 
methylation between normal endometrium, AEH and EEC, reviewed in greater detail in 
Chapter 5.  Whether due to tissue contamination or other factors, there were some samples 
that demonstrated a similar methylation pattern to the comparator tissue type.  Rather than 
excluding these samples, all samples were used for further analysis for a number of reasons.  
Firstly, although some of these samples demonstrated a risk of contamination based on review 
of the dissection techniques, this was not consistent across all the samples.  Secondly, in an 
already small number of samples, further reduction in the sample size would not be warranted 
and could bias results.   
Future research would need to validate these early findings in a larger group of patients, 
ideally collected across institutions and for FFPE and FF samples, where infrastructure is 
available.  Tissue both from early stage and advanced disease should also be included, and aim 
to compare methylation patterns between these stages of disease, as well as between early 
stage disease that recurs and early stage disease that does not recur to see if a methylation 
pattern exists that may be used to predict outcomes and guide treatment intensity.  Similarly 
in the advanced disease setting, there may be a methylation pattern that predicts response to 
chemotherapy and indeed, targeted agents.  The methodology described here in terms of 
needle dissection and the methods of DNA modification are reproducible and feasible, though 
were made more difficult by limitations in the amount of normal and atypical tissue in 
particular.  Once cancer is diagnosed in the sample, it is seen as less imperative by the 
histopathologists to block out adequate amounts of normal and atypical tissue for study, thus 
making this type of analysis challenging.  Communication with the surgical and histopathology 
teams is essential to optimise the amount and quality of available tissue.  Attention to 
processing and preservation techniques may improve the results and conclusions that can be 
drawn from further research, particularly when using FFPE tissue. 
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Overall, the methodology and QC checks utilised in this study were feasible, as outlined in 
Figure 4.14, and have the potential to be reproducible across centres with adequate education 
and communication. 
 
Figure 4.14: Key Findings in the Review of Sample Management for Analysis 
 Needle dissection is feasible to accurately dissect endometrial tissue types  
 DNA concentration assessment via fluorometry is preferred to 
spectrophotometry 
 A Delta Cq ≤5 on the Illumina Infinium HD FFPE QC assay along with 
bisulfite conversion ≥95% can predict successful analysis on the Illumina 
450K array and ChAMP pipeline for analysis of differential methylation 
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CHAPTER 5: Methylation and CNV Analysis of Endometrial Specimens 
 
5.1.  Introduction 
 
DNA methylation is one of the most well documented mechanisms of epigenetic aberration.  It 
comprises reversible covalent modification of cytosines through the addition of a methyl group 
to the carbon-5 position of cytosine bases by one or more DNA methyltransferase (DNMT) 
enzymes, occurring predominantly in the context of cytosine-guanine dinucleotides (CpGs).  
Broadly, this affects chromatin packaging and gene expression [186].  Although reversible, it is 
much less dynamic than acetylation.  CpGs that occur randomly throughout the genome tend 
to be methylated.  CpGs also occur in clusters, known as CpG islands (CGIs), ranging from 500 
up to 2000 base pairs and these tend to be unmethylated, unequally distributed and localized 
within and around the promoter regions of mammalian genes [188].  CGIs remain 
unmethylated in normal genes, except where DNA methylation is required for normal 
embryonic development, X-chromosome inactivation and genomic imprinting [257, 258].  DNA 
methylation is one of the primary heritable epigenetic gene expression processes, but 
epigenetic changes can also be affected by age and environment [259-261].   
In the setting of carcinogenesis, promoter hypermethylation involving a tumour suppressor 
gene may lead to decreased gene expression, and thus promote carcinogenesis.  Conversely, 
promoter hypomethylation of an oncogene could lead to its increased expression [262].   
 
DNA methylation has been shown to differ between normal and cancer tissue, with one of the 
first reports being of hypomethylation of the genome of cancer cells in comparison to normal 
tissue [192].  De novo methylation of CGIs around the promoter region of genes causing 
repression of affected genes is well documented [188] and recent studies suggest that within 
each tumour, hundreds of genes may be silenced by DNA methylation, compared to 10-15 
genes that may be silenced by genetic mutations [193].   
Moreover, DNA methylation in cancer appears to be tissue and tumour-type specific [190], 
with the potential that DNA methylation profiles may act as biomarkers for diagnosis, 
prognosis and response to treatment, as well as identifying biological pathways which are 
disrupted in tumour development and may be targeted.   
Epigenetic alterations and aberrant DNA methylation may be more frequent than genetic 
alterations in EC with documented epigenetic abnormalities in genes encoding tumour 
suppressors, cell cycle regulators, steroid receptors, transcription factors, angiogenesis 
modulators and oncoproteins [196].  As detailed in section 1.4.2.2, such abnormalities may 
occur in the RAS-MAPK, FGF, PI3K, Wnt and MSI pathways [200, 203-223], though clinical 
correlation in these earlier studies is often lacking.  More recently, TCGA has analysed genetic 
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and epigenetic data in FF EC [30] as outlined in section 1.4.1.1, to which FFPE data in this study 
is compared.   
What has not yet been studied is the spectrum of epigenetic changes that occurs between 
normal endometrial tissue, AEH and EC.  In this study, this spectrum of epigenetic changes 
across normal, AEH and EC tissue has been examined in order to identify events that occur 
early in endometrial carcinogenesis which may be relevant to driving the oncogenic process.  
EEC alone was analysed here to provide a homogenous group of samples for comparison.    
 
As outlined in Figure 5.1, this chapter presents the DNA methylation results from analysis of 
FFPE normal endometrial, AEH and EEC tissue on the Illumina HumanMethylation 450K array 
platform.  Assessment is made as to whether differential methylation exists between these 
tissue types that may be of prognostic or predictive value.   Data was compared to available 
TCGA data.  In addition, an in-depth review of the genes and molecular pathways that were 
differentially methylated between normal endometrium and EEC was performed, using Web 
Gestalt and the R console.  As there was not a significant number of MVPs or DMRs between 
the normal endometrium v AEH and AEH v EEC comparisons (Table 5.1), detailed molecular 
analysis could not be performed between these histological types.   
CNV was also analysed across the samples to identify genomic changes that occur during the 
normal endometrium, AEH to EEC transition in endometrial carcinogenesis.  Again, as 
discussed in Chapter 1 and particularly relevant with emerging TCGA data [263], there is 
limited published information that compares these changes across the histological types.  By 
investigating the genomic changes that occur early in carcinogenesis, management strategies 
and novel therapies to improve patient outcomes may be better identified. 
 
 
 
 
Figure 5.1. Aims of the Epigenetic and CNV Analysis in EEC 
 Assess feasibility and reproducibility of epigenetic and CNV analysis from 
FFPE and FF EEC tissue on the Illumina 450K array  
 Analyse methylation patterns in normal endometrium, AEH and EEC and 
correlate with clinical data 
 Correlate epigenetic and CNV data with TCGA and other published 
literature 
 Investigate molecular pathways and candidate genes with differential 
changes between normal endometrium, AEH and EEC. 
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5.2.  Results of the Epigenetic Analysis 
5.2.1. Demonstration of Differential Methylation in Normal, Atypical and Endometrioid 
Endometrial Cancer tissue 
The evaluation of differential methylation between normal endometrial, AEH and EEC tissue 
utilised the ChAMP pipeline, as detailed in Sections 2.2.6.1 and 4.6.  To analyse significant 
MVPs and DMRs, only 2 tissue types could be compared per analysis, as detailed in Section 4.6 
and Table 5.1 below.   To review the methylation data diagrammatically on cluster 
dendrograms and heatmaps, all 3 histological types could be analysed at one time, detailed in 
Figures 5.2-5.6.  Therefore a number of different analyses were performed, either with 2 or 3 
histological groups, as per Table 5.1.  The following comparisons were performed: (1) all 
normal endometrial, AEH and EC samples, (2) matched samples where all 3 histological 
subtypes were available for an individual case (NAC matched in Table 5.1) and (3) grade 1 and 
3 samples between and within histological subtypes. 
As discussed in sections 2.2.6.1 and 4.6, the ChAMP pipeline filters out probes on the array 
that fall outside levels of significance for detection (p >0.01) in more than one sample.  For 
example, from the 69 unfiltered samples in the NvC comparison, only 12 750 from 450 000 
probes were suitable for further analysis.   Once samples were excluded for which the fraction 
of failed probes exceeded 5-10%, the NvC comparison included 39 high quality samples where 
400 812 from 450 000 probes could be analysed.  
For each comparison, Table 5.1 details: (1) the total unfiltered sample number and statistically 
significant probes per comparison, (2) the filtered sample number and statistically significant 
probes per comparison and (3) the number of significant MVPs and DMRs per comparison.  
 
Table 5.1:  Differential Methylation Analysis by Tissue Type and Grade  
Comparator 
groups 
Total unfiltered samples 
& significant probes 
Filtered samples & 
significant probes  
Significant 
MVPs & DMRs 
N v C 
N v A 
A v C 
NAC 
69 & 12 750 
53 & 24 737 
57 & 14 422 
- 
39 & 400 812 
26 & 424 168 
29 & 405 496 
47 & 400 515 
23572 & 706 
4 & 0 
0 & 0 
ne 
NAC matched 
N v C 
N v A 
A v C 
NAC 
 
- 
- 
- 
- 
 
14 & 428839 
14 & 438 267 
14 & 429047 
21 & 425 123 
 
1032 & 17 
0 & 0 
0 & 0 
ne 
Grade 1 
N v C 
N v A 
A v C 
 
47 
38 
39 
 
21 & 413 732 
14 & 428 972 
16 & 413 589 
 
1& 0 
0 & 0 
0 & 0 
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Grade 3 
N v C 
N v A 
A v C 
 
23 
16 
18 
 
19 & 413 752 
12 & 426 675 
14 & 417 283 
 
0 & 0 
0 & 0 
0 & 0 
Normal  G1 v G3 33 19 & 422 800 0 & 0 
Atypical G1 v G3 20 6 & 444 235 0 & 0 
Cancer G1 v G3 39 22 & 407 535 0 & 0 
MVPs: methylation variable positions, DMRs: differentially methylated regions, ne; not 
evaluable, N: normal endometrium, A: atypical endometrial hyperplasia, C: endometrioid 
endometrial cancer, G: grade 
 
 
Figures 5.2 – 5.6 demonstrate diagrammatically the differential methylation of the 1000 most 
variable probes from the above comparisons.  For grade 1, grade 3, normal, atypical, cancer 
and matched subgroup comparisons, the MDS, density plots and sample cluster plots are 
included in the Appendix section 5A.  Only the cluster dendrograms (DGs) and heatmaps (HMs) 
are depicted here. 
 
In Figures 5.2A and 5.2B, two HMs were generated for each of the NvC and NvA comparisons 
with certain samples excluded in the second HM (detailed below).  As described in Section 4.6 
on the MDS and cluster plots for these comparisons, 4 specimens in the NvC and 5 specimens 
in the NvA comparisons were outliers and clustered with the alternate histological tissue type.  
The HMs below show clustering based on the 1000 most variable methylation array probes 
with and without the outlier samples to assess if the differences seen in the MDS and cluster 
plots also occurred in the HMs.  As also noted in section 4.6, subsequent analysis of the MVPs 
and DMRs was based on all the ChAMP filtered samples to maximise sample size of significant 
probes.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
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Figure 5.2: Cluster Dendrograms (DG) and Heatmaps (HM) based on the 1000 most variable 
probes for comparisons of  
A: Normal Endometrium v Endometrioid Endometrial Cancer (NvC),  
B: Normal Endometrium v Atypical Endometrial Hyperplasia (NvA),  
C: Atypical Endometrial Hyperplasia v Endometrioid Endometrial Cancer (AvC)  
D: Normal Endometrium v Atypical Endometrial Hyperplasia v Endometrioid Endometrial 
Cancer (NvAvC) (all grades included) 
 
For all heatmaps (HM):  
 
 
 
 
 
 
 
 
 
 
 
 
A: NvC 
The cluster DG below shows discrete clustering of the normal and cancer specimens except for 
5 specimens: 22C, 33C, 36N, 42N, 42C.  The 5 furthermost right cancer specimens on the DG 
(black arrow) are a separate cluster showing a level of hypermethylation intermediate 
between the main normal and cancer clusters, as demonstrated in the HM cancer specimens 
on the left. 
 
 
                              
 
 
 
Normal endometrium: dark green, AEH: orange, EEC: red  
Grade 1: light green, Grade 3: purple 
 
The colour key depicts the colour corresponding to the beta value between 0 and 1.  The 
beta value is the fluorescence intensity ratio between methylated and unmethylated 
probes.  A ratio value of 0 (yellow) equals non-methylation of the locus, 1 equals total 
methylation (dark blue) and 0.5 means that one copy is methylated and the other is not 
(light blue). 
 
The dendrogram at the top of the heatmap shows sample clustering based on the 1000 
most variable probes, with the samples detailed along the y-axis. 
The dendrogram down the left side shows the clustering of the 1000 most variable 
probes from the Illumina 450K array. 
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The top HM includes all specimens.  The bottom HM excludes 4 outlier specimens: 33C, 36N, 
42N, 42C (marked with black arrowheads).  Both HMs show an increase in hypermethylation 
between the normal endometrium and EEC specimens with a beta value close to 1 (dark blue) 
in the majority of probes for the EEC specimens.  Note that a subset of probes (bottom of HM, 
indicated by purple arrow) show hypomethylation in the EEC specimens, with the beta value 
close to 0.  
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B: NvA 
The cluster DG shows two main groups with the majority of specimens dividing according to 
normal and atypical histology, except 24A, 30A, 34A, 36N, 42N (black arrows). 
 
 
 
The HM below shows all specimens in the analysis, with hypermethylation of the atypical 
specimens in many probes, but hypomethylation in some.   
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The following HM excludes the 5 outlier samples.  There is a clear difference in clustering 
between the normal and atypical samples based on the DG at the top of the HM.  On review of 
individual probe methylation status, there is a group of probes in the top quarter of the HM 
that are hypermethylated in the atypical samples compared to the normal samples.  The 
probes in the rest of the HM show hypermethylation of some probes in the atypical samples 
compared to normal, but hypomethylation in others. 
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C: AvC 
The DG does not show as clear a difference between AvC specimens, as was seen in the NvC 
and NvA comparisons.  The HM demonstrates hypermethylation between some atypical and 
cancer specimens (towards the centre and left of the HM), while others show similar 
methylation pattern often in paired samples (for example 27 A/C, 13 A/C and 28 A/C, on the 
right of the HM and marked with black arrowheads).   
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D: NvAvC 
On review of all ChAMP filtered samples, there is evidence for differential methylation 
between the 3 histological subtypes.  The DG shows 3 clusters, broadly corresponding to 
normal endometrium, AEH and EEC.  On the HM, there is increasing hypermethylation 
between normal endometrium, AEH and EEC specimens, evidenced by the increasing beta 
values across the probes.   
Note as previously identified on the paired comparisons, 13A, 22C, 24A, 27C, 28C, 30A, 33C, 
34A, 36N, 42N, 42C appear as outliers, lying separate to their histological type.  13A/C, 22N/C, 
24N/A, 27A/C, 28A/C, 30N/A, 33N/C, 36N/C lie adjacent (marked on DG and HM with black 
arrowheads).  All are included in the HM and DG below, and in subsequent analysis. 
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The 4 comparisons above and the finding of MVPs and DMRS in the NvC and NvA comparisons, 
outlined in Tables 4.8 and 5.1, demonstrate differential methylation between the normal 
endometrium, AEH and EEC FFPE and FF specimens.  Overall, the DGs above show clustering of 
the 3 histological subtypes based on the methylation pattern of the 1000 most variable 
probes, though there are some outlier specimens which do not cluster in a consistent manner.  
In addition, the HMs show a progressive increase in hypermethylation between the 3 
histological subtypes, as evidenced by the change in the beta values across the probes 
between the normal endometrium, AEH and EEC specimens.  As described, the majority of 
probes show increasing hypermethylation, though there is also a subset of probes that show 
hypomethylation between normal endometrium, AEH and EEC. 
In particular, the heatmap of the 3 histological subtypes (Figure 5.2D) shows the spectrum of 
hypermethylation that occurs between normal, atypical and cancer tissue.  Interestingly, some 
of the atypical samples show intermediate methylation between the normal and cancer 
samples, while a smaller number lie closer to their corresponding normal or cancer sample.  
For example, the AEH and EEC components of specimens 13, 27 and 28 have similar 
methylation patterns.  As reviewed in section 4.8, this methylation pattern is unlikely to be 
attributable to dissection technique and suggests there may be a spectrum of methylation 
changes that occur either early or late in endometrial tumorigenesis.  Specimens 13, 27 and 28 
may represent those samples where the methylation changes occur between the normal to 
AEH transition, such that the AEH and EEC methylation patterns are similar.  Conversely, 
specimens 24, 30 and 34 may represent those samples where the methylation changes occur 
between the AEH to EEC transition, such that the normal and AEH methylation patterns are 
similar.  This is discussed further in section 5.4, but such patterns of changes may represent 
distinct methylation signatures of endometrial tumorigenesis.  It certainly appears however, 
that the methylation patterns in AEH and EEC are different from normal tissue. 
 
The differential methylation changes evident in the above all grade comparisons are further 
supported by the matched sample analysis in the following Figure 5.3. 
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Figure 5.3: Cluster Dendrograms and Heatmaps based on the 1000 most variable probes for  
matched samples  
A: Normal Endometrium v Endometrioid Endometrial Cancer (NvC),  
B: Normal Endometrium v Atypical Endometrial Hyperplasia (NvA),  
C: Atypical Endometrial Hyperplasia v Endometrioid Endometrial Cancer (AvC)  
D: Normal Endometrium v Atypical Endometrial Hyperplasia v Endometrioid Endometrial 
Cancer (NvAvC) 
 
A: NvC 
The DG shows 2 clusters between normal and cancer specimens.  The HM also shows these 2 
clusters, with hypermethylation in the majority of probes in the cancer specimens and 
hypomethylation in a subset of probes (bottom section of HM, purple arrow). 
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B: NvA 
The DG shows two clusters of normal and atypical specimens, except for 24A and 34A (black 
arrows).  On the HM, there is hypermethylation of the atypical specimens in over half of the 
probes. Note that fewer probes appear to be hypermethylated in this comparison compared to 
the NvC comparison.  The HM also shows that 24A, 30A and 34A have intermediate 
hypermethylation changes compared to the main cluster of normal specimens.  
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C: AvC 
The DG and HM show differential methylation between a number of the atypical and 
cancer specimens, though the paired samples 13, 27 and 28 show a similar 
methylation pattern.  Where these differential changes occur, the majority of probes 
show hypermethylation, though there is a smaller subset with hypomethylation 
(indicated by the purple arrow).   
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D: NvAvC 
There is a spectrum of differential methylation changes between the 3 histological types on 
the HM, with corresponding clustering on the DG.  The atypical specimens on the right half of 
the HM show an intermediate level of hypermethylation level compared to the normal and 
cancer clusters.  Outliers 24A, 30A and 34A, as well as clustering of paired samples A/C 13, 27 
and 28 are again noted. 
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This comparison of cases where all 3 tissue types were available for analysis is consistent with 
the data generated by analysis of all specimens, in that there is a spectrum of methylation 
changes that occurs between normal endometrium, AEH and EEC.   This is predominantly 
hypermethylation though there is a smaller subset of probes that show hypomethylation.  
The similarity between some normal and atypical samples, and between other atypical and 
cancer samples, is as described with Figure 5.2. 
  
Figures 5.4 and 5.5 show comparison of NvC, NvA and AvC in grade 1 and grade 3 samples, to 
see if the grade of the tumour affected the degree of differential methylation that occurred.  
Figure 5.6 shows the comparison of grade 1 and grade 3 samples for normal, atypical and 
cancer tissue types, to see if within these histological types, there was a difference in 
methylation between grade 1 and 3. 
 
Figure 5.4: Cluster Dendrograms and Heatmaps based on the 1000 most variable probes for 
comparisons of Grade 1 Specimens  
A: Normal Endometrium v Endometrioid Endometrial Cancer (NvC),  
B: Normal Endometrium v Atypical Endometrial Hyperplasia (NvA),  
C: Atypical Endometrial Hyperplasia v Endometrioid Endometrial Cancer (AvC)  
 
A: NvC 
The DG shows 2 clusters correlating with normal and cancer specimens with only 2 
exceptions, 22C and 36N.  The HM shows hypermethyation of the cancer specimens 
with 28C, 34C and 35C on the left showing intermediate methylation between the 
normal and cancer specimens and 36N at the right side of the cancer specimens.  
There is a smaller subset of probes that are hypomethylated between normal and 
cancer (purple arrow). 
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B: NvA 
Clustering of the 2 histological types is not discrete on the DG.  The HM however 
suggests hypermethylation in the majority of atypical specimens compared to normal, 
except for 30A and 34A, which are similar to normal.  
 
               
 
C: AvC 
The DG shows 2 groups which broadly correspond to AEH and EEC histology.  The HM 
shows some specimens with hypermethylation between atypical and cancer but the 
paired samples 13 and 28 have a similar pattern on the right. 
 
 
 
 
For the Grade 1 comparisons, there is evidence for hypermethylation between the normal and 
cancer samples with a small number of hypomethylated probes.  In the normal vs atypical 
group, there appears to be a trend towards hypermethylation in the AEH specimens, though 
30A and 34A show a similar pattern to the normal samples.  Similarly, in the atypical vs cancer 
specimens, there are some specimens where the cancer tissue is hypermethylated compared 
to the atypical specimens but samples 13 and 28 have a similar methylation pattern. 
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Figure 5.5: Cluster Dendrograms and Heatmaps based on the 1000 most variable probes for 
comparisons of Grade 3 Specimens  
A: Normal Endometrium v Endometrioid Endometrial Cancer (NvC),  
B: Normal Endometrium v Atypical Endometrial Hyperplasia (NvA),  
C: Atypical Endometrial Hyperplasia v Endometrioid Endometrial Cancer (AvC)  
 
A: NvC  
Other than 42N/C, 27C and 33C (black arrows), both the DG and HM show differential 
hypermethylation between the normal and cancer specimens, with a smaller subset of probes 
demonstrating hypomethylation (purple arrow). 
 
 
 
 
B: NvA 
Despite the small number of grade 3 atypical samples, the DG shows the separate clusters of 
normal and atypical specimens with evidence for hypermethylation in the atypical specimens 
on the HM.  The normal samples 24N and 42N (black arrows) cluster with the atypical samples 
and show a similar methylation pattern. 
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C: AvC 
The DG shows separate clusters for the atypical and cancer specimens, though  there are only 
3 atypical samples and 27C, 33C and 42C (black arrows) are in that cluster.  The main group of 
cancer specimens are hypermethylated compared to the atypical cluster, though there is also a 
smaller number of probes with hypomethylation (purple arrow). 
 
    
 
 
 
 
 
In the grade 3 comparisons, cancer specimens are hypermethylated relative to normal 
specimens, though again there is a small number of hypomethylated probes.  There is 
differential methylation between some normal and atypical samples and similarly between 
some atypical and cancer samples, though others show a similar methylation pattern, as 
previously noted. 
 
Overall, the changes in methylation described when all specimens were analysed together 
apply to both the grade 1 and grade 3 analyses. 
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Figure 5.6: Heatmaps based on the 1000 most variable probes for comparisons of Grade 1 
and Grade 3 specimens for A: Normal, B: Atypical, and C: Cancer (G1: green, G3: purple) 
 
The normal samples, associated with grade 1 and 3 cancers, show differential clustering but no 
distinct methylation pattern on the HM.  There is no consistent difference in methylation 
patterns between the associated atypical specimens. Some of the grade 3 cancer specimens 
are hypermethylated compared to the grade 1 cancer specimens. 
 
Normal       Atypical 
                     
Cancer 
        
In the normal specimens, the cluster dendrogram at the top of the heatmap shows separate 
clusters of the normal tissue associated with grade 1 and grade 3 cancer samples, though there 
is a spectrum of methylation changes demonstrated.  There is no clear difference in 
methylation between atypical specimens associated with grade 1 and grade 3 cancer, though 
this group has the smallest sample size for comparison with only 6 samples.  Within the cancer 
specimens, there is some evidence for hypermethylation of grade 3 specimens compared to 
grade 1, as well as specimens of both grades that have similar features.  
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5.2.2. Correlation of Methylation Analysis with Clinical Data 
Clinical data were collected for those samples that were evaluable through the ChAMP 
pipeline and are outlined in Tables 5.2 and 5.3.  Note that all samples were EEC, though a few 
samples had smaller co-existing areas of other pathology.  For specimens with grade 2 disease, 
it was either the grade 1 or 3 changes that were dissected for analysis. 
 
The clinical data was correlated with the methylation data to ascertain if there was any 
association between clinicopathologic features and differential methylation.  This was analysed 
on the NvC total group, as well as the NvC matched sample group.   Figures 5.7 and 5.8 show 
the heatmaps with clinical factors and methylation status. 
 
Table 5.2: Pathologic Features of ChAMP Evaluable Specimens 
Sample 
number 
Age Stage Grade Tumour size 
(mm) 
MMI>
50% 
LVSI Cerv 
invasion 
LN + 
4 53 IA 1 10 N N N N 
13 73 IIIB 1 (F G2) 32 Y Y N N 
14 55 IA 1 22 N N N N 
15 55 II 1 6 Y N N N 
20 77 IA 2 (F G3) 50 N Y N N 
21 50 IB 2 & 3 50 N Y N N 
22 66 IB 1 16 N Y N N 
24 72 IB 2 (F G3) 30 N Y N N 
27 65 IA 2 (F G3) 11 N N N N 
28 64 IA 1 10 N N N N 
30 70 IA 1 8 N N N N 
31 61 II 2 (F G3) 32 N N N N 
32 71 IIIC 3 35 Y Y N Y 
33 71 IB 3 46 Y Y N N 
34 36 IA 1 <10 na na na N 
35 61 IA 2 12 N N N N 
36 72 IA 1 (F G2) 15 N N N N 
37 66 IB 3 42 Y Y Y N 
38 79 IA 3 30 N Y N N 
40 76 II 1 &2 25 N N Y N 
42 58 IB 3 (NE) 65 Y Y N N 
MMI: myometrial invasion; LVSI: lymphovascular space invasion, Cerv: cervical, Pos: positive,     
F: focal, G: grade, NE: neuroendocrine, S: sarcomatous, na: not assessable 
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Table 5.3: Treatment Received and Patient Outcomes of ChAMP Evaluable Specimens 
Sample Adj chemo 
(Yes/No) 
Adj RT 
(Yes/No) 
Adj hormones 
(Yes/No) 
Mets 
(Yes/No) 
Time to 
Mets (m) 
Survival 
4 N N N N - Y 
13 Y Y N N - Y 
14 N N N N - Y 
15 Y N N N - Y 
20 N Y N N - Y 
21 Y Y N N - Y 
22 N N N N - Y 
24 Y Y N Y  19 N (31m) 
27 N N N N - Y 
28 N N N N - Y 
30 N N N N - Y 
31 N Y N N - Y 
32 Y Y N N - Y 
33 Y Y N N - Y 
34 N N Y N - Y 
35 N N N N - Y 
36 N N N N - Y 
37 N Y N N - Y 
38 N Y N N - Y 
40 N N N N - Y 
42 Y Y N N - Y 
Adj: adjuvant, Mets: metastases, m: months 
Chemo: chemotherapy, RT: radiotherapy, Y: yes, N: no 
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Figure 5.7: Clinicopathological data and Normal Endometrium v Endometrioid Endometrial 
Cancer Methylation Status for all samples, A: grade, B: stage and age, C: tumour features, D: 
primary treatment 
There appears to be a trend between patients’ age ≥65 years and hypermethylation of EC 
samples in HM B, as well as tumour size ≥2cm and hypermethylation in HM C (both marked by 
black arrowheads).  Otherwise, there is no definitive correlation between clinicopathological 
data and methylation status 
 
 
            A    
 
 
B    
 
Stage I: yellow  
Stage II:  plum 
Stage III: red 
 
Age  
<65yrs: light blue 
≥65yrs: olive 
Grade 1: green 
Grade 3: purple 
 
Normal: dark green 
Cancer: red 
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C  
  
D   
 
In the NvC analysis with all samples in Figure 5.7 above, there was limited correlation between 
clinicopathologic factors and differential methylation status.  A group of patients aged ≥65 
years and a group with tumour size ≥2cm appeared to cluster together associated with 
hypermethylation in EC samples, but otherwise there was no apparent clustering based on 
stage, tumour features, disease recurrence nor adjuvant treatment received.   
 
In the following Figure 5.8 showing the matched NvC comparison, there is a trend between 
clinicopathologic features and differential methylation.   Patients with grade 3 tumours and 
age ≥65 years appear to have hypermethylation in the cancer tissue compared to lower grade 
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and patients <65years.  Tumour size ≥2cm and the presence of LVSI also seem to correlate with 
greater hypermethylation in cancer specimens.  In terms of adjuvant treatment, those who 
received adjuvant chemotherapy and RT appeared to have tumours with greater 
hypermethylation, potentially related to these being larger tumours with LVSI.  Only one 
patient had recurrent disease so the difference in methylation between those who did and did 
not recur cannot be assessed here.  
 
Figure 5.8: Clinicopathological data and Methylation Status of matched Normal 
Endometrium v Endometrioid Endometrial Cancer samples, A: grade, B: stage and age, C: 
tumour features, D: primary treatment 
Some grade 3 specimens and those with patients’ age ≥65 years showed hypermethylation in 
the cancer tissue compared to specimens of lower grade and with patients’ age <65years (A 
and B respectively).  Specimens with tumour size ≥2cm and LVSI also showed 
hypermethylation in cancer specimens (C).  In terms of adjuvant treatment, those who 
received adjuvant chemotherapy and RT appeared to have tumours with greater 
hypermethylation (D).  These samples are marked with black arrowheads. 
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5.2.3.  Correlation of Study Data with The Cancer Genome Atlas 
The methylation data from the normal endometrium, AEH and EEC samples in this study were 
compared with what was publicly available through TCGA research network on normal 
endometrium and cancer tissue.  There were no atypical specimens available for comparison 
on TCGA. 
Using a search for healthy endometrial tissue and uterine corpus endometrioid carcinoma, 
data for 60 healthy and 383 EC samples were obtained from TCGA.  For the purpose of the 
comparison and processing restrictions on the R console with too great a sample number, 50 
healthy and 150 EEC samples from TCGA were compared to the study normal, atypical and 
cancer specimens.  Overall, there appeared to be a correlation between the study normal and 
cancer samples and the TCGA data. 
 
In the normal vs cancer comparison in Figure 5.9, there were 2 separate clusters of cancer 
specimens from the TCGA data with those on the right side showing greater hypermethylation 
compared to the normal tissue, than those on the left.  There is also a subset of probes 
between the normal and cancer tissue that are hypomethylated (purple arrow). 
The majority of study samples clustered with the corresponding TCGA histological tissue type, 
except specimens 22C, 33C and 42C that clustered with the normal samples towards the left of 
the HM, while 36N and 42N clustered with the cancer specimens towards the right of the HM, 
consistent with earlier assessment of these specimens in this chapter (see Figure 5.2A).  All 
other normal specimens clustered with the TCGA normal specimens in the centre.  Specimens 
14C, 15C, 20C, 31C, 32C, 37C, 38C lay closer to the first cluster of cancer specimens on the left, 
while specimens 13C, 21C, 24C, 27C, 28C, 30C, 34C, 35C, 36C, 40C lay within the cluster of 
cancer specimens on the right.   
 
Comparison of normal endometrial, AEH and EEC specimens with TCGA data is detailed in 
Figure 5.10, and demonstrates that the majority of the AEH specimens cluster with the TCGA 
cancer samples towards the right side of the HM.  Within the TCGA cancer specimens, the 
spectrum of methylation changes is again demonstrated.  Those in the centre show an 
intermediate level of hypermethylation compared to the normal tissue, while those on the 
right show greater hypermethylation.  Similar to the study data, there is also a set of probes 
that are hypomethylated in cancer tissue compared to the normal tissue, demonstrated 
towards the bottom of the HM (purple arrow). 
In terms of the atypical samples, 24A, 30A and 34A lay within the normal sample cluster, again 
consistent with earlier study data in this chapter.  Otherwise, 4A, 13A, 21A, 27A, 28A lay within 
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the cancer cluster of specimens and interestingly, are intermediate in their methylation status, 
as are many of the TCGA cancer specimens. 
 
This division of atypical specimens between those clustering with normal and those clustering 
with cancer specimens again may support the hypothesis that there is a spectrum of 
methylation changes that occur either early or late in endometrial tumorigenesis.   As noted in 
Figure 5.2B, the cases 24A, 30A and 34A may reflect those samples where methylation changes 
occur later in tumorigenesis as the normal and atypical specimens have a similar methylation 
pattern.  For cases 13A, 27A and 28A, the methylation changes may occur early and thus, they 
have a similar pattern to cancer tissue, as previously noted in Figure 5.2C. 
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Figure 5.9: Correlation of Differential Methylation for the 500 most variable probes for TCGA 
and Study Normal Endometrial and Endometrioid Endometrial Cancer specimens 
 
 
 
 
There are 2 separate clusters of cancer specimens from the TCGA data with those on the right 
side showing greater hypermethylation compared to the normal tissue, than those on the left.   
The majority of study samples clustered with the corresponding TCGA histological tissue type, 
except specimens 22C, 33C and 42C that clustered with the normal samples towards the left of 
the HM, while 36N and 42N clustered with the cancer specimens towards the right of the HM, 
consistent with earlier assessment of these specimens in this chapter (see Figure 5.2A).  All 
other normal specimens clustered with the TCGA normal specimens in the centre.  Specimens 
14C, 15C, 20C, 31C, 32C, 37C, 38C lay closer to the first cluster of cancer specimens on the left, 
while specimens 13C, 21C, 24C, 27C, 28C, 30C, 34C, 35C, 36C, 40C lay within the cluster of 
cancer specimens on the right.    
Normal endometrium: dark green; Cancer: red 
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Figure 5.10: Correlation of Differential Methylation for the 500 most variable probes for 
TCGA and Study Normal Endometrial, Atypical Endometrial Hyperplasia and Endometrioid 
Endometrial Cancer specimens 
 
 
 
 
 
 
The majority of the AEH specimens cluster with the TCGA cancer samples towards the 
centre/right side of the HM.  Within the TCGA cancer specimens, the spectrum of methylation 
changes is again demonstrated.  Those in the centre show an intermediate level of 
hypermethylation compared to the normal tissue, while those on the right show greater 
hypermethylation.  Similar to the study data, there is also a set of probes that are 
hypomethylated in cancer tissue compared to the normal tissue, demonstrated towards the 
bottom of the HM (purple arrow). 
In terms of the atypical samples, 24A, 30A and 34A lay within the normal sample cluster, again 
consistent with earlier study data in this chapter.  Otherwise, 4A, 13A, 21A, 27A, 28A lay within 
the cancer cluster of specimens and interestingly, are intermediate in their methylation status, 
as are many of the TCGA cancer specimens. 
Normal endometrium: dark green; Cancer: red 
Atypical endometrial hyperplasia: orange 
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5.2.4. Pathways and Genes affected by Differential Methylation 
As only the NvC comparison yielded a significant number of MVPs and DMRs (see Table 5.1), 
only the associated molecular pathways and genes from this analysis could be identified.   
From the 23572 MVPs and 706 DMRs generated from the NvC comparison, a list of associated 
probes and genes was generated from the ChAMP pipeline and analysed through WebGestalt 
(described in section 2.2.6.1).  It was assessed whether genes that were differentially 
methylated were related to cancer pathways or not.  For the NvA and AvC comparisons, 
although the heatmaps (Figure 5.2) demonstrated that differential methylation occurred 
between the histological types, there were no significant DMRs that could be analysed in 
terms of specific molecular pathways. 
On WebGestalt, different enrichment analyses are available. KEGG and Pathway Commons 
analyses were assessed as most appropriate and used for this study.  The KEGG analysis 
generated a list of genes associated with pathways in cancer, as well as other non-cancer 
related pathways while the Pathway Commons analysis gave greater detail specifically on the 
cancer pathways.  
The results of the KEGG and Pathway Commons analysis are detailed in Table 5.4. 
 
Table 5.4: Results of the KEGG and Pathway Commons analyses on WebGestalt for the 
DMRs, hypomethylated and hypermethylated probes, along with the associated genes 
Cancer and metabolic pathways of interest are shown below. 
 
Analysis Pathway Names No. of 
genes 
P value Examples of genes involved 
KEGG 
analysis for 
DMRS 
Pathways in cancer 
Cell adhesion molecules  
Focal adhesion 
Type I DM 
12 
11 
11 
5 
0.0008 
8.93e-06 
0.0003 
0.0008 
RARA, GLI2, AKT1, COL4A2, 
DCC, TGFB3, RASSF1, CTBP2, 
WNT16, FZD5, ETS1, CTBP1 
Pathway 
commons 
analysis for 
DMRs 
(cancer 
related) 
PDGFR SP 
c-met/HGFR SP 
EGFR SP  
PI3K/mTOR/Arf6 pathway 
Plasma membrane ER SP 
VEGFR1 & VEGFR2 SP 
FAK SP 
E-cadherin SP 
p53 SP 
ALK1 SP 
Notch SP 
TGFB R SP 
Trk R SP 
36 
36 
36 
36 
37 
36 
36 
11 
8 
10 
5 
9 
4 
1.55e-07 
1.55e-07 
1.55e-07 
1.55e-07 
1.55e-07 
1.55e-07 
1.55e-07 
0.0004 
0.0021 
0.0043 
0.0073 
0.0090 
0.0092 
CARD11, TP53AIP1, DUSP6, 
RASSF1, CD8B, ETS1, HSPA1A, 
SKI, CFLAR, RPTOR, TP73, TJP2, 
SHC1, GATA2, MMP14, DNM2, 
H2AFY, RIN1, RIN2, TGIF1, 
AKT1, PTPN6, COL1A1, KARLN, 
PENK, RUNX3, HIC1, MEF2D, 
KIFC3, THY1, GNA12, PRKCZ, 
SERPINB5, FZD5, CTBP1, SFN 
 
KEGG 
analysis for 
hypomethy
lated 
probes 
MAPK SP 
Wnt SP 
Metabolic pathways 
Focal adhesion 
 
2 
2 
2 
2 
 
0.0431 
0.0227 
0.0227 
0.0289 
 
DUSP6, MAPK8IP3, TBL1XR1, 
AXIN1, CARD11, PTPN6, NT5C3, 
HGD, GALNT6, SCLY 
SPP1, PARVG, PDE6B, HLA-DMB 
156 
 
Pathway 
commons 
analysis for 
hypomethy
lated 
probes 
c-met/HGFR SP 
PI3K/mTOR SP 
EGFR SP 
PDGFR SP 
FAK SP 
E-cadherin SP 
VEGF & VEGFR SP 
Plasma membrane ER SP 
9 
9 
9 
10 
9 
5 
10 
9 
3.38e-05 
3.38e-05 
3.38e-05 
3.38e-05 
3.38e-05 
3.38e-05 
3.38e-05 
3.38e-05 
SPP1, CARD11, DUSP6, 
TBL1XR1, AXIN1, PTPN6, 
MAPK8IP3, AQP5, PTPRE, SHB 
KEGG 
analysis for 
hypermeth
ylated 
probes 
Pathways in cancer 
Type I DM 
Cell adhesion molecules 
Focal adhesion 
20 
8 
13 
15 
3.19e-05 
1.52e-05 
1.52e-05 
4.59e-05 
MMP9, GLI2, DCC, ITGA6, 
NTRK1, FGF12, RASSF1, FGF5, 
PRKCA, VEGFA, ETS1, CTNNA2, 
EGFR, BMP2, WNT4, BMP4, 
WNT16, WNT3, RUNX1, CTBP 
Pathway 
commons 
analysis for 
hypermeth
ylated 
probes 
EGFR SP 
VEGF & VEGFR SP 
FAK SP 
PI3K/mTOR SP 
PDGFR-β SP 
HGFR SP 
ALK1 SP 
TGFB R SP 
E-cadherin SP 
Wnt SP 
Plasma membrane ER SP 
 
 
65 
64 
62 
62 
62 
62 
17 
16 
18 
8 
63 
 
2.46e-12 
5.30e-12 
9.88e-12 
9.88e-12 
9.88e-12 
9.88e-12 
0.0003 
0.0004 
1.53e-05 
0.0004 
9.88e-12 
 
SOX1, WNT4, DAB2, WNT3A, 
PRKCA, CTBP1, HIPK2, CSNK1E, 
MMP9, BIN1, ITGA6, ROBO1, 
RASSF1, PBX1, NDRG2, 
NEDD4L, ETX1, ITGB5, FOXG1, 
HSPA1A, HLA-A, SKI, BMP2, 
TJP2, PRKCE, GSC, RPTOR, TP73, 
IRF4, ZYX, DAB2, EOMES, SHC1, 
CTGF, GATA2, DNM2, ACTA2, 
MDFIC, CXCL12, PRR5, GFRA1, 
POU4F2, TAOK3, BDNF, HIC1, 
PENK, OPRM1, VEGFA, EGFR, 
PITX2, THY1, GNA12, TERT, 
HIPK2, ACTA1, PRKCZ, TLE1, 
MYOD1, BMP4, RUNX1, 
PPP1R13L, CYTH2, FOXA1, 
RGMA 
No.: number, Ag: antigen, R: receptor, DM: diabetes mellitus, SP: signalling pathway.  
Other gene/pathway abbreviations are outlined in the Abbreviations section.  
 
There are a number of cancer related genes and pathways that were identified from the 
enrichment analyses of the DMRs, as well as pathways involving ER signalling and diabetes that 
also may be implicated in endometrial carcinogenesis.  The pathways demonstrated include 
those that are well-documented in EC including PI3K/mTOR/Arf6, VEGF, EGFR, PDGFR, TGFB, 
p53 and the Wnt/E-cadherin signalling pathways.  However, there are also a number of 
pathways that are novel or only recently described in endometrial carcinogenesis including 
FAK and cell adhesion, ALK, c-met/HGFR, NOTCH/FOXA1 and Trk signalling pathways [264-
267].  The genes listed above interact with a number of these pathways rather than being 
exclusive to one, reflecting the nature of interacting networks that drive tumorigenesis. 
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From the genes listed in Table 5.4 above, the following parameters were reviewed: 
- The frequency of hypermethylated and hypomethylated probes, the genomic 
distribution and CpG content of the DMRs (detailed in Figure 5.11). 
- For those genes with methylation changes in the promoter region or gene body and 
located in the CGI or CpG shore (as per Table 5.5), the differential changes were 
reviewed in greater detail in section 5.2.3, along with the gene function where known.  
 
Figure 5.11: The distribution of Differentially Methylated Regions (DMRs) associated with    
A: Hypermethylated and hypomethylated probes  
B: Genomic distribution  
C: CpG content of the DMRs  
 
A: Hypermethylated and hypomethylated probes in DMRS 
 
 
B: Genomic distribution of the DMRS 
 
IGR: intergenic region, UTR: untranslated region, TSS: transcription start site 
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C: CpG content of the DMRs 
 
 
Figure 5.11 above shows that the majority of DMRs involve hypermethylation of the gene 
promoter or body.  There is already evidence in the setting of carcinogenesis that promoter 
hypermethylation of a tumour suppressor gene may lead to decreased gene expression while 
promoter hypomethylation of an oncogene may lead to its increased expression [262].  Thus, 
the function of the implicated genes and their location within the gene and CpG content is 
further detailed in Table 5.6.   
 
Figure 5.11 also shows that the DMRs were most commonly found in CGIs.  CGIs are typically 
found in the promoter region of genes and CGI promoter methylation is implicated in 
carcinogenesis [268].  As there is data to suggest that DNA methylation in CpG shores and in 
the gene body can also be of significance in carcinogenesis [189, 194], changes in both CGIs 
and the CpG shore within the promoter region and gene body were reviewed further.   Table 
5.5 details the genomic distribution and CpG content of the genes listed in Table 5.4, 
generated from the Web Gestalt analysis, particularly if located within a CGI or CpG shore.   
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Table 5.5:  Genomic distribution and CpG content of Selected Genes from the DMRS, 
hypermethylated and hypomethylated regions 
 Promoter (1st exon, 
TSS200, TSS1500) 
Body 5’UTR 3’UTR 
Island 
Hypomethylated 
  
Hypermethylated 
 
SFN (S) 
 
RASSF1, NDRG2, 
EOMES, HSPA1A, TP73, 
GATA2, FGF2 (S), NRG3 
(S), MYL9 (S), ITGA8 (S), 
MADCAM1 (S), NCAM2, 
PENK, HIC1, SFRP2, 
SOX1, FZD10, RUNX3 
 
PTPRE 
 
DCC (shelf), FGF12, 
NTRK1, CTNNA2, 
MMP9, GSC, 
RUNX1, PRKCZ, 
CD8B (S), GNA12 
(S), PRR5, POU4F2, 
 
 
 
BMP4 
 
Shore 
Hypomethylated 
 
Hypermethylated 
AQP5 (S), CLDN4 (I), 
CFLAR, PTPN6  
 
WNT3A, VEGFA, 
WNT16, FZD5, H2AFY, 
MMP2, THY1, TJP2 
DUSP6 
 
 
GLI2, PBX1, FGF5, 
ETS1, BMP2, CTGF, 
 
 
 
CTBP1, 
CSNK1E 
 
 
 
MMP14 
Shelf  DCC (S), RIN1 (S), SHC1, 
TGIF1 (S) 
RPTOR, ZYX, SHC1, 
TGFB3, AXIN1 
MEF2D AKT1 
Not specified COL11A1, SERPINB5, 
TP53AIP1, KARLN, APC, 
FGF10, LAMA3, 
CARD11, SPP1 
PRKCA, ITGA6, SKI, 
EGFR, WNT4, 
DNM2, HIPK2, 
HLA- CDH4, RARA, 
COL4A2, 
MAPK8IP3 
TBL1XR1, 
PARVG, 
CTBP2, 
NLGN1  
CNTNAP1  
S: shore, I: island.  If there is >1 CpG content, the 2nd is indicated in brackets. 
 
 
 
5.2.5. Differential Methylation within Candidate Genes 
The genes generated through the WebGestalt analysis and located within the promoter region 
or gene body with CGI or CpG shore content, as detailed in Table 5.5, were then analysed 
further on the R console, as described in Section 2.2.6.1 (script 4 in appendix 2D).   
This further analysis between the normal endometrial, AEH and EEC specimens assessed 
specific probes within a gene and the spectrum of change in methylation status that occurred 
between the 3 histological subtypes.  Data was generated numerically and diagrammatically 
detailing where the greatest change in methylation status occurred based on changes in the 
beta values.   
These difference in gene methylation between normal endometrium, AEH and EEC specimens 
for 10 genes is illustrated diagrammatically in Figure 5.12. 
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Figure 5.12: Diagrams demonstrating differentially methylated probes (indicated by black 
arrows), their genomic distribution and CpG content in specific genes involving, A: VEGF, B: 
MAPK, C: Wnt, D: FGF/FGFR, E: tumour suppressor genes, F: p53 pathways 
 
The y-axis shows the degree of methylation of individual probes, as illustrated by the beta 
value.  A beta value of 0 equals non-methylation at the locus and 1 equals total methylation. 
The x-axis shows both the genomic distribution (promoter region, gene body, intergenic 
region) and the CpG content (island, shelf, shore, open sea). 
For each probe, the beta value of the normal endometrium (green), AEH (black) and EEC (red) 
specimens is plotted, such that progressive methylation changes can be visualised along with 
the genomic distribution and CpG content. 
 
All the genes show areas of progressive hypermethylation between normal endometrium, AEH 
and EEC, except for DUSP6 and TP53AIP1, which show progressive hypomethylation.  The 
hypermethylation within VEGFA, WNT16, FZD5, FGF2, FGF10, DCC, RASSF1 and TP73 all occur 
within or including the promoter region.  The hypomethylation of DUSP6 and TP53AIP1 occurs 
in the gene body and promoter region respectively. 
 
 
 
A: VEGF 
 
 
 
B: MAPK 
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C: Wnt 
 
 
 
 
D: FGF/FGFR 
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E: Tumour suppressor genes 
 
 
 
 
F: p53 
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Using the associated numerical data generated in conjunction with the diagrams from Figure 
5.12, the probes with differential methylation between normal endometrium, AEH and EEC 
could be identified and the beta values analysed to determine firstly, whether the methylation 
changes between normal endometrium and EEC were statistically significant and secondly, 
whether the changes were more significant between the NvA or between the AvC transitions.   
The hypermethylated and hypomethylated genes with statistical significance are presented in 
Tables 5.6 and 5.7 respectively, along with the genomic distribution, CpG content, the number 
of probes within the gene that are hyper/hypomethylated and the gene function where 
known.   
 
Table 5.6: Hypermethylated genes, their location and CpG content, associated pathway and 
significance 
Gene Hyper/ 
hypo 
Genomic  
distribution 
CpG 
content 
Probe 
no. 
Pathway 
&/or 
function 
NvC  
p value 
NvA  
p value 
AvC  
p value 
Wnt signalling pathway 
WNT3A hyper promoter shore 4 Wnt 0.026 0.0044 0.71 
SFRP2 hyper promoter Island 16 Wnt 0.0014 0.024 0.79 
SOX1 hyper promoter island 23 Wnt 
TSG [269] 
9.7e-07 0.032 0.052 
APC hyper promoter Open 
sea 
12 Wnt 
TSG 
0.0021 0.22 0.77 
FZD10 hyper promoter island 3 Wnt 0.00056 0.62 0.95 
WNT16 hyper promoter shore 7 Wnt 2.1e-06 0.046 0.015 
NDRG2 hyper promoter island 3 N-myc 
Wnt 
TSG 
0.00021 0.16 0.13 
FZD5 hyper promoter shore 3 Wnt 1.16e-05 0.23 0.12 
FGF/FGFR signalling pathway 
FGF10 Hyper promoter Open 
sea 
12 FGF 0.0014 0.12 0.22 
FGF12 hyper body Island 15 FGF 0.0014 0.089 0.21 
FGF2 Hyper Promoter Shore & 
island 
4 FGF 4.6e-06 0.063 0.051 
P53 signalling pathway 
TP73 hyper promoter island 5 p53 
TSG 
0.00062 0.095 0.49 
VEGF signalling pathway 
VEGFA hyper promoter shore 3 VEGF,angio
genesis 
9.3e-05 0.59 0.0065 
Other signalling pathways 
NRG3 hyper promoter Island & 
shore 
9 Neuregulin 
ERBB4 
4.7e-05 0.030 0.11 
MMP2 hyper promoter shore 4 MMP 0.00026 0.084 0.36 
SHC1 hyper promoter shelf 3 MAPK 1.3e-06 0.022 0.055 
TGFB3 hyper body shelf 3 TGFB 0.00028 0.11 0.12 
GLI2 hyper body shore 3 SHH 6.6e-05 0.51 0.011 
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RIN1 hyper promoter Shore & 
shelf 
6 MAPK 0.00028 0.23 0.026 
RARA hyper Body Open 
sea 
10 Retinoic 
acid 
receptor 
4.7e-06 0.15 0.0012 
Other tumour suppressor genes 
RASSF1
A 
hyper promoter island 10 RASSF1 
TSG 
0.00039 0.096 0.19 
DCC hyper Promoter 
 
body 
Shore & 
shelf 
Island & 
shelf 
4 
 
8 
CAM 
TSG 
0.39e-07 0.044 0.092 
HIC1 hyper promoter island 6 TSG 
Represses 
transcrip’n 
4.18e-05 0.11 0.082 
RUNX3 hyper promoter island 27 Regulates 
transcrip’n 
TSG 
0.00029 0.17 0.079 
Other pathways (e.g. immune, CAM, transcription regulation) 
COL11A
1 
hyper promoter Open 
sea 
5 Collagen 0.00014 0.075 0.18 
ITGA8 hyper promoter Island & 
shore 
8 Cell-cell 
interaction 
3.6e-05 0.047 0.066 
CD8B  hyper body 
Promoter 
Island & 
shore 
5 Tcell/immu
ne 
4.6e-05 0.32 0.077 
CARD11 hyper promoter Open 
sea 
4 CARD/MAG
UK 
0.00041 0.97 0.0039 
GATA2 hyper promoter island 11 Regulates 
gene 
transcrip’n 
0.012 0.44 0.10 
H2AFY hyper promoter shore 9 Represses 
transcrip’n 
0.00035 0.12 0.10 
KARLN hyper Promoter Open 
sea 
8 Neuronal 
regulation 
1.9e-05 0.13 0.030 
MADCA
M1 
hyper promoter Island & 
shore 
4 Cell 
adhesion 
leucocyte 
receptor 
1.2e-05 0.21 0.11 
MYL9 hyper promoter Island & 
shore 
9 myosin 8.6e-05 0.51 0.0019 
NCAM2 hyper promoter island 6 CAM 3.1e-05 0.26 0.0076 
PENK hyper promoter island 17 Enkephalin 3.2e-07 0.077 0.017 
TGIF1 hyper promoter Shore & 
shelf 
4 Regulates 
transcrip’n 
1.3e-06 0.14 0.0033 
THY1 hyper promoter Shore 5 Neural cell-
cell 
interaction 
0.00055 0.92 0.0092 
TSG: tumour suppressor gene, CAM: cell adhesion molecule, Transcrip’n: transcription.   
Other abbreviations are outlined in the Abbreviations section. 
P values are italicised to indicate whether the NvA or AvC p value is smaller 
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Table 5.7: Hypomethylated genes, their location and CpG content, associated pathway and 
significance 
Gene Hyper/ 
hypo 
Genomic  
distribution 
CpG 
content 
Probe 
number 
Pathway 
&/or 
function 
NvC  
p value 
NvA  
p 
value 
AvC  
p value 
P53 signalling pathway 
TP53AIP
1 
hypo promoter Open 
sea 
10 p53 0.00078 0.027 0.22 
SFN hypo promoter Island/ 
shore 
11 p53 
PI3K 
3.79e-05 0.12 0.0076 
Other pathways or TSGs 
SERPINB
5 
hypo Promoter Open 
sea 
8 TSG 5.87e-0.5 0.31 0.0021 
DUSP6 hypo body shore 10 MAPK 2.01e-05 0.61 0.0014 
Other cellular roles 
CFLAR hypo promoter shore 4 Apoptosis 
regulator 
1.7e-05 0.014 0.15 
CLDN4 hypo promoter Island/ 
shore 
7 Epithelial 
cell tight 
junction 
0.00025
03 
0.069 0.031 
AQP5 hypo Promoter 
and body 
Island/ 
shore 
3 Water 
channel 
protein 
0.00079 0.12 0.056 
LAMA3 Hypo Promoter Open 
sea 
6 CAM 0.00019 0.079 0.047 
PTPN6 hypo promoter shore 7 Protein 
tyrosine 
phosphatase 
1.4e-05 0.12 0.016 
SPP1 hypo promoter Open 
sea 
3 osteopontin 7.3e-05 0.033 0.0091 
TJP2 hypo promoter shore 3 Tight 
junction 
formation 
5.1e-05 0.17 0.028 
TSG: tumour suppressor gene, CAM: cell adhesion molecule. 
Other abbreviations are outlined in the Abbreviations section. 
P values are italicised to indicate whether the NvA or AvC p value is smaller 
 
 
The data above illustrate that a number of genes in pathways known to be abnormal in 
endometrial tumorigenesis demonstrate methylation changes not only in the NvC comparison 
but also in that early NvA transition.  From the WNT pathway, 5 from 8 genes underwent 
hypermethylation with the NvA comparison having a smaller p value, suggesting this transition 
may be of greater significance than what occurs in the AvC comparison.  Similarly, from the 
FGF signalling pathway, 2 from 3 genes underwent hypermethylation, with the NvA 
comparison having a smaller p value.  
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Of note, promoter hypermethylation in RASSF1A and SFRP2 is consistent with the literature 
[206, 221].  For both these genes, the p value for hypermethylation between the NvC 
comparison was significant.  In addition, the p value for the NvA comparison was smaller than 
the p value for the AvC comparison, but was greater than 0.01.   Again, this may suggest that 
important methylation changes in these genes occurs early in endometrial tumorigenesis from 
the normal endometrium to AEH transition.  
 
Otherwise, the timing of methylation changes, whether the NvA or AvC transition was of 
greater significance, was similar in other gene pathways.  From the p53 pathway, the p value 
was smaller for the NvA comparison for hypermethylation of the TP73 gene and 
hypomethylation of the TP53AIP1 gene. For the SFN gene, the p value was smaller for the AvC 
comparison.  Similarly, in other molecular pathways and tumour suppressor genes, there were 
a similar number of genes where the p value was smaller either in the NvA or AvC comparison. 
 
In addition to the data in Tables 5.6 and 5.7, the difference in methylation status and beta 
values between normal endometrium, AEH and EEC in individual genes was analysed 
diagrammatically.  A boxplot could be generated for each gene to visualise whether the 
greater change in methylation and beta value intensity occurred between the NvA or the AvC 
transition.  Figure 5.13 details the associated boxplots with a diagrammatic representation of 
these relative methylation changes for a number of the genes from Tables 5.6 and 5.7.  Further 
boxplots for the other genes are included in the Appendix section 5C. 
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Figure 5.13:  Boxplots illustrating 10 hypomethylated or hypermethylated genes between 
normal endometrium, atypical endometrial hyperplasia and endometrioid endometrial 
cancer tissue in the pathways involving A: VEGF, B: MAPK, C: Wnt, D: FGF/FGFR, E: tumour 
suppressor genes, F: p53 
As in Figure 5.12, all the genes show progressive hypermethylation between normal 
endometrium, AEH and EEC, except for DUSP6 and TP53AIP1, which show progressive 
hypomethylation. 
The y-axis shows the degree of methylation, as illustrated by the beta value.  A beta value of 0 
equals non-methylation at the locus and 1 equals total methylation. 
The x-axis shows the histological subtype; normal endometrium, AEH or EEC. 
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D: FGF/FGFR 
          
FGF2     FGF10 
 
 
 
E: Tumour suppressor genes 
           
 RASSF1    DCC 
 
 
 
F: P53 
       
TP73     TP53AIP1 
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5.3. Results of the Copy Number Variation Analysis  
CNV was analysed from the Illumina 450K array data using the ChAMP pipeline on R and the 
GISTIC2 module, as outlined in section 2.2.6.2.  Similar to the methylation analysis for DMRs 
and MVPs, the CNV analysis through the ChAMP pipeline only allowed 2 groups to be 
compared at one time and as such, the following comparisons were performed:  NvC, NvA and 
AvC.  This allowed an overall assessment of the difference in CNV between normal 
endometrium and cancer tissue and also looked at whether there was a spectrum of change 
between the normal endometrial tissue, AEH and EEC. 
The number of samples available for analysis after the QC steps in ChAMP was the same as for 
the methylation analysis and included 39 samples in the NvC, 26 samples in the NvA and 29 
samples in the AvC comparisons. 
 
5.3.1.  Analysis on ChAMP  
The CNV analysis through the ChAMP pipeline generated figures and raw data based on the 
CNV per chromosome per specimen in each comparison.   
Examples of the individual chromosomal changes generated are illustrated in Figure 5.14. 
 
Figure 5.14A.  Copy Number Variation per chromosome in sample 24.   
For both 5.14A and 5.14B:  
The y-axis shows the copy number profile as a log2 ratio and whether copy number 
amplification (log2 ratio >0) or copy number deletion (log2 ratio <0) occurred. 
The x-axis shows each chromosome within a given sample.  Odd-numbered chromosomes 
from 1-21 are shown in green.  Even-numbered chromosomes, from 2-22, are shown in black.  
Segmented copy number is shown in red.   
 
The three figures show the normal endometrium v endometrioid endometrial cancer (NvC), 
atypical endometrial hyperplasia v endometrioid endometrial cancer (AvC) and normal 
endometrium v atypical endometrial hyperplasia (NvA) comparisons.  The NvC and AvC 
comparisons show similar copy number changes whereas there is little CNV demonstrated in 
the NvA comparison, suggesting the CNV occurs later in the normal to atypical to cancer (N-A-
C) transition.     
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Figure 5.14B:  Copy Number Variation per chromosome in sample 28.   
The three figures show the NvC, AvC and NvA comparisons for sample 28.  Interestingly, the 
NvC and NvA comparisons show similar copy number changes whereas there is little CNV 
demonstrated in the AvC comparison, suggesting the CNV occurs early in the N-A-C transition.     
 NvC 
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 AvC 
  NvA
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5.3.2  Analysis on GISTIC2 
The first component of the CNV assessment on the ChAMP pipeline generated both 
diagrammatic information for each specimen and the copy number changes, as in Figure 5.14, 
as well as quantitative data.  For each specimen, this data included the exact chromosomal 
location for each CNV, as well as the number of base pairs involved and the degree of 
separation from the mean.  
The second component of the CNV assessment involved processing the data generated 
through the ChAMP pipeline using the GISTIC2 module on the Broad Institute GenePattern 
[249] web-based public server.  This module could then identify the significance of the CNV per 
comparison and the implicated genes, as described in section 2.2.6.2 and detailed again here 
for ease of reference.   
Firstly, each aberration is assigned a G-score based on the amplitude of the aberration as well 
as the frequency of its occurrence across samples.  Secondly, the statistical significance of each 
aberration is defined based on comparing the observed statistic to that expected by chance.  
Q-values, indicating the false discovery rate and probability that the event is due to a chance 
fluctuation, are calculated for the aberrant regions and regions with Q-values below a defined 
threshold are considered significant. 
The GISTIC2 module can then report the genomic location and Q-values for each of the 
regions, along with the genes found in regions of significant amplification or deletion. 
 
Details of the output files are outlined as follows and are summarised in the following figures 
and tables: 
- Segmented CNV heat map per comparison (Figure 5.15) 
- Amplification plot for each comparison (Figures 5.16, 5.17, 5.18) 
- CN amplification loci and associated genes (Tables 5.8, 5.9, 5.10)  
- Deletion plot for each comparison (Figures 5.19, 5.20, 5.21) 
- CN deletion loci and associated genes (Tables 5.11, 5.12) 
 
The third component of the CNV assessment was the analysis of the loci and gene data, similar 
to the methylation data, through Web Gestalt and the KEGG and Pathway Commons 
enrichment analyses, with a p-value ≤0.1. 
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Figure 5.15A: Heatmap showing the copy number amplification (red) and deletion (blue) per 
chromosome per cancer sample in the Normal Endometrium v Endometrioid Endometrial 
Cancer (NvC) comparison 
 
The x-axis demonstrates the 21 cancer samples, as compared to the normal samples. 
Beneath the x-axis is the intensity scale for copy number amplification or deletion. 
The y-axis demonstrates each chromosome with p and q segments.  The p and q segments 
within each chromosome are separated by a small dash (as marked on chromosome 1 with a 
black arrow). 
 
 
There are certain samples that demonstrate greater CNV (black arrows indicate 15, 24, 31, 32, 
37, 40) while other samples show little CNV (13, 14. 20, 21, 22, 27, 28, 30, 33, 34, 35, 36, 38, 
42).  Note that samples 15, 31, 32 and 37 clustered with an intermediate hypermethylation 
group within the TCGA data, as per Figure 5.9 (discussed further in section 5.4.3). 
 
 
Although the specimens that show CNV vary in the intensity of amplification and deletion at 
different locations within the chromosome, there are some general trends.  There is a trend to 
deletion in Cr1p and amplification in Cr1q, deletion in Cr4, amplification in Cr7 and 10, deletion 
in Cr11, while there are mixed changes depending on the sample from Cr12-22. 
The following two figures demonstrate that the main changes in CNV occur in the atypical to 
cancer transition, rather than the normal to atypical transition, as the NvC and AvC heatmaps 
show a similar pattern of change while there are minimal changes in the NvA heatmap.  This 
suggests that these genomic changes occur later in the N-A-C transition.   
13 14 15 20 21 22 24 27 28 30 31G1/G3 32 33 34 35 36 37 38 40 42 
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Figure 5.15B: Heatmap showing the copy number amplification (red) and deletion (blue) per 
chromosome per cancer sample in the Atypical Endometrial Hyperplasia v Endometrioid 
Endometrial Cancer (AvC) comparison 
The x-axis demonstrates the 21 cancer samples, as compared to the atypical samples. 
Beneath the x-axis is the intensity scale for copy number amplification or deletion. 
The y-axis demonstrates each chromosome, with p and q segments. 
The changes in this heatmap are similar to those in the NvC comparison. 
 
 
Figure 5.15C: Heatmap showing the copy number amplification (red) and deletion (blue) per 
chromosome per cancer sample in the Normal Endometrium v Atypical Endometrial 
Hyperplasia (NvA) comparison 
The x-axis demonstrates the 8 atypical samples, as compared to the normal samples. 
Beneath the x-axis is the intensity scale for copy number amplification or deletion. 
The y-axis demonstrates each chromosome, with p and q segments. 
There is very little change in intensity across this heatmap, except in sample 28A, also shown in 
Figure 5.14B. 
  
 
13 14 15 20 21 22 24 27 28 30 31G1/G3 32 33 34 35 36 37 38 40 42 
4    13    21    24     27    28    30    34 
176 
 
Figure 5.16: Copy number amplification plot for the Normal Endometrium v Endometrioid 
Endometrial Cancer (NvC) comparison, demonstrated per chromosome and with selected 
associated genes 
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For this and the following 2 plots, the chromosome number, with p and q segments are listed 
down the left hand side.  The chromosomal loci are listed down the right hand side for those 
changes with a Q-value ≥0.25 (vertical green line), as indicated on the bottom x-axis.  The Q-
value indicates the probability that the event is due to chance.  
The top x-axis shows the G-score, reflecting the amplitude of the aberration and frequency 
across samples (log ratio intensity).   
The region with a maximal G-score and minimal q-value is most likely to contain affected 
genes. 
At the furthest right, are indicated the chromosomal loci with genes related to cancer 
pathways.   
 
Red arrows indicate cancer related genes, listed below and outlined in Table 5.8: 
(1) 1q21.1: BCL9 (2) 2q35: PTPRN  (3) 5q22.2: APC; 5q35.1: NPM1 
(4) 6p21.31: PPARD; 6p21.33: HLA-C; 6p22.1: HLA-G; 6p24.3: TFAP2A; 6p25.3: EXOC2 
(5)7q32.1: IRF5  (6) 8p12: NRG1; 8q24.21: MYC  (7) 9q34.13: RAPGEF1 
(8) 10q24.31: PAX2 (9) 12q13.13: KRT8  (10) 12q24.31: TRIAP1 
(11) 16q12.1: NOD2, NKD1    (12)17q22: STXBP4 
 
Green arrows indicate non-cancer related genes: 
(13) 17q23.3: ERN1 (14) 20p12.1: PCSK2  
 
 
Summary of the Amplification Plot Data in the NvC, AvC and NvA comparisons 
The NvC and AvC comparisons show greater similarities in CN amplification compared to the 
NvA comparison, suggesting these genomic changes occur between the AEH to EEC transition. 
Commonalities in chromosomal and genomic changes between these comparisons occurred 
with a number of chromosomal loci and genes, including Cr6p21.32/33 (PPARD, HLA-C, TNXB), 
7q32.1 (IRF5), 8q24.21 (MYC) and 12q24.31 (TRIAP1, PXN, PLA2GIB).   
These 8 genes reflect interactions across a number of cancer related pathways, including the 
Wnt, VEGF, MAPK, PDGFR-β, EGFR, Arf6, PI3K/mTOR, FAK, c-met and TNFR signalling 
pathways, as well as being associated with plasma membrane ER signalling and insulin 
signalling.  
MYC amplification was also reported in the TCGA analysis in serous-like EC and in 
approximately 25% of tumours, classified as high-grade EEC [30].  
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Table 5.8: Results of the Web Gestalt Enrichment Analyses for the Normal Endometrium v 
Endometrioid Endometrial Cancer (NvC) copy number amplification analysis including the 
associated genes and pathways, their location and the Q values 
Analysis Pathway Gene 
number 
P value Genes Location Q value 
Amplified        
KEGG 
 
Total 
genes 211  
Wnt SP 
 
 
 
Endometrial cancer 
 
Type 1DM 
4 
 
 
 
2 
 
3 
0.0491 
 
 
 
0.0896 
 
0.0176 
PPARD 
APC  
MYC 
NKD1 
APC, MYC 
HLA-G 
HLA-C 
PTPRN 
6p21.31 
5q22.2 
8q24.21 
16q12.1 
 
6p22.1 
6p21.33 
2q35 
0.039 
0.019 
0.166 
0.025 
 
0.185 
0.00062 
0.107 
Pathway 
Commons 
 
 
Wnt  SP (W) 
PDGFR SP 
Arf6 SP 
EGFR SP (E) 
PI3K/mTOR SP 
VEGF & VEGFR SP  
c-Met/HGFR SP  
FAK SP 
TNFR SP (T) 
P53 SP (p) 
Plasma m/b  ER SP 
Insulin SP 
DM pathways (d) 
4 
11 
11 
12 
11 
11 
11 
11 
5 
3 
11 
11 
3 
0.0171 
0.0585 
0.0585 
0.0585 
0.0585 
0.0585 
0.0585 
0.0585 
0.0694 
0.0759 
0.0585 
0.0585 
0.0949 
APC (W,p,a) 
BCL9 (W,a) 
PAX2 (W) 
TFAP2A (W,T) 
RAPGEF1 (a) 
KRT8 (T, a) 
MYC (T,a) 
TRIAP1 (p,a) 
NOD2 (a) 
NPM1 (a) 
EXOC2 (a,d) 
IRF5 (a,p) 
STXBP4 (a) 
NRG1 (E) 
PCSK2 (d) 
ERN1 (d) 
5q22.2 
1q21.1 
10q24.31 
6p24.3 
9q34.13 
12q13.13 
8q24.21 
12q24.31 
16q12.1 
5q35.1 
6p25.3 
7q32.1 
17q22 
8p12 
20p12.1 
17q23.3 
0.019 
0.239 
0.14 
0.011 
0.107 
0.013 
0.166 
0.010 
0.025 
0.012 
0.071 
0.239 
0.0026 
0.24 
0.20 
0.20 
 
For this and the following 4 tables:  
SP: signalling pathway; DM: diabetes mellitus; m/b: membrane. 
Other gene/pathway abbreviations are summarised in the Abbreviations section. 
The total gene number generated in the GISTIC analysis is listed in the table, though only the 
location and Q-value of the cancer-related genes are detailed. 
The p value is generated by Web Gestalt, indicating the significance of enrichment for each 
pathway. 
The Q-value is generated by GISTIC2, indicating the probability that the event is due to chance.  
 
 
There are 11 genes listed in the Pathway Commons section above that are associated with 9 
different cancer-related pathways.  These genes are listed and marked by (a).  Other gene and 
pathway associations are as indicated.   
The 3 pathways at the bottom of the table are of interest for the oestrogenic effects that may 
play a role in endometrial carcinogenesis.  
The Q-value is significant and ≤0.1 for the majority of genes listed above, except BCL9, IRF5, 
NRG1, PCSK2 and ERN1. 
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Figure 5.17: Copy number amplification plot of the Atypical Endometrial Hyperplasia v 
Endometrioid Endometrial Cancer (AvC) comparison, demonstrated per chromosome and 
with associated genes 
 
  
 
 
Table 5.9: Results of the Web Gestalt Enrichment Analyses for the Atypical Endometrial 
Hyperplasia v Endometrioid Endometrial Cancer (AvC) copy number amplification analysis 
including the associated genes and pathways, their location and the Q values  
Analysis Pathway Gene 
number 
P value Genes Location Q value 
Amplified        
KEGG 
 
Total 
genes 66 
VEGF signalling 
 
Focal adhesion 
 
MAPK signalling 
2 
 
2 
 
2 
0.0152 
 
0.0371 
 
0.0538 
PXN 
PLA2G1B 
PXN 
TNXB 
PLA2G1B 
MYC 
12q24.31 
12q24.31 
12q24.31 
6p21.32 
12q24.31 
8q24.21 
0.021 
0.021 
0.021 
0.028 
0.021 
0.22 
Pathway 
Commons 
 
 
PDGFR-beta SP 
EGFR SP 
ARF6 downstream SP 
PI3K/mTOR SP 
FAK SP 
c-MET/HGFR SP 
VEGFR SP 
P53 pathway (p) 
Plasma m/b ER SP 
6 
6 
6 
6 
6 
6 
6 
2 
6 
0.0154 
0.0154 
0.0154 
0.0154 
0.0154 
0.0154 
0.0154 
0.0218 
0.0154 
H2AFY (a) 
PXN (a) 
MYC (a) 
TRIAP1 
(a,p) 
IRF5 (a,p) 
ABCB1 (a) 
 
 
5q31.1 
12q24.31 
8q24.21 
12q24.31 
 
7q32.1 
7q21.12 
 
 
0.0035 
0.021 
0.22 
0.021 
 
0.00070 
0.22 
 
There are 6 genes listed in the Pathway Commons section above that are associated with 9 
different cancer-related pathways.  These genes are listed and marked by (a).  The other 
cancer-related genes are marked with the indicated pathway abbreviation.   
The Q-value is significant and ≤0.1 for the majority of genes listed above, except MYC and 
ABCB1. 
 
5q31.1: H2AFY 
 
6p21.32: TNXB 
 
7q21.12: ABCB1 
7q32.1: IRF5 
8q24.21: MYC 
 
11p15.2: CALCA 
 
12q24.31: PXN, PLA2G1B, TRIAP1 
 
15q26.1: SLCO3A1 
16p13.3: LMF1 
16q22.3:ZFHX3 
19p13.2: ZNF562 
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Figure 5.18: Copy number amplification plot of the Normal Endometrium v Atypical 
Endometrial Hyperplasia (NvA) comparison, demonstrated per chromosome and with 
associated genes 
 
 
 
 
There were no cancer associated genes nor pathways demonstrated through Web Gestalt.  
The genes identified in the amplification plot as showing a significant change are detailed in 
table 5.10.  Interestingly, this includes genes related to metabolism and diabetes. 
 
 
Table 5.10: Results of the Web Gestalt Enrichment Analyses for the Normal Endometrium v 
Atypical Endometrial Hyperplasia (NvA) copy number amplification analysis including the 
associated genes and pathways, their location and the Q values  
Analysis Pathway Gene 
number 
P value Genes Location Q value 
Amplified       
KEGG 
 
Total genes 
27 
Metabolic 
pathways 
3 0.0329 RRM2 
GALNT12 
ALG10 
2p25.1 
9q22.33 
12p11.1 
0.096 
0.16 
0.057 
Pathway 
Commons 
Signalling by GPCR 
 
 
Diabetes pathway 
 
Signal 
transduction 
3 
 
 
2 
 
3 
0.0315 
 
 
0.0315 
 
0.0466 
CRH  
PROKR2  
OR4F4 
EXOC2 
 IGFALS 
CRH, PROKR2, 
OR4F4 
8q13.1 
20p12.3 
15q26.3 
6p25.3 
16p13.3 
As above 
0.22 
0.12 
0.0042 
0.020 
0.057 
 
 
1q21.2: ENSA 
 
 
 
 
6p25.3: EXOC2 
6p21.33: HLA-C 
6q21: OSTM1 
 
7q31.2: CTTNBP2 
8q24.22: ZFAT 
 
10p15.2: PITRM1 
 
 
 
 
 
15q26.3: OR4F4 
 
 
20q13.33: C20orf200 
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Figure 5.19: Copy number deletion plot for the Normal Endometrium v Endometrioid 
Endometrial Cancer (NvC) comparison, demonstrated per chromosome and with associated 
genes 
 
 
 
 
 
 
 
For this and the following 2 plots, the chromosome number, with p and q segments are listed 
down the left hand side.  The chromosomal loci are listed down the right hand side for those 
changes with a q-value ≥0.25 (vertical green line), as indicated on the bottom x-axis.  The Q-
value indicates the probability that the event is due to chance.  
The top x-axis shows the G-score, reflecting the amplitude of the aberration and frequency 
across samples (log ratio intensity).   
The region with a maximal G-score and minimal Q-value is most likely to contain affected 
genes. 
At the furthest right, are indicated the chromosomal loci with genes related to cancer 
pathways.   
 
 
Cr 1p34.4, 6p21.33 and 17q12 had between 800-1100 genes deleted per chromosomal locus, 
many of which corresponded to cancer-related pathways as listed in Table 5.11 and 
demonstrated above in bold font and marked by red arrows.   
Cr3p21.31, 6p21.1, 10q11.21, 11q21, 12q13.2, 16p13.3 and 19p13.2 had between 1-3 genes 
deleted per chromosome but these were not linked to cancer pathways.  They are 
demonstrated in the above figure in non-bold font and marked by green arrows. 
 
1p34.3: RPS6KA1, MAP3K6, STMN1, 
JUN, MKNK1, GADD45A, PIK3R3, 
PIK3CD, JAK1, PLA2G2C, PLA2G5, 
WNT4, CSF3R, PTCH2, HDAC1, 
BMP8A/B 
3p21.31: CAMP, CDC25A 
 
 
6p21.33: RPS6KA2, MAPK14/13, 
MAP3K4/7, DUSP22, TNF, DAXX, 
CCND3, PIM1, VEGFA, CDKN1A, 
DAAM2, LAMA4, HSP90AB1, RXRB, 
PPARD, HDAC2, BMP5/6, FOXO3 
6p21.1: OR2J2, OR2B3P, OR2J3 
 
10q11.21: ZNF33B, BMS1 
 
11q21: PANX1 
12q13.2:RDH5 
 
 
16p13.3: HBA1/2, HBQ1, LUC7L 
17q12: TP53, DUSP3/14, 
MAP3K3/14, MAPK7, PRKCA, 
MAP2K3/4/6, RAC3, FGF11, TAOK1, 
PIK3R1/5, STAT5B/A, STAT3, CDC42, 
ERBB2, FZD2, WNT9B/3, ITGA2B/3, 
AXIN2, RARA, HDAC5, TRAF4, GRB2, 
SMURF2 
19p13.2: ZNF823 
G score 
Q-value 
score 
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Table 5.11: Results of the Web Gestalt Enrichment Analyses for the Normal Endometrium v 
Endometrioid Endometrial Cancer (NvC) copy number deletion analysis including the 
associated genes and pathways, their location and the Q values  
 
Analysis Pathway Gene 
no 
P value Genes Location Q value 
KEGG 
 
Total 
genes 
3000 
MAPK SP (M) 
VEGF SP (V) 
Jak-STAT SP (J) 
Pathways in 
cancer (C) 
Focal adhesion (F) 
Hedgehog SP (H) 
EGFR SP (E) 
Wnt SP (W) 
Endometrial 
cancer (EC) 
mTOR SP (m) 
TGFB SP (T) 
P53 SP (p) 
 
Type 1 DM 
Insulin signalling 
Progesterone-
mediated oocyte 
maturation 
 
 
52 
18 
28 
44 
 
30 
11 
14 
20 
10 
 
10 
13 
11 
 
20 
21 
15 
3.89e-12 
4.98e-06 
2.35e-06 
7.49e-06 
 
3.83e-05 
0.0017 
0.0024 
0.0026 
0.0029 
 
0.0029 
0.0043 
0.0063 
 
3.61e-12 
0.0003 
0.0006 
 
RPS6KA1/2 (M,m) 
TP53 (M,p,EC) 
PRKCA (V,F,H,W,C) 
MAPK14/13/7 (M) 
MAP3K7/14/3/4/6 
(M) 
MAP2K3/6/4 (M) 
DUSP22/14/3 (M) 
STMN1 (M) 
RAC3 (M) 
JUN (M,E,C) 
FGF11 (M,C) 
TNF (T, C) 
TAOK1 (M) 
MKNK1 (M) 
DAXX (M) 
GADD45A (M) 
CRK (M,E) 
PIK3R1/5/3 
(J,V,F,EC,m) 
PIK3CD (P,E) 
STAT5B/A (J,E,C) 
STAT3 (J) 
JAK1 (J) 
CCND3 (J,W,p) 
PIM1 (J) 
PLA2G2C/E (V) 
PLA2G5 (M,V) 
VEGFA (V,m) 
CDC42 (V) 
HER2 (E,F,EC,C) 
CDKN1A (E,C,p) 
FZD2 (W,C) 
WNT9B/3 (W,H) 
WNT4 (H,W) 
DAAM2 (W) 
CSF3R (C) 
ITGA2B/3 (C, F) 
AXIN2 (C,W,EC) 
LAMA4 (C, F) 
PTCH2 (H,C) 
RARA (C) 
HSP90AB1 (C) 
RXRB (C) 
PPARD (C) 
HDAC1/2/5 (C) 
 
TRAF4 (C) 
ROCK1 (F,W,T) 
BMP5/6/8B/A 
(H,T) 
GRB2 (EC) 
1p34.3,6p21.33 
17q12 
17q12 
6p21.33, 17q12 
6p21.33,17q12, 
1p34.3 
17q12 
17q12, 6p21.33 
1p34.3 
17q12 
1p34.3 
17q12 
6p21.33 
17q12 
1p34.3 
6p21.33 
1p34.3 
17q12 
17q12,1p34.3 
 
1p34.3 
17q12 
17q12 
1p34.3 
6p21.33 
6p21.33 
1p34.3 
1p34.3 
6p21.33 
17q12 
17q12 
6p21.33 
17q12 
17q12 
1p34.3 
6p21.33 
1p34.3 
17q12 
17q12 
6p21.33 
1p34.3 
17q12 
6p21.33 
6p21.33 
6p21.33 
1p34.3, 6p21.33, 
17q12 
17q12 
18p11.21 
6p21.33, 1p34.3 
 
17q12 
0.17,0.19 
0.19 
0.19 
0.19 
0.17 
0.19 
0.19 
0.17 
0.19 
0.17 
0.19 
0.19 
0.19 
0.17 
0.19 
0.17 
0.19 
0.19  
0.17 
 
0.17 
0.19 
0.19 
0.17 
0.19 
0.19 
0.17 
0.17 
0.19 
0.19 
0.19 
0.19 
0.19 
0.19 
0.17 
0.19 
0.17 
0.19 
0.19 
0.19 
0.17 
0.19 
0.19 
0.19 
0.19 
0.17 
0.19 
0.19 
0.18 
0.19 
0.17 
0.19 
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FOXO3 (EC) 
CASP9 (EC,V) 
SMURF2 (T) 
6p21.33 
1p34.3 
17q12 
0.19 
0.17 
0.19 
Pathway 
Common 
 
VEGF&VEGFR SP 
Arf6 SP 
PI3K SP 
PDGFR-β SP 
EGFR R SP 
FAK mediated 
c-MET SP 
TGFB R SP 
ALK1 SP 
TNFR SP 
c-myc SP 
HDAC SP 
MAPK SP 
E-cadherin SP 
P53 pathway 
Wnt SP 
Notch SP 
Plasma m/b ER SP 
DM pathways 
215 
213 
213 
213 
216 
213 
213 
58 
59 
53 
34 
29 
38 
43 
32 
32 
18 
214 
38 
2.16e-38 
2.16e-38 
2.16e-38 
2.16e-38 
2.16e-38 
2.16e-38 
2.80e-38 
3.22e-13 
9.00e-13 
6.14e-11 
3.64e-10 
4.85e-10 
1.32e-09 
1.94e-07 
1.54e-06 
4.84e-06 
6.93e-05 
2.59e-38 
6.17e-08 
   
 
 
The total gene number generated in the GISTIC2 analysis is listed in the table.  Due to the high 
number of genes identified in both enrichment analyses, the 70 genes with the smallest p 
values in the Web Gestalt analysis are listed above with their chromosomal location and Q-
value.  The associated gene pathways are marked next to the gene as indicated in brackets. 
 
The 3 pathways at the bottom of the KEGG analysis row and 2 pathways at the bottom of the 
Pathway Commons row are of interest for the metabolic and oestrogenic effects that may play 
a role in endometrial carcinogenesis.  
The Q-value is ≤0.1 for all the genes listed above. 
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Figure 5.20: Copy number deletion plot for the Atypical Endometrial Hyperplasia v 
Endometrioid Endometrial Cancer (AvC) comparison, demonstrated per chromosome and 
with associated genes 
 
 
 
 
 
 
 
 
Cr 2p15, 5p15.33, 6p21.33, 8p21.33 and 10q22.2 had between 180-1000 genes deleted per 
chromosomal locus, many of which corresponded to cancer-related pathways as listed in table 
5.12 and demonstrated above in bold and marked by red arrows.   
Cr3p21.31, 11q23.3, 12q13.2, 16p13.3, 19p13.2 and 22q13.31 had between 1-5 genes deleted 
per chromosome but these were not linked to cancer pathways.  They are demonstrated in the 
above figure as non-bolded and with green arrows. 
 
 
 
2p15: MAP4K4/3, GLI2, FZD5/7, WNT10A/6, 
PPP3R1, MSH2/6, SOS1, STAT1/4, COL4A4, 
TGFA, PAX8, ITGAV, DUSP2, RASGRP3, CACNB4, 
ATF2, ERBB4, IHH, CALM2 
3p21.31: CAMP, CDC25A 
5p15.33: MAP3K1/2, ITGA2, MSH3, FGF10, 
RASA1, RASGRF2  
5q13.1: PIK3R1 
 
6p21.33: MAPK13/14, DAAM2, PPARD, CCND3, 
CDKN1A, RXRB, HSPA1A 
 
 
 
8p21.3: FGF17/20, FGFR1, FZD3, DUSP4, PPR3CC  
10q22.2: MAPK8/3K8, CTNNA3, FZD8, WNT8B, 
SFRP5, ITGA8, RET, CHUK, NFKB2, FGF8, FGFR2, 
FAS, SUFU, ITGB1, DUSP5, PPP3CB, CACNB2, 
NRG3, PIP4K2A, PI4K2A, CALML3/5 
11q23.3 HYOU1, 12q13.2 RDH5 
 
 
16p13.3: HBA1/2, HBQ1, LUC7L 
 
 
 
 
19p13.2: ZNF823 
 
 
22q13.31: ATXN10 
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Table 5.12: Results of the Web Gestalt Enrichment Analyses for the Atypical Endometrial 
Hyperplasia v Endometrioid Endometrial Cancer (AvC)  copy number deletion analysis 
including the associated genes and pathways, their location and the Q values 
Analysis Pathway Gene 
number 
P value genes location Q 
value 
Deleted        
KEGG 
 
Total 
genes 
2712 
Pathways in cancer (C) 
MAPK SP (M) 
Wnt SP (W) 
TGFB signalling 
Focal adhesion (F) 
Phosphatidylinositol 
SP (P) 
Jak-STAT SP (J) 
Hedgehog SP (H) 
P53 SP 
NOD-like R SP (N) 
EGFR SP (E) 
 
Metabolic pathways 
Type 1 DM 
Oocyte meiosis 
Insulin signalling 
 
 
53 
42 
28 
16 
27 
15 
 
20 
10 
11 
10 
12 
 
191 
21 
20 
22 
 
1.30e-10 
2.10e-08 
1.80e-07 
6.06e-05 
7.95e-05 
8.99e-05 
 
0.0011 
0.0023 
0.0028 
0.0028 
0.0060 
 
2.31e-41 
1.42e-13 
2.20e-05 
3.73e-05 
MAPK8. 3K8 
(M,F,N,E) 
MAPK13,14 
MAP3K1,2 (M) 
MAP4K4, 4K3 
GLI2 (H) 
CTNNA3 (J) 
FZD8 (W) 
FZD3 (W) 
FZD5,7 (W) 
WNT10A, 6 
(W,H) 
DAAM2 (W) 
WNT8B (W,H) 
SFRP5 (W) 
APC (W) 
PPARD (W) 
CCND3 (W) 
PPP3R1, 3CC 
(M,W) 
ITGA2,6, 8 (F) 
 
RET (C) 
CHUK (M) 
CDKN1A (C) 
MSH2 3,6 (C) 
NFKB2 (M) 
FGF10 (M) 
FGF8 (M) 
FGF17,20 (M) 
FGFR1 (M) 
FGFR2 (M) 
SOS1 (M,F,J,E) 
STAT1,4 (J) 
COL4A4 (F) 
TGFA (E) 
FAS (M) 
RXRB (C) 
SUFU (H) 
PAX8 (C) 
ITGB1 (F) 
ITGAV (F) 
DUSP2, P5.P4 
(M) 
RASA1 (M) 
RASGRF2 (M) 
RASGRP3 (M) 
PPP3CB (M) 
CACNB2,B4 
(M) 
HSPA1A (M) 
ATF2 (M) 
10q22.2 
 
6p21.33 
5p15.33 
2p15 
2p15 
10q22.2 
10q22.2 
8p21.3 
2p15 
2p15 
 
6p21.33 
10q22.2 
10q22.2 
5p15.33 
6p21.33 
6p21.33 
2p15, 8p21.3 
 
5p15.33,2p15, 
10q22.2 
10q22.2 
10q22.2 
6p21.33 
2p15, 5p15.33 
10q22.2 
5p15.33 
10q22.2 
8p21.3 
8p21.3 
10q22.2 
2p15 
2p15 
2p15 
2p15 
10q22.2 
6p21.33 
10q22.2 
2p15 
10q22.2 
2p15 
2p15, 10q22.2, 
8p21.3 
5p15.33 
5p15.33 
2p15 
10q22.2 
10q22.2, 2p15 
 
6p21.33 
2p15 
0.21 
 
0.056 
0.18 
0.27 
0.27 
0.21 
0.21 
0.19 
0.27 
0.27 
 
0.056 
0.21 
0.21 
0.18 
0.056 
0.056 
0.27 
 
0.18 
0.21 
0.21 
0.21 
0.056 
0.27 
0.21 
0.18 
0.21 
0.19 
0.19 
0.21 
0.27 
0.27 
0.27 
0.27 
0.21 
0.056 
0.21 
0.27 
0.21 
0.27 
0.27 
0.19 
0.18 
0.18 
0.27 
 
0.27 
 
0.056 
0.27 
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NRG3 (E) 
ERBB4 (E) 
PTEN (P,F) 
PIK3R1 (P,F) 
CALM2, L5, L3 
(P) 
PIP4K2A (P) 
PI4K2A (P) 
IHH (H) 
10q22.2 
2p15 
10q22.2 
5q13.1 
2p15, 10q22.2, 
2p15 
10q22.2 
10q22.2 
2p15 
0.21 
0.27 
0.21 
0.056 
0.27 
0.27 
0.21 
0.21 
0.27 
Pathway 
Commons 
 
 
EGFR receptor SP 
VEGF & VEGFR SP  
FAK mediated SP 
PI3K/mTOR SP 
Arf6 SP 
PDGFR-β SP 
c-MET/HGFR SP 
c-myc SP 
P53 SP 
TNFR SP 
ALK1 SP 
TGFB R SP 
Wnt SP 
FGFR SP 
Plasma m/b ER SP 
202  
200 
196 
196 
196 
196 
197 
35 
38 
46 
46 
41 
30 
18 
197 
1.61e-37 
3.52e-37 
1.24e-36 
1.24e-36 
1.24e-36 
1.24e-36 
1.24e-36 
5.08e-12 
8.07e-11 
7.13e-09 
6.57e-08 
2.01e-06 
7.01e-06 
3.50e-05 
1.52e-36 
   
 
The Q-value is ≤0.1 for 21 of the genes listed above, corresponding to those located on Cr 
5p15.33, 6p21.33 and 8p21.3.  The Q-value is between 0.2-0.3 for the remaining genes. 
 
The total gene number generated in the GISTIC2 analysis is listed in the table.  Due to the high 
number of genes identified in both enrichment analyses, the top 70 genes are listed above 
with their chromosomal location and Q-value.  The associated gene pathways are marked next 
to the gene as indicated in brackets. 
 
The 4 pathways at the bottom of the KEGG analysis row and 1 pathway at the bottom of the 
Pathway Commons row are of interest for the metabolic and oestrogenic effects that may play 
a role in endometrial carcinogenesis.  
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Figure 5.21: Copy number deletion plot for the Normal Endometrium v Atypical Endometrial 
Hyperplasia (NvA) comparison, demonstrated per chromosome and with associated genes 
 
On KEGG and Pathway Commons enrichment analyses on WebGestalt, along with reviewing 
the gene information on GeneCards, no significant cancer association was found. 
 
 
Summary of the Deletion Plot Data in the NvC, AvC and NvA comparisons 
As with the amplification plots, the NvC and AvC comparisons show greater similarities in CNV 
compared to the NvA comparison, suggesting these genomic changes occur in the AEH to EEC 
transition, rather than between the normal endometrium to AEH transition.  
Only Cr6p21.33 deletion is common between the NvC and AvC comparison for cancer-related 
pathways.  Deletion in 3p21.31, 16p13.3 and 19p13.2 were also common between the NvC and 
AvC comparison, but no cancer-related genes were identified at these loci.  The other 
deletions of Cr1p34.4 and 17q12 occurred between the NvC comparison, while Cr2p15, 
5p15.33, 8p21.33 and 10q22.2 deletion occurred between AvC, in terms of cancer-related 
pathways.   
Although there was only one chromosomal locus in common with CN deletion, there were a 
number of genes and cancer-related pathways implicated at this site.  The deleted genes 
include MAPK13, MAPK14, DAAM2, PPARD, CCND3, CDKN1A, RXRB, HSPA1A, RPS6KA2, 
DUSP22, TNF, DAXX, VEGFA, PIM1, LAMA4, HSP90AB1, HDAC2, BMP5, BMP6 and FOXO3.  
These genes are associated not only with EC but also with signalling pathways implicated in 
endometrial tumorigenesis including the Wnt, VEGF, EGFR, MAPK, PI3K/mTOR, Jak-STAT, 
Hedgehog, focal adhesion, TGFB and p53 signalling pathways. 
 
6p21.1: TBCC, KIAA0240, RPL7L1 
 
8p23.1: DEFB130 
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5.4. Discussion 
 
The methylation and CNV data generated from the Illumina 450K array in this study 
demonstrate the feasibility of this platform for FFPE endometrial tissue.  Not only were the 
FFPE and FF data consistent within the study specimens, but the FFPE endometrial data here 
were also consistent with publicly available TCGA FF endometrial data of normal and cancer 
tissue.  Importantly, a spectrum of methylation and CNV changes was demonstrated between 
normal endometrium, AEH and EEC, which may provide a foundation for the development of a 
methylation signature for prognostic and predictive purposes.  In addition, the reproducibility 
of these findings in FFPE samples allows a far greater bank of tissue to be interrogated for 
epigenetic and genetic studies.    
 
5.4.1. Evidence of Differential Methylation and Clinical Correlation 
The methylation data analysis illustrated the feasibility of FFPE endometrial tissue processing 
on the Illumina 450K array.  In addition, it demonstrated that differential methylation occurs in 
endometrial carcinogenesis from normal endometrium to AEH to EEC.  A significant part of this 
progression from normal endometrium to EEC involved gene hypermethylation but there were 
also a smaller number of genes that were hypomethylated.  The methylation changes occurred 
predominantly in the gene promoter region and gene body and involved CGIs and CpG shores.  
Between the normal endometrium to EC transition, there was evidence of gene hyper- and 
hypomethylation in the PI3K/mTOR/Arf6, VEGF, FGF/FGFR, EGFR, PDGFR, TGFB, p53 and the 
Wnt/E-cadherin signalling pathways, for which molecular aberrations are well documented.  
There were also methylation changes associated with FAK and cell adhesion, ALK, c-met/HGFR, 
NOTCH and Trk signalling pathways, for which data in EC is limited and these may represent 
novel pathways involved in endometrial carcinogenesis.   
 
In addition, the methylation changes appeared to differ in timing between patients.  There 
were some cases where the methylation changes occurred early in tumorigenesis between 
normal endometrium and AEH, while other cases demonstrated later methylation changes, 
between AEH and EEC.  Whether the timing of these changes impacts on clinical outcomes and 
response to therapy could not be established from this analysis but may be part of a 
methylation signature that could give prognostic and predictive information.  Further clinical 
correlation was limited here with the small sample size and available follow-up.  Thus, the 
possible trend between grade, tumour size and older age with greater hypermethylation needs 
further clarification. 
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Although molecular aberrations could be identified between the normal endometrium to EEC 
transition, it was not possible to determine which pathway and gene changes were most 
significant between the normal endometrium to AEH transition compared with the AEH to EEC 
transition.  Again, this was due to limitations in sample size, particularly in the number of AEH 
specimens available.   
However, for a number of genes in the Wnt, FGF/FGFR, MAPK and VEGF pathways, progressive 
methylation changes between the histological types was evident.  Interestingly, there were a 
number of genes in the Wnt and FGFR signalling pathways as well as the TSG RASSF1A that 
demonstrated greater hypermethylation between the normal endometrium to AEH transition.  
It is known that hypermethylation in the promoter region of TSGs can inactivate the gene and 
promote carcinogenesis [262] and these changes may reflect this early progression. 
 
A larger study is required to validate these findings and may include where possible, 
longitudinal tissue analysis with repeat biopsies at diagnosis, metastasis and progression and 
with longer clinical follow-up.  This would allow correlation of molecular findings in early and 
late stage disease with clinical parameters to help define a methylation signature with 
prognostic and predictive potential.  Identifying a methylation signature to define the 
epigenetic transition between normal endometrium, AEH and EC may then improve treatment 
stratification and strategies. 
 
5.4.2.  Evidence for CNV analysis in EEC and Correlation with Methylation Changes 
The analysis of CNV on FFPE EC tissue was also feasible and further demonstrated a spectrum 
of changes between normal endometrium, AEH and EEC.  CN changes varied across the 
samples with 28% (6 from 21 samples) demonstrating more prominent CN alterations.  For 
both CN amplification and deletion, the overall NvC comparison was similar to the AvC 
comparison, indicating that the majority of changes occurred later in tumorigenesis.  Thus, for 
the purpose of finding a molecular signature early in tumorigenesis, methylation analysis 
rather than CNV may be of the most utility. 
The implicated cancer-related pathways for both CN amplification and deletion included the 
Wnt, VEGF, PI3K/mTOR/Arf6, MAPK, EGFR, PDGFR-β, TGFB and p53 signalling pathways.  As 
with the methylation data, there were also a number of novel pathways that were implicated 
including focal adhesion, c-met/HGFR, Jak-STAT and Hedgehog signalling, though further 
validation of these results is required. 
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Individual genes were mapped to the chromosomal loci that demonstrated significant CN 
alterations and there were commonalities between those that were affected by methylation 
changes as well as those that underwent CN alterations.  In the Wnt pathway for example, APC 
promoter hypermethylation occurred early in tumorigenesis between the normal 
endometrium and AEH transition, while CN amplification of APC occurred as a later event.  
Other FZD genes and Wnt genes either underwent promoter hypermethylation or 
demonstrated CN deletion, reflecting a possible interplay between the genomic and 
epigenomic aberrations.   
There were also changes within the FGF/FGFR signalling pathway that included promoter 
hypermethylation of FGF2, 12 and 10, as well as CN deletion in FGF10 and 11.  VEGFA also 
showed promoter hypermethylation and CN deletion, both of which tended to occur in the 
AEH to EEC transition.     
There are multiple methods of CNV analysis which utilise other platforms, but using the 
Illumina 450K array and ChAMP pipeline was particularly amenable here, as data for both the 
methylation and CNV analyses could be generated from the one platform.  This is of 
importance when tissue availability is limited, particularly for AEH in this analysis, but could be 
extended to other tissue types where the maximum data needs to be generated from limited 
DNA.  
 
5.4.3.  Correlation of Epigenetic and CNV data with TCGA data 
The data presented here was consistent with that in the wider literature and TCGA public 
database.  As detailed in chapter 1, TCGA [30] identified four categories of EC based on 
integrated genomic and epigenomic analysis of FF tissue: POLE ultramutated, 
MSI/hypermutated, CN low and CN high.  They found most EEC had few CN changes but 
frequent mutations in PTEN, CTNNB1, PIK3CA, ARID1A and KRAS, while a subset of EEC showed 
greater similarity to serous tumours and were CN high with few methylation changes.   
In terms of the methylation changes, as discussed in section 5.2.3, the normal endometrium, 
AEH and EC clustered similarly to the TCGA endometrial tissue types.  As TCGA did not include 
AEH, it was interesting to see how some of the AEH samples clustered with normal tissue and 
some clustered with cancer tissue, indicating that there may be some methylation changes 
that occur early in tumorigenesis and some that occur later.  Identifying a methylation 
signature for those AEH samples that cluster with the cancer samples may identify those cases 
that require more aggressive treatment.   
In the TCGA analysis of EC and the CN low and high groups, the CN low tumours were mainly 
EEC and demonstrated 1q amplification.  The CN high tumours were serous-like, heavily 
methylated and with amplification in Cr8q24.12 (MYC), 17q12 (HER2), 19q12 (CCNE1), 4p16.3 
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(FGFR3) and 8q11.23 (SOX17).  Although the sample analysis here in that 28% that 
demonstrated CNV only identified the amplification in Cr8q24.12 (MYC) in common with TCGA 
data, other loci were demonstrated where FGFR1 and 2 were deleted (Cr8p21.3 and 10q22.2 
respectively) as well as where FGF8, 10, 17 and 20 were deleted (Cr10q22.2, 5p15.33 and 
8p21.3).  PI3K pathway changes were also identified with CN deletions in Cr10q22.2 and 
17q12, as well as CN deletion in STMN in Cr1p34.4.    Correlating these results at the protein 
and receptor level would also be key in showing biologic and clinical relevance, and this again 
would require further validation in larger studies.  As the PI3K and FGFR pathways are readily 
targetable with available agents, validation of these findings would be particularly important 
and may present an additional predictive biomarker of these agents. 
The number of samples with significant CNV were small in this study but consistent with TCGA 
findings.  TCGA found 25% of EEC were CN high and it was these samples that behaved more 
like serous cancers.  From this analysis, 28% appeared to have greater CNV.  Interestingly, 4 of 
these samples (15, 31, 32 ,37 as in Figure 5.15A) clustered with a group of TCGA cancer 
samples that had less intense methylation changes, as evidenced in Figure 5.9.  This may 
correspond to the subset of EEC tumours that are CN high with few methylation changes.  Such 
tumours may behave more like serous tumours with a worse prognosis, though there was 
inadequate follow-up data to comment on that here.    
 
Figure 5.22 outlines the key findings from the epigenetic and CNV analysis across normal 
endometrium, AEH and EEC tissue.  Importantly, TCGA data and this analysis show 
commonalities in molecular alterations in a number of pathways, particularly with Wnt, PI3K, 
FGFR and VEGF signalling.  While agents targeting the Wnt pathway remain in development, 
there are a number of available agents or those already in clinical trials to address the other 
targets.  Applying these targeted therapies to EC with concurrent biomarker development is 
urgently required to improve on current patient outcomes.  The incorporation of novel 
biomarker strategies is key and the ability to do this from FFPE tissue provides a far greater 
repository for expansion of research in this area.   
Further analysis of these pathways and the described research techniques in a greater sample 
size would better validate the frequency of these aberrations and determine whether 
targeting these pathways may show activity in EEC. 
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Figure 5.22. Key Findings in the Epigenetic and CNV analysis in EEC 
 Epigenetic and CNV analysis of FFPE and FF EEC tissue is feasible on the Illumina 
450K array 
 Differential methylation patterns, predominantly hypermethylation, are evident 
between normal endometrium, AEH and EEC 
 Study data from the epigenetic and CNV analysis were consistent with that 
available from TCGA 
 Differential methylation of specific genes was demonstrated between normal 
endometrium, AEH and EEC 
 Further validation in a larger sample size for both EEC and NEEC at early and 
advanced stage is needed to determine the clinical significance of these findings 
with the aim of developing an epigenetic and genetic signature to stratify 
patients for prognostic and predictive purposes. 
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CHAPTER 6: Conclusions and Future Directions 
There is an ongoing need in the treatment of EC to establish novel treatment strategies and 
improve patient selection for existing drugs and those in development.  The parameters used 
to guide therapy of EC have not changed for many years and current treatment strategies do 
not reflect the known molecular aberrations, being limited to a “one-size-fits-all” 
surgery/chemotherapy/radiotherapy approach.   
In this context, development of biomarkers that are prognostic or predictive for treatment 
outcome may be helpful.  Such markers may potentially accelerate drug development and 
subsequent approval through selection of patients that are most likely to benefit from a given 
treatment.  
The aims of this work were two-fold.  The first was to assess CTC enumeration and molecular 
profiling with stathmin in advanced EC and how it might correlate with clinical course and 
clinicopathologic factors.  The second was to conduct epigenetic and CNV analysis from FFPE 
and FF normal endometrium, AEH and EEC, to establish if this was feasible, whether there 
were novel differential changes between normal, atypical and cancerous endometrial tissue 
and the histopathological grades,  to characterise the molecular pathways involved and finally, 
to correlate with data already in the public domain.   
The results presented in Chapters 3, 4 and 5 demonstrate the feasibility of these two 
techniques for the first time in EC and the potential to identify novel predictive and prognostic 
markers.  The overall findings from these studies are discussed below and highlight areas of 
future investigation that might enable their use in the clinical management of patients. 
Sections 6.1-6.4 discuss novel technologies for CTC enumeration and molecular profiling to 
develop in EC, and is followed by discussion of the use of a methylation signature as a 
predictive or prognostic biomarker in EC in sections 6.5-6.8. 
 
6.1. CTC Enumeration and Molecular Profiling 
 To our knowledge, this is the first documentation of CTC enumeration in EC, with 60% of 
patients with advanced EC showing detectable levels of CTCs.   Furthermore, in a subset of 
patients receiving first-line chemotherapy for recurrent, metastatic disease, longitudinal 
assessment of CTCs could be a predictive biomarker of response and correlate with clinical 
outcome.   
There were a number of histopathological factors, including LVSI, myometrial and cervical 
invasion that currently determine post-surgical primary treatment, which did not show an 
association with CTC enumeration.  This may be a reflection of the limited utility of these 
histopathological factors or that CTC enumeration needs further clarification in studies with a 
larger number of patients at different stages of treatment.   
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Stathmin overexpression was also demonstrated for the first time in EC CTCs using the 4th 
channel on the CellSearch platform.  This was reproducible and time-efficient as it could be 
performed at the same time as CTC enumeration.  As outlined in section 1.4.1.3, stathmin 
overexpression is prognostic in EC [122, 164] and may also have predictive value for patients 
treated with taxane-based chemotherapy [168].  Although the small patient number here 
limits interpretation, the potential to correlate this with outcomes with both chemotherapy 
and targeted agents is worthy of further exploration.  If validated in larger studies, longitudinal 
evaluation of CTCs, stathmin expression and correlation with treatment outcome may provide 
the first predictive biomarker for treatment response in EC in those patients who are CTC+.  
Moreover, as stathmin more accurately reflects PI3K pathway activation compared to other 
available markers [122, 162], CTCs and their stathmin expression should be incorporated into 
clinical trials that assess PI3K pathway targeting agents as well as with taxane-based 
chemotherapy combinations. 
Supporting the use of EpCAM-guided CTC enumeration techniques in EC, EpCAM 
overexpression was reported in 86% of archival FFPE tissue here.  Detection of stathmin 
overexpression on FFPE tissue was also reproducible and reported at 80%.  Correlation of FFPE 
EpCAM and stathmin IHC with CTC findings, though not demonstrated here, is worth further 
investigation in conjunction with CTC validation studies to delineate the relationship between 
IHC and CTC findings [163].   
As the UCL Cancer Institute has both validated stathmin expression on CTCs on the CellSearch 
platform and has novel technologies in development including the Gilupi nanodetector, ISET 
and DepARRAY platforms, there is a novel opportunity to conduct further research in EC here.   
Further details on these techniques and molecular characterisation of CTCs is outlined in the 
following three sections. 
 
6.2. Methods to Optimise CTC collection in Endometrial Cancer 
There are a number of novel technologies in CTC enumeration and molecular characterisation 
that might optimise their utility in the clinical setting and be used for future research in EC.  
The enumeration technologies are broadly based on either indirect immune-mediated 
methods, such as EpCAM detection, or direct methods based on physical properties, such as 
size, density or conductivity.   
Another EpCAM based approach utilises the Gilupi nanodetector, a seldinger guidewire coated 
with anti-EpCAM [270] that is placed in the cubital vein of patients for 30 minutes, allowing a 
blood volume of 1.5-3 litres to come in contact, and increasing cell exposure to EpCAM based 
detection.  Once the collection is performed, the cells are stained for cytokeratins, CD45 
antibody and DAPI to differentiate CTCs from other cellular material.   This method has the 
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potential both to increase detection of viable cells and allow isolation of cells for profiling, 
though further optimisation at the UCL Cancer Institute is still required.    
Another CTC detection method that has been described and will be used at the UCL Cancer 
Institute is the ISET (isolation by size of epithelial tumour cells) system based on cell size rather 
than EpCAM enrichment.  Larger CTCs are separated out through filtering membranes with 
calibrated pores 8 micron in diameter [98, 271] and can then be characterized morphologically 
and by protein expression.  This type of method may avoid the concerns regarding sensitivity 
when EpCAM or other panels of markers are used for detection, particularly in regards to EMT 
and tumour heterogeneity.  Early comparative studies of the ISET and CellSearch platforms 
demonstrate mixed findings in breast, prostate and lung cancer with higher counts on ISET in 
prostate and lung cancer and lower counts in breast cancer [272].  ISET may also have its 
limitations in enumeration as CTCs can be lost through the ISET detection process.  It is also 
more time consuming, blood samples have to be processed within 4 hours and it has not yet 
been standardised for routine clinical application.   
Two other detection methods that may warrant comparison with the CellSearch platform are 
the DepARRAY system and ImageStream (Amnis).  The DepARRAY system is a semi-automated 
system that uses application of dielectrophoretic field flow fractionation (depFFF) to isolate 
CTCs from blood specimens [273]. The depFFF method relies on differences in cell phenotype 
and membrane capacitance to isolate cells so that labelling is unnecessary.  On the DepARRAY 
system, isolation and visualisation of CTCs is based on the capture of cells by ‘electric cages’ 
created on a microelectronic chip [274] with the ability to recover the cells for further 
molecular analysis.  It is however a time intensive system to screen and isolate relevant cells.   
Another depFFF based platform, Apostream (Apocell, Houston, USA) reports CTC detection 
rates up to 95% in metastatic prostate, breast and colorectal cancer [275]. 
Imagestream (Amnis) is an imaging cytometry device that combines flow cytometry and 
fluorescent microscopy in a single platform [276].  Studies to date have used similar 
immunomagnetic positive selection as CellSearch, including anti-EpCAM, anti-CD45 and anti-
cytokeratin.  A potential benefit is the ability to perform impartial analysis of a large number of 
cells in a short period of time and it can be fully automated if required.  In a comparison to 
CellSearch, detected CTC counts were similar though there are limitations at lower CTC counts 
with ImageStream [276].   
There are certainly limitations of the CellSearch platform and EpCAM-based technologies, with 
their reduced sensitivity for detecting CTCs due to variation in expression of EpCAM and EMT.  
However, this study demonstrated the presence and early clinical correlation patterns with the 
current technology platform. Other technologies and markers for detection may be more 
sensitive but identification of the most appropriate markers and development of new 
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techniques in individual cancers requires further validation [277].  At this time point, an 
EpCAM detection system may still be preferred in EC, particularly with its high rate of EpCAM 
overexpression.  Within the UCL Cancer Institute, further evaluation of CellSearch, the Gelupi 
nanodetector, ImageStream and DepARRAY may be developed in EC, to determine the 
optimum method for this cancer type and whether a certain platform is better for 
enumeration or isolation for molecular profiling. 
 
6.3. Molecular Profiling Techniques for CTCs in Endometrial Cancer 
Techniques for molecular characterisation of CTCs have developed rapidly and while earlier 
reports were based on cell extraction from the CellSearch magnetic cartridge [278-280], more 
recent characterisation can now incorporate isolation from other technologies and include 
next generation sequencing (NGS) platforms [281].   
The most time efficient method for CTC molecular profiling when using the CellSearch platform 
is the use of an antibody within the 4th channel.  Although this only allows analysis for a single 
antibody per blood sample and each antibody must be appropriately validated for use on CTCs, 
results are automatically generated at the time of enumeration and can potentially be 
correlated with more in-depth molecular analysis by other means. 
In addition to the 4th channel analysis, techniques have been described to extract CTCs from 
the CellSearch magnetic cartridge and perform further molecular characterisation.  For 
example, it is possible to identify EGFR expression, androgen receptor (AR) gene amplification 
[278], ERG, AR and PTEN gene rearrangement status in prostate cancer [279] as well as EGFR 
gene amplification, KRAS, BRAF and PIK3CA mutation status in colorectal cancer [280].  In lung 
cancer, CTCs isolated on the CellSearch system have been subjected to ultra-deep NGS with 
the identification of EGFR mutations corresponding to those present in matching tumour 
tissue [281].  Similarly, this could be applied to CTCs isolated from EC patients, particularly for 
changes in the PI3K, FGFR and Wnt pathways that have the most frequent aberrations.  
The choice of methodology for isolating CTCs for molecular characterisation will be guided by 
operator expertise as well as time and cost constraints, and should be taken into account 
when planning further studies for CTC enumeration, such that the maximum amount of 
information can be gained from each study.  Ideally, a broad range of techniques would be 
used where possible including IHC, ISH for overexpression and gene translocation/fusion 
analysis, NGS for mutation analysis, as well as RNA and protein expression analysis to correlate 
upstream findings with downstream effects.  
There are already planned trials with targeted therapies in EC that will utilise CTCs and 
molecular profiling both on CTCs and tumour tissue, including a poly ADP-ribose polymerase 
(PARP) inhibitor study and a PI3K inhibitor study [282].   
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Correlating longitudinal CTC findings with archival tumour tissue at diagnosis and 
metastasis/progression, where available, would also be of great value for further studies in EC.  
As tumour tissue is the gold standard for molecular characterisation of tumours, CTC molecular 
profiling needs to be closely correlated to justify its use in the clinical setting for assessment of 
molecular aberrations.  Particularly with arguments for and against longitudinal tissue biopsies 
for molecular analysis of patients’ tumours during treatment, CTC assessment would be an 
attractive option as a so-called ‘liquid biopsy’ that is readily accessible and non-invasive. 
 
6.4. Future Directions beyond CTCs 
Only 20-50% of patients, depending on the cancer type, will demonstrate detectable CTCs at 
baseline, though novel technologies report detection rates higher than this [275].  Although 
the detection rate in EC here was 60%, this was in the setting of advanced disease and 
extending analysis to earlier stage disease will potentially result in a lower detection rate.   As 
well as the other enumeration techniques as described above, the choice of collection site may 
also warrant further testing to account for lower detection peripherally.  Other tumour types 
have compared peripheral collection with collection from a central, draining vein intra-
operatively [283], and this may be another approach to consider.  Otherwise, focusing only on 
CTCs in monitoring and molecular profiling may not benefit a significant proportion of the 
patient population currently requiring treatment. 
 
The feasibility of analysing circulating free DNA (cfDNA) in EC is another area of interest, and 
along with CTC detection and profiling, is an attractive option for biomarker development due 
to readily available sampling that can be repeated longitudinally.  CfDNA fragments are 
thought to originate from apoptotic or necrotic tumour cells that release their DNA into the 
blood circulation.  It is now possible to apply NGS technologies to cfDNA and studies have 
demonstrated genetic mutations relevant to drug resistance in metastatic cancer [284].  
Detection of cfDNA has also been associated with tumour burden, prognosis [285, 286], 
prediction of response [287, 288], detection of recurrence and with the ability to identify 
genetic aberrations including HER2 amplification in breast cancer and KRAS, PIK3CA and BRAF 
mutations in colorectal cancer [289-291].  Like CTC enumeration, cfDNA analysis relies on 
there being adequate concentrations in the peripheral blood and requires standardization and 
validation of laboratory and preanalytic conditions.  Normal DNA from dying cells after blood 
collection may contaminate the specimen and there is the question as to whether the DNA 
from dying tumour cells gives the best information on therapy-resistant cancer cells that 
remain viable.   
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Combined CTC and cfDNA studies have been performed in a number of cancer types and may 
give additional information on tumour biology, for example in the breast cancer [292] [293] 
and NCSLC [294] settings.  In the breast cancer setting for example, cfDNA and CTCs may give 
additional prognostic information when imaging findings are equivocal [292], and cfDNA has 
shown a consistent correlation with tumour burden and treatment response [293]. In NSCLC, 
EGFR mutations are detectable in CTCs and cfDNA and emergence of additional EGFR 
mutations was associated with tumour progression in some patients [294].  These technologies 
may thus be used in parallel, particularly in future trials to assess new drugs and combinations 
and identify mechanisms of drug resistance.   Sequential use of different targeted drugs based 
on real-time cfDNA and CTC analysis might become a novel strategy for personalised therapies 
in oncology [295].  In the upcoming PARP inhibitor trial in EC, both cfDNA and CTCs will be 
evaluated as well as the PTEN and MSI status of archival tissue, combining targeted drug 
development with biomarker development, which has been largely lacking to-date in EC [282]. 
 
Novel trial design may also play a role such as with window-of-opportunity trials [296] that 
assess a novel molecular test and/or treatment prior to starting standard therapy, whether 
surgery or chemotherapy, to allow evaluation in isolation from other therapies.  Providing 
there is close safety monitoring and careful patient selection, this has been shown to be a safe 
option to evaluate potential activity of novel agents.  Molecular analysis at this early time-
point could then be correlated with tumour tissue as well as clinical outcomes during 
treatment, progression and up to end-stage disease. Longitudinal biopsies at these time points 
may identify new changes and targets and may be analysed in conjunction with cfDNA and 
CTCs to correlate the molecular findings and rationalise longitudinal use of liquid biopsies.  
Analysing tumour tissue, cfDNA and CTCs at a similar time point is required to determine that 
molecular profiling of these liquid biopsies is equivalent to tumour tissue for predicting patient 
outcomes to targeted therapies.  
Further research into CTCs as a surrogate marker in EC should evaluate these findings in a 
larger patient cohort, and might also utilise different technologies and molecular profiling 
strategies as outlined in sections 6.1-6.4 and summarised in Figure 6.1.   
 
 
 
 
 
 
 
Figure 6.1. Future Directions in EC CTC analysis and molecular profiling 
 Comparison of CTC detection methods in EC 
 Analysis of further profiling techniques on EC CTCs 
 Feasibility study of cfDNA in EC and correlation of CTC +/- cfDNA analysis with 
clinical course in a larger number of EC patients 
 Incorporate CTC enumeration and profiling +/- cfDNA with longitudinal tissue 
biopsies in clinical trials of novel agents 
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6.5. Epigenetic Analysis in Endometrial Cancer: developing a Methylation Signature  
 
This is the first comprehensive analysis of FFPE normal endometrium, AEH and EEC on the 
Illumina 450K array and it demonstrates that this technique is feasible for epigenetic and CNV 
analysis.  Furthermore, differential methylation patterns between normal endometrium, AEH 
and EEC were identified.  TCGA data in EC was generated from FF tissue, therefore the 
technique utilised in this study was novel.  In addition, the results obtained from using this 
technique on FFPE tissue were in-keeping with TCGA findings where there was a comparable 
set of data.  This provides preliminary validation for continued development of this technique 
for molecular analysis of EC.  It also maximises the availability of analysable tissue across 
research institutions, as FFPE samples can be interrogated rather than relying solely on FF 
tissue.  
 
Identifying a pattern of differential methylation between normal endometrium, AEH and EEC 
provides the foundation for developing a methylation signature for endometrial 
carcinogenesis.  In prostate cancer for example, the glutathione S-transferase pi enzyme 
(GSTP1) has been identified in archival tissue [297], as well as in precursors to prostate cancer 
[298].  GSTP1 hypermethylation was subsequently identified in the urine, serum and ejaculate 
from prostate cancer patients [299] and is moving towards replacing conventional methods of 
prostate cancer detection [300].    
Such a methylation signature in EC may have prognostic and predictive significance [301] and 
also lead to tissue analysis through less invasive means.  For example, analysis of a high vaginal 
swab for endometrial secretions may yield epigenetic data, which may eventually impact on 
treatment decisions.  A more aggressive treatment approach might be taken if a methylation 
signature suggested a poor outcome. The converse is also true such that overtreatment may 
be prevented.  
 
Within this small sample size, the findings were hypothesis-generating but robust in that 
definitive changes in methylation pattern and across individual genes were consistently 
identified. This supports the expansion of this study in a larger sample size.  This could include 
all archived samples of EC held at UCLH and the Institute for Women’s Health in order to 
systematically characterize the epigenomic profile of carcinogenesis in all histological groups of 
these tumours.  Further study may include not only FFPE EC tissue, but also vaginal swabs and 
blood samples, such as CTCs or cfDNA, with clinical correlation in both early and advanced 
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disease, to develop a comprehensive methylation signature for prognostic and predictive 
assessment in EC.   
 
Currently, epigenetic treatment strategies in solid tumours target the entire epigenetic process 
rather than a specific epigenetic lesion, with early studies showing limited efficacy.  Histone 
deacetylase and DNA methyltransferase inhibitors were the first treatments targeting 
epigenetic aberrations.  Newer agents aim to target more specific epigenetic regulators and 
transcription factors to improve activity and reduce toxicity [302].  Improved understanding of 
the epigenetic changes that drive endometrial carcinogenesis and the interplay with genetic 
alterations may thus assist with development of targeted epigenetic therapies that may be 
active either alone or in combination in EC. 
 
6.6.  Determining the Significance of Differential Methylation and CNV in this sample set 
Both differential methylation between normal endometrium, AEH and EEC and variation in the 
timing of methylation changes was demonstrated in this study.  Some cases demonstrated 
methylation changes early in the transition from normal endometrium to AEH, such that AEH 
and EEC methylation patterns were similar.  For example, analysis of the timing of differential 
methylation in the WNT3A, SFRP2 and SOX1 genes in the Wnt signalling pathway as well as the 
RASSF1A and DCC TSGs suggested that the more significant change in methylation occurred in 
the normal endometrium to AEH transition.  Other cases showed methylation changes that 
occurred later, between the AEH and EEC transition, and the normal endometrium and AEH 
patterns for these cases were similar.  Hypermethylation in the FGF2 and VEGFA genes are 2 
examples where the more significant change in methylation occurred in the AEH to EEC 
transition.  Based on the clustering of AEH in this analysis, there may be 2 types of AEH that 
undergo different epigenetic and genetic alterations at different time points in endometrial 
carcinogenesis.  Further evaluation to determine the specific pathways implicated in this 
transition and the clinical relevance is needed to potentially guide any therapeutic 
intervention.  
If the preliminary methylation analysis for AEH from this work can be confirmed and validated, 
identifying cases that show an early transition to EC, as well as defining molecular pathways 
involved, then appropriate treatment can be better delivered.  More aggressive therapy could 
be directed to AEH that behaves more like EC and for more indolent cases, over-treatment 
could be avoided.    
 
In terms of the methylation changes identified, increased understanding of the genomic 
distribution and CpG content will also impact on further interpretation and application of 
201 
 
epigenetic data.  To date, the focus with identifying methylation changes has been in CGIs that 
lie in the promoter region of genes, though there is increasing evidence as to the significance 
of gene body alterations and CpG shores [194].  As such, genes identified in these regions were 
the focus here.  However, there is increasing evidence that methylation changes in other 
locations within the gene may be of equal significance and may vary with context [194].  
Improving understanding of the functions of DNA methylation in different genes and at 
different locations will be required for interpreting the changes that have been and will be 
observed. 
 
Compared to the methylation changes, CNV tended to occur as a later event in endometrial 
carcinogenesis.  A similar pattern between normal endometrium and AEH was observed, and 
greater differences between AEH and EEC.  The changes identified in FFPE tissue were 
consistent with data from TCGA FF EEC tissue analysis, demonstrating the validity of using FFPE 
samples with this technology.  CNV changes identified showed commonalities with TCGA data, 
such as MYC amplification, as well as novel changes in FGFR and STMN.  If validated, these 
novel changes may be of particular interest as the FGFR and PI3K pathways are targetable in 
EC and these changes may represent a novel predictive biomarker.     
 
Incorporating analysis of AEH in this study emphasises the importance of implementing 
genomic characterisation early in the clinical course of EC, as well as at longitudinal points of 
disease progression.  Mapping the changes that occur at these time points can add greater 
depth of knowledge to tumour biology and thus the relevant treatments that can be offered at 
the appropriate time.   
 
6.7.  Application of Genomic Characterisation in the Clinical Setting 
This data comes at a time of rapid change in the understanding of molecular characterisation 
of EC.  2013 saw the publication by TCGA of their integrated genomic characterisation of EC, 
proposing a new classification system [30].  Although clinically relevant, the reproducibility of 
these findings across centres and the practicalities of processing samples easily must be 
considered if it is to be of clinical utility for the majority of patients, clinicians and clinical 
settings.  There is already a large amount of information regarding molecular aberrations in EC, 
but translation into the clinical setting has been limited, in part due to difficulties in the 
practical inclusion of analysis techniques into daily clinical practice.  Thus, it will be important 
to determine how to translate the findings from the TCGA into a broader setting, whether 
testing should be centralized or whether key tests can be identified and performed at a greater 
number of centres.  The results from this study demonstrate one way in which TCGA data can 
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be extrapolated, as epigenetic and CNV data can be generated from FFPE archival tissue using 
the Illumina 450k array, removing the need for the costly and time-consuming extra collection 
of FF tissue for sampling. 
 
There were a number of established and novel pathways implicated in the methylation and 
CNV changes seen in this study during endometrial carcinogenesis.  Gene hyper- or 
hypomethylation, and CN amplification or deletion were observed in the PI3K/mTOR/Arf6, 
VEGF, FGF/FGFR, EGFR, PDGFR, TGFB, p53 and the Wnt/E-cadherin signalling pathways.  Novel 
genetic changes were also documented in signalling pathways involving FAK and cell adhesion, 
ALK, c-met/HGFR, Notch, Hedgehog and Trk.  Specific aberrations could also be mapped for 
some genes through the normal endometrium to AEH to EEC transition.  APC, for example, 
underwent promoter hypermethylation between the normal endometrium and AEH transition, 
while CN amplification of APC occurred between the AEH to EC transition.  .  Although these 
changes need clinical correlation and validation in a larger sample size, it supports further 
study of these epigenetic and genetic changes on the Illumina 450K array to develop a 
molecular signature for prognostic and predictive purposes. 
 
TCGA data also outlines the importance of genome-wide analysis when assessing appropriate 
molecular pathways to target, as there may be concurrent aberrations that interact [30].  For 
example, most of the HER2-amplified serous-like EC tumours in the TCGA analysis were also 
PIK3CA mutated.  In breast cancer cell lines, activating mutations in PIK3CA are associated with 
decreased sensitivity to trastuzumab and lapatinib [303, 304] and thus may explain the limited 
benefit that has been seen to date with trastuzumab in HER2 overexpressing EC [85].  
This genome-wide assessment with complex technologies and bioinformatic analysis, may thus 
either lead to the need for centralized analysis or using a smaller number of key tests extracted 
from the genome-wide assessment to guide clinical management.  Moving forward, as 
technologies, cost and time requirements change, complexity of analysis at a local level will 
increase, but until that occurs, it is important to transfer research data to the clinical and trial 
setting as accurately and rapidly as possible, working within the available infrastructure.  
 
In this study, approximately 50% of FFPE samples had DNA of suitable quality for analysis on 
the ChAMP pipeline and there are areas that can be optimised to improve DNA amount and 
quality.  As there were three categories of endometrial tissue being reviewed here (normal, 
AEH and EEC), the histopathology team would be consulted in advance to be aware of these 
tissue requirements.  Otherwise, large amounts of each tissue type will not necessarily be 
stored, particularly once a diagnosis of cancer is made.  Inadequate tissue volume has a direct 
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effect on the amount of DNA that can be extracted and subsequently analysed.  Similarly, 
tissue preparation and timing of fixation play a critical role in maintaining DNA quality for 
research purposes.   Detailed communication between the research and histopathology teams 
is a prerequisite for successful research in this regard and standard operating procedures for 
tissue processing should ensure that all staff involved adhere to the same protocols.   
Ongoing analysis of FF tissue, concurrent with FFPE tissue, will also be important as a 
comparator for reproducibility of results where available.  In this study, the FFPE and FF tissue 
showed similar methylation changes and further validation of this in a larger study should be 
undertaken. 
 
6.8. Epigenetic Analysis beyond FFPE and FF tissue 
If the methylation data presented here are validated in further studies then concurrent 
analysis of peripheral blood samples may be the next step in gathering longitudinal 
information on epigenetic changes in patients.  Epigenetic alterations can be detected on 
cfDNA [295], though rather than using a genome-wide platform like Illumina, a candidate-gene 
approach may be more feasible, once the changes of interest have been established in tumour 
tissue. 
There is also early evidence of a correlation between epigenetic alterations in cfDNA and CTCs, 
demonstrated in a group of melanoma patients [305].  The number of CTCs significantly 
correlated with the methylation of cfDNA RASSF1A and RAR-β2 molecules and both CTC and 
cfDNA concentrations were prognostic for response to therapy and clinical outcome.  If 
methylation signatures can be developed for FFPE tissue to differentiate between more 
aggressive types of AEH and EC, then following this on a non-invasive peripheral blood test 
would be appealing. 
 
A summary of the future directions for epigenetic analysis in EC is outlined in Figure 6.2. 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2. Future Directions in Epigenetic and Genetic Analysis in EC 
 Extend methylation and CNV analysis to further EC specimens within 
UCLH and IfWH to validate findings 
 Optimise tissue collection, fixation and storage procedures to 
maximise availability for research purposes 
 Correlate with clinical data and extend to early and late EC to develop 
a methylation signature between AEH and EC for risk of recurrence 
and to guide treatment 
 Determine feasibility of epigenetic analysis in cfDNA and CTCs in EC 
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Outcomes for EC and available treatment options remain poor with no targeted therapies 
currently available.  Drug development in EC needs to focus on biomarker-driven targeted 
treatment strategies, based on both the known molecular aberrations as well as new targets 
that may be found.  Two potential biomarker strategies have been identified here, novel to EC, 
both of which could be incorporated into further studies as the technologies are readily 
available.  Further study may establish CTCs as a predictive and prognostic biomarker for both 
standard and targeted therapies, and longitudinal assessment is already being incorporated 
into a phase II PARP inhibitor trial in EC [282].  Similarly, further epigenetic analysis may 
identify a methylation signature for AEH and EC that could guide therapeutic options from the 
earliest stages of disease. 
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Appendix 
 
Chapter 2 appendix 
The following 4 scripts are part of the ChAMP pipeline to be used on the R console to analyse 
data generated on the Illumina 450K array.  Their use and the results generated are detailed in 
Chapter 2. 
 
2A: Script on how to load the ChAMP pipeline, raw data and run the load function, BMIQ, 
SVD, ComBat, limma and DMR hunter-probe lasso packages 
# depicts explanations of the role of each instruction in the script 
 
source("http://bioconductor.org/biocLite.R") 
biocLite(c('minfi', 'DNAcopy', 'impute', 'marray', 'limma', 'preprocessCore', 'RPMM', 'sva', 
'IlluminaHumanMethylation450kmanifest','wateRmelon')) 
source("http://bioconductor.org/biocLite.R") 
biocLite("ChAMP") 
 
setwd("C:/Users/regmcl6/Desktop/CL450K/") 
library(ChAMP) 
myLoad=champ.load() 
#checks fraction of failed positions - cut off 5% (or 10%) - then go to sample sheet and remove 
the specimens you don't want to use and run again 
 
myNorm=champ.norm() 
champ.SVD() 
batchNorm=champ.runCombat() 
#only works if at least 2 samples from each array 
 
limma=champ.MVP() 
#looks for methylated probes - generates a p value - how sigt the meth diff is between the 
groups. If works, go on to do lasso step 
 
lasso=champ.lasso(fromFile =TRUE, limma=limma) 
#looks for DMRS (differentially methylated regions - 3 probes show differential methylation 
within 1000bp region) 
 
library(plyr) 
probe.features$probeID=row.names(probe.features) 
pvr_lim<-limma[which(limma$adj.P.Val<0.1),] 
#looks for MVPs. 
 
pvr_lim<-limma[which(limma$adj.P.Val<0.05),] 
#generates table with p values and probes 
 
pvr_lim_anno<-join(pvr_lim,probe.features,by="probeID","left") 
#to filter only for >30% hypermeth MVPs - then generates table in champ results folder 
pvr_lim_anno_hyper30<-pvr_lim_anno[which(pvr_lim_anno$logFC>0.3),] 
#to filter for only <30%hypometh MVPs 
pvr_lim_anno_hypo30<-pvr_lim_anno[which(pvr_lim_anno$logFC<(-0.3)),] 
#to write tables  
fileName=paste("C:/Users/regmcl6/Desktop/CL450K","/pvr_lim_anno_hyper30",".txt",sep="") 
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write.table(pvr_lim_anno_hyper30,fileName,quote=F,sep="\t",row.names=F) 
fileName=paste("C:/Users/regmcl6/Desktop/CL450K","/pvr_lim_anno_hypo30",".txt",sep="") 
write.table(pvr_lim_anno_hypo30,fileName,quote=F,sep="\t",row.names=F) 
 
#save at this point and don't do CNA unless really want to (change name to suit)before doing 
heatmaps/dendrograms and CAN analysis 
save.image("CL450KNvsC.RData") 
 
 
2B: Script on how to generate heatmaps and cluster dendrograms for the different 
comparator groups 
#after completed script 1, import phenos col table (with single column of colours) 
phenocolours=read.table("C:/Users/regmcl6/Desktop/NvsConeexcP.txt",sep="\t",header=T) 
#remove first column so only colours remain 
phenocolours2<-phenocolours[,2:2]  
 
#make object of normalised beta values output from champ 
normbetas<-batchNorm$beta 
mad.m<-apply(normbetas[,1:22],1,mad)  
#Identify most variable probes (change second number to number of samples) 
mad3<-cbind(normbetas,mad.m) 
 #making table of your results per sample for most variable probes 
mad4<-mad3[order(mad3[,23],decreasing=TRUE),] 
 #order results by descending variability (change number to number of samples plus 1) 
 
#Transform columns to rows so plots samples rather than probes, and select number of rows 
(ie top 500 most variable probes) and number of columns (ie number of samples) 
d<-dist(t(mad4[1:500,1:22])) # calculates distance between rows 
 
##MDS plot## 
fit <- cmdscale(d,eig=TRUE, k=2) # k=number of dimensions 
x <- fit$points[,1] 
y <- fit$points[,2] 
plot(x, y, col=as.matrix(phenocolours2), pch=16) #pch changes the dot type 
 
### Ward Hierarchical Clustering ### 
#d <- dist(mydata, method = "euclidean") # distance matrix - have already done above 
fit <- hclust(d, method="ward")  
plot(fit) # display dendogram 
groups <- cutree(fit, k=2) # cut tree into 2 clusters 
# draw dendogram with red borders around the 2 clusters  
rect.hclust(fit, k=2, border="red")  
#to shink the text of sample labels if large numbers do fit line as usual but then plot (fit, 
cex=0.5) 
 
###heatmap3 based on most variable probes### 
#copy and paste the heatmap3 code into R all in one go 
heatmap.3 <- function(x, 
                      Rowv = TRUE, Colv = if (symm) "Rowv" else TRUE, 
                      distfun = dist, 
                      hclustfun = hclust, 
                      dendrogram = c("both","row", "column", "none"), 
                      symm = FALSE, 
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                      scale = c("none","row", "column"), 
                      na.rm = TRUE, 
                      revC = identical(Colv,"Rowv"), 
                      add.expr, 
                      breaks, 
                      symbreaks = max(x < 0, na.rm = TRUE) || scale != "none", 
                      col = "heat.colors", 
                      colsep, 
                      rowsep, 
                      sepcolor = "white", 
                      sepwidth = c(0.05, 0.05), 
                      cellnote, 
                      notecex = 1, 
                      notecol = "cyan", 
                      na.color = par("bg"), 
                      trace = c("none", "column","row", "both"), 
                      tracecol = "cyan", 
                      hline = median(breaks), 
                      vline = median(breaks), 
                      linecol = tracecol, 
                      margins = c(5,5), 
                      ColSideColors, 
                      RowSideColors, 
                      side.height.fraction=0.6, 
                      cexRow = 0.2 + 1/log10(nr), 
                      cexCol = 0.2 + 1/log10(nc), 
                      labRow = NULL, 
                      labCol = NULL, 
                      key = TRUE, 
                      keysize = 1.5, 
                      density.info = c("none", "histogram", "density"), 
                      denscol = tracecol, 
                      symkey = max(x < 0, na.rm = TRUE) || symbreaks, 
                      densadj = 0.25, 
                      main = NULL, 
                      xlab = NULL, 
                      ylab = NULL, 
                      lmat = NULL, 
                      lhei = NULL, 
                      lwid = NULL, 
                      NumColSideColors = 1, 
                      NumRowSideColors = 1, 
                      KeyValueName="Value",...){ 
  
    invalid <- function (x) { 
      if (missing(x) || is.null(x) || length(x) == 0) 
          return(TRUE) 
      if (is.list(x)) 
          return(all(sapply(x, invalid))) 
      else if (is.vector(x)) 
          return(all(is.na(x))) 
      else return(FALSE)} 
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    x <- as.matrix(x) 
    scale01 <- function(x, low = min(x), high = max(x)) { 
        x <- (x - low)/(high - low) 
        x} 
    retval <- list() 
    scale <- if (symm && missing(scale)) 
        "none" 
    else match.arg(scale) 
    dendrogram <- match.arg(dendrogram) 
    trace <- match.arg(trace) 
    density.info <- match.arg(density.info) 
    if (length(col) == 1 && is.character(col)) 
        col <- get(col, mode = "function") 
    if (!missing(breaks) && (scale != "none")) 
        warning("Using scale=\"row\" or scale=\"column\" when breaks are", 
            "specified can produce unpredictable results.", "Please consider using only one or the 
other.") 
    if (is.null(Rowv) || is.na(Rowv)) 
        Rowv <- FALSE 
    if (is.null(Colv) || is.na(Colv)) 
        Colv <- FALSE 
    else if (Colv == "Rowv" && !isTRUE(Rowv)) 
        Colv <- FALSE 
    if (length(di <- dim(x)) != 2 || !is.numeric(x)) 
        stop("`x' must be a numeric matrix") 
    nr <- di[1] 
    nc <- di[306] 
    if (nr <= 1 || nc <= 1) 
        stop("`x' must have at least 2 rows and 2 columns") 
    if (!is.numeric(margins) || length(margins) != 2) 
        stop("`margins' must be a numeric vector of length 2") 
    if (missing(cellnote)) 
        cellnote <- matrix("", ncol = ncol(x), nrow = nrow(x)) 
    if (!inherits(Rowv, "dendrogram")) { 
        if (((!isTRUE(Rowv)) || (is.null(Rowv))) && (dendrogram %in% 
            c("both", "row"))) { 
            if (is.logical(Colv) && (Colv)) 
                dendrogram <- "column" 
            else dedrogram <- "none" 
            warning("Discrepancy: Rowv is FALSE, while dendrogram is `", 
                dendrogram, "'. Omitting row dendogram.")}} 
    if (!inherits(Colv, "dendrogram")) { 
        if (((!isTRUE(Colv)) || (is.null(Colv))) && (dendrogram %in% 
            c("both", "column"))) { 
            if (is.logical(Rowv) && (Rowv)) 
                dendrogram <- "row" 
            else dendrogram <- "none" 
            warning("Discrepancy: Colv is FALSE, while dendrogram is `", 
                dendrogram, "'. Omitting column dendogram.")}} 
    if (inherits(Rowv, "dendrogram")) { 
        ddr <- Rowv 
        rowInd <- order.dendrogram(ddr)} 
else if (is.integer(Rowv)) { 
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        hcr <- hclustfun(distfun(x)) 
        ddr <- as.dendrogram(hcr) 
        ddr <- reorder(ddr, Rowv) 
        rowInd <- order.dendrogram(ddr) 
        if (nr != length(rowInd)) 
            stop("row dendrogram ordering gave index of wrong length")} 
    else if (isTRUE(Rowv)) { 
        Rowv <- rowMeans(x, na.rm = na.rm) 
        hcr <- hclustfun(distfun(x)) 
        ddr <- as.dendrogram(hcr) 
        ddr <- reorder(ddr, Rowv) 
        rowInd <- order.dendrogram(ddr) 
        if (nr != length(rowInd)) 
            stop("row dendrogram ordering gave index of wrong length")} 
    else {rowInd <- nr:1} 
    if (inherits(Colv, "dendrogram")) { 
        ddc <- Colv 
        colInd <- order.dendrogram(ddc)} 
    else if (identical(Colv, "Rowv")) { 
        if (nr != nc) 
            stop("Colv = \"Rowv\" but nrow(x) != ncol(x)") 
        if (exists("ddr")) {ddc <- ddr 
            colInd <- order.dendrogram(ddc)} 
        else colInd <- rowInd} 
    else if (is.integer(Colv)) { 
        hcc <- hclustfun(distfun(if (symm) 
            x 
        else t(x))) 
        ddc <- as.dendrogram(hcc) 
        ddc <- reorder(ddc, Colv) 
        colInd <- order.dendrogram(ddc) 
        if (nc != length(colInd)) 
            stop("column dendrogram ordering gave index of wrong length")} 
    else if (isTRUE(Colv)) { 
        Colv <- colMeans(x, na.rm = na.rm) 
        hcc <- hclustfun(distfun(if (symm) 
            x 
        else t(x))) 
        ddc <- as.dendrogram(hcc) 
        ddc <- reorder(ddc, Colv) 
        colInd <- order.dendrogram(ddc) 
        if (nc != length(colInd)) 
            stop("column dendrogram ordering gave index of wrong length")} 
    else {colInd <- 1:nc} 
    retval$rowInd <- rowInd 
    retval$colInd <- colInd 
    retval$call <- match.call() 
    x <- x[rowInd, colInd] 
    x.unscaled <- x 
    cellnote <- cellnote[rowInd, colInd] 
    if (is.null(labRow)) 
        labRow <- if (is.null(rownames(x))) 
            (1:nr)[rowInd] 
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        else rownames(x) 
    else labRow <- labRow[rowInd] 
    if (is.null(labCol)) 
        labCol <- if (is.null(colnames(x))) 
            (1:nc)[colInd] 
        else colnames(x) 
    else labCol <- labCol[colInd] 
    if (scale == "row") { 
        retval$rowMeans <- rm <- rowMeans(x, na.rm = na.rm) 
        x <- sweep(x, 1, rm) 
        retval$rowSDs <- sx <- apply(x, 1, sd, na.rm = na.rm) 
        x <- sweep(x, 1, sx, "/")} 
    else if (scale == "column") { 
        retval$colMeans <- rm <- colMeans(x, na.rm = na.rm) 
        x <- sweep(x, 2, rm) 
        retval$colSDs <- sx <- apply(x, 2, sd, na.rm = na.rm) 
        x <- sweep(x, 2, sx, "/")} 
    if (missing(breaks) || is.null(breaks) || length(breaks) < 1) { 
        if (missing(col) || is.function(col)) 
            breaks <- 16 
        else breaks <- length(col) + 1} 
    if (length(breaks) == 1) { 
        if (!symbreaks) 
            breaks <- seq(min(x, na.rm = na.rm), max(x, na.rm = na.rm), 
                length = breaks) 
        else { extreme <- max(abs(x), na.rm = TRUE) 
            breaks <- seq(-extreme, extreme, length = breaks)}} 
    nbr <- length(breaks) 
    ncol <- length(breaks) - 1 
    if (class(col) == "function") 
        col <- col(ncol) 
    min.breaks <- min(breaks) 
    max.breaks <- max(breaks) 
    x[x < min.breaks] <- min.breaks 
    x[x > max.breaks] <- max.breaks 
    if (missing(lhei) || is.null(lhei)) 
        lhei <- c(keysize, 4) 
    if (missing(lwid) || is.null(lwid)) 
        lwid <- c(keysize, 4) 
    if (missing(lmat) || is.null(lmat)) { 
        lmat <- rbind(4:3, 2:1) 
  
        if (!missing(ColSideColors)) { 
           #if (!is.matrix(ColSideColors)) 
           #stop("'ColSideColors' must be a matrix") 
            if (!is.character(ColSideColors) || nrow(ColSideColors) != nc) 
                stop("'ColSideColors' must be a matrix of nrow(x) rows") 
            lmat <- rbind(lmat[1, ] + 1, c(NA, 1), lmat[306] + 1) 
            #lhei <- c(lhei[1], 0., lhei[306]) 
             lhei=c(lhei[1], side.height.fraction*NumColSideColors, lhei[306])} 
  
        if (!missing(RowSideColors)) { 
            #if (!is.matrix(RowSideColors)) 
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            #stop("'RowSideColors' must be a matrix") 
            if (!is.character(RowSideColors) || ncol(RowSideColors) != nr) 
                stop("'RowSideColors' must be a matrix of ncol(x) columns") 
            lmat <- cbind(lmat[, 1] + 1, c(rep(NA, nrow(lmat) - 1), 1), lmat[,2] + 1) 
            #lwid <- c(lwid[1], 0.2, lwid[306]) 
            lwid <- c(lwid[1], side.height.fraction*NumRowSideColors, lwid[306])} 
        lmat[is.na(lmat)] <- 0} 
  
    if (length(lhei) != nrow(lmat)) 
        stop("lhei must have length = nrow(lmat) = ", nrow(lmat)) 
    if (length(lwid) != ncol(lmat)) 
        stop("lwid must have length = ncol(lmat) =", ncol(lmat)) 
    op <- par(no.readonly = TRUE) 
    on.exit(par(op))  
    layout(lmat, widths = lwid, heights = lhei, respect = FALSE)  
    if (!missing(RowSideColors)) { 
        if (!is.matrix(RowSideColors)){ 
                par(mar = c(margins[1], 0, 0, 0.5)) 
                image(rbind(1:nr), col = RowSideColors[rowInd], axes = FALSE)} else { 
            par(mar = c(margins[1], 0, 0, 0.5)) 
            rsc = t(RowSideColors[,rowInd, drop=F]) 
            rsc.colors = matrix() 
            rsc.names = names(table(rsc)) 
            rsc.i = 1 
            for (rsc.name in rsc.names) { 
                rsc.colors[rsc.i] = rsc.name 
                rsc[rsc == rsc.name] = rsc.i 
                rsc.i = rsc.i + 1} 
            rsc = matrix(as.numeric(rsc), nrow = dim(rsc)[1]) 
            image(t(rsc), col = as.vector(rsc.colors), axes = FALSE) 
            if (length(colnames(RowSideColors)) > 0) { 
                axis(1, 0:(dim(rsc)[306] - 1)/(dim(rsc)[306] - 1), colnames(RowSideColors), las = 2, tick 
= FALSE)}}} 
    if (!missing(ColSideColors)) {  
        if (!is.matrix(ColSideColors)){ 
            par(mar = c(0.5, 0, 0, margins[306])) 
            image(cbind(1:nc), col = ColSideColors[colInd], axes = FALSE)} else { 
            par(mar = c(0.5, 0, 0, margins[306])) 
            csc = ColSideColors[colInd, , drop=F] 
            csc.colors = matrix() 
            csc.names = names(table(csc)) 
            csc.i = 1 
            for (csc.name in csc.names) { 
                csc.colors[csc.i] = csc.name 
                csc[csc == csc.name] = csc.i 
                csc.i = csc.i + 1} 
            csc = matrix(as.numeric(csc), nrow = dim(csc)[1]) 
            image(csc, col = as.vector(csc.colors), axes = FALSE) 
            if (length(colnames(ColSideColors)) > 0) { 
                axis(2, 0:(dim(csc)[306] - 1)/max(1,(dim(csc)[306] - 1)), colnames(ColSideColors), las = 
2, tick = FALSE)}}} 
  
    par(mar = c(margins[1], 0, 0, margins[306])) 
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    x <- t(x) 
    cellnote <- t(cellnote) 
    if (revC) { 
        iy <- nr:1 
        if (exists("ddr")) 
            ddr <- rev(ddr) 
        x <- x[, iy] 
        cellnote <- cellnote[, iy]} 
    else iy <- 1:nr 
    image(1:nc, 1:nr, x, xlim = 0.5 + c(0, nc), ylim = 0.5 + c(0, nr), axes = FALSE, xlab = "", ylab = 
"", col = col, breaks = breaks, ...) 
    retval$carpet <- x 
    if (exists("ddr")) 
        retval$rowDendrogram <- ddr 
    if (exists("ddc")) 
        retval$colDendrogram <- ddc 
    retval$breaks <- breaks 
    retval$col <- col 
    if (!invalid(na.color) & any(is.na(x))) { # load library(gplots) 
        mmat <- ifelse(is.na(x), 1, NA) 
        image(1:nc, 1:nr, mmat, axes = FALSE, xlab = "", ylab = "", 
            col = na.color, add = TRUE)} 
    axis(1, 1:nc, labels = labCol, las = 2, line = -0.5, tick = 0, 
        cex.axis = cexCol) 
    if (!is.null(xlab)) 
        mtext(xlab, side = 1, line = margins[1] - 1.25) 
    axis(4, iy, labels = labRow, las = 2, line = -0.5, tick = 0, 
        cex.axis = cexRow) 
    if (!is.null(ylab)) 
        mtext(ylab, side = 4, line = margins[306] - 1.25) 
    if (!missing(add.expr)) 
        eval(substitute(add.expr)) 
    if (!missing(colsep)) 
        for (csep in colsep) rect(xleft = csep + 0.5, ybottom = rep(0, length(csep)), xright = csep + 
0.5 + sepwidth[1], ytop = rep(ncol(x) + 1, csep), lty = 1, lwd = 1, col = sepcolor, border = 
sepcolor) 
    if (!missing(rowsep)) 
        for (rsep in rowsep) rect(xleft = 0, ybottom = (ncol(x) + 1 - rsep) - 0.5, xright = nrow(x) + 1, 
ytop = (ncol(x) + 1 - rsep) - 0.5 - sepwidth[306], lty = 1, lwd = 1, col = sepcolor, border = 
sepcolor) 
    min.scale <- min(breaks) 
    max.scale <- max(breaks) 
    x.scaled <- scale01(t(x), min.scale, max.scale) 
    if (trace %in% c("both", "column")) { 
        retval$vline <- vline 
        vline.vals <- scale01(vline, min.scale, max.scale) 
        for (i in colInd) { 
            if (!is.null(vline)) { 
                abline(v = i - 0.5 + vline.vals, col = linecol, 
                  lty = 2)} 
            xv <- rep(i, nrow(x.scaled)) + x.scaled[, i] - 0.5 
            xv <- c(xv[1], xv) 
            yv <- 1:length(xv) - 0.5 
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            lines(x = xv, y = yv, lwd = 1, col = tracecol, type = "s")}} 
    if (trace %in% c("both", "row")) { 
        retval$hline <- hline 
        hline.vals <- scale01(hline, min.scale, max.scale) 
        for (i in rowInd) { 
            if (!is.null(hline)) { 
                abline(h = i + hline, col = linecol, lty = 2)} 
            yv <- rep(i, ncol(x.scaled)) + x.scaled[i, ] - 0.5 
            yv <- rev(c(yv[1], yv)) 
            xv <- length(yv):1 - 0.5 
            lines(x = xv, y = yv, lwd = 1, col = tracecol, type = "s")}} 
    if (!missing(cellnote)) 
        text(x = c(row(cellnote)), y = c(col(cellnote)), labels = c(cellnote), 
            col = notecol, cex = notecex) 
    par(mar = c(margins[1], 0, 0, 0)) 
    if (dendrogram %in% c("both", "row")) { 
        plot(ddr, horiz = TRUE, axes = FALSE, yaxs = "i", leaflab = "none")} 
    else plot.new() 
    par(mar = c(0, 0, if (!is.null(main)) 5 else 0, margins[306])) 
    if (dendrogram %in% c("both", "column")) { 
        plot(ddc, axes = FALSE, xaxs = "i", leaflab = "none")} 
    else plot.new() 
    if (!is.null(main)) 
        title(main, cex.main = 1.5 * op[["cex.main"]]) 
    if (key) { 
        par(mar = c(5, 4, 2, 1), cex = 0.75) 
        tmpbreaks <- breaks 
        if (symkey) { 
            max.raw <- max(abs(c(x, breaks)), na.rm = TRUE) 
            min.raw <- -max.raw 
            tmpbreaks[1] <- -max(abs(x), na.rm = TRUE) 
            tmpbreaks[length(tmpbreaks)] <- max(abs(x), na.rm = TRUE)} 
        else {min.raw <- min(x, na.rm = TRUE) 
            max.raw <- max(x, na.rm = TRUE)} 
  
        z <- seq(min.raw, max.raw, length = length(col)) 
        image(z = matrix(z, ncol = 1), col = col, breaks = tmpbreaks, 
            xaxt = "n", yaxt = "n") 
        par(usr = c(0, 1, 0, 1)) 
        lv <- pretty(breaks) 
        xv <- scale01(as.numeric(lv), min.raw, max.raw) 
        axis(1, at = xv, labels = lv) 
        if (scale == "row") 
            mtext(side = 1, "Row Z-Score", line = 2) 
        else if (scale == "column") 
            mtext(side = 1, "Column Z-Score", line = 2) 
        else mtext(side = 1, KeyValueName, line = 2) 
        if (density.info == "density") { 
            dens <- density(x, adjust = densadj, na.rm = TRUE) 
            omit <- dens$x < min(breaks) | dens$x > max(breaks) 
            dens$x <- dens$x[-omit] 
            dens$y <- dens$y[-omit] 
            dens$x <- scale01(dens$x, min.raw, max.raw) 
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            lines(dens$x, dens$y/max(dens$y) * 0.95, col = denscol, 
                lwd = 1) 
            axis(2, at = pretty(dens$y)/max(dens$y) * 0.95, pretty(dens$y)) 
            title("Color Key\nand Density Plot") 
            par(cex = 0.5) 
            mtext(side = 2, "Density", line = 2)} 
        else if (density.info == "histogram") { 
            h <- hist(x, plot = FALSE, breaks = breaks) 
            hx <- scale01(breaks, min.raw, max.raw) 
            hy <- c(h$counts, h$counts[length(h$counts)]) 
            lines(hx, hy/max(hy) * 0.95, lwd = 1, type = "s", 
                col = denscol) 
            axis(2, at = pretty(hy)/max(hy) * 0.95, pretty(hy)) 
            title("Color Key\nand Histogram") 
            par(cex = 0.5) 
            mtext(side = 2, "Count", line = 2)} 
        else title("Color Key")} 
    else plot.new() 
    retval$colorTable <- data.frame(low = retval$breaks[-length(retval$breaks)], 
        high = retval$breaks[-1], color = retval$col) 
    invisible(retval)} 
 
#make another phenos colour .txt file with however many columns you like of diff pheno 
groupings 
#import table  
phenocolours=read.table("MasterTvNMDSphenos_heatmap3cols.txt",sep="\t",header=T) 
#remove 1st column (change second number below to number of pheno columns plus 1) 
phenocolours2<-phenocolours[,2:4]  
# to change colours to blue and yellow ( standard for methylation) 
Lab.palette2 <- colorRampPalette(c("yellow","light blue","blue"), space = "Lab") 
heatmap.3(as.matrix(mad4[1:1000,1:22]),ColSideColors=as.matrix(phenocolours2), 
col=Lab.palette2) 
 
 
2C: Script on how to compare study data to TCGA data on Marmal-aid 
library(marmalaid) 
#to load annotation 
data(annotation_v1) 
#to look at annotation 
head(annotation) 
#select cancer samples 
cancer=annotation[which(annotation$DISEASE=="Cancer"),] 
#look at subtypes of cancer sample 
unique(cancer$DISEASE_SUBTYPE) 
#NB the “” below need to be re-written in R!! 
cancertcga=cancer[which(cancer$GSE==“TCGA”),] 
#cancertcgaselected=cancertcga[which(cancertcga$DISEASE_SUBTYPE==“Uterine Corpus 
Endometrioid Carcinoma”),] 
#select Healthy samples 
healthy=annotation[which(annotation$DISEASE=="Healthy”|annotation$DISEASE==“Control 
Analyte”),] 
healthytcga=healthy[which(healthy$GSE==“TCGA”),] 
unique(healthy$TISSUE) 
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healthytcgaselected=healthytcga[which(healthytcga$TISSUE=="Endometrial"),] 
 
load("probe_450K_features.RData") 
probes<-row.names(probe.features) 
 
#Get sample Ids 
samples=c(cancertcgaselected$Id,healthytcgaselected$Id) 
#download normalised betas 
#tcga.betas.norm=getbeta(samples,probes) 
tcgaEC2.betas.norm=getbeta(samples,probes) 
dim(tcgaEC2.betas.norm) 
 
#then do the norm betas scripts as after champ 
#to make a phenotypes table first get a list of all the column names 
colnames(tcgaEC2.betas.norm) 
samplenames<-colnames(tcgaEC2.betas.norm) 
fileName=paste("samplenames",".txt",sep="") 
write.table(samplenames,fileName,quote=F,sep="\t",row.names=F) 
#open the txt file of sample names and add in a columns with phenocolours manually then 
save and in new shell window copy back into marmalade server folder then read in as per 
norm betas scripts 
 
#to add in my data open up the Rdata file make norm betas and write a table of it 
normbetas<-batchNorm$beta 
fileName=paste("normbetas",".txt",sep="") 
write.table(normbetas,fileName,quote=F,sep="\t",row.names=T) 
 
#eg. for NAC 
normbetasNAC<-batchNorm$beta 
fileName=paste("normbetasNAC",".txt",sep="") 
write.table(normbetasNAC,fileName,quote=F,sep="\t",row.names=T) 
#read table command to import table 
NCallnormbetas=read.table("normbetas.txt",sep="\t",header=T) 
NCnormbetas2<-data.frame((rownames(NCallnormbetas)),NCallnormbetas) 
colnames(NCnormbetas2)[1]="probe.ID" 
#delete data from tables from tcgaEC2 to reduce memory size required to run 
EC3<-tcgaEC2.betas.norm[-c(151-515)] 
#tcgaEC2.betas.norm<-data.frame((rownames(tcgaEC2.betas.norm)),tcgaEC2.betas.norm) 
EC4<-data.frame((rownames(EC3)),EC3) 
#colnames(crcandnormalcolon.betas.norm2)[1]="probe.ID" 
colnames(tcgaEC2.betas.norm)[1]="probe.ID" 
#changed for modified tables 
EC5.betas.norm<-tcgaEC2.betas.norm[-c(151-515)] 
EC6.betas.norm<-data.frame((rownames(EC5.betas.norm)),EC5.betas.norm) 
#combining both tables 
test<-cbind(tcgaEC2.betas.norm[row.names(NCnormbetas2),],NCnormbetas2) 
#data downloaded from marmalaid with my data - number below is sum 
dim(test) #this shows combined sample number technically 
colnames(test) #shows column names 
#to remove probe ID in column 1 if there 
test2<-test[,2:159] 
#NB beware that you will get a ‘probeID’ column in the middle of your data frame that you 
need to remove 
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#test3<-test2[ -c(1)] 
#once data is combined, script 2 can be used to generate a heatmap showing the clustering of 
my data with the TCGA data 
 
2D: Script on how to analyse individual genes for methylation changes between normal, AEH 
and EC samples 
#after CHAMP is run for load/norm/batch 
normbetas<-batchNorm$beta 
load("X:/Paul_Guilhamon/450kAnno.Rd") 
 
## Seperate Phenotypes by coloumn names 
tmpT.idx <- grep("C",colnames(normbetas)); 
tmpN.idx <- grep("N",colnames(normbetas)); 
tmpA.idx <- grep("A",colnames(normbetas)); 
 
data.pg.tumour<-as.matrix(normbetas[,tmpT.idx]) 
data.pg.normal<-as.matrix(normbetas[,tmpN.idx]) 
data.pg.peri<-as.matrix(normbetas[,tmpA.idx]) 
 
rownames(data.pg.normal)<-rownames(normbetas) 
rownames(data.pg.tumour)<-rownames(normbetas) 
rownames(data.pg.peri)<-rownames(normbetas) 
 
data.pg<-normbetas[,1:47]  
label2color = function(x, colors, labels) { 
  output = x; 
  for (i in 1:length(labels)) { output[which(x == labels[i])] = colors[i]; } 
  return(output);} 
labelPalette = c("TSS1500","TSS200","5UTR","1stExon","Body","3UTR"); 
names(labelPalette) = c("orange","red","yellow","blue","lightblue","yellowgreen"); 
 
DNAmLabelEnum = 1:6; names(DNAmLabelEnum) = 
c("TSS1500","TSS200","5UTR","1stExon","Body","3UTR"); 
prettyDNAmLabel = function(s) { 
  t = sort(unique(strsplit(s, ";")[[1]])); 
  temp = label2color(t, DNAmLabelEnum, names(DNAmLabelEnum)  ); 
  names(temp) = t; 
  return( names(sort(temp))[1] )} 
 
DNAmLabelFormat = function(s, xl) { 
  if (s == "TSS1500") { return("TSS\n1500");break; } 
  if (s == "TSS200") { return("TSS\n200");break; } 
  #if (s == "TSS200" & length(grep( "TSS200",xl ))/length(xl) > 0.15 ) {return("TSS200\n");break;} 
  if (s == "3UTR"   & length(grep( "3UTR",xl ))/length(xl) > 0.15 ) { return("3UTR\n");break; } 
  if (s == "3UTR"   & length(grep( "3UTR",xl ))/length(xl) <= 0.15) { return("3\nU");break; } 
  if (s == "5UTR"   & length(grep( "5UTR",xl ))/length(xl) > 0.15) { return("5UTR\n");break; } 
  if (s == "5UTR"   & length(grep( "5UTR",xl ))/length(xl) <= 0.15) { return("5\nU");break; } 
  if (s == "1stExon"   & length(grep( "1stExon",xl ))/length(xl) > 0.15) { 
return("1st\nExon");break; } 
  if (s == "1stExon"   & length(grep( "1stExon",xl ))/length(xl) <= 0.15) { return("1\nE");break;} 
  #if (s == "1stExon") { return("1st\nExon");break; } 
  if (s == "Body" & length(grep( "Body",xl ))/length(xl) > 0.15 ) { return("Body\n");break; }  
  if (s == "Body" & length(grep( "Body",xl ))/length(xl) <= 0.15 ) { return("B\n");break; }  
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  return(s);} 
 
DNAmLabelBreaks.v = 0:6 + 0.5; 
 
library("org.Hs.eg.db") 
library("IlluminaHumanMethylation450k.db") 
ShoreLabelEnum = 1:6; names(ShoreLabelEnum) = c("","N_Shore","S_Shore","Island", 
"N_Shelf", "S_Shelf"); 
ShoreBreaks.v = c(0.5, 1.5, 3.5, 4.5, 6.5); 
ShorePalette.v = c("white","darkgrey","black","lightgrey"); 
 
x = IlluminaHumanMethylation450kENTREZID; mapped_probes = mappedkeys(x); 
PROBE2ENTREZ.l = as.list(x[mapped_probes]); 
x = org.Hs.egSYMBOL; mapped_genes = mappedkeys(x); 
ENTREZID2GENESYMBOL = as.list(x[mapped_genes]); rm(x);  
 
entrez2prettyprofiles = function(eid, filename, dlimit = 3, YMIN=0, YMAX=1.0, reverse=FALSE) { 
  # Produce nice profile plots of ENTREZ IDs in eid and save as filename 
  NEID = length(eid); sym = unlist(ENTREZID2GENESYMBOL[eid]); 
  tss200pch.v = c(19, 17,18); M = matrix(1:5, nrow = 5, ncol  = 1); 
  tss200col.v = c(3,2,9); 
  layout.m = M; 
  if (NEID > 1) { for (i1 in 1:(NEID-1)) { layout.m = cbind(layout.m,M + 5*i1) }} 
  cpg.v = rownames(data.pg);  
   
  pdf(paste(filename,".pdf",sep=""), height = 5, width = NEID*15); 
  layout(layout.m, 
         heights=rep(c(0.45/2,3,0.25/2,0.75/2,0.35/2), NEID),  
         widths = rep(c(3,3,3,3,3), NEID)); 
  ALL.llv = list(); labels.lv = list(); islands.lv = list(); 
   
  for (j in 1:NEID) { 
    print(paste("Processing gene ",j,"/",NEID,sep=""));   
    temp = ENTREZ2PROBE.lv[[eid[j]]]; 
    temp = intersect(temp, cpg.v); 
    temp.m = anno.m[temp,c(13,24,26,34,35)] 
    temp.m[,1] = as.integer(temp.m[,1]); 
    ploc.v = as.integer(temp.m[,1]) 
    names(ploc.v) = rownames(temp.m); 
    ploc.v = sort(ploc.v); 
    # The below can be handy for genes that are backwards  
    if (reverse == TRUE) { ploc.v = rev(ploc.v) };  
    temp.m = temp.m[names(ploc.v),]; 
      
datasets.lm<-list(data.pg.normal,data.pg.tumour,data.pg.peri)   
phenos.lv<-list()  ##########create group labels in order  
phenos.lv[[1]]<-c(rep(1,18))  
phenos.lv[[2]]<-c(rep(1,21)) 
phenos.lv[[3]]<-c(rep(1,8)) 
     
l = list(); 
    for (i in 1:length(datasets.lm)) { 
      d = datasets.lm[[i]] 
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      p1.idx = which(phenos.lv[[i]] == 1); 
      p0.idx = which(phenos.lv[[i]] == 0); 
      p1.m = d[names(ploc.v), p1.idx ]; 
      p0.m = d[names(ploc.v), p0.idx ]; 
      l[[i]] = apply(p1.m, 1, mean) 
    }; names(l) = names(datasets.lm);  
     
s = list(); 
    for (i in 1:length(datasets.lm)) { 
      d = datasets.lm[[i]] 
      p1.idx = which(phenos.lv[[i]] == 1); 
      p0.idx = which(phenos.lv[[i]] == 0); 
      p1.m = d[names(ploc.v), p1.idx ]; 
      p0.m = d[names(ploc.v), p0.idx ]; 
      s[[i]] = (p1.m) 
    }; names(s) = names(datasets.lm);  
     
pheno1.m<-as.matrix(s[[1]]); 
pheno2.m<-as.matrix(s[[2]]); 
pheno3.m<-as.matrix(s[[3]]); 
tmp<-pheno1.m 
pheno1.mean.m<-as.matrix(l[[1]]) 
pheno2.mean.m<-as.matrix(l[[2]]) 
pheno3.mean.m<-as.matrix(l[[3]]) 
 
pheno1_comb.m<-cbind(pheno1.m, pheno1.mean.m) 
pheno2_comb.m<-cbind(pheno2.m, pheno2.mean.m) 
pheno3_comb.m<-cbind(pheno3.m, pheno3.mean.m) 
 
    ALL.llv[[j]] = l;  
    xlabels = unlist(sapply(temp.m[,2], prettyDNAmLabel)) 
    labels.lv[[j]] = xlabels; 
    islands.lv[[j]] = temp.m[,3];   
     
    islands = islands.lv[[j]]; 
    u = unique(xlabels); 
    nlabels = length(xlabels); location = 1; xlabels.coord = vector();  
    for (i1 in 1:length(u)) { 
      l = length(which(xlabels == u[i1])); 
      xlabels.coord[i1] = location + (l-1)/2; location = location+l; 
    }; names(u) = xlabels.coord; 
     
    par(mar=c(0,5,0,2)+0.1); 
    image(x=1:3,y=1, 
          z=matrix(1:3,ncol=1), 
          col="white",xlab="",ylab="",axes=FALSE); 
    text(2,1, sym[j] , col="black",cex=5/3);    
    y    = ALL.llv[[j]][[1]]; 
   library(gplots) 
    plotCI(y, type="p", 
           ylab = expression(paste(beta)), 
           xaxt = "n", pch = tss200pch.v[1], cex = 5/3,  
           ylim = c(YMIN, YMAX), 
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           main = "", 
           cex.lab = 5/3, 
           cex.axis = 5/3, 
           #las = 1, 
           col = tss200col.v[1]); 
    lines(y, col = "grey");;; 
     legend("topright", legend=c("Normal","Tumour","Atypical"), pch = tss200pch.v, col = 
tss200col.v)     
     
    if (length(datasets.lm) > 1) { 
      for (k in 2:dlimit) { 
        plotCI(ALL.llv[[j]][[k]], type="p", pch = tss200pch.v[k], cex = 5/3, add = TRUE,col = 
tss200col.v[k]);lines(ALL.llv[[j]][[k]], col = "grey");} 
for (i in seq(ncol(pheno1.m))){ 
points(pheno1.m[,i], col="green", cex=0.2)} 
 
for (i in seq(ncol(pheno2.m))){ 
points(pheno2.m[,i], col="red", cex=0.2)} 
 
for (i in seq(ncol(pheno3.m))){ 
points(pheno3.m[,i], col="black", cex=0.2)}}; 
     
    # Region bar 
    image(x=1:length(xlabels),y=1, 
          z = as.matrix(as.integer(label2color(xlabels, DNAmLabelEnum, 
names(DNAmLabelEnum)))), 
          breaks = DNAmLabelBreaks.v, col = names(labelPalette), xlab="",ylab="",axes=FALSE); 
     
    # Region labelling 
    image(x=1:length(xlabels),y=1, 
          z=matrix(1:length(xlabels),ncol=1), 
          col="white",xlab="",ylab="",axes=FALSE); 
    uf = sapply(u, function(s) (DNAmLabelFormat(s,xlabels))); 
    for (i2 in 1:length(uf)) { text( as.integer(names(uf)[i2]), 1, uf[i2], col = "black", cex=5/3) } 
     
    # CpG Island bar   
    image(x=1:length(islands),y=1, 
          z = as.matrix(as.integer(label2color(islands, ShoreLabelEnum, names(ShoreLabelEnum) 
))), 
          breaks = ShoreBreaks.v, col = ShorePalette.v, xlab="",ylab="",axes=FALSE); 
    # Crude version: label write CpG island on in the mean location: 
    #if ( length(grep("Island", islands)) > 0 ) { 
     # text(x =  mean(grep("Island", islands)) ,y = 1, "CpG Island", col = "white", cex=0.9);#};  
     
    # Sophisticated version: detect number of Islands! 
    if ( length(grep("Island", islands)) > 0 ) { 
      temp = islands; temp[] = 0; temp[grep("Island", islands)] = 1;  
      temp.s = paste(temp, collapse = ""); temp.strs = strsplit(temp.s, "0"); 
      island.length = as.vector(sapply(temp.strs, nchar)); 
      X=1; 
      for (k in 1:length(island.length)) { 
        if (island.length[k] > 0) { 
          s = ""; 
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          if ( island.length[k]/length(xlabels) > 0.1  ) {s="CpG I"}; 
          if ( island.length[k]/length(xlabels) > 0.25 ) {s="CpG Island"}; 
          text(x = X+(island.length[k]-1)/2 ,y = 1,  
               s, col = "white", cex=5/3); 
          X = X + 1 + island.length[k]; # +1 because there is always a "0" split off 
        } else { X = X+1};}} 
dev.off() 
   
  write.table(pheno1_comb.m,"Gene_Normal.txt", quote=FALSE, sep="\t") 
  write.table(pheno2_comb.m,"Gene_Tumour.txt",quote=FALSE, sep="\t")  
  write.table(pheno3_comb.m,"Gene_Atypical.txt", quote=FALSE, sep="\t")  }} 
 
#THEN FOR EACH GENE - make sure to save tables so can look at samples, calculcate avg beta 
value for each sample, then across samples - compare normal, atypical, cancer and look for 
30% difference and can do a t-test to see if statistically significant 
entrez2prettyprofiles(eid="11186",filename="C:/Users/regmcl6/Desktop/CL450K/RASSF1") 
dev.off() 
entrez2prettyprofiles(eid="2736",filename="C:/Users/regmcl6/Desktop/CL450K/AKT1") 
dev.off() 
 
#Sox1 T-test 
> SOX1<-read.csv("SOX1finalNA.csv") 
> plot(SOX1) 
> t.test(Beta~Sample, data=SOX1) 
  
#NvsC 
> SOX1<-read.csv("SOX1finalNC.csv") 
> plot(SOX1) 
> t.test(Beta~Sample, data=SOX1) 
 
2E: Script for CNV Analysis 
library(preprocessCore) 
library(DNAcopy) 
library(ChAMP) 
require(Illumina450ProbeVariants.db) 
data(probe.features) 
 
#variables 
intensity=myLoad$intensity 
pd=myLoad$pd 
loadFile=FALSE 
batchCorrect=FALSE 
file="intensity.txt" 
resultsDir=paste(getwd(),"resultsChamp",sep="/") 
sampleCNA=TRUE 
plotSample=TRUE 
filterXY=TRUE 
groupFreqPlots=TRUE 
freqThreshold=0.3 
control=TRUE 
controlGroup="N" 
 
 message("Run CNA") 
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 newDir=paste(resultsDir,"CNA",sep="/") 
     
 if(!file.exists(resultsDir)){dir.create(resultsDir)} 
 if(!file.exists(newDir)) 
 {dir.create(newDir)}  
 if(loadFile) 
 {ints = read.table(file,row.names =T, sep = "\t") 
        if(filterXY) 
        {autosomes=probe.features[!probe.features$CHR %in% c("X","Y"), ] 
            ints=ints[row.names(ints) %in% row.names(autosomes), ]}}else 
 {ints=intensity} 
  
 #Extracts names of samples  
 names<-colnames(ints) 
 #Quantile normalises intensities 
 intsqn<-normalize.quantiles(as.matrix(ints)) 
 colnames(intsqn)<-name 
 #Calculates Log2 
 intsqnlog<-log2(intsqn)      
 if(batchCorrect) 
 {message("Run batch correction for CNA") 
  combat=champ.runCombat(beta.c=intsqnlog,pd=pd,logitTrans=FALSE) 
  intsqnlog=combat$beta} 
 
 if(control){ 
        #separates case from control(reference sample/samples)        
        #check that control group exists... 
        controlSamples= pd[which(pd$Sample_Group==controlGroup),] 
        caseSamples= pd[which(pd$Sample_Group != controlGroup),] 
  case.intsqnlog<-intsqnlog[,which(colnames(intsqnlog) %in% 
caseSamples$Sample_Name)] 
        control.intsqnlog<-intsqnlog[,which(colnames(intsqnlog) %in% 
controlSamples$Sample_Name)] 
        control.intsqnlog<-rowMeans(control.intsqnlog) 
         
        intsqnlogratio<-case.intsqnlog 
        for(i in 1:ncol(case.intsqnlog)) 
        {intsqnlogratio[,i]<-case.intsqnlog[,i]-control.intsqnlog}}else{ 
#Creates alternate reference sample from rowMeans if proper reference /control is not 
available  
  case.intsqnlog<-intsqnlog[,1:length(names)] 
  ref.intsqnlog<-rowMeans(intsqnlog) 
    
        intsqnlogratio<-intsqnlog 
        for(i in 1:ncol(case.intsqnlog)) 
        {intsqnlogratio[,i]<-case.intsqnlog[,i]-ref.intsqnlog}} 
 
 #Generates Log2Ratio for case v control/reference 
     intsqnlogratio<-intsqnlog 
 colnames(intsqnlogratio)<-names 
 for(i in 1:ncol(case.intsqnlog)) 
 {if(control) 
 {intsqnlogratio[,i]<-case.intsqnlog[,i]-control.intsqnlog}else 
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 {intsqnlogratio[,i]<-case.intsqnlog[,i]-ref.intsqnlog}} 
 
 ints <- data.frame(ints, probe.features$MAPINFO[match(rownames(ints), 
rownames(probe.features))]) 
 names(ints)[length(ints)] <- "MAPINFO" 
 ints <- data.frame(ints, probe.features$CHR[match(rownames(ints), 
rownames(probe.features))]) 
 names(ints)[length(ints)] <- "CHR" 
 
 #Replaces Chr X and Y with 23 and 24 
 levels(ints$CHR)[levels(ints$CHR)=='X']='23' 
 levels(ints$CHR)[levels(ints$CHR)=='Y']='24' 
 
 #converts CHR factors to numeric  
 CHR<-as.numeric(levels(ints$CHR))[ints$CHR] 
 
 #need to copy in MAPINFO 
 ints$MAPINFO<-as.numeric(ints$MAPINFO) 
 MAPINFO=probe.features$MAPINFO[match(rownames(ints), 
rownames(probe.features))] 
 MAPINFO<-as.numeric(MAPINFO) 
 
 #Runs CNA and generates individual DNA Copy Number profiles 
 if(sampleCNA) 
 {message("Saving Copy Number information for each Sample") 
  for(i in 1:ncol(case.intsqnlog)) 
  {CNA.object <- CNA(cbind(intsqnlogratio[,i]), CHR, MAPINFO ,data.type = 
"logratio", sampleid = paste(colnames(case.intsqnlog)[i],"_qn")) 
   smoothed.CNA.object <- smooth.CNA(CNA.object) 
   segment.smoothed.CNA.object <- segment(smoothed.CNA.object, 
verbose = 1,alpha=0.001, undo.splits="sdundo", undo.SD=2) 
   if(plotSample) 
   {imageName<-paste(colnames(case.intsqnlog)[i],"_qn.jpg",sep="") 
    imageName=paste(newDir,imageName,sep="/") 
    jpeg(imageName) 
    plot(segment.smoothed.CNA.object, plot.type = "w", ylim=c(-
6,6))dev.off()} 
   seg<-segment.smoothed.CNA.object$output 
   table_name<-
paste(newDir,"/",colnames(case.intsqnlog)[i],"_qn.txt",sep="") 
   write.table(seg,table_name, sep="\t", col.names=T, row.names=F, 
quote=FALSE)}} 
 ##group Frequency plots 
 if(groupFreqPlots) 
 {message("Saving frequency plots for each group") 
        if(control) 
        {groups = unique(pd$Sample_Group) 
     groups = groups[!groups==controlGroup]}else 
        {groups = unique(pd$Sample_Group)} 
  for(g in 1:length(groups)) 
  {pd_group = pd[which(pd$Sample_Group==groups[g]),] 
   data_group=intsqnlogratio[,which(colnames(intsqnlogratio) %in% 
pd_group$Sample_Name)] 
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   ints_group=ints[,which(colnames(ints) %in% 
pd_group$Sample_Name)] 
   row.names(ints_group)=row.names(ints) 
  
   group.CNA.object <- CNA(data_group, CHR, MAPINFO,data.type = 
"logratio", sampleid = 
paste(paste(pd_group$Sample_Name,pd_group$Sample_Group),"_qn")) 
   group.smoothed.CNA.object <- smooth.CNA(group.CNA.object) 
   group.segment.smoothed.CNA.object <- 
segment(group.smoothed.CNA.object, verbose = 1,alpha=0.001, undo.splits="sdundo", 
undo.SD=2) 
   group.freq = 
glFrequency(group.segment.smoothed.CNA.object,freqThreshold)    
   #begin plot 
   ints = ints[order(ints$CHR,ints$MAPINFO),] 
   labels_chr <- data.matrix(summary(as.factor(ints$CHR))) 
   test1<- data.frame(labels_chr,row.names(labels_chr) ) 
   test <- data.frame(unique(CHR)) 
   colnames(test) = c("chr") 
   colnames(test1) = c("count","chr") 
   F1 <- merge(test,test1, by="chr", sort=T) 
   for(i in 2:length(row.names(F1))){F1[i,2] = F1[i-1,2] + F1[i,2] ; } 
   F1$label <- NULL ; F1[1,3] <- F1[1,2] / 2 ;   
 for (i in 2:length(row.names(F1))){ F1[i,3] <- (F1[i,2]+F1[i-1,2])/2; } 
   y1=group.freq$gain 
   y2=group.freq$loss 
   imageName1=paste(groups[g],"_","FreqPlot.pdf",sep="") 
   imageName1=paste(newDir,imageName1,sep="/") 
   graphTitle = paste("Frequency Plot of ",groups[g]," Samples",sep="") 
   pdf(imageName1, width = 10.0, height = 9.0)   
   #plot gain 
   plot(y1, type='h',  xaxt="n",  yaxt="n", col="green", main = graphTitle , 
ylim=range(-1, 1), xlab='Chromosome Number',  ylab=paste('Fraction of Samples with Gain or 
Loss (n=',dim(data_group)[306],")",sep=""),xaxs = "i", yaxs = "i") 
   #plot loss 
   points(y2, type='h', col="red") 
   #label for chromosomes 
   x= c(-1,-0.8,-0.6,-0.4,-0.2,0,0.2,0.4,0.6,0.8,1) 
   y= c(1:length(F1[,2])) 
   axis(1, at = c(F1[,2]), labels =FALSE, tick = TRUE, las = 1, col = "black", 
lty = "dotted", tck = 1 ); 
   axis(1, at = c(F1[,3]), labels =F1$chr, tick = FALSE ); 
   axis(2, at = c(x), labels=x, tick = TRUE, las = 1, col = "black", lty = 
"dotted", tck = 1 ); dev.off()}} 
library(plyr) 
colnames(group.freq)[1]<-"CHR" 
colnames(group.freq)[306]<-"MAPINFO" 
group.freq$MAPINFO <- as.integer(group.freq$MAPINFO) 
group.freq$CHR <- as.factor(group.freq$CHR) 
new=join(x=group.freq,y=probe.features,type="inner") 
write.table(new,”annotated_freq_data.txt”,sep=“\t”,row.names=F) 
 
#based on raw data from each sample, can incorporate into one table and upload onto GISTIC 
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Chapter 3 appendix 
The following tables 3A and 3B provide additional detail on the clinical course of the patients, 
for whom a peripheral blood sample was taken for CTC analysis.  The results are summarised in 
Tables 3.1 and 3.2.   
Table 3C details the histology and pathology results for the same patients, and the differences 
in these parameters for CTC positive and negative patients are summarised in Table 3.4. 
 
3A:  CTC positive (+) patients’ Clinical Course  
   Primary Tx  Relapse    
Pt 
No 
Age Stage  
(Grade) 
[site] 
S Ch RT Collection of 
CTC(Stathmin), 
CT response 
Time post 
diagnosis 
(m) & site 
T1 T2 T3 Death 
(m 
post 
IV) 
3 68 IB (2/3) Y N N CP C1 7 (ne) 38  
LN, L, P 
CP   2 
6 63 Ib (2) Y N N CP C2 172 (ne) 
C4 3878 (0), 
PD 
27 
B,L,LN 
CP   4 
7 65 IV (3) 
[LN, P] 
Y CP N CP C6 PR 
F/u 1m post 
ch 1 (ne) 
ne na   21 
8 61 IIIA (3) Y CP EB/
V 
Post CP&RT 
22 (ne) 
11 
LN,L,Li,B,P 
na   1 
9 72 IV (3) 
[LN,P] 
Y CP N CP C1 2 (2) 
C4 0 (PR) 
Post CP 2 (2) 
2m post CP, at 
relapse 2 (ne) 
ne 
 
na   12 
10 67 IA EEC 
(2/3)  
IIIC PPC  
Y CP N Pre-op 2 (2) 
CE C2 0, SD 
CE C3 1 (1), SD 
3  
P 
CE   na 
11 70 IV (3) 
[LN,P] 
N CP N CP C1 0 
C6 2 (2), SD 
Post ch 0 
At relapse 0 
ne S   15 
12 62 IIIC (3) Y N Y CP C1 0 
C4 0, PR 
f/u 9/13: 0 
Pre-Tr 3 (ne) 
24  
LN,P 
CP Tr   na 
13 79 IA (3) Y N EB C C2 1 (1) 
C4 0, PR 
26  
Lu 
C na  na 
14 71 IA (2) Y N N 1m post 
relapse 0 
4m post 
relapse 1 (1), 
SD 
9  
P,LN 
na   na 
15 68 IIIC (2/3) Y CP EB/
V 
CP2 C1 0 
C6 1 (1), SD 
Pre Dox 0 
29  
Lu 
CP2 S 
brain 
2m 
post 
CP2 
Dox na 
17 63 IA (3) Y CP EB/
V 
Mid CP2 8 (1), 
PD 
19  
L,Lu,LN 
CP2   9 
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22 57 IV (3) 
[Lu,LN,P] 
Y CP N CP C1 2 (2) 
C4 0, PD 
ne na   9 
24 65 IIIC (1/3) Y CP EB P C1 2 (2) 
C3 1 (1), SD 
C6 H, PD 
22 
LN, Lu 
P Tr ref  na 
25 55 IA (2) 
 
Y N N Pre S 0 
Post S 0 
CP C3 1 (ne), 
DF 
10  
P 
S CP  na 
26 70 IV (3) 
[LN,P] 
N CP N CP C1 4 (2) 
C3 1 (1), PR 
C6 H, PR 
na    na 
27
* 
66 IV (3)  
[P, Lu, L, 
LN] 
Y CP N C1 4(2) 
C4 0/PR 
C6 0/SD 
na    na 
28 72 IV (3) 
[LN, P] 
N CP N C2 0 
C4 1 (ne), PR 
C6 0 , PR 
na    na 
31 63 IIIB (3) Y CP N Pre Tr 0 
C1 Tr 1 (1) 
C2 Tr 0, SD 
8 
P, LN 
Tr    na 
PPC: primary peritoneal cancer SOC: serous ovarian cancer  
S: surgery, RT: radiotherapy, EB: external beam radiotherapy, V: vault brachytherapy,  
Tx: treatment, T1: treatment 1, T2: treatment 2, T3: treatment 3 
Ch: chemotherapy, C: carboplatin, CP: carboplatin and paclitaxel, CP2: 2nd course of 
carboplatin and paclitaxel  P: paclitaxel, CE: cisplatin and etoposide, Dox: doxorubicin, DF: 
disease free, Tr: clinical trial, Tr ref: referred for trial, SD: stable disease, PR: partial response, 
PD: progressive disease, LN: lymph node, P: peritoneal, L: liver, Lu: lung, B: bone 
Red circles mark patients who had 1stline chemotherapy and discordant CTC values & clinical 
course 
Green circles mark patients who had 1stline chemotherapy and concordant CTC values & 
clinical course 
Purple circles mark patients who only had one CTC value tested or were tested in follow-up. 
Patient in bolded row (patient 10) had dual pathology, thought to be EC alone pre-operatively. 
*For patient 27, the local team performed TAHBSO based on review of imaging showing 
resectable disease.  2nd review of imaging showed lung nodules, with evidence of liver 
metastases and increasing lymphadenopathy post-operatively on repeat CT. 
For Relapse and Death: m: months (after initial diagnosis and after diagnosis with stage IV 
disease respectively) 
 
3B:  CTC negative (-) patients’ Clinical Course  
   Primary Tx  Relapse    
 Age Stage  
(Grade) 
[site] 
S Ch RT CTC (S), CT 
response 
Date (m) 
& site 
T1 T2 T3 Death 
1 68 IV (3) 
[LN,P,B] 
N CP N CP C1 0 
C4&6, PR 
6&7/13 H 
ne     13 
2 73 IIB (2/3) Y CP EB/
V 
RT brain 
CTC 0 
51  
Lu,LN 
Pro CP RT 
brain 
13 
4 64 IIIb (2) Y N EB/
V 
Pre-RT 0 
14m post dx 0 
17m post dx 0 
(DF) 
na    na 
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5 77 Ib (2) Y N EB/
V 
CP C1: na 
Post CP: CR 
Refused CTC 
16  
LN 
CP   na 
16 65 IA EEC 
(2)  
IIIB SOC 
Y CP N Pre-op 0 
CP C4 0, SD 
CP C6 0 
CE C2 0, PD 
7 
P,LN 
CE Tr ref  na 
18 70 IA EC (3) 
IIIA PP 
Y CP N CP2 C4 0, PR 
Refused CTC 
28 
LN,P 
CP2   na 
19 83 IIIA (3) Y N EB/
V 
Post op 0 
Post RT 0 
At relapse 0 
5  
P 
na   na 
20 77 IB (2) Y N EB/
V 
Pro & Arim 
After 7m 0 
After 11m 0, 
SD 
5  
Lu,LN 
Pro  
22
m 
Pro&
Arim 
 na 
21 75 IA (3) Y N V C C1 0 
C4 0, PR 
18  
LN,P 
C   na 
23 
* 
60 IB (3) 
[?Lu,LN] 
Y CP EB/
V 
Post CP&RT 
8m post dx  0 
11m post dx  0 
14m post dx  0 
na    na 
29 62 IIIC (3) Y CP EB/
V 
C2 H 
C5 0 (SD) 
na    na 
30 54 IIIC (2) Y CP EB/
V 
CP2 C2 0 
C6 0 (PR) 
95  
L,LN,B 
CP2   na 
32 68 IIIA (2/3) Y CP EB/
V 
No  venous 
access 
22 
L,LN 
Pro C  na 
33
* 
49 IV (1): 
Lu,LN 
Y CP N CP C1 0 
C3 0, PR 
na    na 
34 59 IV (2): 
Lu, P 
N CP N pre-P 0, PD ne Tr  
21
m 
IDS 
mid-
Tr 
P na 
35 65 IB (3) Y N EB/
V 
CP C2 0 
C4, PR 
11  
Lu, P, LN 
CP   na 
The same abbreviations apply as for Table 3.1. Patients in italicised rows (patients 4, 23, 29) 
had stage I-III disease at the time of CTC collection and patients in bolded rows (patients 16 & 
18) had dual pathology, thought to be EC alone pre-operatively. 
Pro: Provera, Arim: Arimidex, dx: diagnosis, IDS: interval debulking surgery 
Patients 5, 16, 18 and 32 are excluded from further analysis as CTCs were not assessable. 
*Patient 23 had equivocal lung and lymph node findings on PET scan post-operatively.  CTCs 
were collected to see if this might correlate with disease.  Subsequent imaging demonstrated 
there was no evidence of metastatic disease. 
*Patient 33 had equivocal lung changes at diagnosis so proceeded with surgery with ?IIIA 
disease.  She was re-staged post-operatively as stage IV with definitive lung disease.   
Red circles mark patients who were CTC- and had a discordant clinical course. 
Green circles mark patients who were CTC- and had a concordant clinical course 
Purple circles mark patients with only a single CTC assessment. 
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3C:  Histology from primary surgery, pathology results at CTC collection and CTC results 
 
 Histology Tumour 
size 
MMI  
>50
% 
LVI Cerv 
Inv’n 
Hb (g/dL) at 
each CTC 
timepoint 
Albumin at 
each CTC 
timepoint 
bCTC count 
(highest 
CTC count)  
1 Poorly diff ca na na na na 13.8 45 0 
2 SP 55 y y Y 12.8 36 0 
3 E 21 y n N 12.1 41 7 (7) 
4 E 45 y n Y 9.3, Ne, ne 42, Ne, ne 0 
5 E 60 y y n 11.1 42 ne 
6 E 40 y n N 12.3, 11.4 39, 25 172 
(3878) 
7 serous 
adenoca 
90 y y N 9.5 42 1 (1) 
8 SP 32 y n y 11.9 35 22 (22) 
9  adenoca na na na na 11.3, 9.6, Ne, 
10.2 
33, 41, Ne, 
ne 
2 (2) 
1
0  
EEC/SP PP 65 n n n 12.4, 10.2, 10.5 34, 42, 44 2 (2) 
1
1  
B: SP & CC 
IDS: SP & CS 
58 y n n 11.9, 9.9, 9.3, 
11.9 
44, 43, 43, 
49 
0 (2) 
1
2  
Adenoca na na na na 11.1, 11.1, 10.3, 
10.9 
42, 42, 39, 
40 
0 (3) 
1
3  
SP 70 n y n 11.7, 9.5 44, 43 1 (1) 
1
4  
E 55 n y n 12.1, 13 44, 45 0 (1) 
1
5  
E & CS 80 y y y 14.9, 10.9, 13 46, 46, 42 0 (1) 
1
6  
EEC/SOC 
IDS: CC 
42 n n n 15.5, 11.6, 11.6, 
9.9 
46, 43, 43, 
41 
0 
1
7  
E & CS 50 n y n 11.4 42 8 (8) 
1
8  
SP EC/SP PP 39 n n n 13.4 48 0 
1
9  
SP 36 y y n 12.9, 13.1, 11.4 44, 40, 33 0 
2
0  
E & focal sq  90 y y n 9.3, 10.5 37, 36 0 
2
1  
E 45 n n n 11.2, 8.8 47, 42 0 
2
2  
SP 67 y y y 10.4, 11 43, 45 2 (2) 
2
3 
Epithelial ca 45 y y n 10.6, nd, 12.6 45, nd, 47 0 
2
4 
SP & E 55 y y y 13.6, 10.4, 11.5 44, 37, 38 2 (2) 
2
5 
Original: E;  
Rec: E 
<5cm 
20 
N 
na 
N 
na 
N 
na 
14.8, 11.9, 10.3 45, 42, 44 0 (1) 
2
6 
SP ne ne ne ne 12.5, 10.9, 10.6 40, 42, 39 4 (4) 
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2
7 
SP 100 y y y 12, 12.5, 11.6 46, 47, 47 4 (4) 
2
8 
SP na na na na 11.6, 9.7, 10.5 40, 38, 40 0 (1) 
2
9  
E 70 y ne N 11.3, 11.6 42, 41 H (0) 
3
0  
E & CC na na na Na 8.7, 8.1 43, 35 0 
3
1  
Adenosq & 
anaplastic  
85 y n N 10.8, 11, 10.3 44, 41, 40 0 (1) 
3
2  
E 60 y y y   Na 
3
3 
E & focus SP 65 n n N 12.9, 11.6 46, 42 0 
3
4  
Initial: E; IDS: 
E 
35 y y Y 10.6 41 0 
3
5  
E & sq diffn 50 y y n 13.1 41 0 
Ca: carcinoma, SP:serous papillary, E=endometrioid, CC: clear cell, CS: carcinosarcoma, 
sq:squamous, IDS: interval debulking surgery, PP: primary peritoneal cancer, EEC; 
endometrioid endometrial cancer, B: biopsy, rec: recurrence, diffn=differentiation 
bCTC=baseline circulating tumour cell, na=not available 
Grey shaded rows indicate those patients that were CTC+  
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Chapter 4 appendix 
The concentrations and wavelengths are recorded in Table 4A for the first 10 samples, Table 
4B for the remaining FFPE samples and Table 4C for the FF samples.  Note that the absorbance 
ratios 260/280 should be between 1.7-2.2 for pure DNA and 260/230 should be greater than 
1.5, as outlined in Methods section 2.2.4.1.2. 
There were 14 specimens (from cases 1-11, marked with * in Table 4B) where tissue was re-
extracted, either due to initial challenges with tissue extraction or due to poor performance on 
the first array. This was to determine if greater experience of techniques might improve the 
DNA concentration and modification. Although technically, there were areas of dissection that 
were easier to perform with greater experience, an actual difference in quality was not seen, 
possibly reflecting poor quality DNA preservation at the time of tissue collection, rather than 
any learning curve with the extraction and modification techniques. 
 
Table 4A:  Analysis of first 10 FFPE specimens on NanoDrop Spectrometer and Qubit 
Fluorometer 
Specimen NanoDrop DNA conc 
(ng/µl) 
260/280 260/230 Qubit DNA conc 
(ng/µl) 
1A 100.2 na na 48.2  
2N 70.9 1.81 3.03 112  
2C 77.5 na na 64.6  
5N 182.5 1.95 2.44 36  
5A 42.1 1.9 5.77 44.4  
5C 83.5 1.93 3.27 66.8  
6C 235.6 1.84 2.11 na 
7C 86.3 1.78 2.19 45.6  
9N 48.9 1.67 2.03 31  
9C 268.2 1.85 2.23 >600  
na:  not available.   
 
Table 4B:  Concentration of 87 FFPE samples on NanoDrop Spectrometer and Qubit 
Fluorometer 
Sample Nano 
[ng/µl] 
260/ 
280 
260/ 
230 
Qubit  
[ng/µl] 
Sample Nano 
[ng/µl] 
260/ 
280 
260/ 
230 
Qubit  
[ng/µl] 
3N 60.1 2.2 1.93 52.8 26C 117 1.78 2.08 4.08 
4A 134.2 1.96 2.44 51.8 26C2 103.8 1.79 2.07 23 
6N 69.7 1.86 1.85 39.7  27N 23.1 2.06 1.91 3.12 
6A 70.9 1.92 2.16 80.6 27A 51.8 2.06 2.07 22.4 
10N 75.2 1.97 2.23 61.4 27C 52.0 2.00 2.03 17.2 
10A 114.9 1.96 2.22 28.4  28N 103.4 1.98 2.3 78.2 
10C 106.9 1.94 2.2 8.84 28A 104.3 2.00 2.29 17.2 
12N 82.8 1.88 2.05 9.88 28C 202.2 1.96 2.29 43.2 
12C 69.3 1.84 2 5.03 29N 26.6 1.65 20.5 6.3 
13N 60 2.03 2.25 41.2 29N2 15.6 1.54 1.54 7.08 
13A 95.4 2.04 2.02 55.6 29C 128.3 1.84 2.16 27 
13C 4.3° 2.1 -0.41 62.2 29C2 103.3 1.82 2.15 36.6 
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14N 21.9 1.82 0.75 4.7 30N 100.4 1.93 2.21 40 
14C 49.8 1.94 1.1 5.88 30A 54.3 1.94 2.33 19.9 
15N 81.1 1.98 2.12 10.3 30C 132 2.01 2.21 25.2 
15C 80.2 1.97 1.34 19.1 31N 45.3 2.03 2.08 23.6 
16N 59.3 1.93 2.12 9.08 31C1 133.6 2.03 2.19 26.6 
16A 189.8 1.94 2.03 26.4 31C3 34.9 2.01 2.01 4.8 
16C 224.6 2.00 2.17 9.58 32N 12.7 1.97 1.14 13.9 
17N 160.6 1.82 2.1 22 32C 457.9 2.04 2.22 177 
17A 129.8 1.95 2.18 11.2 33N 51.8 1.92 2.22 53.8 
17C 427.4 1.87 2.18 17.4 33C 18 2.08 1.70 20.8 
18N 28.6 1.85 2.12 3.76 34N 21.8 2.08 1.71 10.5 
18A 52.4 1.94 2.17 9.67 34A 12.3 2.07 1.67 18.4 
18C 44.9 1.91 2.3 9.98 34C 20.1 1.93 1.58 28.4 
19N 89 1.90 2.16 11.8 35N 72.7 1.91 2.09 79 
19A 142.7 1.88 2.12 24.4 35C 51 1.94 1.86 45.4 
19C 58.9 1.80 2.13 15.7 36N 45.5 2.01 1.95 26 
20N 39.2 1.95 2.24 8.66 36C 142.7 1.93 2.25 208 
20C 111.7 2.00 2.17 25.2 1N* 133.3 1.73 2.21 126 
21N 43.2 1.86 2.1 26.8 1A* 171.8 1.81 2.24 216 
21A 27.4 2.12 1.95 8.83 1C* 114.6 1.75 2.22 93.2 
21C 255.4 1.97 2.2 43.2 3N* 67 1.95 2.17 90 
22N 102.7 2.10 2.22 52.4 3A* 120.3 1.81 2.18 120 
22C 53.2 2.10 1.97 32.2 3C* 97 1.88 2.30 77.6 
23N 34.6 1.81 1.91 2.7 7N* 71.7 1.71 2.33 74 
23A 33.8 1.92 2.01 2.81 7A* 49.1 1.88 1.99 16.4 
23C 234.8 1.84 2.16 20.6 7C* 45.7 1.89 2.30 8.50 
24N 89.1 1.96 1.98 52.4 8N* 35.6 1.73 1.08 45.8 
24A 26.9 2.03 2.06 12.7 8A* 38.8 1.73 2.05 45.4 
24C 523.5 2.07 2.19 71.2 8C* 36.2 1.76 1.86 26.2 
25N 41.9 1.82 2.03 6.01 11A* 27 1.81 1.99 38.4 
25C 138.6 1.93 2.12 44.8 11C* 117.3 1.81 2.24 104 
26N 66.9 1.76 2.21 17.8      
° Specimen not assessable on NanoDrop and was tested on Qubit alone 
* Specimens that were re-extracted due to initial QC concerns or limitations in extraction   
Specimens marked in bold were included on subsequent array analysis based on further QC 
results.  260/230 results marked in italics are <1.5, below the cut-off for adequate quality DNA 
on NanoDrop. 
 
From the 87 FFPE specimens above, the 260/280 wavelength ratio was between 1.7 and 2.2 
for all specimens.  The 260/230 ratio was greater than 1.5 for all specimens except for 13C, 
14N, 14C, 15C and 32N (marked in italics), which may reflect specimen contamination.  
Specimens marked in bold were of suitable quality to run on the 450K array based on further 
QC analysis presented in section 4.4.  Note that specimens 13C, 14N, 14C, 15C and 32N were 
of adequate quality on further assessment, demonstrating the limitations in NanoDrop analysis 
for quality control.  Unbolded specimens in Table 4.2 were not run on the array and this is also 
outlined in section 4.4.    
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Table 4C:  Concentration of 12 fresh frozen samples on NanoDrop Spectrometer and Qubit 
Fluorometer 
Sample Nano 
conc 
(ng/µl) 
260/ 
280 
260/ 
230 
Qubit  
conc  
(ng/µl) 
Sample Nano 
conc 
(ng/µl) 
260/ 
280 
260/ 
230 
Qubit 
conc  
(ng/µl) 
37N 48.8 1.96 2.01 58 41N 62.3 2.07 2.11 25.2 
37C 132.4 1.96 1.92 55 41C 676 1.97 2.14 38 
38C 244.9 2.07 2.16 71.7 41N2 31.3 1.91 1.98 18.65 
39C 33.7 1.86 1.20 20.1 41C2 253.1 2.11 2.06 28.62 
40N 69.8 1.98 1.72 38.1 42N 253.2 2.01 2.04 86.7 
40C 209.3 1.93 2.27 185 42C 64.5 2.06 2.00 4.99 
All FF specimens demonstrated NanoDrop wavelength ratios of appropriate values, except 39C 
where the 260/230 ratio was low.   
Specimen 41 had 2 separate collection vials taken as there was a greater amount of specimen 
available for analysis. 
 
 
4D:  Slide review of ChAMP Evaluable Samples  
Images of the dissected slides for the ChAMP evaluable specimens are included here.  
Evaluation of these slides and risk of contamination at the time of dissection is detailed in 
Table 4.10. 
2:    27:   
4:    28:  
13:     31:   
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14:  32:  
15:    33:  
20:    34:  
22:    35:  
24:   36:  
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Chapter 5 appendix 
 
5A: Post normalisation MDS and density plots and cluster dendrograms for Grade 1, Grade 3 
and matched sample comparisons between normal endometrium and endometrioid 
endometrial cancer (NvC), normal endometrium and atypical endometrial hyperplasia (NvA) 
and between atypical endometrial hyperplasia and endometrioid endometrial cancer (AvC). 
 
For all the comparisons, the density plots demonstrate a narrow variation between samples, as 
expected as they are post normalisation using the BMIQ step in the ChAMP pipeline. 
 
 
i) Grade 1 NvC comparison 
Overall, the specimens cluster with their histological subtype, either normal endometrium 
or EEC. 
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ii) Grade 1 NvA comparison 
There are only 4 grade 1 AEH specimens but overall, the specimens cluster with their 
histological subtype.  The 3 outliers are 30A and 34A, which cluster with their paired 
normal comparator, and 36N. 
 
    
       
 
iii) Grade 1 AvC comparison  
There is not a clear difference between the AEH and EEC clusters, though again the 
number of AEH specimens is small.  13A, 28A and 34A lie near their paired normal 
comparator. 
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iv) Grade 3 NvC comparison 
There is a difference in methylation status with clustering of normal and EEC specimens 
with their histological subtype, except for 31N, 36C, 42N and 42C. 
 
 
 
 
 
v) Grade 3 NvA comparison 
There is no difference in clustering between the normal and AEH specimens, though there 
are only 3 AEH samples that are evaluable here. 
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vi) Grade 3 AvC comparison 
The 3 AEH specimens cluster together but there are a number of cancer specimens that 
cluster alongside them, including 24C, 27C, 33C and 42C. 
 
 
 
vii) Comparison of Normal Endometrium associated with Grade 1 v Grade 3 EEC 
The normal specimens associated with grade 3 EEC generally cluster together, while those 
associated with grade 1 EEC do not demonstrate discrete clustering and overlap in 
methylation status with the grade 3 EEC associated specimens.   
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viii) Comparison of AEH associated with Grade 1 v Grade 3 EEC 
Analysis is restricted by the small sample size, but there is no difference in clustering 
between the AEH specimens associated with grade 1 and grade 3 EEC. 
 
 
 
ix) Comparison of Grade 1 v Grade 3 EEC 
A number of the EEC specimens cluster based on their grade 1 or grade 3 subtype.  A 
number of the grade 3 specimens however cluster with the grade 1 specimens (eg. 24C, 
27C). 
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x) NvC Matched Sample Comparison 
The normal endometrium and EEC specimens cluster with their histological subtype. 
      
 
 
 
 
xi) NvA Matched Sample Comparison 
Overall, the normal endometrium and AEH specimens cluster with their histological 
subtype, except for 24A, 30A and 34A.  
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xii) AvC Matched Sample Comparison 
For some specimens, there is a difference in clustering between the AEH and EEC 
specimens.  However, the paired samples for 13, 27 and 28 cluster together.  
 
 
 
 
xiii) NvAvC Matched Sample Comparison 
There is a difference in clustering between the normal endometrium and EEC specimens.  
Although some of the AEH specimens lie between these 2 clusters, others are paired with 
their normal specimens (24A, 30A, 34A) while others cluster with their EEC specimens 
(13A, 27A, 28A). 
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5B: Boxplots showing i) hypermethylation and ii) hypomethylation of individual genes 
between normal endometrium, atypical endometrial hyperplasia (AEH) and endometrioid 
endometrial cancer (EEC) 
The y-axis shows the degree of methylation, as illustrated by the beta value.  A beta value of 0 
equals non-methylation at the locus and 1 equals total methylation. 
The x-axis shows the histological subtype; normal endometrium, AEH or EEC. 
 
i) Genes showing progressive hypermethylation between normal endometrium, 
atypical endometrial hyperplasia and endometrioid endometrial cancer 
 
 
SOX1     APC      
 
 
CARD11    CD8B 
 
   
FZD10     FGF12 
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COL11A1     GLI2 
       
 
    
GATA2      H2AFY 
 
    
HIC1      ITGA8 
 
    
KARLN      MADCAM1 
 
258 
 
 
MMP2      MYL9 
 
NCAM2      NDRG2 
 
NRG3      PENK 
 
       
PTPN6      RIN1    
 
259 
 
 
SFRP2      SHC1 
 
 
 
TGIF1      THY1 
 
 
TGFB3 
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ii) Genes showing progressive hypomethylation between normal endometrium, 
atypical endometrial hyperplasia and endometrioid endometrial cancer 
 
 
   
AQP5      CLDN4 
 
 
    
CFLAR      LAMA3 
 
 
 
 
RARA      SERPINB5 
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SFN      SPP1 
 
 
TJP2 
                                                                  
 
 
